Virus evolution in the progression of natural feline immunodeficiency virus infection by Bęczkowski, Paweł
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Bęczkowski, Paweł (2013) Virus evolution in the progression of natural 
feline immunodeficiency virus infection. PhD thesis 
 
 
http://theses.gla.ac.uk/4186/ 
 
 
 
 
 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given. 
 
  
 
Virus evolution in the progression of natural 
feline immunodeficiency virus infection 
 
Submitted in the fulfilment of the requirements of the degree of 
Doctor of Philosophy 
 
by Paweł Bęczkowski, DVM 
 
 
College of Medical, Veterinary and Life Sciences 
MRC-Centre for Virus Research 
University of Glasgow 
 
December 2012 
 
  
2 
 
Abstract 
Feline immunodeficiency virus (FIV) is an important pathogen of domestic cats 
which in some cases can lead to feline AIDS. It shares many similarities with its 
human counterpart and is studied to understand correlates of immune-
protection and mechanisms of disease progression in cats, both to improve the 
welfare of infected cats and as an animal model for the pathogenesis of HIV 
infection in humans.  
FIV is believed to evolve during the course of infection as a result of the error 
prone nature of reverse transcriptase and recombination between viral variants, 
but relatively little is known about this process in naturally occurring infection. 
Ultimately, it remains unknown why some infected cats remain healthy while 
others progress to AIDS rapidly.  
The studies reported in this thesis addressed this lack of knowledge by 
examining sequential blood samples obtained during the course of natural FIV 
infection in a population of 44 privately owned domestic cats. 
Employing Bayesian coalescent framework, it was demonstrated that the FIV env 
gene is relatively stable genetically. Although not necessary a prerequisite, this 
is likely to explain why many naturally infected cats can remain healthy and do 
not progress to AIDS. By determining the cell tropism of isolated viral variants, it 
was shown that sick cats were more likely to harbour viruses of the “late” 
phenotype than healthy animals, similar to the co-receptor switch observed 
during the progression of HIV infection. Intra-host diversity analyses highlighted 
a likely role for the leader region of the env gene in viral pathogenesis. 
Furthermore, recombination was demonstrated to be abundant in natural 
infection, indicating a requirement for the current phylogenetic classification of 
FIV to be revised. 
By assessing the strength and breadth of neutralising antibodies (NAbs), it was 
shown that NAbs did not appear to influence the course of natural FIV infection, 
arguing against a role in controlling infection and disease progression. 
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Following an examination of samples collected from a group of privately owned 
Australian vaccinates, it was shown that the Fel-O-Vax FIV vaccine did not 
induce cross-reactive neutralising antibodies. Furthermore, in the country where 
commercial FIV vaccine is licenced, we identified and characterised the virus 
strain which was likely able to establish infection in vaccinated cat and raised 
concerns of vaccine’s efficacy. 
Overall this study broadens our understanding of natural FIV infection, and 
highlights that much can be learned, not from the similarities but rather by 
studying the differences between the feline and human lentiviruses. Such 
comparative studies are likely to contribute to design of highly desirable, safe 
and fully efficacious lentiviral vaccines. 
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Chapter 1. Introduction 
1.1 Overview 
Feline immunodeficiency virus (FIV) is a lentivirus of domestic cats (Felis catus), 
which in its natural host induces acquired immunodeficiency syndrome (AIDS), 
mirroring human immunodeficiency virus (HIV) infection (Elder et al., 2010). 
Both FIV and HIV induce a progressive decline in circulating CD4+ T lymphocytes, 
lead to inversion of the CD4:CD8 ratio and subsequently cause 
immunosuppression that paves the way to opportunistic infections, neoplasia and 
death. Therefore, as well as being an important pathogen of domestic cats, FIV 
has significant comparative value to better understand correlates of immune-
protection and mechanisms of disease progression in HIV infected humans. 
1.2 Discovery and origins 
FIV, initially described as feline T-lymphotropic virus, was first isolated in 
Petaluma, California, USA in 1986 from a domestic cat suffering from multiple 
symptoms consistent with immunodeficiency like syndrome in humans (Pedersen 
et al., 1987). Since its discovery, FIV infection of the domestic cat has been 
shown to be distinct amongst the non-primate lentiviruses, namely caprine 
arthritis-encephalitis virus (CAEV), Maedi Visna virus (MVV), equine infectious 
anaemia virus (EIAV) and bovine immunodeficiency virus (BIV), since FIV alone 
may cause an AIDS like disease in its natural host. 
FIV most likely originated between 3.1 and 0.7 million years ago among wild 
felids in Africa and disseminated through species within the Panthera lineage, 
subsequently infecting ancestors of the African lion, jaguar and eventually 
spreading among New World cats as species-specific strains (Pecon-Slattery et 
al., 2008). The evolution of FIV-Fca (FIV of Felis catus) is characterized by a long 
monophyletic branch (Pecon-Slattery et al., 2008). Taken together with the 
relatively recent origin of the cat (which was domesticated around 10,000 years 
ago in the Middle East (Driscoll et al., 2007)), it has been suggested that 
acquisition of the virus was much more recent for the domestic cat compared to 
the lion or puma. Subsequent world-wide dissemination of the virus was likely 
triggered by the domestication process (Pecon-Slattery et al., 2008). 
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Furthermore, an analysis of viral sequence divergence and disease pathogenesis 
amongst the Felidae, suggested different periods of virus-host co-evolution 
(Troyer et al., 2008). From this perspective, in the majority of cases, the least 
pathogenic viruses co-evolve with their hosts for longer periods of time, whereas 
more virulent strains have more recent origins. This pattern seems to be 
reflected in the disease inducing potential of different species specific FIVs, with 
FIV-Pco (FIV of the puma) being the least pathogenic while FIV-Fca is the most 
pathogenic. Although FIV infection in pumas and lions is believed to be 
asymptomatic, recent evidence suggests that infected lions may exhibit mild 
immunodeficiency symptoms, subsequently affecting the lifespans of infected 
individuals (Roelke et al., 2009). Similar observations have been made recently 
in SIV-infected chimpanzees, which had previously been regarded as 
asymptomatic carriers of the virus (Terio et al., 2011). Nevertheless, the 
evolutionary evidence, together with the pathogenic potential of FIV-Fca, is 
suggestive of a rather short period of virus-host coadaptation and relatively 
recent acquisition of the virus by domestic cats (Pecon-Slattery et al., 2008). 
1.3 Virus biology 
1.3.1 Genomic organisation 
FIV shares a similar genomic organisation with other retroviruses (Miyazawa et 
al., 1994) which consists of three major open reading frames (ORFs): gag, pol 
and env, accompanied by three accessory genes: vif, ref and orf-a, all bounded 
by long terminal repeats (LTRs) within the provirus (Talbott et al., 1989), 
(Miyazawa et al., 1994), (Figure 1-1). The genome contains approximately 9400 
nucleotides and sequence analysis revealed that, despite the fixed pattern of 
genomic organisation, FIV is more closely related to equine infectious anaemia 
virus (EIAV), bovine immunodeficiency virus (BIV) or caprine arthritis-
encephalitis virus (CAEV) than to the primate immunodeficiency viruses (SIV and 
HIV) (Olmsted et al., 1989). Similarly to other retroviruses, the gag, pol and env 
genes encode structural, enzymatic and envelope polyproteins; respectively 
these are cleaved and further proteolytically processed into proteins composing 
mature virions (Miyazawa et al., 1994). The FIV genome contains additional 
accessory and regulatory genes: vif, orf-A and rev (Miyazawa et al., 1994). The 
vif gene encodes a highly conserved hydrophilic protein which counteracts 
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cytidine deamination by the APOBEC3G host restriction factor (Zielonka et al., 
2010). It also has a role for FIV replication; viruses with a deleted vif gene are 
unable to replicate in vivo (Shen et al., 2007). The protein encoded by the 
regulatory rev gene is involved in trafficking of viral RNA from the nucleus to the 
cytoplasm by binding to the Rev response element (RRE) on incompletely spliced 
viral mRNA (Malim et al., 1989), (Na et al., 2010). Orf-A has multiple functions 
including influencing the cell cycle, increasing translation and mediating virus 
release from the cell (de Parseval and Elder, 1999), (Gemeniano et al., 2003), 
(Gemeniano et al., 2004). The accessory genes: vpr, vpu and nef (which are 
present in HIV-1) are absent in FIV particles (Miyazawa et al., 1994). 
 
 
Figure 1-1 Genomic organisation of FIV proviral DNA. The genome of FIV consists of 3 
major open reading frames (ORFs): gag – encoding: matrix (MA), capsid (CA) and 
nucleocapsid (NC), pol – encoding: protease (PR), reverse transcriptase (RT), dUTPaze (DU) 
and integrase (IN) and env – encoding: surface unit domain (SU) and transmembrane 
domain (TM) of the envelope glycoprotein. Additionally, in close proximity to the env gene, 
there are 2 accessory genes: vif, orf-a as well as one regulatory gene: rev. Within the 
provirus, the ORFs are flanked by long terminal repeats (LTRs). 
 
The Long Terminal Repeats (LTRs) of the retroviral genome consist of U3 (unique 
3’ end), R (repeat) and U5 (unique 5’ end) non-coding regions and flank the 
provirus at both ends. The U3 region of the LTR contains promoter and enhancer 
elements which are involved in regulating viral gene expression in infected cells 
(Sparger et al., 1992), (Miyazawa et al., 1994).  
1.3.2 Virion structure 
The FIV virion (Figure 1-2) is a spherical particle of approximately 120 nm in 
diameter containing two copies of positive, single stranded RNA (Talbott et al., 
1989). Structural (Gag), enzymatic (Pol) and envelope (Env) precursor products 
of the three major retroviral genes are proteolytically processed and assemble 
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into the mature virions. The Gag polyprotein consist of: the nucleocapsid NC 
(p7), matrix MA (p17) and capsid CA (p24) proteins. The viral core consists of the 
p24 CA protein which surrounds the viral RNA, bound to zinc finger motifs of NC 
(Elder et al., 1992). MA builds the outer shell facing the lipid bilayer. Protease 
PR (p13), reverse transcriptase RT (p51), integrase IN (p31) and, unique to FIV, 
deoxyuridine pyrophosphatase DU (p14) are contained within the viral capsid and 
are enzymatic products of pol (Talbott et al., 1989). The RT enzyme facilitates 
DNA synthesis from viral RNA (Goff, 1990). IN is responsible for the integration of 
proviral DNA into the DNA of the host cell, while PR cleaves the precursor 
proteins. 
 
Figure 1-2 Schematic structure of FIV virion. vRNA, viral RNA; MA, matrix; CA capsid; NC 
nucleocapsid; RT, reverse transcriptase; IN, integrase; PR, protease; DU, deoxyuridine 
pyrophosphatase; SU and TM; surface and transmembrane units of the envelope 
glycoprotein. 
 
DU is involved in preventing the misincorporation of dUTP into DNA and 
facilitates infection of non-dividing cells with low levels of endogenous DU, such 
as macrophages (Lerner et al., 1995). Hence FIV DU deletion mutants achieve 
lower burdens in macrophages compared to dividing T cells (Lerner et al., 1995).   
1.3.2.1 Envelope glycoprotein 
The envelope glycoprotein (Env) is exposed on the viral surface and influences 
almost every aspect of virus biology. Polyprotein Env precursors are synthesized 
on the rough endoplasmic reticulum (RER) and further processed and 
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glycosylated in the lumen of the RER (Leonard et al., 1990). Subsequently, the 
Env precursor is cleaved in the Golgi apparatus at the furin site to form the 
surface (SU) and the transmembrane proteins (TM) (McCune et al., 1988). TM 
and SU are non-covalently associated and form the viral envelope. SU is 
responsible for virus-host interactions, mediates viral entry through its interplay 
with CD134 and CXCR4 and (since it is heavily glycosylated) also facilitates 
immune evasion (Willett et al., 2008), (Samman et al., 2010). Structurally, the 
SU glycoprotein has five variable regions (V1 to V5) distributed amongst five 
relatively conserved regions (Pancino et al., 1993b). The TM domain holds SU 
within the viral membrane and plays an essential role, via its fusion peptide 
(FP), in the fusion of viral and cellular membranes (Bosch et al., 1989), (Freed et 
al., 1992). The TM comprises approximately 340 amino acids and consists of an 
ecto-domain, a highly conserved transmembrane domain (TMD) and a 
cytoplasmic tail (CT) (Checkley et al., 2011). Conserved, yet prone to some 
variability (Jobes et al., 2006), a number of cystein residues forming disulphide 
bonds is distributed throughout SU and TM and these residues are integral in the 
formation of the three dimensional structure of the glycoprotein (Leonard et al., 
1990). The FIV Env is heavily glycosylated with host derived glycans that 
encompass exposed epitopes, thus contributing to protecting the virus from host 
immune response (Stephens et al., 1991). 
1.3.3 The retroviral life cycle 
The FIV replication cycle resembles that of HIV and other retroviruses (Freed, 
2012) (Figure 1-3). However, there are several unique features of the FIV life 
cycle attributable to its genomic organisation (Talbott et al., 1989), 
characteristics of its RT (Huisman et al., 2008b) and, most importantly, its initial 
interaction with target cells (Shimojima et al., 2004). 
1.3.3.1 Virus-cell interaction 
Retroviral infection commences with the interaction of the viral Env with 
specific receptors on the surface of susceptible cells. The HIV Env preferentially 
binds, via the CD4 molecule, T helper lymphocytes and cells of the myeloid 
linage such as monocytes and macrophages (Maddon et al., 1986), (Sattentau 
and Weiss, 1988). The interaction of the viral envelope glycoprotein with CD4 
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alone is not sufficient for fusion of viral and cellular membranes; subsequent 
viral entry is facilitated by a secondary interaction with a chemokine co-
receptor such as CXCR4 (Feng et al., 1996), (Bleul et al., 1997) or CCR5 (Alkhatib 
et al., 1996), (Trkola et al., 1996a). The utilisation of these two major co-
receptors partially explains the differential cell tropism of the virus. Generally, 
X4 strains are T-cell tropic (Correa and Munoz-Fernandez, 2001), while R5 
dependent strains preferentially target memory CD45RA+ T cells and 
macrophages (Collman et al., 1989). Nevertheless, macrophage tropic X4 strains 
also have been identified (Simmons et al., 1998), highlighting that other 
determinants within Env play a role in cell tropism. 
 
Figure 1-3 The FIV replication cycle: binding of the primary CD134 and the CXCR4 co-
receptor; membrane fusion and viral entry; reverse transcription within the pre-integration 
complex; proviral DNA-integrase nuclear entry and integration; transcription; translation; 
assembly at the plasma membrane, virion release and maturation. 
 
Indeed dual tropic R5X4 strains, which utilize both co-receptors, also have been 
described (Yi et al., 1999).  
FIV has a similar cell tropism to HIV, but unlike its human counterpart it utilizes 
feline CD134 as its primary entry receptor (Shimojima et al., 2004) and CXCR4 as 
a coreceptor (Willett et al., 1997b), (Richardson et al., 1999). CD134 belongs to 
the tumour necrosis factor/nerve growth factor receptor superfamily 
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(TNFR/NGFR) (Locksley et al., 2001) and is expressed on feline CD4+T cells in 
vitro (Shimojima et al., 2004) and in vivo (Joshi et al., 2005), concordant with 
viral tropism and the progressive depletion of the CD4+ lymphocyte subset that 
occurs during the course of infection. The structure of CD134 resembles that of 
classical TNFR molecules, with an extracellular binding domain comprising three 
cysteine rich domains (CRD1, CRD2, CRD3) and an additional C-terminal domain 
(Bodmer et al., 2002). 
Various strains of FIV differ in the affinity of their interaction with the primary 
receptor (Willett et al., 2006a). The PPR strain of FIV achieves productive 
infection following an interaction with the cysteine rich domain 1 (CRD1) of 
CD134 (de Parseval et al., 2005), while primary strains such as GL-8 require a 
more stringent interaction involving determinants on the cysteine rich domain 2 
(CRD2) of CD134 (Willett et al., 2006a), (Willett et al., 2006b). It has been 
proposed that viral variants such as GL-8, isolated in early stage disease require 
a complex interaction with the receptor, while chronic infections are 
accompanied by the emergence of strains (such as PPR or B2542) requiring less 
stringent interactions with CD134, resulting in a broader cell tropism (Willett et 
al., 2010). 
Fusion of viral and cellular membranes permits the viral core to enter the host 
cytoplasm where, in common with all retroviruses, reverse transcription takes 
place (Gilboa et al., 1979). 
1.3.3.2 Reverse transcription 
Reverse transcription of the viral RNA (vRNA) into a double stranded DNA copy 
(known as the provirus) occurs within the pre-integration complex (PIC) while 
vRNA is still virion associated. Reverse transcription commences shortly after 
budding (Oude Essink et al., 1996), (Huang et al., 1997) and is catalysed by the 
virion associated, error-prone RT enzyme (Temin and Mizutani, 1970). Reverse 
transcription is primed by the formation of RT–cellular tRNA complex (Harada et 
al., 1975), (Mak and Kleiman, 1997), which subsequently binds to the primer 
binding site (PBS) located close to the 5’ end of the viral genome (Figure 1-4 A). 
The 3’ end of the tRNA primes synthesis of single strand cDNA until it reaches 
the end of the 5’ R region of the viral genome. This mid-product is termed 
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antisense strong stop DNA (minus ssDNA). At the same time, the RNase H domain 
of RT mediates degradation of the RNA template annealed to the minus ssDNA, 
thus allowing its release (Figure 1-4 A).  
 
Figure 1-4 Schematic diagram of reverse transcription. For a description of each step (A-E) 
please refer to the text. RNase H, Ribonuclease H; tRNA, transfer RNA; first DNA strand = (-) 
strand DNA in purple; second DNA strand = (+) strand DNA in blue and light green. Modified 
from (Sarafianos et al., 2001). 
 
Released minus ssDNA in the process of first strand transfer binds to the 3’ R 
region of the viral genome and subsequently acts as a primer for RT, allowing 
the (-) strand DNA synthesis. Meanwhile, the RNase H domain of RT digests the 
RNA template, with the exception of the resistant polypurine regions (PPT) 
(Figure 1-4 B). The PPT primes subsequent (+) strand DNA synthesis, which is 
carried by another RT-tRNA complex (Figure 1-4 C). Thus synthesised, the 
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positive sense strong stop DNA (plus ssDNA) in the process of second strand 
transfer binds to the 3’ end of (-) strand DNA (Fig 1-4 D). Reverse transcription 
then continues until the complementary strand is synthesised, leading via the 
strand displacement process to synthesis of double stranded DNA, flanked at 
each end by long terminal repeats (LTRs) (Figure 1-4 D, E). 
Reverse transcription occurs within the virion and the resulting proviral DNA is 
later trafficked into the nucleus and incorporated into the host cell genome by 
the virally encoded integrase (IN). 
1.3.3.3 Integration 
Similarly to reverse transcription, integration is well conserved among 
retroviruses. In the course of 3’ end processing, the integrase (IN) removes two 
nucleotides from both 3’ ends of the proviral DNA and subsequently cleaves the 
host cellular DNA. In the process of strand transfer, the 3’ ends of previously 
prepared proviral DNA are connected to the ends of cleaved cellular DNA. This 
process is completed by host repair enzymes which fill the gaps in the insertion 
site. 
Following integration, the proviral DNA serves as a template for the synthesis of 
viral RNA which is subsequently used by the cell machinery for translation. 
1.3.3.4 Assembly and release 
The synthesis of viral proteins is followed by viral assembly at the plasma 
membrane of the host cell, a process mediated by the Gag precursor polyprotein 
(Luttge and Freed, 2010). Gag domains: matrix (MA), capsid (CA), nucleocapsid 
(NC) and C-terminal peptide (p2) (Lin et al., 2006) each play an important role 
in this process. The MA domain directs Gag to the plasma membrane and allows 
Env incorporation into virions (Freed, 1998). CA advances formation of the 
conical core surrounding the viral RNA and pol-encoded enzymes. The NC domain 
recognizes one or more packaging signals (Ψ) within the viral RNA and mediates 
its trafficking into the assembling virion (Browning et al., 2003). FIV Gag, 
despite differences in the sequences between viruses, is able to package SIV and 
HIV-1 RNA containing Ψ sites (Browning et al., 2001), suggesting that the 
structure of the Ψ sites plays a role. Indeed it has been demonstrated that FIV 
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genomic RNA can adopt two conformations (Kenyon et al., 2011). One of the 
conformations has an exposed dimerization initiation site and hence may 
facilitate RNA packaging (Kenyon et al., 2011).  
Budding, the final step of assembly and release, is also mediated by Gag (Luttge 
and Freed, 2010). Unique to FIV, the p2 peptide and its highly conserved PSAP 
motif interact directly with the ESCRT (endosomal sorting complex required for 
transport) machinery and is essential for budding of the virion (Luttge et al., 
2008). 
Virion maturation, mediated by the viral protease (PR), proceeds shortly after 
virion release (Kohl et al., 1988). It involves cleavage of the Gag-Pol polyprotein 
precursors and formation of the respective mature proteins. Maturation is 
associated with a change of morphology such that virions become fully 
infectious. 
1.4 Epidemiology 
1.4.1 Prevalence 
FIV-Fca is a host specific virus that is distributed world-wide among domestic 
cats. The prevalence of FIV infection varies significantly between geographic 
areas (Hosie and Beatty, 2007) and various cat populations, with estimates 
ranging from 1% in healthy, low risk cats in Germany to 44% in sick, high-risk 
populations in Japan (Yamamoto et al., 1989), (Ishida et al., 1989), (Hartmann, 
1998). Adult, male cats with outdoor access have a significantly higher risk of 
infection (Yamamoto et al., 1989), (Gleich and Hartmann, 2009). It has been 
estimated that approximately 11% of cats world-wide may be infected with FIV 
(Courchamp and Pontier, 1994). 
1.4.2 Transmission 
FIV spreads mainly via the inoculation of virus in saliva during biting, associated 
with mating and territorial fights (Pedersen et al., 1989). Virus can also be 
transmitted vertically from infected queens to kittens (O'Neil et al., 1996). 
Sexual, trans-mucosal transmission has been reported only experimentally 
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(Bishop et al., 1996), and although FIV can be isolated from semen (Jordan et 
al., 1998), the role of this route in natural infection is unknown.  
1.4.3 Diversity and classification 
Based on sequence diversity, FIV is currently classified into five distinct subtypes 
or clades (A to E) with up to 26% variability in the V3-V5 region of the env gene 
(Sodora et al., 1994), (Kakinuma et al., 1995), (Pecoraro et al., 1996). Despite 
its world-wide distribution, geographical clustering of FIV is apparent (Figure 
1-5). Subtype A is the only subtype identified to date in the UK (Samman et al., 
2011) and is the most prevalent subtype in Australia (Kann et al., 2006), the 
west coast of USA, South Africa (Sodora et al., 1994), (Bachmann et al., 1997)  
and northern Japan (Kakinuma et al., 1995).  
 
Figure 1-5 Worldwide distribution of FIV subtypes. Adopted from (Hosie et al., 2009).  
 
Subtype B has been isolated from cats in eastern Japan (Nishimura et al., 1998), 
the east coast of USA (Bachmann et al., 1997), Brazil (Teixeira et al., 2012) and 
in the south of Europe (Pistello et al., 1997), (Steinrigl and Klein, 2003), (Duarte 
and Tavares, 2006). Subtype C has been described in Canada (Reggeti and 
Bienzle, 2004), New Zealand (Hayward and Rodrigo, 2008) and Taiwan (Kurosawa 
et al., 1999) while subtypes D and E have been identified only in Japan 
(Nishimura et al., 1998) and Argentina (Pecoraro et al., 1996) respectively. 
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Several studies identified cats infected with intra-clade recombinants in Canada 
(A/B), USA (A/C, A/B/C), Japan (A/B, B/D), New Zealand (A/C) and even the UK 
(A/C) (Reggeti and Bienzle, 2004), (Bachmann et al., 1997), (Carpenter et al., 
1998) (Hayward and Rodrigo, 2008) and (Samman et al., 2011). These findings 
highlighted the substantial limitations of the current subtype A-E classification, 
which is based on a short V3-V5 fragment of the env gene (Hayward and Rodrigo, 
2008). Moreover, the existence of recombinant viruses has implications for 
molecular diagnosis of FIV infection. Furthermore, in the USA, New Zealand and 
Japan (where the current FIV vaccine is licensed), the existence of recombinant 
viruses has implications for vaccine efficacy. 
1.4.4 Detection and diagnosis 
FIV infection is usually suspected in outdoor, adult, male, sick cats with bite 
wounds and various degrees of gingivo-stomatitis (Hartmann, 1998). Such cats, 
as well as high risk animals living in shelters, newly acquired cats of unknown 
origin and cats to be vaccinated, should be tested routinely for FIV (Little et al., 
2011). Once cats have acquired FIV infection, they remain infected for life; cats 
subsequently produce antibodies against the virus and therefore ELISA based 
screening tests for antibodies against p24 or p15 viral proteins are sufficient for 
diagnosis in unvaccinated cats (Hartmann, 1998). Antibodies against the virus 
can be detected in some cats 2 to 4 weeks post experimental infection 
(Yamamoto et al., 1988) but the majority of cats will seroconvert within 60 days 
following exposure (Barr, 1996). 
The IDEXX SNAP® FIV/FeLV Combo PetCheck FIV antibody test is most commonly 
used in the clinical setting and has been shown to have very high sensitivity and 
specificity (Levy et al., 2004b); however it is recommended that in-house results 
should be confirmed, especially for low risk cats, where the likelihood of false 
positive results is higher (Jacobson, 1991). There are several confirmatory tests 
available, with virus isolation considered the gold standard; however, it is not 
used routinely due to high labour costs (Levy et al., 2004b). Additional soluble 
antibody testing, immuno-fluorescence assay (IFA) or Western blot analysis were 
shown to have variable performances (Levy et al., 2004b) and are used as 
confirmatory measures in different countries based on their availability. 
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Positive serology results in kittens from infected and vaccinated queens should 
be interpreted with caution, since maternally derived antibodies (MDA) may 
persist for up to 20 weeks (MacDonald et al., 2004). In such cases, kittens should 
be re-tested after 6 months of age (Richards, 2005). 
The FIV vaccine (Fel-O-Vax, Fort Dodge) currently available in the USA, 
Australia, Japan and New Zealand confounds the diagnosis of infection (Little et 
al., 2011). Cats sero-convert within a few weeks of vaccination; vaccine induced 
antibodies can persist for up to four years (Levy et al., 2008a) and cannot be 
distinguished from those produced against naturally acquired viruses. It is  
a significant challenge for practitioners to differentiate infected cats from those 
which have been vaccinated, as well as cats which were vaccinated and 
subsequently become infected. An experimental discriminatory ELISA test has 
been developed (Kusuhara et al., 2007). It is based on differences in reactivity 
of sera from vaccinated and FIV infected cats to a synthetic TM peptide and 
formalin-treated whole FIV antigen (Kusuhara et al., 2007). This test was shown 
to accurately distinguish infected from vaccinated cats, regardless of 
vaccination status, with 97.1% specificity (Levy et al., 2008b). Nevertheless, this 
diagnostic approach has been tested only in an experimental setting and is still 
not available commercially. There are numerous PCR assays of variable 
performance to aid FIV diagnosis, with sensitivities and specificities ranging from 
41% to 98% (Bienzle et al., 2004), (Crawford et al., 2005). Research is being 
carried out to improve their sensitivity; nevertheless the diagnosis of FIV 
infection in countries where vaccination is widespread poses a significant 
challenge. 
1.5 Pathogenesis 
1.5.1 Course of disease 
Despite the differences between the feline and human lentiviruses, the disease 
course following FIV infection is very similar to that of HIV (Willett et al., 1997a) 
(Figure 1-6). Following infection, the primary acute phase (lasting from 2 to 8 
weeks) is characterised by a peak of viral replication and various non-specific 
clinical signs such as anorexia, lethargy and fever (del Fierro et al., 1995). 
Complete blood counts may disclose neutropenia (Pedersen et al., 1989). 
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Generalized lymphadenopathy develops during this period as a result of 
stimulation of the germinal centres in lymph nodes and can persist for up to  
9 months post exposure (Pedersen et al., 1989), (del Fierro et al., 1995). The 
virus replicates to high levels in dendritic cells, macrophages and CD4+ T 
lymphocytes, reaching peak levels in plasma 8 to 12 weeks post infection.  
 
Figure 1-6 Course of disease. Following FIV infection there is an acute peak viremia which is 
restricted by the adaptive immune response within approximately 8 weeks. The chronic, 
“asymptomatic” phase follows, lasts for several years and is characterized by a robust CTL 
response, relatively low viral loads, a progressive decline in CD4+T lymphocytes and the 
emergence of anti-Env neutralising antibodies. Eventually, disease leads to the onset of an 
immunodeficiency like syndrome which lasts for several weeks and ultimately leads to 
death. PVL, plasma viral load; CTL, cytotoxic T lymphocytes; SU, surface unit of the Env 
glycoprotein; p24, viral capsid protein. Adapted from (Weiss, 1993). 
 
During this phase, the numbers of CD4+ and CD8+ lymphocytes decline, but 
inversion of the CD4:CD8 ratio (which is likely to persist during the lifetime of 
the cat) is associated with the subsequent excess production of a subset of CD8+ 
T cells in response to infection, aimed at clearing the pathogen (Egberink and 
Horzinek, 1992), (Pantaleo and Koup, 2004), (Yamamoto et al., 2007). The acute 
phase of infection is followed by the silent phase with no clinical signs, which 
may last several years or be lifelong; this chronic phase is typically marked by 
a lack of clinical signs and supressed plasma viral loads. It is not known why 
some cats remain “asymptomatic” for their life time, while others progress and 
develop disease rapidly (Kahler, 1996), (Addie et al., 2000). Nevertheless, FIV 
infection may lead to immunodepletion, affecting cell-mediated immunity in 
particular and associated with an increased frequency of opportunistic 
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infections, the onset of chronic inflammatory conditions, neoplasia and 
subsequently death (Shelton et al., 1989b), (Hutson et al., 1991), (Gabor et al., 
2001b). 
1.6 Correlates of immune protection 
The immunopathogenesis of FIV in many aspects resembles that of HIV infection, 
with both viruses targeting CD4+ T cells, CD4+CD25+ T regulatory cells, 
monocytes, macrophages, glial cells, CD8+ T cells and B cells (Dow et al., 1990), 
(English et al., 1993), (Hein et al., 2000), (Vahlenkamp et al., 2004), (Joshi et 
al., 2005). FIV infection elicits an early vigorous innate immune response, 
followed by adaptive, cell mediated and humoral responses which fail to clear 
the virus (Beatty et al., 1996). Loss of CD4+ T cells results in dysfunction of  
B and T cells and subsequently (months to years post infection) leads to the well 
documented failure of the immune system (Ackley et al., 1990), (Torten et al., 
1991), (Taniguchi et al., 1991), (Hoffmann-Fezer et al., 1992). A paradox of 
lentiviral infection is the combination of immunosuppression together with 
prolonged, global immune hyper-activation (Tompkins and Tompkins, 2008). 
1.6.1 Cell mediated immunity  
Cytotoxic CD8+ T-lymphocytes (CTLs) develop as a specific response to the virus 
as early as 2 weeks post exposure, prior to the development of the antibody 
response (Beatty et al., 1996). The vigorous response is correlated with down 
regulation of viral replication and the decline in plasma viral load during the 
stage of infection with no clinical signs (Bucci et al., 1998), (Hohdatsu et al., 
2003). The antiviral activity of CD8+ T cells is mediated through cytotoxic and 
non-cytotoxic mechanisms. Classical, FIV specific, MHC class I restricted 
cytotoxic T lymphocytes primed against the Gag, Pol and Env proteins were 
detected in the peripheral blood during the acute stage of infection (Flynn et 
al., 1995a), (Beatty et al., 1996), while precursors of those cells were identified 
in lymph nodes and spleen during the “asymptomatic” phase (Song et al., 1992), 
(Song et al., 1995). Populations of non-specific, CD8+ T cells targeting the virus 
via non cytotoxic, either contact-dependent (Bucci et al., 1998), (Gebhard et 
al., 1999) or contact-independent (Hohdatsu et al., 1998), (Choi et al., 2000) 
mechanisms have also been described. Such non-antigen specific CD8+ T cells 
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were shown to appear before MHC restricted cytotoxic lymphocytes, as early as 
one week post infection (Flynn et al., 2002) and were associated with decreased 
levels of cell associated virus by 12 weeks post infection (Bucci et al., 1998). 
Increased numbers of CD8+ T-cells are maintained throughout infection, 
declining only at the terminal stages of disease (Ackley et al., 1990), (English et 
al., 1994). 
1.6.2 Humoral immunity 
Infection with FIV elicits an antibody response directed against Gag and Env 
proteins within 2 to 4 weeks post infection (Yamamoto et al., 1988), (Egberink 
et al., 1992), (English et al., 1994). Virus neutralizing antibodies (VNAb) develop 
soon after the antigen specific CTL response and provide additional immunity 
against the virus (Inoshima et al., 1996). Antigen specific B cell hyper 
stimulation is manifested by increased plasma immunoglobulin G (IgG) levels 
(Ackley et al., 1990). Although VNAb titres increase progressively during the first 
30 weeks post infection (Inoshima et al., 1996), it has been suggested that 
autologous and heterologous VNAb in HIV infected individuals may take up to  
8 months to fully develop (Moog et al., 1997), (Bower et al., 2004). VNAbs are 
believed to have an important role in controlling FIV infection. This is attributed 
to the interaction of immunoglobulins with the SU trimers on the virion surface 
and subsequent blockage of the interaction between the virus and its receptor, 
thus preventing infection (Spenlehauer et al., 2001), (Labrijn et al., 2003). An 
additional mechanism of protection has been associated with the presence of 
autoantibodies recognizing the primary receptor for FIV, CD134 (Grant et al., 
2009). The presence of autoantibodies against CD134 correlated with improved 
health status and lower viral load amongst FIV infected cats (Grant et al., 2009). 
Passively transferred maternal antibodies have been shown to protect kittens 
against challenge with laboratory adapted strains of FIV (Pu et al., 1995). 
However, antibody dependent enhancement, rather than restriction of infection, 
has also been reported (Siebelink et al., 1995). Thus, the role of VNAbs in vivo 
may be either harmful or beneficial. Nevertheless, while VNAbs may neutralise 
FIV in vitro, in the majority of cases there does not appear to be any correlation 
with clinical signs of disease in vivo (Yamamoto et al., 1991), (Tozzini et al., 
1993). 
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1.6.3 Intrinsic immunity 
Recently discovered retroviral restriction factors have a role in innate immunity 
that control almost every stage of the retroviral life cycle (Bieniasz and Cullen, 
2000), (Huthoff and Towers, 2008), (Malim and Bieniasz, 2012). Whereas 
adaptive immunity requires time to fully develop, intrinsic resistance factors act 
immediately following infection, directly blocking viral replication and assembly 
(Goff, 2004), (Huthoff and Towers, 2008). Intrinsic immunity to HIV is dependent 
on the activity of the host’s interferon stimulated genes (ISGs) that encode 
proteins such as: APOBEC3G (apolipoprotein B messenger RNA (mRNA)-editing 
enzyme catalytic polypeptide-like 3 G) (Sheehy et al., 2002), Trim5α (tripartite-
motif-containing 5α) (Stremlau et al., 2004) and Tetherin/BST-2 (bone marrow 
stromal cell antigen 2) (Neil et al., 2008). Of these, the cat genome only 
encodes functional feline APOBEC3G (McEwan et al., 2009) and Tetherin/BST-2 
proteins (Dietrich et al., 2011a). 
APOBEC3G is a cytidine deaminase, which acts during reverse transcription, 
editing cytidine to uracil in the negative strand viral cDNA, resulting in an 
accumulation of guanosine to adenosine substitutions in the positive strand viral 
DNA (Bishop et al., 2008) which is often seen as an accumulation of premature 
stop codons (Vartanian et al., 1991). 
Feline Tetherin/BST-2 prevents the release of the FIV virion, retaining it on the 
cell surface (Dietrich et al., 2011b). However, despite tethering the virion on 
the cell surface, tetherin is unable to prevent cell-cell spread of FIV infection 
(Dietrich et al., 2011b).  
1.6.4 Immune dysfunction 
Despite the activity of the innate, intrinsic and adaptive immune responses, FIV 
infection results in exhaustion of the immune system and subsequently leads to 
immunodeficiency. T cell dysfunction (including impaired proliferative 
responses) in FIV infection is more pronounced than B cell dysfunction, which 
only appears to fail to respond to T dependent antigens (Siebelink et al., 1990). 
Weakened cell mediated immunity is attributed to the diminished number of 
CD4+ T cells and consequently decreased release of cytokines such as IFN-γ and 
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IL-2 (Davidson et al., 1993b). Thus, FIV infected cats are not only more prone to 
neoplasia (Terry et al., 1995) but exhibit more pronounced symptoms associated 
with intra-cellular pathogens such as Listeria monocytogenes (Dean et al., 1998) 
or Toxoplasma gondii (Davidson et al., 1993a).  
The pathogenesis of FIV infection and subsequent immunodeficiency cannot be 
attributed solely to the depletion of CD4+ T cells and impaired cellular 
immunity. Immune activation and the impaired regenerative capacity of the 
progenitor immune cells appear to be as important in the development of 
immunodeficiency as direct targeting of CD4+ T cells by the virus (Appay and 
Sauce, 2008), (Khaitan and Unutmaz, 2011). 
1.7 Prognostic indicators for FIV infection 
Predicting the likely outcome of an infection is of great significance in designing 
an appropriate therapeutic approach. Surrogate markers for HIV infection have 
been well described and are valuable in monitoring both responses to therapy as 
well as the likelihood of disease progression (Churchill, 1997), (Smith and Stein, 
2002), (Shaunak and Teo, 2003), (Katzenstein, 2003), (Okonji et al., 2012). 
In contrast, relatively few studies have focused on the course of naturally 
acquired FIV infection and prognostic indicators of disease progression are not 
well established. The staging of natural infection is complex, because of the 
variable pathogenicity of infecting strains (Pedersen et al., 2001) and there 
remains uncertainty as to the role of FIV as a causative agent of morbidity and 
mortality in cats (Hofmann-Lehmann et al., 1997), (Kohmoto et al., 1998b), 
(Addie et al., 2000).  
Nevertheless, in the clinical setting there is a substantial need for surrogate 
markers, which would aid the identification of animals which are likely to 
remain free of clinical signs or progress rapidly to immunodeficiency. 
Haematological abnormalities such as anaemia, thrombocytopenia, neutropenia 
and lymphopenia are very common in FIV infected cats and were proposed as 
potential indicators of advanced disease (Shelton et al., 1990), (Fleming et al., 
1991), (Callanan et al., 1992), (Sparkes et al., 1993), (Hart and Nolte, 1994). 
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However, the value of these parameters is confounded by the non-specificity of 
cytopenias, which may be associated with other non-viral conditions. 
Biochemical abnormalities include hypergammaglobulinaemia (Hopper et al., 
1989), (Miro et al., 2007), (Takano et al., 2012), although the potential 
prognostic value may be problematic due to the chronic nature of polyclonal  
B cell activation. 
Analysis of CD4 and CD8 lymphocyte subsets revealed that the CD4:CD8 ratio 
remains inverted throughout FIV infection but, in contrast to HIV infection 
(Uppal et al., 2003), several studies found no correlation between alterations of 
lymphocyte subsets and disease progression (Hoffmann-Fezer et al., 1992), 
(Walker et al., 1994), (Walker et al., 1996).  
Other markers, such as the degree of p24 antigenaemia (Lombardi et al., 1994b) 
or alterations in neopterin levels (Beatty et al., 1997), have been evaluated, but 
showed no correlation with disease progression. 
Extrapolating from HIV infection, the plasma viral load (PVL) has been 
postulated as a potential prognostic indicator for FIV infection. A study focusing 
upon disease progression in SPF cats experimentally infected with two strains of 
FIV of different virulence observed a correlation between disease progression 
and increased plasma viral loads (Diehl and Hoover, 1995). Similarly, 
a relationship between PVL, disease progression and survival time was found in  
a study of naturally infected cats in Japan (Goto et al., 2002). 
As outlined above, an accurate assessment of the likely outcome of infection in 
individual cats is problematic due to the lack of reliable prognostic indicators. 
Differences between FIV and its human counterpart often make it difficult to use 
similar surrogate markers of disease progression; specific factors may perform 
better. A recent study demonstrated that the presence of autologous antibodies 
targeting a cryptic epitope on CD134, which is only exposed following binding of 
the FIV SU, correlated with detachment of the virion from the cell surface and 
inhibition of infection. Anti-receptor antibodies were found in 63% (143/226) of 
the examined cats and their presence correlated with decreased PVL, improved 
health and survival of FIV infected cats (Grant et al., 2009). Although these 
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results need to be further evaluated in different cohorts, they have potential for 
the development of ELISA based approaches to FIV prognosis.  
1.8 Treatment 
It is recommended that FIV infected cats should be examined every 6 months 
together with an assessment of complete blood counts (CBC) and body mass 
(Hosie et al., 2009). Depending on the severity of the abnormalities detected, 
animals should receive supportive treatment, which may be accompanied by the 
inclusion of antiretrovirals and immune modulators (Hosie et al., 2009).  
Supportive treatment will depend on the presentation of clinical problems, 
taking into account that treatment of FIV infected cats may require higher 
therapeutic doses along with extended courses of therapy. The use of 
corticosteroids to treat oral lesions in FIV infected cats is controversial and 
against the accepted wisdom that such drugs themselves cause 
immunosuppression (Wallis, 2007). Nevertheless, as suggested for the long term 
management of HIV patients, low doses of prednisolone may be clinically 
beneficial, leading to increased numbers of circulating CD4+ lymphocytes 
(Andrieu et al., 1995), (Andrieu and Lu, 2004).  
Anaemias that often present in FIV infected cats with chronic renal failure can 
be successfully treated with human EPO (erythropoietin) (Arai et al., 2000).  
Another therapy yet to be validated in natural infection, but which could 
potentially be beneficial in younger cats, is the use of insulin-like growth factor -
1 (IGF-1) to stimulate thymic regeneration of peripheral T-cells with (Woo et al., 
1999). 
Therapy with feline interferon-ω may contribute to slight increases in CBC 
values, but further evaluation of its efficacy in the field is needed (de Mari et 
al., 2004). Better documented is the antiviral effect of human interferon-α to 
treat FIV infected cats (Tompkins, 1999), (Pedretti et al., 2006), although 
efficacy is lost following the development of VNAbs three to seven weeks after 
its administration (Zeidner et al., 1990). 
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Classical antiviral drugs, such as Zidovudine and Plerixafor used in HIV infected 
patients, can also be used for the treatment of FIV infected cats. Zidovudine, 
a thymidine analogue that inhibits the reverse transcriptase, is well tolerated by 
cats and was shown to be effective in the therapy of sick cats (Hartmann et al., 
1992). The bicyclam derivative, Plerixafor blocks the CXCR4 chemokine co-
receptor and was shown to significantly decrease proviral load in FIV infected 
cats, with no side effects reported (Hartmann et al., 2012). 
1.9 FIV vaccination 
Studying FIV pathogenesis in its natural host provides a remarkable opportunity 
to learn about correlates of immune protection and gives hope for the 
development of a fully protective vaccine against the virus and subsequently its 
human counterpart, HIV. To date, various FIV vaccine studies resulted in 
a number of significant discoveries, embraced by the release of the first 
commercial FIV vaccine in 2002 (Uhl et al., 2002). Nevertheless, full protection 
against the virus remains elusive (Dunham et al., 2006). Vaccine development is 
confounded by several significant challenges attributed to the peculiar features 
of the virus biology as well as host dependent factors.    
1.9.1 Challenges to FIV vaccine development 
A major obstacle to FIV vaccine development is the remarkable genetic diversity 
of the viral Env glycoprotein, which on a nucleotide level varies up to 15% within 
a specific subtype and up to 26% between subtypes (Burkhard and Dean, 2003). 
Owing to the error-prone nature of the retroviral reverse transcriptase, the 
within-host level FIV quasispecies variability is up to 3.7% over the V3-V5 region 
of the env gene (Sodora et al., 1994). Intra-host diversity can be further 
elevated following superinfection and recombination between co-infecting 
viruses, potentially resulting in the production of highly diverse quasispecies 
(Kyaw-Tanner et al., 1994), (Hayward and Rodrigo, 2008). This enormous 
plasticity of the viral Env glycoprotein is reflected in the diverse, evolving 
number of antigenic determinants on the viral SU protein and the emergence of 
viral escape mutants during the course of infection. In addition, antigenic 
determinants on the viral surface are heavily glycosylated by host derived 
glycans which render them inaccessible to antibodies (Dacheux et al., 2004). 
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The ability of lentiviruses to infect memory and non-dividing cells leads to the 
establishment of latent infection; latently integrated provirus is not accessible 
to either the humoral or the cellular immune systems (Curran et al., 2000). 
When a cell harbouring proviral DNA becomes activated, it sheds infectious 
virions capable of infecting other targets, subsequently broadening the pool of 
latently infected cells which remain unseen by the immune system. Latently 
infected cells in immune privileged sites such as the central nervous system 
(CNS) are practically inaccessible for either immune surveillance or the majority 
of therapeutic drugs. 
Immunization induced enhancement of FIV infection is poorly understood and is 
a major concern for the development of safe, effective vaccines. Several FIV 
vaccine candidates failed to protect cats; rather vaccination rendered cats more 
susceptible to infection (Hosie et al., 1992), (Richardson et al., 1997), (Karlas et 
al., 1998), (Karlas et al., 1999), (Giannecchini et al., 2002), (Dunham et al., 
2006). It has been demonstrated that passive transfer of plasma from vaccinated 
cats displaying enhanced infection led to enhanced viral infection in 
unvaccinated controls, suggesting that antibodies lie at the basis of this 
mechanism, presumably enhancing virus entry into target cells (Siebelink et al., 
1995). One possible explanation is that VNAbs target epitopes on the Env 
glycoprotein, altering its conformation and facilitating virus binding directly to 
the co-receptor without requiring an interaction with the primary receptor 
molecule (Guillon et al., 2002). Another possible mechanism is associated with 
vaccine-induced activation of cell mediated immunity and quantitative 
enhancement of susceptible memory T cells, expanding the target population for 
the challenge virus (Wahl and Orenstein, 1997). Vaccine induced enhancement 
accounted for the recent clinical failure of Merck’s prototype adenovirus based 
HIV-1 vaccine (Hanke, 2008), highlighting the importance of this phenomenon in 
the development and testing of prospective vaccine candidates. 
FIV infection, despite inducing strong immune responses, is never completely 
eradicated and cats remain infected for life (Ishida et al., 1989). Spontaneous 
recovery from infection has not been documented and therefore it is tempting to 
speculate that FIV infection cannot be cleared by vaccine approaches mimicking 
natural adaptive immune responses (Garber and Feinberg, 2003). Nevertheless, 
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based on our current understanding of the correlates of immune protection, it is 
believed that an efficacious vaccine should achieve full protection by stimulating 
both humoral and cell mediated responses (Patterson et al., 2004). The more 
recently discovered antiviral intrinsic immunity (Bieniasz and Cullen, 2000), 
extends our understanding of immunity against viruses and offers an interesting 
approach that could be exploited to aid the development of effective retroviral 
control strategies (Poeschla, 2011).  
Finally, the experimental design of vaccine trials is crucial to deliver informative 
and comparative data for prospective vaccines. Candidate vaccines should be 
evaluated in conditions most closely resembling natural exposure to the virus, 
including the route of infection, the dose and nature of the challenge inoculum. 
Unfortunately, in the majority of studies, vaccinated cats have been challenged 
with virus by intravenous or intraperitoneal inoculation, routes that do not 
reflect the natural route of transmission. Similarly, the dose of challenge 
inoculum used in those studies usually exceeded that of natural infection (Pu et 
al., 1997). The biggest difficulty, however, lies in the choice of challenge 
inoculum. Very often viruses used in vaccine challenge studies did not reflect 
those circulating in the field but resembled less pathogenic, laboratory adapted 
strains. It is important to emphasize that only field trials, in which cats are 
either free roaming or housed together, would determine the true efficacy of 
candidate vaccines (Matteucci et al., 2000), (Kusuhara et al., 2005b). 
1.9.2 Proposed FIV vaccines 
Several types of vaccines, ranging from subunit through recombinant to live 
attenuated virus vaccines, have been tested in the feline lentiviral model 
system, yielding variable outcomes that ranged from full protection to 
enhancement of infection. Interpretation of these data is difficult, due to the 
variation in experimental design between laboratories. Variables include the 
choice of challenge inoculum, as well as the methodology used for the 
evaluation of candidate vaccines.  
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1.9.2.1 Subunit vaccines  
FIV subunit vaccines, composed of either the entire or fragments of viral 
structural proteins such as p24 CA protein, SU and TM glycoproteins, have been 
tested, sometimes in combination with immunostimulating complexes (ISCOMs). 
Despite numerous FIV vaccine studies employing the subunit approach (Hosie et 
al., 1992), (Lombardi et al., 1994a), (Flynn et al., 1995b), (Verschoor et al., 
1996), (Hosie et al., 1996), (Richardson et al., 1998), (Finerty et al., 2000), 
(Pistello et al., 2006), the majority did not confer protective immunity, with 
some vaccine candidates rather inducing immune enhancement of infection 
(Hosie et al., 1992), (Siebelink et al., 1995), (Osterhaus et al., 1996), (Huisman 
et al., 1998). 
1.9.2.2 Recombinant vaccines 
Immunogenic viral proteins or their fragments can be synthesised endogenously 
following transgene delivery by gene transfer vectors (plasmid DNA, viruses and 
bacteria). Major FIV transgenes used in recombinant vaccines included the entire 
env (Richardson et al., 1997), (Richardson et al., 2002) or fragments encoding SU 
glycoproteins (Cuisinier et al., 1997), (Cuisinier et al., 1999), (Boretti et al., 
2000), (Leutenegger et al., 2000). Several studies employed the gene transfer 
technique to deliver whole proviral DNA, bearing deletions in various viral genes 
(Flynn et al., 2000), (Lockridge et al., 2000), (Gupta et al., 2007). The outcomes 
of those trials, depending on the challenge strain, were diverse, ranging from 
partial protection and suppression of viral replication (Hosie et al., 1998) to 
enhancement of infection (Cuisinier et al., 1997). Bacterial (Tijhaar et al., 
1997), (Stevens et al., 2004) and viral vectors (Gonin et al., 1995), (Tellier et 
al., 1998) have been tested in FIV vaccines studies; however, neither approach 
offered satisfactory protection. 
1.9.2.3 Live attenuated vaccines 
Live attenuated vaccines display reduced virulence but are still capable of 
replication. Attenuated viruses can revert to full virulence through mutation and 
recombination with live viruses and therefore this type of vaccine (due to safety 
concerns) has received less attention in FIV research. Indeed, one study 
documented reversion to virulence of the attenuated Petaluma strain of FIV 
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following challenge with the clade B, FIV M2 virus (Pistello et al., 1999). 
Although a few studies documented some degree of protection, depending on 
the route of challenge (Kohmoto et al., 1998a), (Pistello et al., 2003), (Pistello 
et al., 2005), the use of live attenuated vaccines in confining FIV infection is 
limited, due to potential safety concerns. 
1.9.2.4 Inactivated vaccines 
Inactivated vaccines have been the most promising FIV vaccine candidates to 
date. The inactivation process results in the production of killed, non-infectious 
viruses, capable of inducing immune responses. Inactivated vaccines include 
whole inactivated: i) cell free, and ii) cell associated, virus vaccines. Cell 
associated whole inactivated virus compositions can be purified more cost 
effectively. Several studies have been conducted using inactivated vaccines 
(Yamamoto et al., 1991), (Yamamoto et al., 1993), (Hosie et al., 1995), (Hosie 
and Flynn, 1996), (Matteucci et al., 1996), (Matteucci et al., 1997) with results 
ranging from protection to enhancement as described for other types of 
vaccines. Nevertheless, those studies informed the development of the 
commercial dual subtype inactivated vaccine (Fel-O-Vax), which consists of  
the clade A Petaluma and clade D Shizuoka strains of FIV, derived from FL4 and 
FeT-1 cells respectively (Pu et al., 2001). The Fel-O-Vax vaccine has been shown 
to protect cats against homologous clade A and heterologous clade B challenges 
(Pu et al., 2001), (Pu et al., 2005), (Kusuhara et al., 2005b) but not against the 
more virulent GL-8 isolate of FIV (Dunham et al., 2006). Lack of protection 
against this European isolate, which shares properties with the viruses most 
likely to be transmitted in the field, poses questions about the efficacy of Fel-O-
Vax against field strains of FIV.  The vaccine remains to be rigorously evaluated 
in countries where the vaccine is licenced.  
1.10 Viral quasispecies theory 
The quasispecies theory was first proposed to model the early evolution of 
mutation prone, self-replicating macromolecules which are believed to give the 
origin of life on Earth (Eigen, 1971), (Eigen and Schuster, 1977). Later, the 
principles of this theoretical framework were adopted to model the evolution of 
rapidly replicating RNA viruses (Holland et al., 1982).   
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Accordingly, at the intra-host level, RNA viruses are present not in the form of  
a single genotype, but rather as an assembly of closely related viral variants, 
called a quasispecies (Holland et al., 1982), (Holland et al., 1992), (Eigen, 1993), 
(Domingo and Holland, 1997). Quasispecies theory assumes that those viral 
variants resemble a cloud of closely connected genotypes which jointly 
contribute to their characteristics (Biebricher and Eigen, 2005) (Figure 1-7). The 
generation of polymorphic populations and the potentially high intra-host 
diversity of RNA viruses are features attributable to their biology as well as the 
unique characteristics of retroviral reverse transcription (Domingo et al., 1978), 
(Domingo, 2000). 
 
Figure 1-7 Simplified schematic illustration of viral quasispecies. Quasispecies are 
represented as a cloud of closely related genotypes linked through mutation to parental 
master sequence. Each circle corresponds to one viral replication cycle. (Modified from 
(Lauring and Andino, 2010) ).  
 
Owing to the error prone RT and viral recombination, many potentially 
beneficial mutations can arise, lending retroviruses the tremendous ability to 
adapt to the challenging landscape within the host. Nevertheless, viral variants 
are subjected to scrutinizing selection processes and only very few of the 
generated mutations become fixed within the quasispecies (Coffin, 1995), 
(Anderson et al., 2004), (Biebricher and Eigen, 2005). The theory assumes that 
mutations occur constantly at a high rate (Domingo, 1998), (Domingo et al., 
2006). Therefore, the Darwinian fitness of an individual variant becomes 
insignificant and is replaced by the connectedness of the quasispecies cloud (Bull 
et al., 2005). A well-connected cloud is represented by viral variants that arise 
during replication and are viable and capable of generating successors and 
further contributing to diversity within the cloud. In contrast, a poorly 
connected cloud is characterised by the generation of viral particles unable to 
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produce further progeny. Within the hypothetical framework of the quasispecies 
theory, it is the cloud of quasispecies rather than the individual genome that 
comprises the unit of selection (Domingo, 1998). 
The quasispecies framework makes several theoretical assumptions, thought to 
be valid to describe fast self-replicating molecules, and has been described as 
the only well placed theory to model the evolution of RNA viruses (Domingo, 
2000). At the same time, this concept received wide criticism, being regarded as 
causing confusion in describing viral evolution (Moya et al., 2000), (Comas et al., 
2005). Nevertheless, the evidence shows that the quasispecies theory principle 
fits well into the mutation and selection concept of population genetics (Wilke, 
2005). It seems to be more in agreement than in conflict with Darwinian 
evolution, and provides an additional theoretical framework for understanding 
the evolution of asexual, haploid, self-replicating RNA viruses (Wilke, 2005), 
(Lauring and Andino, 2010). 
1.10.1.1 Quasispecies diversity and pathogenicity 
Intra-host diversity and the plasticity and dynamics of quasispecies are 
important for disease pathogenesis (Lauring and Andino, 2010). In HIV infection, 
the enormous potential to adopt to changing environments is reflected by the 
existence of R5, X4 and R5X4 viral variants with different cell tropisms  (Karlsson 
et al., 2004), (Clevestig et al., 2005), (Gorry et al., 2005). Similarly, HIV immune 
escape mutants emerge during the course infection, providing further evidence 
for the plasticity of quasispecies in response to landscape alterations within the 
host (McKeating et al., 1989), (Arendrup et al., 1992), (Guillon et al., 2006). 
In FIV, VNAb escape mutants were shown to emerge during the course of 
infection (Samman et al., 2010), (Willett et al., 2010) as well as viral variants 
displaying different cell tropisms (Willett et al., 2006b), (Willett et al., 2008), 
(Willett et al., 2010), suggesting that FIV quasispecies also possess significant 
plasticity in adapting to a challenging host environment.  
This enormous lability is also a feature of other RNA viruses, such as influenza 
and hepatitis C virus (HCV) (Beigel et al., 2005), (Dawood et al., 2009), (Rong et 
al., 2012). The ability of these genomes to adapt to various challenges during 
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infection poses significant obstacles for the development of effective 
therapeutic and vaccine strategies (Gerrish and Garcia-Lerma, 2003). Moreover, 
by contrasting the ability of a single genotype of neurotropic poliovirus infecting 
alone with the ability of diverse quasispecies to cause disease, it has been 
demonstrated that the diversity of the infecting population does indeed have 
a profound influence on disease pathogenesis (Vignuzzi et al., 2006), (Lauring 
and Andino, 2010). This highlights the importance of studying naturally occurring 
infections, which is the focus of this thesis. 
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1.11 Scope and aims of this thesis 
The main goal of this thesis was to assess predictors of the long term outcome 
and disease progression in cats naturally infected with FIV. Additionally, we 
evaluated humoral immune responses induced by the commercial FIV vaccine in 
privately owned cats. 
Specific aims of the project were: 
1) To define the clinical presentation of FIV infection and to assess clinically 
available predictors of disease progression. 
2) To quantify viral evolution, diversity and quasispecies composition in cats 
naturally infected with FIV. 
3) In functional studies, to examine naturally occurring wild type FIV 
variants for: 
a) susceptibility to neutralisation by homologous plasma, and 
b) usage of the viral receptors CXCR4 and CD134,  
in order to examine the relationship between the emergence of neutralising 
antibody resistant variants, cell tropism and FIV disease stage. 
4) To assess the humoral immune response induced by the commercial FIV 
vaccine against reference isolates as well as an Australian field isolate of 
FIV, which most likely overcame vaccine induced protection. 
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Chapter 2. Materials and methods 
2.1 Molecular biology techniques 
2.1.1 Polymerase chain reaction and primers 
Amplification of full length FIV env genes (approx. 2500 bp) was performed using 
a two-step nested PCR protocol due to the high variability of wild type viruses 
circulating in cat population. First round PCR reactions were performed using 
the Phusion Blood Direct PCR Kit (Finnzymes, Hitchin, UK) followed by 
sequencing of PCR product to inform the primer design for the second round PCR 
which was performed using Roche High Fidelity Master (Roche, Mannheim, 
Germany). 
Primers used for first round blood direct amplification were designed to bind to 
conserved regions of the viral genome, based on an alignment of diverse 
complete genome FIV sequences isolated previously in our laboratory (GL-8, 
TOT-1, KNG) and those available on the GenBank (accession numbers: U11820.1 
(B2542), M36968.1 (PPR), NC.001482 (FIV NC), M25381.1 (Petaluma), EF455612.1 
(FIV YF125), AF474246.1 (FIV C)), to ensure product amplification from all clades 
of FIV that occur worldwide. Primers used for first round amplification were: 2F2 
and 1R4 binding from position 6203 for the forward primer and from 9148 for the 
reverse primer respectively of the full genome of reference FIV-PPR (accession 
number: M36968.1). Primers designed specifically for each cat for second round 
PCR had Not1 and Sal1 digestions sites incorporated and were designed to 
amplify full length FIV env genes, binding from position 6285 for the upstream 
and 8852 for the downstream primer respectively of the full length genome of 
reference FIV-PPR.   
Primers were synthesised by Eurofins MWG (Ebersberg, Germany) and shipped in 
lyophilised form. Upon arrival, oligonucleotides were re-suspended in nuclease 
free water at a stock concentration of 100 pmol/µl and stored at -20°C until 
required. Primers used for amplifications were equilibrated to a working 
concentration of 10 pmol/µl and were stored short term at 4°C. Sequences of all 
primers used in this study are listed in Appendix 1. 
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2.1.1.1 Blood direct PCR 
Blood direct PCR was performed using Phusion Blood II Direct PCR Kit 
(Finnzymes). The kit employs high fidelity Phusion Blood II DNA Polymerase to 
amplify directly from blood without prior sample preparation or DNA extraction. 
Phusion Blood II DNA is a proofreading polymerase with 25 fold greater accuracy 
than Taq DNA polymerase, determined with a modified lacI-based method (Frey, 
1995). Blood samples collected in lithium heparin were used as templates and 
reactions in total volumes of 50 µl were set up using thermo-cycling conditions 
as per manufacturer’s instructions (Appendix 2). The optimal blood template 
concentration was found to be 7% of total reaction volume and the optimal 
annealing temperature for the 2F2/1R4 primer set was 64.5°C. Following 
amplification, PCR products were separated using gel electrophoresis, visualised 
under UV light, excised with a sterile scalpel, gel purified (section 2.1.2), 
sequenced and subsequently used as a template for second round PCR reactions.  
2.1.1.2 Roche High Fidelity PCR Master 
Roche High Fidelity PCR Master (Roche, Mannheim, Germany) was selected for 
its inherent proofreading activity in order to amplify full length FIV env genes 
from gel purified products amplified directly from blood. The primers were 
specifically designed for each cat and sequences are listed in Appendix 1. Not1 
and Sal1 digestions sites were incorporated downstream and upstream in the 
primer sequences respectively to facilitate cloning of amplified wild type FIV 
envs. Mastermix and thermo-cycling conditions were set as per manufacturer’s 
instructions (listed in Appendix 2). Typically, 20 ng of gel purified blood direct 
PCR product was used as the template in each 50 µl reaction. 
2.1.2 Gel electrophoresis and purification of PCR products 
PCR and restriction digested PCR products were examined by gel 
electrophoresis. Generally, samples were mixed with 10x loading dye, loaded in 
1% agarose gel containing ethidium bromide (10 mg/ml) and run for 1 hour at 
100 V. Bands were visualised under UV light, photographed and excised using  
a sterile scalpel. 
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PCR products were purified from agarose using QIAquick Gel Extraction Kit 
(Qiagen, Crawley, UK) following the manufacturer’s instructions. This works on 
the principle of DNA being precipitated by isopropanol, then absorbed onto 
a silica column. Contaminants pass through the column during the ethanol 
washing steps and DNA is subsequently eluted in 50 µl of water. 
2.1.3 Restriction enzyme digestion and ligation 
Second round PCR products and vector (VR1012) (Hartikka et al., 1996) were 
double digested at 37°C for three hours by high fidelity Not1HF/Sal1HF 
restriction endonucleases (New England BioLabs, Hitchin, UK). Restriction 
endonucleases were usually used at 1 U of each enzyme per reaction but DNA 
concentrations were always adjusted according to manufacturer’s instructions, 
assuming that 1 U of each restriction enzyme is able to digest 1 µg of DNA in an 
hour at 37°C. All reactions were set up in NEBuffer 4 buffer, as recommended by 
the manufacturer and brought to total volume of 20 µl. Following restriction 
enzyme digestion, reactions were gel electrophoresed, examined under UV light 
and gel purified as described above. 
Double Not I/Sal I digested DNA (insert) was ligated into VR1012 (vector) using 
T4 DNA Ligase (Promega, Southampton, UK) at 1 U/µl at 14°C for 16-18 hours. 
For each ligation, a ratio of 1:3 (vector: insert) was used in a final volume of 20 
µl. Ligated constructs were directly used for transformation. Negative controls, 
containing empty vector were set up alongside to assess ligation efficiency in 
subsequent transformations.  
2.1.4 Transformation 
Escherichia Coli MAX Efficiency® DH5α™ Competent Cells (genotype 
F- φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-,mk+) phoA supE44 
λ-thi-1 gyrA96 relA1) (Invitrogen) were transformed using the heat shock 
protocol as per manufacturer’s instructions. Briefly, 30 µl DH5α™ Competent 
Cells were thawed on ice, 0.5-1 µg of ligated construct added, incubated for 30 
minutes on ice followed by heat shock at 42°C for 40 seconds and further 2 
minute incubation on ice. Transformed competent cells were diluted in 400 µl of 
SOC medium and incubated for 1 hour at 37°C on orbital shaker at 225 rpm. 
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Cultures were spread on freshly prepared LB agar plates containing kanamycin 
(Sigma Aldrich, Gillingham, UK) at 50 µg/ml. Plates were incubated for 16-48 
hours at 30°C due to the inherent instability of primary FIV envs. Colonies were 
picked and screened for the desired vector/insert constructs by double  
Not I/Sal I restriction digestion of the isolated DNA. Alternatively screening was 
performed on a large scale by colony PCR. 
2.1.5   Colony screening 
2.1.5.1 Colony PCR 
Colony screening PCR was performed using GoTaq Hot Start DNA Polymerase 
(Promega). Colonies were picked from agar plates, re-suspended in 20 µl of 
nuclease free water and immediately moved to 4°C. Mastermix and thermo-
cycling conditions (Appendix 2) were set up as per manufacturer’s instructions 
with minor modifications. In brief, PCR reactions contained 2 µl of re-suspended 
colonies, 10 µl 5x GoTaq Flexi Green Buffer, 1 µl 2mM dNTPs, 3 µl of MgCl2, 
10 mM of each primer, 0.25 µl (1U) GoTaq hot start polymerase and nuclease 
free water to final volume of 50 µl. Primers VR1012_fwd and VR1012_rev were 
used to amplify ~ 2500 bp env insert desired in positive transformants. Primer 
sequences are listed in Appendix 1. Positive colonies were identified following 
gel electrophoresis and the visualisation of PCR products under UV light. 
Colonies were classified as positive when PCR products approximately 2500 bp in 
size were observed. This method proved to be robust and time efficient and was 
mainly used in the 96 well plate format to achieve high throughput screening of 
transformed colonies. 
2.1.5.2 Small scale DNA preparation 
The QIAquick Minikit (Qiagen) was used according to the manufacturer’s 
instructions to isolate plasmid DNA for small scale colony screening. The 
QIAquick Minikit works on the principle of plasmid DNA selectively binding under 
appropriate salt and pH conditions to the anion-exchange tip of the spin column. 
RNA, proteins, metabolites, and other impurities are removed in washing steps. 
Finally plasmid DNA is eluted in 50 µl high-salt buffer. Isolated plasmid DNA was 
subjected to double Not1/Sal1 restriction digest for 1 hour at 37°C, the products 
were gel electrophoresed for 40 minutes at 100 V and analysed under UV light.  
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Positive transformants were identified by comparing the digestion pattern to 
that of the positive control run in parallel.   
2.1.6 Midi plasmid DNA preparation 
The PureLink HiPure Plasmid Midiprep Kit (Invitrogen) was used for the isolation 
of larger amounts of plasmid DNA, necessary for downstream applications. The 
HiPure Midiprep columns, similar to Miniprep columns, are anion-exchange 
chromatography columns.  
Following initial screening, as described above, positive transformants were 
inoculated in 4 ml of LB Broth containing kanamycin (Sigma Aldrich) at 50 
mg/ml, and incubated overnight at 30°C in an orbital shaker. The following day, 
cultures were scaled up to 250 ml volume of LB Broth containing kanamycin, 
grown in conical flasks in orbital shaker at 30°C for another 16-24 hours and 
finally centrifuged at 5000 rpm (~4600 x g) in a Beckman Coulter Avanti J-E 
centrifuge for 10 minutes at 4°C. 
All further plasmid DNA isolation steps were performed as per manufacturer’s 
instructions. DNA was precipitated with isopropanol and washed with 70% 
ethanol. DNA pellets were air dried under laminar flow sterile conditions, then 
re-suspended in 200 µl of TE buffer and stored at 4°C. 
Glycerol stocks of positive clones were prepared by mixing 820 µl of culture from 
the first inoculum with 180 µl of sterile 80% glycerol. All glycerol stocks were 
catalogued and immediately stored at -80°C. 
2.1.7 DNA sequencing  
PCR products and plasmid DNA were sequenced using Sanger’s chain terminator 
sequencing method, either in-house or by a commercial sequencing company 
using a 96 well plate format (Source BioScience, Nottingham, UK).  
Sequencing reactions prepared in-house were set up using Big Dye Terminator 
v1.1 kit (Applied Biosystems, Warrington, UK). Sequencing primers at 3.2 pmol 
per reaction were: VR1012_fwd, VR1012_rev, Memphis780_fwd and 
Memphis2090_rev for sequencing of cloned FIV envs. Primers 2F2 and 1R4 were 
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used for sequencing of Phusion Blood II Direct amplified PCR products. Thermo-
cycling conditions were set up as per manufacturer’s instructions and are listed 
in Appendix 2. Purification of sequencing reactions was performed either by 
precipitation with 70% alcohol or, on a larger scale, by using the 96 well DyeEx 
purification kit (Qiagen) following the manufacturer’s protocol to separate 
molecules based on their molecular weight by gel-filtration chromatography. 
During the clean-up of sequencing reactions, dye terminators are retained in gel 
filtration material while the DNA fragments are recovered from the flow 
through. 
Purified reactions were re-suspended in 20 µl of highly-deionised formamide 
(HiDi) (Applied Biosystems) and transferred to 96 well sequencing plates. 
Sequencing was performed on an in-house ABI Prism 3700 Genetic Analyser 
(Applied Biosystems). 
An external commercial sequencing service was also used (Source BioScience) to 
aid sequencing of the large number of plasmid DNA products generated in the 
study. Each Plasmid DNA concentration was equilibrated to 100 µg/µl and sent 
by post in 96 well plate format to Source BioScience, Nottingham. Sequencing 
results were available to download from the company’s server within 24-48 
hours upon samples arrival. This approach proved to be extremely time and cost 
efficient in comparison with in-house sequencing. 
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2.2 Cell culture 
2.2.1 Plasma and PBMCs collection 
Blood samples were obtained either in Chicago, IL or Memphis, TN, USA from 
cats enrolled in the study (described in detail in Chapter 3) by jugular 
venipuncture, collected into lithium heparin tubes and immediately shipped at 
4ºC. Blood samples were in transit for 3 to 5 days before arrival at the Retrovirus 
Research Laboratory at the University of Glasgow. Upon arrival, plasma was 
separated by centrifugation at 2000 rpm (~ 370 x g) for 10 minutes, and stored in 
200 µl aliquots at -80°C until required. The remaining blood pellets were used 
for blood direct amplification with Phusion Blood II Direct PCR Kit (described in 
section 2.1.1.1) and collection of peripheral blood mononuclear cells (PBMCs). 
PBMCs were collected in order to set up virus isolations and confirm the FIV 
status of cats enrolled in the study. PBMC collection was performed by flash lysis 
of erythrocytes. Briefly, blood pellets were diluted in 1 ml of PBS, transferred to 
a universal container containing 20 ml of pre-warmed red blood cell lysis buffer 
and incubated at room temperature for up to 10 minutes until the solution 
became clear. Lysed erythrocytes and intact PBMCs were centrifuged for  
5 minutes at 1000 rpm (~200 x g) in the Eppendorf 5810R centrifuge (Rotor A-4-
81), supernatants discarded and the PBMCs were washed twice with PBS-BSA 
buffer and collected in 1.5 ml eppendorf tubes before being immediately used 
for virus isolation. 
2.2.2 Virus isolation 
To exclude the possibility of false positive diagnosis by SNAP FIV/FeLV Combo 
Test (IDEXX) used in clinical setting,  all cats enrolled in the study had their FIV 
status confirmed by virus isolation, considered the gold standard in FIV infection 
diagnosis (Hosie et al., 2009). Approximately 107 fresh PBMCs were co-cultivated 
with 2 x 106 of Mya-1 cells (section 2.2.3.1.1) in 5 ml of complete RPMI 1640 in 
T25 cell culture dishes (Corning, Warrington, UK) and cells were observed under 
an inverted cell culture microscope daily. Cytopathic effect such as syncytia 
formation, cell swelling and cell death visible under the microscope were 
indicative of viral replication, which was further confirmed by screening co-
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cultivation supernatants for reverse transcriptase activity or FIV p24 capsid 
protein (section 2.3.1 and 2.3.2). Positive cultures were harvested by 
centrifugation at 1000 rpm (~200 x g) for 5 minutes and supernatants were 
collected in 5 ml containers for long term storage at -80°C. Cell pellets were 
washed in PBS, centrifuged again at 1000 rpm (~200 x g) for 5 minutes and 
stored at -80°C. 
2.2.3 Cells 
Frozen aliquots of each cell line were recovered from liquid nitrogen by rapid 
thawing in a 37°C water bath. Cells were washed in 10 ml of medium, 
centrifuged at 1000 rpm (~200 x g) for 5 minutes and re-suspended in 5 ml of 
complete RPMI 1640 or DMEM before being moved to T25 tissue culture dishes 
(Corning). All cells were grown in humidified incubators in an atmosphere of 5% 
of CO2 at 37°C. Recovered cells were examined daily and, once confluent, were 
passaged and scaled up as required. 
2.2.3.1 Suspension cells and their maintenance 
Suspension cells were maintained in RPMI 1640 medium (Invitrogen, Paisley, UK) 
supplemented with 10% heat inactivated fetal bovine serum, 50 µM  
2-mercaptoethanol, 2 mM glutamine, 0.11 mg/ml sodium pyruvate, 100 IU/ml 
penicillin and 100 mg/ml streptomycin, subsequently referred to as complete 
RPMI 1640. Centrifugation of suspension cells was performed at 1000 rpm (~200 x 
g) for 5 minutes, unless stated otherwise. 
2.2.3.1.1 Primary feline T lymphoblastoid cell line 
The feline primary T lymphoblastoid cell line, Mya-1, was established by 
prolonged cultivation of PBMCs isolated from a 5 month old specific pathogen 
free (SPF) cat previously inoculated with blood collected from a 3 year old cat 
seronegative for FeLV, FeCoV and seropositive for FIV and FeSFV (Miyazawa et 
al., 1989). Mya-1 cells were shown to be free from endogenous retroviruses and 
exogenous FIV (Miyazawa et al., 1989) and proved useful for the propagation of 
FIV. Mya-1 cells are interleukin-2 (IL-2) dependent and were maintained in 
complete RPMI 1640 medium supplemented with 100 IU/ml of IL-2 (provided by 
T. Miyazawa). Cells were maintained at a density of 1 x 106 cells per ml before 
 61 
 
being passaged. To minimise cell damage during passage, centrifugation was 
performed at 800 rpm (~128 x g) for 5 minutes with no braking. 
2.2.3.1.2 CLL-CD134 cells 
The canine chronic lymphocytic leukaemia cell line CLL was established by 
extended in vitro culture of PBMC isolated from a leukaemic dog; CLL cell line is 
CD3+ CD4− CD8− CD134−. Stable transduction of the CLL cell line with feline 
CD134 (primary receptor for FIV) rendered cells susceptible to productive FIV 
infection (Willett et al., 2006b). CLL-CD134 cells grow well in suspension and 
were maintained by subculturing into fresh medium every 3-4 days at 1:10 
dilution. Cells were maintained in complete RPMI 1640 medium as described 
above and selected with 400 µg/ml of Geneticin 418 (Invitrogen).  
2.2.3.2 MCC cells 
The MCC cell line was derived from an abdominal mass from a 13 year old 
castrated cat and has the phenotype of a large granular lymphocyte (LGL) 
(Cheney et al., 1990). MCC cells are CD134 negative but, when stably transduced 
with different chimeric constructs of CD134 can be used to elucidate the role of 
CD134 in FIV entry and the complexity of the virus-receptor interaction (Willett 
et al., 2006b), (Willett et al., 2006a). MCC-CD134 lines expressing three chimeric 
CD134 molecules (MCC-FFF, MCC-FFHH and MCC-HHH) were used to reveal 
different utilization of CD-134 by diverse strains of FIV (Willett et al., 2006b). 
MCC cells and MCC-CD134 were cultured in complete RPMI 1640 medium and 
maintained by addition of the selection antibiotic Geneticin 418 (Invitrogen). 
2.2.3.3 Adherent HEK-293 cells and their maintenance 
The HEK 293 cell line was generated following transformation of human 
embryonic kidney cells by a DNA fragment of human Adenovirus 5 (Graham et 
al., 1977) and since has been widely used  in molecular biology for transfections. 
HEK 293 cells were cultured in disposable tissue culture dishes (Corning) and 
maintained in high glucose (4.5 g/l) Dulbecco’s modification of Eagle’s medium 
(DMEM) (Invitrogen) supplemented with 10% heat inactivated fetal bovine serum, 
2 mM glutamine, 0.11 mg/ml sodium pyruvate, 100 IU/ml penicillin and 100 
mg/ml streptomycin. Cells were selected with 400 µg/ml of Geneticin 418 
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(Invitrogen) and passaged into fresh medium at 1:10 ratio, usually every 3-4 
days. Medium was removed, the confluent cell monolayer was washed with PBS 
and then treated with 0.25% trypsin prior to incubation at 37°C for 5 minutes or 
until the cell monolayer detached. Detached cells were washed with complete 
DMEM to stop trypsin activity, centrifuged at 1000 rpm for 5 minutes and 
resuspended in fresh DMEM before being subcultured in preparation for 
transfection the next day. 
2.2.4 Cryogenic preservation and storage 
For long term storage, cells were pelleted at 1000 rpm (~200 x g) for 5 minutes 
and re-suspended to a density of 5x106 cells/ml in cryo-preservation medium 
containing 70% complete medium, 20% heat inactivated foetal bovine serum and 
10% dimethyl sulphoxide (DMSO), transferred into 2 ml cryo-preservation tubes 
(Nunc, Denmark) and taken at a constant rate of -1°C/minute to -80°C in a cryo-
freezing container (Nalgen, USA) filled with isopropanol, before long term 
storage in the vapour phase of liquid nitrogen. 
2.2.5 Transient transfection of adherent cells and pseudotype 
production 
HIV-luc (FIV) pseudotypes were prepared by transfecting 293T cells with plasmid 
VR1012 (Vical Inc., San Diego, USA) expressing a specific wild type FIV env gene 
and the HIV-1 NL4-3 based vector with deleted env and vpr genes and bearing 
the luciferase reporter gene (Figure 2-1) (Connor et al., 1995). Such constructs 
are capable of a single round of infection only and deliver the luciferase 
reporter gene to target cells, permitting quantification of infection efficiency. 
 
Figure 2-1 Schematic representation of HIV NL 4-3 strain based vector expressing firefly 
luciferase reprorter gene inserted into nef gene. pNL4-3-Luc-E
-
R
-
luc contains defective vpr 
gene (Δvpr) and 5' frame shift within the env gene (Δenv), preventing the expression of the 
envelope glycoprotein. Adopted from (Akkina et al., 1996). 
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293T cells were transiently transfected using Superfect transfection reagent 
(Qiagen) following the manufacturer’s instructions. Superfect assembles DNA 
together in compact structures and binds it to the cell surface before the 
complex is taken inside the cell via endocytosis. One day prior to transfection, 
0.5 x 106 293T cells were plated into each well of a 6 well culture cluster 
(Corning) in 2ml of complete DMEM and incubated overnight until 70-80% 
confluent. The following day, 2 µg of HIV pNL4-3-Luc-E-R-luc and 2 µg of each FIV 
env expressing VR1012 were mixed with 10 µl of Superfect Transfection Reagent 
(Qiagen), added to 100 µl of serum free DMEM and incubated for 15 minutes at 
room temperature to allow formation of transfection complexes. Transfection 
complexes were then mixed with 600 µl of complete DMEM, immediately 
transferred drop-wise to each well and incubated for 3 hours at 37°C, 5% CO2. 
Following incubation, the cells were washed with 1 ml PBS, 2 ml of fresh 
complete DMEM was added and the cells were incubated in 6 well cell culture 
clusters at 37°C, 5% CO2 for 72 hours. Culture fluids containing pseudotypes 
were harvested, centrifuged at 1000 rpm (~200 x g) for 5 minutes, passed 
through 0.45 µm filters, aliquoted and stored at -80°C until required. 
To monitor transfection efficiency, titres were assessed by incubating 50 µl of 
each pseudotype with 50 µl of 0.5x106 CLL-CD134 cells in a CulturPlate™-96 assay 
plate (Perkin Elmer, Beaconsfield, UK) at 37°C, 5% CO2. Following 72 hours 
incubation, 100 µl HTS steadylite substrate for luciferase (Perkin Elmer) was 
added to each well and the luciferase activity was quantified by single photon 
counting on 1450 MicroBeta luminometer (Perkin Elmer). 
2.2.6 Receptor usage assay 
MCC FFF, MCC F(FH)H, MCC HHH and CLL-CD134 cells (described above) were 
seeded (1 × 104 cells per well) in triplicate in a CulturPlate™-96 assay plate (Perkin 
Elmer). The cells were infected with 50μl of each HIV-luc (wild type FIV) 
pseudotype alongside reference controls of HIV-luc (FIV GL-8) and HIV-luc (FIV 
B2542). Following 72 hours incubation at 37°C, 5% CO2, luciferase activity was 
quantified following the addition of 100 μl of Steadylite HTS™ (Perkin Elmer) 
substrate for luciferase and single photon counting using a MicroBeta luminometer 
(Perkin Elmer). 
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2.2.7 Virus neutralisation assay 
Plasma samples (detailed in Chapter 3) were tested for virus neutralising 
antibodies (VNAb) using the HIV-luc (FIV) pseudotypes described above. Plasma 
samples were diluted 10, 100, 1000 and 10000 fold in complete RPMI 1640 
medium. 25 μl of each dilution were incubated in triplicate for one hour at 37°C 
with 25 μl of HIV-luc (FIV) luciferase pseudotype and then 50 μl (5 × 104 cells) of 
CLL-CD134 (Willett et al., 2006b) were added. The cells were cultured in 
CulturPlate™-96 assay plates (Perkin Elmer) for 72 hours. Luciferase activity was 
quantified as described above and fold neutralisation was calculated by dividing 
the mean luciferase counts of no plasma control wells with the mean luciferase 
counts for each plasma dilution. 
2.3 Protein based quantitative techniques 
Mya-1/PBMC cell culture  fluids (described in section 2.2.2) were examined each 
day from day 5 of co-cultivation for reverse transcriptase (RT) activity by Lenti 
RT Activity Kit (Cavidi, Uppsala, Sweden) or for p24 capsid protein by FIV Pet 
Check ELISA (IDEXX Laboratories, Netherlands). Selection of screening technique 
was based on the availability of reagents from their manufacturers.  
2.3.1 Reverse transcriptase activity detection assay 
200 µl of co-cultivation cell culture fluid was centrifuged at 1000 rpm (~92 x g) 
for 5 minutes and supernatant collected. 10 µl of supernatant was used to screen 
for reverse transcriptase (RT) activity using the Lenti RT Activity kit which 
detects or quantifies lentiviral reverse transcriptase activity. It is based on the 
principle of DNA-strand synthesis on template RNA coated plates by the reverse 
transcriptase present in each sample tested. The synthesised double stranded 
DNA/RNA molecule is targeted by alkaline phosphatase conjugated α-BrdU 
antibody. Quantification of the product is facilitated by addition of  
a colorimetric alkaline phosphatase substrate, the activity being proportional to 
the reverse transcriptase activity in the sample. Reaction mixture and  
Poly A plates coated with RNA template were prepared as per manufacturer’s 
instructions. All steps were carried out following the semi quantitative protocol. 
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2.3.2 p24 ELISA 
Culture fluids were collected as described above and 100 µl of cell culture 
supernatant was used to screen co-cultivations for FIV p24 capsid protein 
employing the commercial ELISA PetCheck FIV test kit (IDEXX Laboratories, 
Netherlands), an enzyme-linked immunosorbent assay that detects viral p24 
capsid protein either in plasma samples or cell culture supernatants. Screening 
was performed following the manufacturer’s protocol and absorbance values 
were measured using 405 nm filter.  Samples were classified as positive or 
negative by comparing spectrophotometry values to positive and negative 
controls provided by the manufacturer.  
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2.4 In silico techniques 
2.4.1 Sequence assembly and alignments 
Sequence data generated in house from ABI 3700 Genetic Analyser were base 
called and initially analysed using Sequencing Analysis Software v5.4 (Applied 
Biosystems, UK). All sequence data, whether generated in-house or by  
a commercial sequencing company, were further assembled in DNA Dynamo 
(Blue Tractor Software, UK). The full length FIV env sequence (approx. 2500 bp) 
from each clone was assembled by using 3 sequencing reads overlapping by 
approximately 200 bp and manually checked for mismatches. Assembled 
sequences were saved in FASTA format for further analysis. 
2.4.2 Phylogenetic analysis 
Phylogenetic analyses were performed using various software packages, 
depending on specific research questions and are described in detail in Chapter 
4. In summary, nucleotide and peptide sequence alignment was performed using 
Muscle algorithm (Edgar, 2004) in MEGA5 software package (Tamura et al., 
2011). DNA sequences were translated to corresponding sequences using Virtual 
Ribosme (Wernersson, 2006). Final alignments were curated manually following 
codon optimization by submission of MUSCLE aligned peptide sequences and 
corresponding not aligned nucleic acid sequences to RevTrans 1.4 Server 
(Wernersson and Pedersen, 2003). Phylogenetic trees were constructed using the 
Maximum Likelihood method under HKY nucleotide substitution model (Tamura 
et al., 2011) in MEGA5. Evolutionary divergence between sequences was 
calculated using Maximum Composite Likelihood model (Tamura et al., 2004) in 
MEGA5. Recombination testing and estimate of selection were performed with 
the HyPhy software package (Pond et al., 2005). Evolutionary rates were 
estimated using Bayesian Evolutionary Analysis Sampling Trees (BEAST) v 1.4.6 
software (Drummond and Rambaut, 2007). N-linked glycosylation sites were 
predicted using N-GlycoSite online tool available at Los Alamos, National 
laboratory server (Zhang et al., 2004). Highlighter analysis was performed by 
submitting aligned protein or nucleic acid sequences into highlighter tool 
available at the same Los Alamos server. 
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2.4.1 Graphs and statistical analyses 
All graphs and statistical analyses were performed in GraphPad Prism v 5.00 
(GraphPad Software, San Diego, California, USA). 
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Chapter 3. Study group 
Studying a naturally acquired infection in the natural host species presents many 
challenges. The major problem is not at the level of recruiting but rather it is 
difficult to retain the involvement of study participants over a sufficiently long 
period of time to collect sufficient useful data. This may explain why, despite 
over 25 years of FIV research, relatively little is known about the longitudinal 
course of FIV infection in its natural host. 
It became apparent during the first phase of this study that it may be extremely 
difficult (if not impossible) to retain the privately owned cats belonging to single 
households across the United Kingdom that were initially recruited for this 
project. The distress caused to cats and their owners that were associated with 
phlebotomy during the relatively frequent visits to the veterinarians were cited 
as the main reason for failing to arrange the follow-up appointments and 
subsequently opting out from the study. To address this problem, which would 
have biased the project and its research questions significantly, we recruited 
naturally infected cats from two separate locations in the United States. We 
believe that the unique characteristics of the selected populations, in particular 
the highly dedicated, well informed owners, were key to the success of this 
study. 
In this chapter, the study population comprising 44 American cats naturally 
infected with FIV that were recruited to the Glasgow FIV Project is described. 
The complete interpretation of the molecular properties of the isolated viral 
envelopes described later in this thesis, as well as the virus-host interactions at 
the level of viral entry and the humoral immune responses to the virus would not 
have been possible without linking it to clinical data.  
In this chapter the timeline of the project is described, giving an overview of the 
study population, the distribution of parameters such as age, length of infection, 
health status, CD4:CD8 ratio, and other clinical and pathological observations in 
the context of a diverse cat population infected with naturally acquired FIV. An 
attempt has been also made to evaluate and identify potential prognostic 
indicators amongst the parameters which are accessible for veterinarians in  
a clinical setting. 
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3.1 Materials and methods 
Recruitment, physical examinations, bleeding, clinical data collection and 
retention of all the cats recruited for the study were performed by our 
collaborator, Dr Annette Litster, Purdue University, West Lafayette, IN, USA and 
her colleagues. Post mortem examinations of deceased cats and necropsy 
reports were provided by the Animal Disease Diagnostic Laboratory of Purdue 
University. Clinical pathology results and lymphocyte flow cytometer analyses 
were delivered by IDEXX laboratories, Westbrook, ME, USA. 
3.1.1 Animals 
Forty four FIV infected cats were enrolled in the Glasgow FIV Project, comprising 
our “study group”. Within the study group, 27 cats were homed in the Memphis 
Crew’s FIV sanctuary, referred to as “Memphis group”, and 17 cats had been 
rehomed from PAWS Chicago, referred to as “PAWS Chicago group”. Details of 
the study group are described mainly on a population level in each section of 
this chapter, highlighting individuals only when significant information can be 
learned from specific cases. Detailed clinical data concerning the individual cats 
are provided on the CD that accompanies this thesis. 
3.1.2 Statistical analysis and graphs 
Graphing and statistical data analyses were performed using GraphPad Prism 
version 5.00 for Windows (GraphPad Software, San Diego, California, USA).  
Descriptive data were shown as means and interquartile range (IQR) (median, 
5th, 95th quartile). Data were expressed as numbers and percentages. The paired 
and unpaired t-test was used to detect differences between laboratory 
parameters. Significance was set at a p value < 0.05.  
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3.2 Ethical approval and owners’ consent 
The study and its aims were reviewed and approved by the University of Glasgow 
and the Purdue University Ethics Committees. 
Cats from Memphis Crew’s FIV shelter had been accepted in the past into the 
sanctuary that had been established for FIV infected cats. Therefore, the cats’ 
owner and carer, being very much aware of the implications of FIV infection, 
gave her consent for her cats to participate in the Glasgow-Purdue-IDEXX study 
without further education, understanding that the proposed (free of charge) 
veterinary health check-ups, haematology and biochemistry analyses would have 
a positive impact on the long term health of her cats. 
PAWS Chicago cats were either still living in the PAWS adoption centre or had 
been rehomed into single cat households at various times before the study 
commenced. These cats were well cared for by PAWS staff and fully dedicated 
owners, who had been made aware of their FIV status and health implications at 
the time of adoption. Prior to recruitment to the study, cat owners were 
contacted again, informed about the aims of the project and the importance of 
regular check-ups and follow up blood sampling during the length of the study. 
Owners who were willing for their cats to participate in the project were 
provided with written information sheets and consent forms which were signed 
and returned to the study co-ordinator. 
3.3 Eligibility criteria for selection and participation  
All cats from the two populations were initially selected into the study based 
solely on the basis of a history of FIV infection.  At the time of enrolment, the 
FIV infection status was confirmed using the SNAP FIV/FeLV Combo Test (IDEXX), 
regardless of breed, sex, age and health status. 
To exclude the possibility of false positive and negative SNAP FIV/FeLV Combo 
testing, initially the infection status of all enrolled cats was further confirmed in 
our laboratory by virus isolation (described in detail in Chapter 2), considered to 
be the “gold standard” for FIV diagnosis (Hosie et al., 2009). 
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3.3.1 Study group size 
The University of Glasgow FIV Prognosis Project (referred to as Glasgow FIV 
Study) forms part of a larger collaborative Glasgow-Purdue-IDEXX FIV study. It is 
important to emphasise that cats were enrolled by Dr Litster for the 
collaborative study over the period of 2 years (enrolment was completed in 
February 2012, at the time of writing this thesis). In total, 91 naturally infected 
FIV-positive cats and 93 FIV-negative matching control cats were enrolled for 
this study.  
For the Glasgow FIV study, 44 FIV infected cats from two distinct locations in the 
USA (Memphis, TN and Chicago, IL) were included. We were aware that by 
selecting and including cats from two populations (each with different 
geographic locations, housing conditions as well as health care access) minimised 
bias of the study. Indeed, it became evident that analysis of the two populations 
allowed a useful comparison of the effects of long-term FIV infection in shelter 
cats compared to single-household cat populations. The total number of 44 cats 
included in the study was chosen for logistic reasons. 
3.3.1.1 Memphis study group size 
All cats from the Memphis study population lived together in a single household, 
referred to as “FIV sanctuary”, and were cared for by one family. At the time of 
enrolment, 50 FIV positive cats were housed together in the Memphis Crew’s FIV 
sanctuary, from which for logistic reasons, 27 were randomly selected and 
included in this study. 
3.3.1.2 PAWS Chicago study group size  
The Chicago population cats were obtained (usually but not exclusively) 
following feral cat trapping in various parts of Chicago as part of the PAWS 
Chicago rehoming and adoption initiative. PAWS cats were well cared for by 
dedicated owners who were aware of their FIV status, had access to professional 
health care and all of these cats were living in single cat households, with the 
exception of two cats who had been rehomed together and were living in the 
same household. Another exception was two cats that had been rehomed in pairs 
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with two other FIV positive cats not enrolled in the project. There were 17 cats 
in total from the Chicago population that were included in this study. 
3.3.2 Coding and identifying system 
A standardised scheme to code and identify the study participants was 
established to facilitate data collection and analysis. The coding system that was 
developed is described in detail below and was used throughout the entire 
project and this thesis. This scheme was useful for data collection and to allow 
all results to be related back to each study participant. 
3.3.2.1 Memphis cats 
Each cat from the Memphis FIV Sanctuary was assigned the letter “M” followed 
by a number from 1 to 50 (assigned randomly to each cat’s name). The names of 
the Memphis cats and their corresponding codes are listed in Table 3-1. 
Table 3-1 Coding system for Memphis Crew’s FIV Sanctuary cats. Letter “M” followed by 
number from 1 to 50 were randomly assigned to each cat’s name. There are 27 cats coded 
according to this scheme. 
No. Code Cat Name  No. Code Cat Name 
1 M1 Truman  15 M28 Franklin 
2 M2 Jasmine  16 M29 Stormy 
3 M3 Sidney  17 M30 Buddy 
4 M5 Mrs Wootrie  18 M31 Mae 
5 M8 Ted  19 M32 Buzz 
6 M10 Rocket   20 M33 Slater 
7 M11 Indy  21 M41 Charlie 
8 M12 Tank  22 M44 Layla 
9 M14 Cinnamon   23 M46 Mandy  
10 M15 Domino Crews  24 M47 Wrigley 
11 M16 Tiger  25 M48 Edgar 
12 M20 Freddie Mercury  26 M49 Buster  
13 M25 Shelby  27 M50 Seamus 
14 M26 Brian May     
 
3.3.2.2 PAWS Chicago cats 
Each cat from PAWS Chicago was assigned a code with the letter “P” followed by 
a number from 1 to 22 (randomly assigned to each cat’s name). The names of 
the Chicago cats and their corresponding codes are listed in Table 3-2. 
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Table 3-2 Coding system for cats from PAWS Chicago. Letter “P” followed by number from 
1 to 22 randomly assigned to each cat’s name. There are 17 cats coded according to this 
scheme. 
No. Code Cat Name  No. Code Cat Name 
1 P1 York Cat   10 P11 Boots  
2 P2 Smudge   11 P13 Athena Ramona 
3 P4 Obiwan   12 P14 Jinx  
4 P5 Frisco Hamilton   13 P15 Franco  
5 P6 Ingrid   14 P17 Blondie  
6 P7 Luther   15 P18 Stosh/Jack 
7 P8 Orangello Mac   16 P21 Iko  
8 P9 Rocky   17 P22 Big Tuna  
9 P10 Buddy Sammy      
 
3.3.3 Study timeline and collection dates 
FIV prognosis project began on the 1st of October 2009 and the first blood 
samples from 27 Memphis cats were collected 4 months later on the 1st of 
February 2010. Subsequent follow up samples from the Memphis cats were 
collected at 6 monthly intervals until the end date of 9th of July 2011, such that 
a total of 4 samples were collected from each cat over a period of 18 months. 
The first blood samples from the PAWS Chicago cats were obtained on the 10th of 
May 2010, with follow up samples being collected at 6 monthly intervals until 
the last samples were obtained on the 6th of November 2011. Similarly to the 
Memphis group, 4 samples from each PAWS Chicago cat were collected over  
a period of 18 months. 
To facilitate data management letters “A”, “B”, “C” and “D” were assigned to 
each collection date as described in details in Table 3-3. 
Table 3-3 Blood collection dates with assigned corresponding codes (“A”,”B”,”C”,”D”) for 
Memphis and PAWS cat populations. 
 Collection date 
Code A B C D 
Memphis 01/02/2010 18/07/2010 22/01/2011 09/07/2011 
PAWS 10/05/2010 15/11/2010 16/05/2011 06/11/2011 
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Blood sample collections were synchronized in order to facilitate the study, not 
only logistically but also allowing the synchronisation of sample processing with 
on-going experiments in the laboratory. 
3.3.4 Assignment of follow up results 
Throughout this thesis, the blood/plasma samples and the results generated 
from these samples are denoted thus: the code for each cat followed by the 
code for each collection time point. For example M1A indicates a plasma sample 
collected from Memphis cat M1 (Truman) at time point A (01/02/2010) and P1A 
indicates a plasma sample from PAWS Chicago cat P1 (York cat) at time 
point A (10/05/2010). 
Samples collected at terminal stage disease are denoted with letter “T” in 
brackets placed after the code for each cat’s name and the sample collection 
date. For example M11C(T) indicates a terminal blood sample collected from 
Memphis cat M11 (Indy) at time point C (22/01/2011) where (T) signals that the 
cat had died before the subsequent sampling time. 
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3.4 Study group detailed characteristics 
An overview and the study group characteristics are described separately for the 
Memphis and PAWS Chicago populations, with summaries for each study group at 
the end of each paragraph. 
Detailed signalement, clinical history, physical examination data, weights and 
lymphocyte subset data obtained by flow cytometry were assessed every  
6 months and are listed on the CD that accompanies this thesis. 
3.4.1 Breed composition 
Cats recruited in the study mainly belonged to the domestic short haired (DSH) 
breed. This was particularly reflected in the PAWS Chicago group where 16 cats 
were DSH (94%) and only one belonged to the domestic long haired (DLH) breed 
(6%). In the Memphis group there were 20 DSH (74%), 4 DLH (15%) and 3 Siamese 
cross (11%) cats.  
Breed composition within the study group was heterogeneous, where DSH 
constituted 82%, DLH 11% and Siamese cross 7% of the enrolled cats.  
3.4.2 Age distribution 
Accurate dates of birth for each cat were rarely available. The age of the cats 
enrolled in the study was estimated by Dr Litster (the range +/- 1 year), based 
on a physical examination and the clinical history provided by the cats’ owners.  
As demonstrated in Figure 3-1, in the Memphis population, the median age at 
the time of recruitment was 5 years, ranging from 2 to 10 years. In the Chicago 
group, the median cat age was estimated to be 4 years, ranging from 1 to 9 
years. For the combined study group (Memphis and Chicago), the median age 
was estimated as 4.5 years (range 1-10 years). 
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Figure 3-1 Age distribution at the time of recruitment. From left to right: First box and 
whisker plot showing age distribution within Memphis population (median 5 years), second 
and third plots show age distribution within PAWS (median 4 years) and whole study 
(median 4.5 years) populations. Data presented as interquartile range (IQR), (median, , 5
th
, 
25
th
, 75
th
 and 95
th
 quartile). 
 
3.4.3 Duration of infection prior to enrolment 
FIV first diagnosis dates were available from each cats’ clinical history. In most 
cases, for obvious reasons, it was not known exactly when the cats acquired FIV 
and therefore the dates of infection have been estimated by calculating the 
midpoint between the date of birth and the first diagnosis date. This rather 
crude, but only available, approach was applied to most of the cases with the 
exception of cat M10 which was known to be positive at the age of 6 months and 
cat M1 where there was clear evidence for vertical transmission of the virus. 
The average length of FIV infection at the time of recruitment in the Memphis 
group was estimated to be 3.9 years (median 3.3 years) ranging from 1.3 to 8.8 
years.  PAWS Chicago cats were estimated to be infected with FIV on average for 
2.8 years (median 2.9 years) ranging from 0.8 years to 5.4 years.  The estimated 
duration of infection for the whole study group was calculated to be 3.5 years on 
average (median 3.3 years), ranging from 0.8 years to 8.8 years (Figure 3-2). 
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Figure 3-2 Estimated length of infection at the time of enrolment. From left to the right: 
Memphis population (median 3.3 years), PAWS population (median 2.9 years), study group 
(median 3.5 years). Data presented as interquartile range (IQR), (median, , 5
th
, 25
th
, 75
th
 and 
95
th
 quartile). 
 
3.4.4 Age at time of FIV infection 
It was difficult to estimate the cats’ age at the time of FIV exposure for the 
study population. However, it is very important to attempt to do so, in order to 
understand the epidemiology of infection and the age-related immune status of 
infected cats at the time of exposure to the virus. Hence, estimates of the ages 
of the cats at the time of first infection were calculated as the midpoint 
between the dates of birth and dates at which FIV was first diagnosed. 
It was estimated that cats from the Memphis group had been infected with FIV 
at the age of 1 (median 0.8 years), on average (Figure 3-3). Vertical transmission 
from mother to kitten had been documented in the Memphis population and the 
range extended to 2.3 years as a result of a 9 year old cat. 
Cats from the PAWS Chicago population were estimated to have been exposed to 
the virus at the age of 1.7 years (median 1.1 years) on average, ranging from 0.2 
years in a 1 year old cat to 3.9 years in 8 years old cat. 
For the whole study group, the average age at the time of infection was 
estimated to be 1.3 years, ranging from 0 to 3.9 years. 
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Figure 3-3 Estimated age at FIV infection. Memphis (median 0.8), Chicago (median: 1.1), 
study group (median: 0.9). 
 
The age at the time of first exposure to the virus can influence the course of FIV 
infection (George et al., 1993) and may determine the outcome of disease 
(Akhtardanesh et al., 2010). Previous epidemiological observations suggest that 
first natural exposure to the virus occurs at the age of 1 year approximately 
(Grindem et al., 1989), (Ishida et al., 1989), (Yamamoto et al., 1989), similar to 
the findings reported here. 
3.4.5 Sex distribution and reproductive status 
All cats enrolled in the study had been neutered prior to adoption and rehoming. 
In the PAWS group there were 3 female (3/17, 18%) and 14 male (14/17, 82%) 
cats. The Memphis group consisted of 9 females (9/27, 33.3%) and 18 males 
(18/27, 66.6%). As shown in Figure 3-4, in the whole study group there were 12 
female spayed (12/44, 27%) and 32 male neutered (32/44, 73%) cats. This finding 
is consistent with previously published data (Gruffydd-Jones et al., 1988), (Hosie 
et al., 1989), (O'Connor et al., 1991), (Yilmaz et al., 2000), (Spada et al., 2012) 
which demonstrated that FIV infection is more prevalent in male than in female 
cats. 
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Figure 3-4 Sex distribution amongst cats recruited to the study. Memphis group (n=27) 
consisted of 18 males and 9 females, Chicago (n=17) of 14 males and 3 females. There were 
32 males and 12 females in the whole study group (n=44). 
 
3.4.6 Body weight 
Body weight, and its alteration over the course of disease, is a commonly used 
parameter for the assessment of the overall health status of the patient. For the 
Memphis group, weights were recorded by the cats’ owner each month, with the 
last weight data being collected in September 2011. Body weights for the PAWS 
Chicago cats were recorded by Dr Lister every 6 months during check-up visits at 
the time of blood sampling, with the last weights being recorded in November 
2011. 
To analyse alterations in body mass we compared weights at enrolment with the 
last available body weight from each cat (terminal in case of deceased cats). 
Figure 3-5 shows alterations of body weight comparing live and deceased 
Memphis cats. 
In the Memphis population, 10 of 27 cats remained alive during the study period. 
3 cats gained weight, 2 cats retained their weight and 5 cats lost weight (up to 
34% of initial body mass). Marked weight loss between recruitment and terminal 
measurement was pronounced amongst the group of deceased cats. On average, 
the cats that died lost 59.9% of their body mass between enrolment (median 3.9 
kg)  and terminal stage disease (median 1.9 kg); this weight loss was statistically 
significant (paired t-test, p< 0.0001) (Figure 3-5). 
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Figure 3-5 Body weights of deceased (red) and alive (green) Memphis cats as of September 
2011. Enrolment weights are compared with the last available weight from each cat. 
 
The Chicago cats (Figure 3-6) gained 0.6 kg in their body mass, on average, over 
a period of 18 months (median 5.8 kg vs. 6.4 kg, paired t-test, p=0.35). Only one 
cat (P2) from this group died. The increased body weight of cat P2 at the 
necropsy was most likely attributed to the fluid retention caused by the 
congestive heart failure (CHF) as revealed by post mortem examination. 
Therefore the CHF confounds the body weight estimates in this case.  
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Figure 3-6 Body weights of alive (green) and one deceased (red) Chicago cat as for 
December 2011. Enrolment weights are compared with last available weight from each cat. 
 
 81 
 
In conclusion, body weight can be, and very often is, used as a parameter to 
assess general health in veterinary medicine. It is not unusual, however, to 
observe weight loss during the progression of various diseases. Indeed it is very 
nonspecific parameter and, although body weights can be assessed easily both 
by owners and clinicians to monitor the health status of FIV infected cats, its 
prognostic value is limited. 
3.4.7 Lymphocyte subsets and CD4:CD8 ratio 
Changes in lymphocyte population have been widely reported in HIV infection, 
with inversion of the CD4:CD8 ratio being indicative of disease progression to 
AIDS (Margolick et al., 2006). In cats, decreased CD4+ helper T lymphocyte 
counts, increased or stable CD8+ cytotoxic T lymphocyte counts and 
subsequently inversion of the CD4:CD8 ratio has been described in both naturally 
acquired (Novotney et al., 1990), (Tompkins et al., 1991), (Hoffmann-Fezer et 
al., 1992), and experimental FIV  infections (Ackley et al., 1990), (Barlough et 
al., 1991), (Tompkins et al., 1991), (Torten et al., 1991), (Bishop et al., 1992), 
(Lehmann et al., 1992), (Hanlon et al., 1993). 
In order to assess the prognostic value of lymphocyte subset assessments in our 
study population, we monitored these parameters in blood samples collected 
over period of 18 months. Reference ranges for these values were established 
from 44 sex- and age-matched control cats from similar geographical locations. 
Bearing in mind the differences between the two populations of cats enrolled in 
the study, a three-way comparison of lymphocyte subsets and CD4:CD8 ratios 
were conducted: one for the Memphis group, a second for the Chicago group and 
third for the entire study group. Figure 3-7 compares the CD4:CD8 ratios 
obtained over 18 months for the FIV infected Memphis cats with reference values 
(median, 5th, 95th quartile) acquired from uninfected, healthy control cats from 
a similar geographic location. The CD4:CD8 ratio values for the FIV infected cats 
were profoundly reduced compared to the values for the seronegative control 
cats. The median value (from four separate time points) for FIV infected cats 
(0.8) is below the 5th quartile for the control value (1.03).  
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Figure 3-7 CD4:CD8 ratio of FIV positive Memphis cats (in red) and matched FIV negative 
control cats from the Memphis area (in green). At the time of enrolment, data were collected 
from 27 FIV positive cats and 27 FIV negative controls; 6 months later from 23 surviving FIV 
positives; 12 months later from 21 surviving positive cats and 14 negative controls; 18 
months later from 16 surviving FIV positive cats. 
 
A highly significant (unpaired t-test, p< 0.0001) difference in CD4:CD8 ratios was 
observed between FIV positive cats from the Memphis population and 
seronegative controls. This observation was consistent at the time of enrolment 
and 12 months later (Figure 3-7). Similarly, the CD4:CD8 ratio in surviving FIV 
infected cats was maintained over a period of 18 months at a consistently low 
level (median values: 0.89, 0.73, 0.69, 0.81 for each time point), characteristic 
for FIV infection. 
The CD4:CD8 ratios for the PAWS Chicago FIV infected cats are compared with 
reference values acquired from healthy seronegative controls from the same city 
in Figure 3-8. As observed in the shelter Memphis population, there was  
a significant difference in the CD4:CD8 lymphocyte ratio (unpaired t-test, 
p< 0.0001) between FIV positive and control cats; the range (0.08-1.37) was 
below the median value (1.88) for the control cats. The CD4:CD8 ratios in the 
Chicago FIV positive cats were maintained over a 12 month period at a relatively 
low level, with median values of 0.78, 0.75 and 0.65 for each time point, in 
agreement with previous observations in the Memphis population and as 
published previously. Despite the generally better health status of the Chicago 
cats, their CD4:CD8 ratios were lower (median 0.73) than those of the Memphis 
shelter population (median 0.8). 
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Figure 3-8 CD4:CD8 lymphocyte ratios of FIV infected PAWS Chicago cats (red) and 
matched uninfected control cats from Chicago (green). At enrolment, data represent 17 FIV 
positive cats and 11 FIV negative controls; at 6 and 12 months, data represent 16 surviving 
FIV positive cats and 21 uninfected control cats. 
 
This observation led us to question whether differences in CD4:CD8 ratios would 
be observed between FIV-infected cats with and without clinical signs in the two 
populations. 
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Figure 3-9 CD4:CD8 ratio of FIV positive Memphis cats (in red), Chicago cats (in green) and 
the whole study group (in orange) separating cats classified as healthy and not healthy at 
the time of recruitment. Data collected at enrolment. 
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Figure 3-9 shows a comparison of the ratios in cats that were classified as 
“healthy” or “not healthy” for each group and for the combined study 
population. No statistically significant divergence was observed (unpaired t-test, 
p=0.84 for Memphis, p=0.97 for Chicago and p=0.99 for the study group) between 
the CD4:CD8 lymphocyte ratios in unhealthy (ranging from 0.16 to 1.86) 
compared to healthy cats (ranging from 0.08 to 2.24). 
As in HIV infection, the observed differences in CD4:CD8 ratios could be the 
result of either a loss of CD4+ cells or an increase of CD8+ cells (or both). To 
determine the kinetics of the CD4:CD8 ratio inversion over the course of 
infection, we compared absolute CD4+ and CD8+ T lymphocyte numbers from 17 
cats that died during the study. 
In Figure 3-10, the lymphocyte subset values of the 17 cats that died are shown 
from the time of enrolment and death. 
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Figure 3-10 The number of CD4+ and CD8+ lymphocytes and CD4:CD8 ratio at enrolment 
and terminally from 17 FIV infected Memphis cats that died during the study. The different 
CD4:CD8 ratios between the two time points reflect decreases in circulating CD4+ T helper 
lymphocytes (green) and is shown in the two last box and whisker plots. 
 
The observed decrease in CD4+ helper T cell numbers (medians 0.41 K/µl and 
0.18 K/µl respectively) was statistically significant (paired t-test, p=0.0009). 
There was no difference however in the number of circulating CD8+ cytotoxic  
T cells (medians 0.44 K/µl and 0.38 K/µl respectively). Therefore, we concluded 
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that in the FIV infected cats, the observed decreased CD4:CD8 ratio (where 
median terminal value fell below the 25% percentile of the value at enrolment) 
could mainly be attributed to the loss of CD4+ T helper lymphocytes.  
Further analysis of the total lymphocyte counts in the deceased cats showed that 
the decrease in absolute lymphocyte numbers between enrolment (median 
1.73K/µl) and death (median 1.25 K/µl) was the result not only of a loss of 
CD4+T cells, but also by depletion of CD21+ B cells (median counts at enrolment 
0.26 k/µl versus 0.17 K/µl in terminal samples; paired t test, p=0.01). 
The hallmark of FIV infection is an inverted CD4:CD8 ratio which, as 
demonstrated above and in previous studies, is the consequence of a loss of 
CD4+ T cells. In our study we provide further evidence that FIV infected cats, 
regardless of their living conditions and health status, have altered proportions 
of CD4+ and CD8+ lymphocyte subsets, with the range falling below the median 
value for seronegative control cats. We observed a statistically significant 
difference in CD4:CD8 ratio between the time of enrolment and the terminal 
sampling of deceased cats; there was no significant difference between 
generally healthy, “asymptomatic” single household Chicago cats and deprived, 
more symptomatic Memphis shelter cats (median values 0.8 and 0.73 
respectively). This finding questions the prognostic value of CD4:CD8 ratio in 
staging FIV infection and predicting the onset of immunodeficiency. By 
comparing absolute numbers of lymphocyte subsets, it is possible to distinguish 
FIV positive and negative individuals. However, healthy and unhealthy FIV 
infected cats could not be distinguished on the basis of their CD4:CD8 cell ratios. 
No correlation was seen between FIV associated immunodeficiency and inverted 
CD4:CD8 ratio. Both groups of cats had low CD4:CD8 ratios with median values 
less than 1, regardless of their health status. In fact, cat P4 which had the 
lowest CD4+ lymphocyte count from all (0.09 K/µl) and the lowest CD4:CD8 ratio 
(0.08) at the time of enrolment was classified as healthy and remains alive 
twenty four months later. Similar observations have been reported in FIV 
infected cats previously (Novotney et al., 1990) and HIV infected humans (Levy, 
1988) where seropositive individuals remain asymptomatic despite significant 
loss of CD4+ T lymphocytes.  
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Hence the prognostic value of monitoring CD4+ T lymphocyte numbers or 
CD4:CD8 ratios in FIV infection appears to be limited in the light of these 
findings. There may be marked deviation amongst lymphocyte subset numbers in 
cats as well as variation in virulence amongst circulating wild type FIVs. The 
variability of CD4:CD8 ratio values amongst healthy and not healthy cats limits 
their use for predicting the progression of disease. 
3.4.8 Health status 
Assessment of the health status and general condition of an FIV infected cat is 
essential in order to stage the phase of infection and to monitor disease 
progression and, according to ABCD guidelines (Hosie et al., 2009), should be 
performed every 6 months. To monitor disease progression, at least two scoring 
systems have been adopted from those used in human medicine. One protocol, 
proposed by Ishida (Ishida and Tomoda, 1990) and described in (Shelton et al., 
1990), is based on the staging system used in HIV infection (Asymptomatic 
carrier (AC), AIDS-related complex (ARC) and AIDS). The second is Karnofsky’s 
scoring system, which is used mainly in cancer patients and has been modified 
for use in feline medicine (Hartmann and Kuffer, 1998). 
After an initial assessment of our study population and consultations with other 
feline medicine specialists, we realised that while those protocols may be useful 
in well-controlled, experimental settings, neither is practical in staging FIV-
infected cats in our study. Instead we classified cats by their general health 
condition. Cats suffering only minor clinical abnormalities were classified as 
healthy. When more than two abnormalities were detected on physical 
examination, cats were classified as not healthy. 
The health status of each cat has been evaluated at 6 monthly intervals by the 
experienced feline medicine specialist, Dr Litster. At each clinical examination 
heart and respiration rates were measured, general appearance evaluated and 
lymph nodes, musculoskeletal, cardiovascular, respiratory, digestive, urogenital 
systems were examined, together with a neurological examination. During the 
examination of the oral cavity, the degree of faucitis/gingivostomatitis 
characteristic of FIV infection was graded using a scale of 0 to 3. At the time of 
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enrolment there were 12 healthy (44%) and 15 not healthy (56%) cats in the 
Memphis population. 
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Figure 3-11 Health status at enrolment. Memphis (n=27): healthy (n=12), not healthy (n=15); 
Chicago (n=17): healthy (n=10), not healthy (n=7); Study group (n=44): healthy (n=22), not 
healthy (n=22). 
 
The proportion of healthy cats in the PAWS Chicago population was greater than 
in the Memphis group, with 10 healthy (59%) and 7 not healthy (41%) cats. In the 
combined study group there were equal numbers of healthy and not healthy 
animals at the time of enrolment (Figure 3-11). 
Within the Memphis population, 12 cats initially classified as healthy and 15 cats 
classified as unhealthy remained in their assigned groups throughout the study. 
However, 17 cats from the Memphis cohort become anorexic, showed significant 
weight loss (Section 3.4.6) and eventually died at various time points (Table 
3-5).  
It is important to emphasize that 6 of 12 cats initially classified as healthy (50%) 
and 11 of 15 unhealthy cats (73%) died during the study (Fisher’s exact test, 
p=0.2566). 4 of 9 cats (44%) which were diagnosed post mortem with lymphoma 
were classified as healthy and, surprisingly, in none of the cases were any 
abnormalities detected during clinical examination which included palpation of 
peripheral lymph nodes. This raises the question of when a basic clinical 
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examination will detect such abnormalities and when lymphoma presents 
clinically. 
Table 3-4 Abnormalities detected during clinical examinations of 44 FIV (+ve) cats over 
period of 18 months. 
 Memphis (27) Chicago (17) Study group (44) 
Description Cats with abnormalities (number), (%) 
Dental/oral cavity (faucitis) 19 (70%) 12 (71%) 31 (70%) 
Skin (alopecia, dermatitis) 12 (44%) 10 (59%) 22 (50%) 
Ears  4 (15%) 3 (18%) 7 (16%) 
Ocular disease (mucopurulent discharge) 5 (19%) 2 (12%) 7 (16%) 
Cardio-vascular  2 (7%) 3 (18%) 5 (11%) 
Digestive tract  4 (15%) 0 (0%) 4 (9%) 
Respiratory (URI, nasal discharge) 2 (7%) 0 (0%) 2 (5%) 
Lymph nodes 0 (0%) 0 (0%) 0 (0%) 
Uro-genital 0 (0%) 0 (0%) 0 (0%) 
Neurologic 0 (0%) 0 (0%) 0 (0%) 
Musculoskeletal 0 (0%) 0 (0%) 0 (0%) 
Weight loss/anorexia 22 (81%) 0 (0%) 22 (50%) 
 
Within the Chicago population, 10 cats (59%) were classified as healthy at the 
time of enrolment and the remaining 7 cats (41%) were unhealthy. All but one 
cat remained in this classification over the period of study. A single cat died and 
had not shown any abnormalities on physical examination, despite being 
diagnosed post mortem with hypertrophic cardiomyopathy (HCM). 
The clinical abnormalities detected during the examinations are listed in Table 
3-4. The most common presentation across both populations was gingivo- 
stomatitis/faucitis, detected in 70% of cats. However, although the remaining 
30% of cats were classified as normal on oral examination, each cat had at least 
one minor abnormality detected in their mouth during one examination. The 
second most common clinical sign (50% of cases) was a skin abnormality, not only 
limited to various types of dermatitis but notably including non-healing fight 
wounds and the presence of fleas (Ctenocephalides felis) (3 Memphis cats). 
Ocular disease with mucopurulent discharge was recorded in 16% of cases. Other 
abnormalities included digestive system signs that presented as mild bowel 
thickening on palpation in 9% of cases, while upper respiratory infections with 
nasal discharge were seen in 5% of cases. No abnormalities were detected on 
examination of musculoskeletal, urogenital or neurologic systems. Surprisingly, 
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none of cats displayed lymphadenopathy, nor even slightly enlarged peripheral 
lymph nodes on any of the four occasions when they were physically examined.  
Additional health problems not detected during examination, but reported by 
owners and/or the cats’ regular veterinarians, included: urinary tract infections 
(8 cats, 18%), skin allergy (1 cat, 2%), diabetes (1 cat, 2%) and diarrhoea (1 cat, 
2%). 
FIV infection subsequently leads to immunosuppression, which in many cases can 
progress to feline AIDS. Infected cats are at greater risk of opportunistic 
infections, neoplasia and neurological disorders. Time to disease progression and 
death of 17 out of 27 cats (63%) in the Memphis cohort within 18 months of 
observation was unexpectedly high in comparison to 18% drop off rate reported 
by Barr during two years of observation (Barr, 2000). The health status of cats in 
the Chicago cohort was similar to a household reported previously (Addie et al., 
2000), where FIV infection did not affect the cats’ life expectancy, at least over 
a period of 2 years. There are several clinical abnormalities associated with FIV 
infection, with gingivostomatitis being the most common. Despite the fact that 
one study (Quimby et al., 2008) did not observe an association between FIV 
infection and gingivostomatitis, the high prevalence of this abnormality in our 
study group was in agreement with previous reports (Bandecchi et al., 1992), 
(Hofmann-Lehmann et al., 1995), (Knotek et al., 1999), (Hosie et al., 2009). 
Ulcero-proliferative lesions are often painful and can eventually lead to tooth 
loss. Because gingivostomatitis is usually not seen in experimentally infected SPF 
cats, exposure to other infective agents (such as co-infection with feline 
calicivirus (FCV)) may be responsible for the manifestation of this syndrome in 
natural infections (Tenorio et al., 1991), (Reubel et al., 1994). Other 
abnormalities attributed to FIV-induced dysregulation and impairment of 
immune surveillance (Barlough et al., 1991), (Reche Jr et al., 2010) included 
dermatitis, ocular disease, renal insufficiency, lower urinary tract and other 
opportunistic infections. Although neurologic abnormalities have been reported 
to be very common in natural and experimental, acute and chronic FIV infections 
(Dow et al., 1990), (Abramo et al., 1995), (Podell et al., 1997), (Podell et al., 
1999) we observed neither behavioural nor motor abnormalities in our study 
group. 
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The relationship between FIV infection and disease is unclear, with some studies 
reporting that virus infected cats are at increased risk of morbidity and mortality 
(Muirden, 2002) while others observed no such association (Norris et al., 2007), 
(Akhtardanesh et al., 2010). It is difficult to associate mortality and morbidity 
with FIV infection when examining cats within the whole study group, but an 
association became apparent when the two populations were examined 
separately. Our observations in the Memphis population indicated that poor 
living conditions, exposure to opportunistic pathogens and limited healthcare 
access play a major role in more rapid disease onset. In contrast, the Chicago 
cats living in generally much better conditions in single households remained 
alive and in relatively good health compared to the Memphis population. In spite 
of the difficulties elucidating an association with disease, and given the short 
observation period of this study, nevertheless disease associated with FIV 
infection appears more pronounced in shelter cats, living in more demanding 
conditions. Cats living in single households and not exposed to opportunistic 
pathogens were more likely to remain free of clinical signs, in accord with the 
observations of many clinicians whose expert opinion is that FIV in such cases 
does not cause severe clinical abnormalities.  
3.4.9 Cat deaths during the study 
During the two years of study, 1 of 17 (5.9%) cats from the Chicago cohort and 
17 of 27 cats (63%) from the Memphis group died. The mortality rate of 63% in 
the Memphis population over a relatively short period of time was unexpected. 
Figure 3-12 illustrates the percentage survival of Chicago versus Memphis cats, 
highlighting a marked difference in survival between the two populations.  The 
causes of death and possible associations with FIV infection were established 
following post mortem examinations (Table 3-5). Hypertrophic cardiomyopathy 
and congestive heart failure were associated with death of the single Chicago 
cat. For the Memphis group, necropsy data were not available for two cats (M33 
and M14), no diagnoses were made post mortem for another two cats (M44 and 
M50) and in 4 other cases various degrees of respiratory tract infection and 
subsequent pneumonia were associated with mortality.  
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Post mortem examinations revealed that the most prominent cause of death in 
the Memphis group was lymphoma; various anatomical types were recorded in  
9 out of 15 Memphis cats (60%) that were examined post mortem. 
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Figure 3-12 Kaplan Mayer survival curves for Memphis (red) and Chicago (black) groups. 
Difference in survival rate is statistically significant (Gehan-Breslow-Wilcoxon Test 
p=0.0006). Survival rates in Memphis and PAWS populations were 37% and 94% 
respectively. 
 
Other pathological changes not directly associated with mortality but most likely 
linked with FIV infection included lymphoid hyperplasia and lymphoid depletion, 
noted in 13 of 16 cats (81%) that were examined post mortem. These were 
pronounced in various tissues, mainly in spleen and lymph nodes but in 4 cats 
Peyer’s patch atrophy was also observed. The second most notable abnormalities 
were erythroid and myeloid bone marrow hyperplasia, seen in 9 out of 16 cats 
(56%). Multifocal lymphocytic interstitial nephritis, possibly associated with FIV 
infection as reported previously (Ishida et al., 1992), was detected in 6 cats 
(37.5%) and was the third most common abnormality detected post mortem. 
FIV infection is generally associated with immune suppression but, paradoxically, 
immune hyper-activation is equally important in the pathogenesis of disease and 
the development of the AIDS-like syndrome. B cell activation, manifest as 
polyclonal hypergammaglobulinemia, expansion of CD8+ T cells with an 
activated phenotype and subsequent CD8+ T cell lymphocytosis are both directly 
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and indirectly associated with abnormalities detected post mortem. The lymph 
node follicular hyperplasia and dysplasia seen amongst the cats in this study 
have been reported previously in acute and terminal stage disease (Yamamoto et 
al., 1988), (Shelton et al., 1989a), (Matsumura et al., 1993). Reactive changes 
within bone marrow seen in 56% of cats have been documented in HIV and FIV 
infections as well as various other disorders (Geller et al., 1985), (Breuer et al., 
1998), (Bain et al., 2009) and are regarded as non-pathognomonic. 
Upper respiratory tract (URT) signs presented in 4 cats; these were initially mild 
but became more severe over a relatively short period of time, perhaps 
associated with impairment of cell mediated immunity leading to opportunistic 
infections. URT infections are very common in FIV infected cats and have been 
previously reported in the literature (Pedersen et al., 1989), (Yamamoto et al., 
1989).  
The renal damage observed in 33% of cases may have been associated with 
deposition of viral-antibody immune complexes or may have resulted from direct 
viral infection of renal epithelium and thrombotic micro-angiopathy (TMA). 
Direct infection of epithelial cells within several parts of the nephron has been 
documented in HIV-associated nephropathy, predominantly in Africans (Ross et 
al., 2001), while deposition of virus-antibody complexes accounts for the 
majority of nephropathies in Caucasians (Nochy et al., 1993), with immune 
complex-mediated glomerulonephritis being the most common manifestation. 
The mechanism of TMA kidney damage is poorly understood, but it seems that 
epithelial cell damage caused by the virus may cause platelet activation and 
deposition in the renal microvasculature (Röling et al., 2006). Although it is 
difficult, based only on anatomical pathology data, to elucidate the mechanism 
of interstitial nephropathies in our study population, extrapolating from HIV 
(Melica et al., 2011), it appears that prolonged immune stimulation and massive, 
non-specific, FIV-driven B cell activation and subsequent interstitial 
lymphoplasmacytic infiltration may be highly associated with the type of 
nephropathy seen amongst the FIV study cats. 
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Table 3-5 Cats deceased during the study. Health status, date and cause of death. 
Cat Date of death Status Cause of death 
M26 15/04/2011 Not Healthy Chronic focal granulomatous nematode larval pneumonia; Bone marrow hyperplasia 
M30 19/09/2011 Euthanized Not Healthy 
Lymphoid depletion; Aelurostrongylus abstrusus pneumonia; Left front leg suppurative dermocellulitis; Bone marrow 
hyperplasia, with erythroid and myeloid hyperplasia 
M49 18/06/2011 Healthy Lymphoma - Bone marrow 
M41 03/02/2011 Not Healthy Lymphoma - Bone marrow and lymph nodes 
M14 02/08/2011 Not Healthy No necropsy performed 
M48 05/03/2010 Not Healthy Lymphoma - Bone marrow and lymph nodes 
M11 04/02/2011 Healthy Lymphoma – multicentric 
M44 14/04/2010 Not Healthy Undetermined/Emaciation/Nephritis/Pancreatitis 
M31 01/03/2011 Not Healthy Lymphoma - Bone marrow 
M46 23/07/2011 Healthy Lymphoma - Bone marrow 
M5 18/05/2011 Not Healthy Lymphoma - Bone marrow 
M10 25/07/2011 Healthy Lymphoma - Bone marrow and lymph nodes 
M50 27/10/2010 Healthy Undetermined/Emaciation 
M25 04/09/2011 Healthy Upper and lower bacterial respiratory infection, probably secondary to viral infection 
M3 04/03/2010 Euthanized Not Healthy Lymphoma – Retrobulbar 
M33 29/05/2010 Not Healthy No necropsy performed 
P2 13/12/2010 Healthy Cardiac failure – HCM 
M16 21/06/2011 Not Healthy Pulmonary congestion and oedema with focal bacterial bronchopneumonia 
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3.4.10 FIV associated lymphoma  
FIV-associated neoplastic transformations, predominantly lymphomas, have been 
documented in both natural and experimental FIV infections (Pedersen et al., 
1989), (Poli et al., 1994), (Terry et al., 1995), (Gabor et al., 2001b) (Shelton et 
al., 1989b) ranging from 1 to 27% of cases (Feder and 1990), (Zenger, 1990), 
(Hutson et al., 1991), (Ravi et al., 2010) with the highest rate of 50% reported in 
an Australian retrospective study (Gabor et al., 2001b). In our study the rate was 
strikingly higher; 53% of all cases in Memphis cluster diagnosed with various 
anatomical types of lymphoma as shown in Table 3-6. 
Table 3-6 Organs with neoplastic lymphocyte infiltrates among cats post mortem diagnosed 
with lymphoma. 
Cat Organ involved 
 
Bone 
marrow 
Lymph 
node 
Spleen Kidney Liver Jejunum Tongue Trachea Heart Eye 
M11 + + + + + + + + +  
M41 + + +        
M5 + + +        
M48 + +         
M10 + +         
M31 +          
M49 +          
M46 +          
M3          + 
 
Post mortem examinations revealed that four cats had lymphoma limited to  
a single site (retro-bulbar site in 1 case and bone marrow in 3 cases), while in 
five other cats varying degrees of dissemination were seen. Bone marrow 
involvement was noted in all but one case. The second most common site for 
lymphomas was nodal, seen in 5 cats (56%), accompanied by splenic lymphoma 
in 3 cases (33%). The youngest cat (M11) presented with a disseminated form 
involving kidney, liver, jejunum, heart, trachea and tongue (glossal lymphoma). 
Lymphoma cats from the Memphis cohort had a median age of 6 years (ranging 
from 3 to 10 years). Differentiation of T-cell and B-cell antigen expression in the 
lymphoma tissue was not performed and the phenotype of those lymphomas is 
unknown. In light of previous studies, however (Poli et al., 1994), (Terry et al., 
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1995), (Gabor et al., 2001b) it is predicted that the majority, if not all, were of 
B-cell origin. 
The high prevalence of lymphoma raised questions of environmental, host, viral 
and other factors that may be associated with lymphoma development in the 
Memphis cohort. The first candidate causative agent would appear to be FIV. 
One likely mechanism of cancer development, proposed both in FIV (Barr et al., 
1993), (Callanan et al., 1996) and in HIV (Safai et al., 1987), (O'Hara, 1989) 
infections, may be attributed to virally induced immune suppression and lack of 
anti-neoplastic immune control capacity (Penn, 1986).  Another mechanism 
could be attributed to a high viral mutation rate and infection of dividing cells, 
rendering the cells more prone to neoplastic transformation. Most importantly 
however, viral integration into host genome and subsequent alteration of 
cellular transcription profiles, either by activation of cellular oncogenes or 
interrupting tumour suppressor genes, could explain neoplastic transformations 
following retroviral infection. This mechanism has been linked with neoplasia 
following infection with FeLV (Jackson et al., 1993), MuLV (Suchman et al., 
1995) and MMTV (Nusse and Varmus, 1982). Viruses from other families also have 
been shown to provoke carcinogenesis via a similar mechanism, for example 
human papilloma virus (Baker et al., 1987). Although clonal integration and 
possible subsequent dysregulation of the cellular transcription profile was 
demonstrated in two studies (Beatty et al., 1998), (Wang et al., 2001), the 
majority of studies did not observe integration of FIV proviral DNA in lymphomas 
(Terry et al., 1995), (Callanan et al., 1996), (Endo et al., 1997). Therefore it 
appears that while insertional mutagenesis may be directly associated with 
carcinogenesis in rare cases of FIV and possibly one case of HIV  infection 
(Shiramizu et al., 1994), in the majority is induced by a different, indirect 
mechanism (Levine, 1992). It is possible that lentivirus-induced dysregulation of 
the immune system may reveal the oncogenic potential associated with other 
viruses, as occurs with human herpes virus 8 (HHV8) which leads to development 
of Kaposi’s sarcoma (Rabkin et al., 1991) in HIV-infected patients. Kaposi’s 
sarcoma (KS) is recognized as an AIDS defining cancer and its manifestation is 
highly associated with HIV infection; the likelihood of KS development is 300 fold 
higher in HIV-infected individuals compared to patients receiving 
immunosuppressive therapies (Beral et al., 1990), clearly indicating a synergistic 
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effect between the two viruses. On the other hand, lymphomas associated with 
HIV infection have been linked also with Epstein-Barr virus (EBV) coinfection, 
proposed to occur through prolonged B-cell activation (Shibata et al., 1993). 
Prolonged B cell antigenic stimulation is a potential mechanism for lymphoma 
development in FIV infected cats, as suggested previously (Hutson et al., 1991). 
Recent studies demonstrated serological responses to EBV (Chiou et al., 2005), 
(Milman et al., 2011) and the presence of EBV-like viral DNA and protein (Huang 
et al., 2012b) in malignant lymphocytes of domestic dogs diagnosed with 
lymphoma. It was suggested that canine EBV-like virus may be linked with B-cell 
lymphomagenesis, as antibody titres against the viral antigens p18-VCA and p23-
VCA were significantly higher in dogs with lymphoma compared to healthy dogs 
(Huang et al., 2012b).  
The high number of lymphoma cases arising in the Memphis cluster compared to 
the Chicago cohort was striking and merits further investigation. Firstly, 
carcinogenesis may be attributed to environmental factors as the living 
conditions were very different for the Memphis cats compared to the Chicago 
cats. The presence of carcinogens in the environment cannot be ruled out, but 
the Memphis cats lived in more demanding conditions, with poorer healthcare 
which may have led to weakened anti-neoplastic immune surveillance, resulting 
in neoplasia in this cohort. We examined FIV strain variability and the possibility 
that the Memphis FIV strains had greater oncogenic potential than the strains 
infecting the Chicago cohort but a comparison of long terminal repeat sequences 
revealed no significant differences (data not shown). Host factors, such as breed 
were unlikely to play a role, as the cats affected with lymphomas, as well as the 
cats in the Chicago cohort were DSH. Based on the epidemiological situation, it 
seems likely that the occurrence of lymphoma in the Memphis cluster may be 
associated with an infectious agent. A role for FeLV infection was excluded 
based on FIV/FeLV Snap test (IDEXX) results which were negative for FeLV 
antigen. However, we cannot exclude the possibility of latent FeLV infection, 
with FeLV provirus remaining integrated in the host genome within the bone 
marrow cells in the absence of detectable antigenaemia. Cats that are latently 
infected with FeLV test negative on routine antigen testing (Jackson et al., 
1993), (Gabor et al., 2001a) and hence some cats in our study group may have 
been latently infected with FeLV. However, a recent report employing two 
 97 
 
different PCR assays failed to detect FeLV proviral DNA in blood, tumour or bone 
marrow samples from FeLV antigen negative cats that developed lymphoma 
(Stutzer et al., 2011). Hence it is unlikely that latent FeLV infection is the cause 
of this malignancy in antigen negative cats. Furthermore, FeLV involvement in 
lymphoma may have been overestimated, particularly in the last 20 years where 
effective vaccine and eradication programs have marginalised the impact of 
FeLV infection. In our study population, it is likely that the FeLV antigenemia 
corresponds to a lack of proviral FeLV DNA integration, implying that there is no 
significant FeLV involvement. Although this hypothesis will be tested in our 
laboratory, there is likely to be a factor other than FeLV triggering 
carcinogenesis in these cats. 
In light of early findings in HIV cancer patients, it was suggested that lymphoma 
could be triggered by the recently discovered HHV-6 isolated from HIV patients 
by the same group (Salahuddin et al., 1986). More recently it was shown that 
HHV-6 can cause persistent infection by inserting its DNA into chromosomes 
(Pellett et al., 2011); the region of insertion was subsequently mapped to 
telomeres (Arbuckle and Medveczky, 2011). This recent finding and the 
identification of the site of insertion in chromosomal fragments responsible for 
aging and carcinogenesis, sheds light on the mechanisms by which HHV-6 can 
lead to neoplastic transformation. Mechanism of persistent, latent infection with 
HHV-6 is unique amongst human herpesviruses; all other known to date human 
herpes viruses establish latency as nuclear circular episome (Poffenberger and 
Roizman, 1985). This phenomenon is not only limited to HHV-6 as another 
herpesvirus, Marek’s disease virus (MDV) that infects chicken and induces T cell 
lymphoma, has also been shown to integrate its DNA into chromosomes (Kaufer 
et al., 2011). Strikingly, the chromosomal integration sites of MDV harbour 
telomeric repeat sequence, identical to that of the host telomeres and the site 
of MDV integration has been shown to be similar to that of HHV-6 (Kaufer et al., 
2011). It is tempting to speculate that in cats from the Memphis cluster (and 
possibly in others including wild felids), carcinogenesis may be triggered by an as 
yet unidentified feline virus belonging to the herpesvirus family and integrated 
on host telomeres. It is possible that, similar to chromosomally integrated HHV-6 
(Arbuckle and Medveczky, 2011), such a virus could be transmitted vertically 
through germinal cells and may be fixed in the cat population worldwide. This 
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hypothesis is supported by recent research on MDV and HHV-6. At the same time, 
cats are the species most prone to developing lymphoma and leukaemia, which 
are responsible for over 30% of all feline tumours, compared to any other animal 
species. In many cases neither FIV nor FeLV can be linked with those 
malignancies, indeed one study reported lymphoma in specific pathogen free 
(SPF) cats that had never been exposed to either FeLV or FIV (Jarrett et al., 
1984). Lymphoma development in the immunocompromised cats within the 
Memphis cohort requires further investigation and will be addressed in our 
laboratory with the aim of identifying viruses which have the potential to be 
linked with feline lymphomas. 
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3.5 Discussion 
In this chapter we discussed detailed characteristics of cats recruited to our 
study, to describe the clinical status of the enrolled cats as well as factors to 
which the study population had been exposed and which are relevant to the 
interpretation of the results presented later in this thesis. We emphasized the 
diversity of the study population and the significant differences between the 
Memphis and Chicago cohorts. Indeed, it become apparent during the 
observation period that completely different clinical outcomes of FIV infection 
arose in the two populations. Despite some initial doubts about enrolling cats 
from two separate cohorts (one of which contained cats living together and 
potentially infecting each other), our study of two cohorts has proved to be very 
useful in elucidating the different outcomes of natural infection in diverse 
populations. 
Studying natural infection can be very challenging and as highlighted above it 
was necessary to make estimations when defining the ages of cats, the time 
when virus was first encountered and duration of infection. Although it would 
have been possible to define these parameters as unknown, estimates were 
made based on clinical examination and the histories that were available from 
the adoption centre or owners. It is important to recognize, however, that these 
estimates are crude and not necessarily accurate. But in spite of these 
problems, the estimates appeared to be consistent with previous studies 
(Grindem et al., 1989), (Ishida et al., 1989), (Yamamoto et al., 1989) and 
provided a basis for the interpretation of the results presented in this thesis. 
One of the aims of this chapter was to identify potential prognostic markers that 
could be used by clinician to stage disease and estimate the likelihood of 
progression to AIDS. Unlike HIV infection, there are no well-established 
prognostic indicators for FIV disease progression. Analysing all haematological 
and biochemical parameters and their potential prognostic value were beyond 
the scope of this study. Instead, this chapter focused on analysing lymphocyte 
subsets as well as alterations in body weight during the course of infection. Body 
weight changes between alive and deceased cats were significant, but this is 
non-specific; weight loss may be observed in any wasting disease and therefore 
is not necessarily attributable to FIV infection. Despite significant differences 
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between CD4 and CD8 lymphocyte subset numbers between FIV-infected and 
uninfected cats, it is difficult to distinguish “asymptomatic” cats with no clinical 
signs from “symptomatic” cats displaying clinical signs by comparing lymphocyte 
subset numbers. Although, with some limitations, CD4:CD8 lymphocyte ratio 
values can be used in monitoring HIV infected patients (Margolick et al., 2006), 
these ratios are of limited use for staging and estimating the likelihood of 
disease progression in cats.  
Unfortunately it was not possible to include plasma viral RNA load (PVL) data in 
this chapter, since the estimation of PVL among the cats enrolled in this study is 
still on going. Bursts in viral replication and correlation between increased PVL 
and immunodeficiency have been reported in HIV infection (Katzenstein, 2003) 
and in one study examining kittens experimentally infected with two diverse 
strains of FIV (Diehl et al., 1996). The usefulness of PVL as a prognostic 
surrogate marker in naturally infected cats is under investigation and such data 
will further broaden our understanding natural FIV infection. 
Accurate determination of the health status, and therefore classification of cats 
in the study group as either “symptomatic” or “asymptomatic” has been 
problematic, in spite of the examinations being conducted by an experienced, 
board certified feline medicine specialist. Some cases were initially classified as 
“healthy” but subsequently died during the study and some cases initially 
classified as “not healthy” are still alive at the time of writing this thesis. It has 
become apparent, while monitoring the Memphis population, that the health 
status of FIV infected cats can deteriorate over a few days. This especially 
applies to cases of lymphoma which can develop within few weeks without any 
abnormalities having been detected on prior clinical examination, particularly in 
cases where lymph node involvement revealed post mortem was not detected 
during physical examination. 
Striking differences in survival rate were observed between the cats in the 
Memphis and Chicago cohorts. The differences in the housing conditions of the 
two cohorts have been described above and might have impacted upon  
the different clinical outcomes of FIV infection observed between the two 
groups. Despite the relatively short observation period, it has become clear that 
housing conditions, nutrition and access health care can dramatically influence 
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the survival time of an FIV-infected cat. It seems that cats, even with 
compromised immune systems (defined by comparing lymphocyte subset values) 
can remain relatively healthy when living in single cat households and receiving 
supportive treatment when necessary. On the other hand, as observed in the 
Memphis cohort, overcrowded shelter conditions and lack of regular healthcare 
can significant increase morbidity and mortality. Indeed some studies (Addie et 
al., 2000), (Ravi et al., 2010) and the impression of veterinary practitioners 
suggest that the outcome of natural FIV infection is not as dramatic as some of 
the cases described under experimental conditions (Diehl et al., 1995b). 
Whereas the cats in the Chicago cohort remained relatively healthy during the 
monitoring period, the cats in the Memphis cohort represented the other 
extreme; in this cohort disease progression, and particularly oncogenesis, was 
dramatic. 
The most common cause of the morbidity observed in the Memphis cohort was 
neoplasia, as discussed above. Although virus-induced immunodysregulation can 
be linked with neoplastic transformation of B-cells, a direct carcinogenic role for 
FIV seems unlikely (Magden et al., 2011). Potentially, another unknown 
infectious agent that could become reactivated in immunocompromised cats 
could be associated with the high incidence of lymphoma among our study 
group. This hypothesis remains to be tested and as a first step, samples from 
these cats will be subjected to next generation sequencing to identify potential 
novel agents related to the lymphomas. 
The results presented in this chapter were limited by the 18 month follow-up 
period of the study. Furthermore, the inclusion of cats from more diverse 
geographic locations would have increased the variability in virulence of wild 
type FIVs examined and their possible contribution to the onset of disease. 
Nevertheless, based on the relatively large number of cases examined and the 
differences between the two geographically distinct cat populations in the study 
population, it can be concluded that while FIV infection may not be associated 
with severe immunodeficiency in many cases, poor or overcrowded living 
conditions, especially in shelters, have a significant impact on the FIV-infected 
cat’s immune system and subsequently lead to the more rapid onset of disease 
and death. 
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Based on these observations, FIV infected cats can remain in relatively good 
health when living in stable, single cat households. No signs of disease were 
observed in the cats within the Chicago cohort that were housed in single cat 
households over a 24 month period. The average duration of the “asymptomatic” 
phase of FIV infection remains unknown and this question will be addressed by 
observing study participants over the next 5 years. 
It is crucial not to underestimate the importance of careful selection of study 
participants as well as the critical interpretation of clinical studies where the 
selection of study subjects (even when based on power calculations) can 
dramatically influence the outcome and conclusions of the research study.  The 
selection of study participants from different locations and housing conditions 
minimized potential results bias. It is apparent that the conclusions of this 
research would have been very different indeed, had efforts been focused on 
only one of the cohorts presented in this study. 
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Chapter 4. Molecular epidemiology of FIV 
Deciphering FIV evolution is essential in understanding the virus interaction with 
the host immune system. In this chapter, viral diversity and evolution are 
quantified in order to examine the influence on the outcome of natural 
infection. This knowledge can aid in the development of more effective 
diagnostic tests, control strategies and, ultimately, may inform the design of  
a fully protective vaccine since the limited efficacy of the FIV vaccine that is 
currently available is largely attributed to the high genetic diversity of wild type 
viruses. 
Serial samples were collected from 44 cats naturally infected with FIV and 
multiple full-length env sequences from each subject were subjected to 
evolutionary analyses. A relatively low overall within-host env sequence diversity 
was observed, indicating the presence of largely homogenous viral populations 
within most cats, regardless of their health status. We observed, however, 
relatively high within-host diversity and evolutionary rate of the leader/signal 
fragment of the env gene, suggesting that this fragment may play an important 
role in regulating viral replication and infectivity. Employing rigorous 
recombination testing, we report for the first time the major role of 
recombination in generating env gene diversity; our findings highlight profound 
limitations in the current phylogenetic classification of FIV. By contrasting the 
evolution of a.) non- recombinant and recombinant sequences and b.) env 
sequences of viruses isolated from healthy and sick animals, we observed 
considerable alterations in their evolutionary kinetics. Lastly, examining the 
global pattern of potential N-linked glycosylation sites between and within cats 
over the study period, we described a potential dual role in maintaining 
glycoprotein integrity and contributing to immune evasion. 
The results of this study shed new light on the evolution of FIV, illustrating the 
relatively high genetic stability of the virus in natural infection. Recombination, 
rather than nucleotide misincorporation by the viral reverse transcriptase, 
appears to generate viral diversity on the population level. Furthermore, the 
altered evolutionary dynamics observed in the terminal stage of disease are 
more likely to be a result rather than a cause of immunodeficiency. 
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4.1 Introduction 
FIV is currently assigned to five distinct subtypes, denoted A, B, C, D and E, 
based on the diversity of the V3-V5 region of the env gene (Nishimura et al., 
1998). Subtype A is prevalent in the west coast of USA (Sodora et al., 1994) and 
Australia (Kann et al., 2006) and is found exclusively in the UK (Samman et al., 
2011), while subtype B is most prevalent on the east coast of USA (Sodora et al., 
1994) and central (Steinrigl and Klein, 2003) and southern (Duarte and Tavares, 
2006) Europe. Subtype C has been identified in California (Sodora et al., 1994) 
and Canada (Bachmann et al., 1997), (Reggeti and Bienzle, 2004) and subtype D 
in Japan (Hohdatsu et al., 1996), (Nishimura et al., 1998), while the putative 
subtype E was reported in Argentina (Pecoraro et al., 1996). Hence, despite 
extensive movement of humans and their cats, geographical clustering of FIV 
(based on the current classification) is still evident, although subtypes A, B and 
C have been found in more than one continent. The majority of published 
sequences represent only the short 700bp V3-V5 region of FIV env and therefore 
likely contain too little information to represent an accurate phylogenetic 
classification; full-length gene sequence is required to enable the precise 
detection of recombination and to permit an accurate phylogenetic 
classification. 
Recombination, together with point mutations introduced by the error prone 
reverse transcriptase (Preston and Dougherty, 1996) and the activity of host 
restriction factors (Chiu and Greene, 2006), is regarded as the most important 
mechanism of generating genetic diversity among retroviruses on both the 
population and the intra-host level (Charpentier et al., 2006), (Onafuwa-Nuga 
and Telesnitsky, 2009). Two features of the retroviral life cycle increase the 
likelihood of recombination: 1) the presence of two RNA genomes within each 
viral particle and 2) the feature of reverse transcriptase (RT) which tends to 
switch between those RNA molecules during provirus synthesis (Zhuang et al., 
2002), (Levy et al., 2004a). Specific features of RT may result in the synthesis of 
recombinant DNA with a mixed ancestry, originating from both RNA molecules 
(Basu et al., 2008). Although in HIV-1 infection recombination occurs between 
homologous viral variants of similar fitness at an exceptionally high rate (Kuwata 
et al., 1997), (Jetzt et al., 2000), its significance in generating genetic diversity 
increases dramatically when a cell becomes infected with two or more 
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genetically distinct virions (Blackard et al., 2002). Recombination may occur 
between virions of the same or different subtypes, resulting in the generation of 
intra- or inter-subtype recombinants respectively (Blackard et al., 2002). 
Recombination can have profound implications on the fitness of the generated 
viral quasispecies and subsequently on pathogenesis and the clinical outcome of 
infection (Tebit et al., 2007). Intra- and inter-subtype recombinants have been 
identified in HIV infection (Robertson et al., 2000), with some being present as 
unique recombinant forms (URF) with limited transmission and commonly 
circulating recombinant forms (CRF) accounting for over 20% of infections in 
several countries (Peeters and Sharp, 2000). 
Although FIV recombinants have been identified (Bachmann et al., 1997), 
(Carpenter et al., 1998), (Reggeti and Bienzle, 2004), (Hayward and Rodrigo, 
2008), the frequency of recombination and the prevalence of CRF amongst 
naturally infected cats is unknown. Given the limitations of the majority of 
previous studies, which focused upon relatively small fragments of DNA 
sequences, it is apparent that the occurrence and role of recombination in 
natural FIV infection may have been underestimated. There is a significant lack 
of knowledge in FIV molecular epidemiology; how prevalent are recombinant 
sequences? What is their composition amongst field isolates and what role does 
recombination play in generating intra-host viral diversity? 
The majority of FIV phylogeny research has focused upon sequence variation at 
the population level (Olmsted et al., 1992), (Sodora et al., 1994), (Pistello et 
al., 1997), (Carpenter et al., 1998), (Teixeira et al., 2010), (Samman et al., 
2011) and has highlighted substantial diversity. In contrast, less is known about 
the mutation rate of FIV and within-host viral diversity in natural infection 
(Motokawa et al., 2005), (Huisman et al., 2008b). In HIV-1 infection quasispecies 
composition varies greatly, with some studies reporting diversity of 10% (Delwart 
et al., 1997). It has also been demonstrated that intra-host diversity may 
influence the outcome of disease and viral diversity correlated with the stage of 
infection (Delwart et al., 1997), (Shankarappa et al., 1999). Similar data is not 
available for FIV; how does the quasispecies composition contribute to the 
clinical outcome of infection? Is there a correlation between viral diversity and 
disease progression? 
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Natural selection acting on viral sequences shapes their genetic variation and 
creates viral diversity. Selection measures have been applied previously to 
assess forces acting upon the evolution of different genes and different regions 
within the same gene (Choisy et al., 2004). For example in HIV-1 infection, the 
gag gene is under negative selection (Kils-Hutten et al., 2001), while env gene 
evolution is generally shaped by positive selection (Wolfs et al., 1990). The gag 
gene encodes structural proteins and its conserved nature is essential to 
maintain viral integrity; inversely the HIV-1 env gene is constantly under immune 
selection pressure and sequence variation permits immune evasion (Yamaguchi 
and Gojobori, 1997). Extrapolating from HIV research, it would be predicted that 
FIV env should be under the same positive selection pressure as its human 
counterpart, but relatively little is known of selection forces acting upon FIV env 
in naturally infected cats. Is FIV env evolution in natural infection driven by 
positive selection? Is the selection pressure distributed uniformly across the gene 
or exerted at particular regions?  
Furthermore, little research has been conducted to elucidate rates of FIV 
evolution (Greene et al., 1993), (Hayward and Rodrigo, 2010). No data are 
available concerning rates of evolution of the entire FIV env gene in the 
domestic cat. Evolutionary studies of HIV-1 infection (Lukashov et al., 1995), 
(Zhang et al., 1997), (Leitner and Albert, 1999), (Shankarappa et al., 1999), 
(Korber et al., 2000) suggest that within-host evolution is influenced by both 
viral and host-dependent factors. Some studies reported increased evolutionary 
rates during the early stages of infection, declining towards terminal stage 
disease (Delwart et al., 1997), (Shankarappa et al., 1999), while others did not 
observe a similar correlation (Mikhail et al., 2005). Nevertheless the assumption 
that, in immunocompetent individuals, virus is under constant pressure and 
evolves at a high rate to adapt to a changing environment provides a plausible 
explanation for the differences in evolutionary rates at different stages of 
disease (Lukashov et al., 1995). It is apparent that rates of evolution are equally 
dependent on the host as viral factors, as demonstrated by comparing the 
evolutionary tempo of different HIV-1 subtypes (Abecasis et al., 2009) as well as 
differences in replication rates of HIV-1 and HIV-2 (MacNeil et al., 2007b). It has 
been hypothesized that FIV clade B viruses are evolutionary older and more host-
adapted, hence less pathogenic, than those of clade A (Sodora et al., 1994). Are 
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there differences in the evolutionary rates of different strains of FIV identified 
as non-recombinant and recombinant? Are recombinant sequences less host-
adapted and do they evolve at a higher rate? Are different regions of the gene 
evolving at the same or different rates? Finally, can we predict the outcome of 
infection by analysing rates of viral evolution? 
Highly variable, glycosylated surface proteins of enveloped retroviruses play an 
important role in the immune evasion (Zhang et al., 2004). N-linked 
glycosylation is the process of post-translational modification in which 
carbohydrate is attached to the nitrogen atom of asparagine on viral envelope 
precursor (Marshall, 1974); alterations in glycosylation pattern may influence the 
conformation of the viral glycoprotein and render variants bearing mutations 
more (or less) susceptible to host immune responses. Hence, it is important to 
analyse the global glycosylation patterns amongst viruses from our study 
population in order to understand viral immune evasion and its possible role in 
disease progression. FIV Env (Pancino et al., 1993b), similarly to HIV Env (Myers 
and Lenroot, 1992), is heavily glycosylated and is referred to as having an 
immunologically silent glycan shield (Moore and Sodroski, 1996). The number of 
potential N-linked glycosylation sites (PNGS) in HIV and SIV is highly variable 
(Wolinsky et al., 1992) and for HIV-1 gp120 has been estimated to range from 18 
to 33 (Korber et al., 2001). To our knowledge, due to the relatively low number 
of full length FIV env sequences available in GenBank, no analyses of global FIV 
cross-clade N-glycosylation sequons has been performed to date. What is the 
global distribution of PNGS on the FIV envelope glycoprotein? How can 
alterations in PNGS patterns facilitate immune evasion and do these correlate 
with the emergence of escape mutants and subsequent disease progression?  
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4.2 Materials and methods 
4.2.1 FIV ORF env sequences 
Multiple full-length FIV env sequences (~2500 bp) were isolated from three serial 
blood samples collected over a period of 12 months from cats recruited in the 
study and described in detail in Chapter 3. Multiple FIV env genes were amplified 
directly from blood, cloned and sequenced according to the protocol detailed in 
Chapter 2. 
There were 355 serial env sequences from 44 cats available for analysis from the 
two cohorts, as detailed below. Analyses were performed using the entire env 
DNA sequences (with the exception of N-linked glycosylation analyses where 
amino acid sequences were used) and, when appropriate, also the three 
fragments: 1) leader/signal region (approx. 509 bp in length), 2) V3-V5 region 
(approx. 630bp) and 3) remaining concatenated fragments of the entire env 
after exclusion of the V3-V5 region, denoted NV (approx. 1900bp). 
4.2.1.1 Memphis cohort 
There were 228 envs available from cats in the Memphis cohort, with 2 to 27 
sequences being obtained from each cat (Table 4-1). 
Table 4-1 Number of sequences isolated from each time point from each Memphis cat. 
No Cat Time point Available 
sequences 
No Cat Time point Available 
sequences 
  A B C    A B C  
1 M5 4 3 3 10 15 M41 3 0 10 13 
2 M11 3 3 (*6) 18 24 (*27) 16 M49 3 0 3 6 
3 M14 3 1(*3) 5 9(*11) 17 M2 0 0 2(*3) 2(*3) 
4 M15 3 2(*3) 3 8(*9) 18 M3 2(*3) 0 0 2(*3) 
5 M28 3 5 3 11 19 M8 0 0 2 2 
6 M30 5 15(*16) 5 25(*26) 20 M10 2 0 0 2 
7 M46 3 3 3 9 21 M20 1(*2) 0 0 1(*2) 
8 M47 3 2(*3) 2(*3) 7(*9) 22 M29 0 0 4 4 
9 M1 2(*3) 0 3 5(*6) 23 M44 2 0 0 2 
10 M16 4 0 2 6 24 M32 3 0 0 3 
11 M25 3 0 3 6 25 M50 4(*5) 0 0 4(*5) 
12 M26 3 0 3 6 26 M12 0(*1) 0 0(*2) 0(*3) 
13 M31 1(*2) 0(*2) 13 14(*17) 27 M48 0(*3) 0 0 0(*3) 
14 M33 7(*8) 14(*16) 0 21(*24)       
          Total 202(*228) 
* including sequences containing a premature stop codon. 
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The number of sequences available for analysis varied according to the 
availability of follow up samples, since 67% of Memphis cats died during the 
study. Accordingly, sequences from 3 time points (A, B, C) were available only 
from 8 cats. For 9 cats, sequences were available from the first and the last 
time point (A, C) and for the remaining 11 cats, sequences were accessible only 
from one time point and were therefore excluded from the majority of 
evolutionary analyses. From the total number of 228 sequences, 26 contained 
premature stop codons (Table 4-1). It is important to acknowledge that 
sequences with premature stop codons (although cannot take part in 
downstream evolution) bear the signature of evolutionary process and for this 
reason their inclusion in the analyses is justified. 
4.2.1.2 Chicago cohort 
There were 127 env gene sequences available for analysis from 16 Chicago cats, 
with 2 to 18 sequences obtained from each animal over 12 months (Table 4-2). 
The seventeenth cat (P1) was excluded from the analyses, as this cat was not 
brought back for blood sampling after the initial sampling. Accordingly, 
sequences from 3 time points were obtained from 6 cats and sequences from  
2 time points were available from an additional 6 animals. For the remaining  
4 cats, data were available only from one time point. From the total of 127 
sequences, 23 contained premature stop codons. 
Table 4-2 Number of sequences generated for each time point for each Chicago cat. 
No Cats Time point Available 
sequences 
No Cats Time point Available 
sequences 
  A B C    A B C  
1 P4 3 4 3(*4) 10(*11) 9 P7 0(*3) 1 1(*4) 2(*8) 
2 P5 2(*3) 3(*4) 3 8(*10) 10 P9 3 0 3 6 
3 P6 3 2 5 10 11 P10 3 1 0 4 
4 P13 3 3 3 9 12 P11 0 2 4 6 
5 P14 2 4(*5) 3 9(*10) 13 P15 0(*2) 0(*3) 0(*3) 0(*8) 
6 P17 2 4 2 8 14 P18 0 1 0 1 
7 P21 0 3 2(*3) 5(*6) 15 P8 5 0 0(*3) 5(*8) 
8 P2 3 15 0 18 16 P22 0 0 3 3 
          Total 104 (*127) 
* including sequences containing a premature stop codon. 
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4.2.1.3 Reference sequences 
A limited number of complete env sequences was available in GeneBank; fifteen 
reference sequences were included in this analysis: FIV Aomori 1; D37814.1, FIV 
Aomori 2; D37811.1, FIV C; AF474246.1, FIV Dixon; L00608.1, FIV Dutch; X60725, 
FIV Fukuoka; D37817.1, FIV Sendai 1; D37816, FIV Shizuoka; AY139094.1, FIV 
UK2; X57001, FIV UK8; X69494, FIV USIL2489; U11820.1, FIV Yokohama; 
D37815.1, FIV Petaluma M25381.1, FIV PPR X69496.1, FIV Leviano FJ374696.1 
and four V3-V5 region sequences representing Clade E: FIV Argentina E D84496, 
FIV Argentina E D84498, FIV Argentina E D84500, RUS14 EF447297. The selected 
sequences represented a good geographical, intra- and inter-clade distribution, 
with overall env diversity exceeding 26%. The env sequence M49C C76 (2583 base 
pairs in length) was selected as a reference sequence in this study. 
4.2.2 Multiple sequence alignment 
Multiple sequence alignments are a crucial prerequisite for phylogenetic analysis 
and were conducted using the Muscle algorithm (Edgar, 2004) in the MEGA 5 
software package (Tamura et al., 2011). Before Muscle alignment was 
performed, all DNA sequences were translated to the corresponding peptide 
sequences using Virtual Ribosome (Wernersson, 2006). Final alignments were 
curated manually following codon optimization by submission of MUSCLE aligned 
peptide sequences and reverse translation to nucleic acid sequences using the 
RevTrans 1.4 Server (Wernersson and Pedersen, 2003). Particular attention was 
paid to ensure re-positioning of incorrect gapping in sequences of various 
lengths. Alignments were numbered according to positions in the M49C C76 
sequence and were saved in FASTA and NEXUS formats for downstream analyses. 
The data set included one master alignment of all sequences and specific 
alignments based on the master alignment were prepared for the purpose of 
various analyses (available on the accompanying CD). 
4.2.3 Phylogenetic trees 
Maximum likelihood (ML) trees were constructed under the HKY nucleotide 
substitution model in MEGA5 (Tamura et al., 2011). Statistical support for ML 
trees was estimated using bootstrapping analysis (Efron et al., 1996) with 1000 
replicates. The HKY model selection was based on jMODELTEST analysis (Posada, 
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2008), since this model has been shown to perform best for the majority of 
retrovirus data sets (Shapiro et al., 2006). All trees were examined and prepared 
for presentation in FigTree v 1.3.1 (http://tree.bio.ed.ac.uk/). The initial ML 
tree was constructed using the entire data set (355 wild type and 19 reference 
sequences) and examined thoroughly for non-monophyletic clustering of intra-
host viral variants. Due to size restrictions and for clarity, the tree presented 
here generally includes one sequence per individual. In cases of non-
monophyletic clustering of variants from some cats, all inconsistently assigned 
sequences were included and highlighted in the tree shown in this chapter.   
4.2.4 Recombination testing 
All sequences, including the reference env sequences obtained from GeneBank 
were subjected to rigorous three fold recombination testing. The initial 
recombination analysis was performed with the Datamonkey webserver (Delport 
et al., 2010), employing Single Breakpoint (SBP) and Genetic Algorithm 
Recombination Detection (GARD) methods (Kosakovsky Pond et al., 2006). 
Neighbour joining trees for each recombination segment identified by GARD and 
assessed by Akaike Information Criterion (AIC) (Sugiura, 1978) were constructed 
within Datamonkey webserver and prepared for presentation in FigTree v 1.3.1. 
Additional testing was performed in RDP4 v4.16 (Martin et al., 2010) employing  
a range of various detection methods such as RDP (Martin and Rybicki, 2000), 
BOOTSCAN (Martin et al., 2005), Maximum Chi Square (Smith, 1992), GENECONV 
(Padidam et al., 1999), CHIMAERA (Posada and Crandall, 2001) and Sister 
Scanning (SISCAN) (Gibbs et al., 2000). Representative figures visualizing 
recombination breakpoints were generated in SimPlot software v 3.5.1 (Lole et 
al., 1999). SimPlot computes and plots the similarity of each sequence to the set 
of reference sequences in a window of adjustable size (which was set to 200bp 
for this study). 
4.2.5 Intra-host diversity 
Intra-host sequence variation amongst the entire env sequences and three 
fragments of the gene (V3-V5, NV and the leader/signal) isolated from each cat 
were calculated as average and highest Kimura-2-Parameter (K2P) pairwise 
distances (Kimura, 1980), employing the Maximum Composite Likelihood model 
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(Tamura et al., 2004) in the MEGA 5 software package (Tamura et al., 2011). 
The codon positions included were 1st, 2nd, 3rd and non-coding. The K2P 
parameter is estimated as following a nucleotide by nucleotide comparison of 
the set of sequences under analysis (Kimura, 1980). 
4.2.6 Selection (dN/dS ratio) 
Nucleotide sites under diversifying/purifying selection at p<0.05 were identified 
and dN/dS ratios for every codon in the alignment were estimated using the 
Single Likelihood Ancestor Counting (SLAC) method incorporated in the 
Datamonkey webserver (Delport et al., 2010). The measure of selection is 
determined by the omega value (ω), the ratio of non-synonymous (dN) to 
synonymous mutations (dS) at each nucleotide site. A higher proportion of non-
synonymous mutations at a given site (ω>1) indicates evidence for positive 
(diversifying) selection. Inversely, the dominance of synonymous mutations at  
a particular site (ω<1) indicates negative (purifying) selection. An equal rate of 
synonymous and non-synonymous mutations (ω=1) indicates no selection (Yang 
et al., 2000). Synonymous substitutions reveal mutation rates, while non-
synonymous substitutions may be influenced by selective pressure exerted by the 
immune system (Yang et al., 2000). 
4.2.7 Rates of molecular evolution 
Rates of evolution of full length and fragments (V3-V5, NV and the leader/signal 
fragment) of FIV env sequences for each cohort and the entire study group were 
estimated using Bayesian Evolutionary Analysis Sampling Trees (BEAST) version 
v.1.7.1 (Drummond and Rambaut, 2007). Additional data sets incorporated into 
the BEAST analysis included non-recombinant and recombinant sequences and 
sequences from alive and deceased cats. 
The BEAST software package employs the Bayesian Markov Chain Monte Carlo 
(MCMC) method to estimate the rates of molecular evolution, offering the 
advantage of incorporating specific prior information into the analysis. The 
output of BEAST is presented as posterior probability distributions for all 
estimated parameters (Drummond et al., 2002). 
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Sequence alignments from animals from which data were available from more 
than 1 time point: 17 Memphis cats (197 taxa) and from 12 Chicago cats (108 
taxa) were saved in NEXUS format prior to loading into BEAUti. The calibration 
information was included in the taxa names as the fraction of the year 
corresponding to the dates of blood sampling. Subsequently, the dates of each 
taxum were estimated by BEAUti and incorporated into the analysis. The HKY 
evolutionary model of substitution with four category gamma distribution 
selecting (1+2), 3 partitions into codon positions (Shapiro et al., 2006) was used. 
The BEAUti-generated XML file was used to run a Bayesian evolutionary analysis 
in the BEAST program using unconstrained root prior. The analyses were 
performed estimating independent trees for each cat, with a single clock rate 
across all trees, under strict and relaxed lognormal clock models with uniform 
distribution clock rate priors. The length of MCMC chain was set for 200 000 000 
iterations with 20 000 000 burn-in but in some instances was run shorter or 
longer, until convergence was obtained.  
The BEAST generated output log file was analysed in TRACER v1.5. Estimates of 
mean clock rate, 95% HPD (highest posterior density) lower and 95% HPD higher 
intervals were collected following the analysis of the posterior distribution for 
each parameter, ensuring that the Effective Sample Score (ESS) was greater than 
100 since this indicates sufficient sampling of the posterior distribution 
(Drummond et al., 2002). 
4.2.8 Identification of potential N-linked glycosylation sites 
Potential N-linked glycosylation sites, and their positions in the protein 
alignment, were identified using the N-GlycoSite tool available at Los Alamos 
National Laboratory web server http://www.hiv.lanl.gov/. Potential N-linked 
glycosylation sites comprise an asparagine residue presented in the context of 
another amino acid succeeded by serine or threonine in following sequence: 
asparagine-X-serine or asparagine-X-threonine, where X can be any amino acid 
(Marshall, 1974) except proline (Gavel and von Heijne, 1990). Figures 
representing the sequence wide number of N-linked glycosylation sites were 
prepared in GraphPad Prism v 5.00 (GraphPad Software, San Diego California 
USA) using data output from N-GlycoSite tool.   
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4.3 Results 
4.3.1 Phylogenetic inference 
The Maximum Likelihood (ML) tree based on the HKY model and with bootstrap 
support of 1000 replications was constructed using the entire data set (not 
shown due to the size). The initial tree was carefully examined for evidence of 
non-monophyletic clustering of multiple sequences isolated from each 
individual. Intra-host sequences isolated from the majority of individuals (n=40, 
93%) clustered together forming monophyletic groups. Sequences from three 
animals (7%) isolated from different time points showed inconsistent 
phylogenetic assignment. Sequences from cat P8 from time point A clustered 
together with clade A viruses, while sequences from the same animal from time 
point C were assigned to clade B. A similar pattern was noted with sequences 
from cat P21; sequences from time point B and time point C were classified as 
clade B and clade A respectively. The env genes from cat M5 were all assigned to 
clade B, but sequences from the last time point did not cluster together with 
sequences from the previous two time points.  
The knowledge gained following the examination of the initial tree described 
above was used to construct a further ML tree based on the same model, 
generally containing one sequence per individual but including all non- 
monophyletic sequences isolated from the animals described above and rooted 
on the reference clade C env sequence (accession number AF474246.1) (Figure 
4-1). Analysis of the tree that was generated after excluding data from cats with 
inconsistent clade assignment revealed that sequences from 25 animals (61%) 
clustered together with previously published clade B reference sequences, while 
sequences from 16 individuals (39%) were assigned to clade A.  The number of 
env genes classified as clade A (7, 50%) and B (7, 50%) were equally distributed 
in the Chicago cats, while this distribution was skewed in favour of clade B (67%) 
in the Memphis cohort. Sequences with incongruent assignment from cats P8, 
P21 and M5 are highlighted in blue, orange and with a red star respectively 
(Figure 4-1). 
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Figure 4-1 Maximum likelihood tree based on the HKY model, rooted on a clade C reference 
FIV env. Percentage bootstrap values are shown next to branches. The tree is drawn to 
scale, with branch lengths measured in the number of substitutions per site. The analysis 
included 54 nucleotide sequences (representative of a total of 355 sequences) and 19 
reference sequences. Tree branches representing clade A, clade B, clade C, clade D and 
clade E viruses are highlighted in red, green, orange, blue and turquoise respectively. Taxa 
with inconsistent clade assignments from cats P21 and P8 are highlighted in orange and 
blue respectively. Non-monophyletic taxa from cat M5 are marked with red stars. Reference 
sequences accession numbers as in materials and methods section. Leaves of taxa 
classified by ML as clade A, but subsequently identified as A/B recombinants are 
highlighted in green. 
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It was notable that sequences from cats M1, M10 and M11 clustered together in 
the ML tree (Figure 4-1); further examination of the nucleotide alignment 
revealed that the sequences were highly similar, with overall K2P mean distance 
of 0.3%. The ML tree of sequences from those individuals based on the HKY 
model and bootstrap support of 1000 replications rooted on the clade B env 
reference sequence (accession number U11820.1) is presented in Figure 4-2 (root 
removed for clarity). On this tree, one sequence from the male cat M10 (M10A 
C285) appeared at the root of the whole group. Examination of the clinical 
records of these cats revealed that they are closely related to each other, with 
cat M1 being the offspring of cat M11. Given the housing conditions, clinical 
history and date of first FIV diagnosis of these 3 cats, it is likely that cat M1 
acquired the virus vertically (cat M11). It is also likely that M10 sired cat M1. 
A description of the ages, duration of infection and clinical history for these cats 
that provides support for the above hypothesis is presented in detail in Chapter 
3 and a CD that accompanies this thesis. 
 
Figure 4-2 Maximum likelihood tree of 35 env sequences isolated from 3 closely related cats 
(M1, M10 and M11 highlighted in blue, red and green respectively) rooted on reference clade 
B env sequence (root removed for clarity). The tree is drawn to scale, with branch lengths 
measured in the number of substitutions per site. Bootstrap values greater than 70% are 
shown next to branches. 
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4.3.2 Recombination  
Initial recombination analysis involved Single Breakpoint (SBP) testing of the 
entire data set within the Datamonkey web server and provided evidence for 
recombination, giving grounds for further recombination testing using more 
sophisticated methods. 
Examining the Memphis sequences, Genetic Algorithms for Recombination 
Detection (GARD) provided evidence of four breakpoints (positions in nucleotide 
alignment: 354, 576, 1575, 1947) with significant topological incongruence 
(p=0.01) (Table 4-3). The submitted alignment was further spliced by GARD at 
the breakpoints into five segments: 1) 1-562; 2) 563-989; 3) 990-1752; 4) 1753-
2286 and 5) 2287-2625, which were used to create five NJ trees, one for each 
segment (Figure 4-5). Examination of these GARD-determined trees revealed 
that sequence segments from 18/27 (67%) Memphis animals showed consistent 
clade assignment and represent non-recombinant clade B envs, while only one 
individual (M8) (1/27; 4%) yielded non-recombinant clade A sequences. Clade 
A/B recombinant sequences were identified in 8/27 (29%) cats. Recombinant 
sequences had different mosaic compositions and were classified in three 
groups: 1) sequences from cats M2, M33, M47 and M50 in which only the first 
segment (1-562) belonging to clade B, while the remaining four segments 
consistently clustered as clade A, 2) sequences from cats M20 and M41 in which  
only the last segment (2287-2625) was assigned to clade B, while all other prior 
segments were assigned to clade A, and 3) sequences from M31 and M41 in which 
the first (1-562) and the last (2287-2625) segments clustered with clade B, while 
the 3 central segments (563-2286) were assigned to clade A (Table 4-3). Next, 
RDP software was used to examine putative parents contributing to the mosaic 
structure of recombinant sequences. RDP consistently identified the clade A, FIV 
Dixon strain (L00608.1) as a putative major parent and determined  
clade B Chicago strains P10BC64 and P2BC24 as putative minor parents for M2, 
M31, M33, M47, M50 and M20, M48 respectively. The analyses and generation of 
figures representing recombination breakpoints were performed for all 
recombinant Memphis sequences in SimPlot (data summarised in Table 4-3).  
A representative SimPlot analysis is shown in Figure 4-3, illustrating 
recombination breakpoints determined by the similarity of the Memphis M31 
query sequence to two putative clade A and B parental sequences. 
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Figure 4-3 Similarity analysis of Memphis A/B recombinant sequence (M31) and two 
reference sequences (clade A, DIXON (L00608.1) in red and clade B, FIV_B (U11820.1)  in 
green) performed in SimPlot. Each line represents the percentage similarity of the query 
M31 sequence to the reference sequences. Recombination breakpoints are placed at the 
intersections of the red and green curves (positions 562 and 2287 on the X axis). 
 
For the Chicago sequences, GARD also provided evidence for four recombination 
breakpoints (p=0.01) and splice aligned sequences into five segments: 1) 1-354; 
2) 355-576; 3) 577-1575; 4) 1576-1947 and 5) 1948-2589 (Table 4-4). The 
locations of the breakpoints in this cohort were different compared to the 
Memphis sequences; nevertheless recombination hotspots between the leader 
and the stem of the V1/V2 region (approx. position 565) and at the V5 (approx. 
position 1600) loop of the SU region of Env were common among recombinants 
from both cohorts. Recombination analysis revealed that sequences from 7 cats 
(50%) were non-recombinant and consistently clustered with the reference clade 
B env sequence. In contrast to the Memphis cohort, there were no pure  
clade A env sequences amongst the Chicago cats; Sequences from the remaining 
7 animals (50%) were identified as A/B recombinants. The mosaic composition of 
the recombinant sequences fell into two groups: 1) sequences from cats P4, P5, 
P7 and P13 in which segment 2 (355-576) belonged to clade B while the rest of 
the sequence (1-354 and 577-2589) clustered with clade A and 2) sequences from 
cats P14 and P18 in which segments 1 and 2 (1-576) were assigned to clade B and 
the remaining part of the sequence (577-2589) clustered with clade A (Table 
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4-4). A similarity plot representative for the Chicago recombinants in relation to 
reference A and B env sequences is shown in Figure 4-4. 
 
 
Figure 4-4 Similarity analysis of PAWS A/B recombinant sequence (P21C) and two reference 
sequences (clade A, DIXON (L00608.1) in red and clade B, FIV_B (U11820.1) in green) 
performed in SimPlot. Each line represents the percentage similarity of the query M31 
sequence to the reference sequences. Recombination breakpoints are placed at the 
intersections of the red and green curves (positions 576, 1576 and 1947 on the X axis). 
 
The Chicago data set also included env sequences from the remaining cats P8 
and P21, identified previously as forming non monophyletic groups (section 
4.3.1). Recombination analysis revealed that P8 sequences from time point  
C were non-recombinant clade B, while time point A sequences were classified 
as A/B recombinants. For cat P21, time point B sequences appeared to be 
entirely clade B, while time point C sequences showed an incongruent 
assignment and were identified as clade A/B mosaics (Table 4-4). 
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Table 4-3 GARD and RDP recombination testing results of Memphis sequences. Segments clustering with clade A and clade B viruses are denoted in red 
and green respectively. The final clade assignment following recombination testing is shown in the column “CLADE”. Non recombinant and recombinant 
sequences are denoted NR and R respectively. RDP determined major and minor parents for mosaic recombinant sequences are shown in the final two 
columns.  
  GARD DETERMINED BREAKPOINTS RDP DETERMINED RECOMBINANTS 
VIRUS SEGMENT 1  
(1-562) 
SEGMENT 2 
(563-989) 
SEGMENT 3 
(990-1752) 
SEGMENT 4 
(1753-2286) 
SEGMENT 5 
(2287-2625) 
EVIDENCE OF 
RECCOMBINATION 
CLADE MINOR 
PARENT 
MAJOR 
PARENT 
M1 B B B B B NR B NR NR 
M2 B A A A A R A/B P10BC64 DIXON 
M3 B B B B B NR B NR NR 
M5AϮ B B B B B NR B NR NR 
M5CϮ B B B B B NR B NR NR 
M8 A A A A A NR A NR NR 
M10 B B B B B NR B NR NR 
M11 B B B B B NR B NR NR 
M12 B B B B B NR B NR NR 
M14 B B B B B NR B NR NR 
M15 B B B B B NR B NR NR 
M16 B B B B B NR B NR NR 
M20 A A A A B R A/B P2BC24 DIXON 
M25 B B B B B NR B NR NR 
M26 B B B B B NR B NR NR 
M28 B B B B B NR B NR NR 
M29 B B B B B NR B NR NR 
M30 B B B B B NR B NR NR 
M31 B A A A B R A/B P10BC64 DIXON 
M32 B B B B B NR B NR NR 
M33 B A A A A R A/B P10BC64 DIXON 
M41 B A A A B R A/B P10BC64 DIXON 
M44 B B B B B NR B NR NR 
M46 B B B B B NR B NR NR 
M47 B A A A A R A/B P10BC64 DIXON 
M48 A A A A B R A/B P2BC24 DIXON 
M49 B B B B B NR B NR NR 
M50 B A A A A R A/B P10BC64 DIXON 
Ϯ sequences from the same individual but different time points with previously identified non-monophyletic clustering. 
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Figure 4-5 NJ trees for each of five GARD determined segments of Memphis sequences.  Trees A, B, C, D and E represent phylogenetic inference of 
segments 1 (1-562), 2 (563-989), 3 (990-1752), 4 (1753-2286) and 5 (2287-2625) respectively. Recombinant sequences are indicated by various shapes placed 
next to sequence names - note various clade assignment for each sequence segment from the same individual at each of the trees (e.g. follow red triangle 
for M31). Reference clade A sequences (DIXON, SENDAI, PETALUMA, GL-8) are highlighted in red, clade B (FIV-B) in green, clade C (FIV_C) in orange and 
clade D (FIV_D) in blue and the clades of tree branches are identified accordingly. All trees are rooted on the FIV_C reference env sequence. 
A. Segment 1 B. Segment 2 C. Segment 3 D. Segment 4 E. Segment 5 
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Table 4-4 GARD and RDP recombination testing results of Chicago sequences. Segments clustering with clade A and B viruses are highlighted in red and 
green respectively. The final clade assignment following recombination testing is shown in the column “CLADE”. Note that there were no pure non-
recombinant clade A envs in this cohort. Non recombinant and recombinant sequences are denoted NR and R respectively. RDP determined major and 
minor parents for mosaic recombinant sequences are shown in the final two columns. 
 GARD DETERMINED BREAKPOINTS RDP DETERMINED RECOMBINANTS 
VIRUS SEGMENT 1  
(1-354) 
SEGMENT2 
(355-576) 
SEGMENT3 
(577-1575) 
SEGMENT4 
(1576-1947) 
SEGMENT5 
(1948-2589) 
EVIDENCE OF 
RECCOMBINATION 
CLADE MINOR PARENT MAJOR 
PARENT 
P2 B B B B B - B NR NR 
P4 A B A A A + A/B P10BC64 DIXON 
P5 A B A A A + A/B P10BC64 DIXON 
P6 B B B B B - B NR NR 
P7 A B A A A + A/B P10BC64 DIXON 
P8AϮ B B A A A + A/B P10BC64 DIXON 
P8CϮ B B B B B - B NR NR 
P9 B B B B B - B NR NR 
P10 B B B B B - B NR NR 
P11 B B B B B - B NR NR 
P13 A B A A A + A/B P10BC64 DIXON 
P14 B B A A A + A/B P10BC64 DIXON 
P15 B B A A A + A/B P10BC64 DIXON 
P17 B B B B B - B NR NR 
P18 B B A A A + A/B P10BC64 DIXON 
P21BϮ B B B B B - B NR NR 
P21CϮ B B A B A + B/A P10BC64 DIXON 
P22 B B B B B - B NR NR 
Ϯ sequences from the same individual but different time points with previously identified non-monophyletic clustering. 
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Figure 4-6 NJ trees for each of five GARD determined segments of Chicago sequences. Trees A, B, C, D and E represent phylogenetic inference of 
segments 1 (1-354), 2 (355-576), 3 (577-1575), 4 (1576-1947) and 5 (1948-2589) respectively. Recombinant sequences are indicated by various shapes placed 
next to sequence names - note various clade assignment for each sequence segment from the same individual at each of the trees (e.g. follow red triangle 
for P14). Reference clade A sequences (DIXON, SENDAI, PETALUMA, GL-8) are highlighted in red, clade B (FIV-B) in green, clade C (FIV_C) in orange and 
clade D (FIV_D) in blue and the clades of tree branches are identified accordingly. All trees are rooted on the FIV_C reference env. 
A. Segment 1 B. Segment 2 C. Segment 3 D. Segment 4 E. Segment 5 
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4.3.3 Intra-host viral diversity 
The K2P overall mean and highest pairwise distances representing the intra-host 
diversity of the entire env sequences and the three fragments (leader, V3V5 and 
NV) from the Memphis cohort are presented in Table 4-5. The average mean 
pairwise distance for the entire env was calculated as 0.57% (median 0.3%; range 
from 0% to 5.5%), while the mean highest pairwise distance was estimated as 
1.1% (median 0.5%; range from 0% to 11.7%). The average mean pairwise 
distances for the leader, V3V5 and NV regions were estimated to be 0.77% 
(median   0.3%; range from 0% to 6.3%), 0.79% (median 0.2%; range from 0% to 
8.9%) and 0.44% (median 0.3%; range 0% to 2.2%) respectively.  
Table 4-5 Average and highest K2P distances (as percentages) for the leader, V3V5, NV 
fragments as well as the entire env sequences from each Memphis cat obtained over 12 
months.  
Cat 
OVERALL MEAN AND HIGHEST PAIRWISE DISTANCE (%) 
entire env leader V3V5 NV 
mean highest mean highest mean highest mean highest 
M1 0.2 0.4 0.2 0.4 0.2 0.5 0.2 0.3 
M2† 0.8 0.9 1.6 1.8 0.9 1.3 0.8 0.8 
M3† 0.9 1 1.3 1.6 0.9 1.1 0.9 1 
M5‡ 5.5 11.7 6.3 13.7 8.9 19 2.2 4.7 
M8† 1.9 1.9 2 2 2.5 2.5 1.7 1.7 
M10† 0.3 0.3 0.2 0.2 0.2 0.2 0.3 0.3 
M11 0.3 0.7 0.5 1.8 0.5 1.1 0.3 0.7 
M12 0.5 0.7 0.3 0.4 1.4 1.8 0.3 0.2 
M14 0 0.2 0 0.2 0 0 0.1 0.2 
M15 0.1 0.2 0.2 0.6 0 0.2 0.1 0.2 
M16 0.2 0.4 0.5 1 0.1 0.2 0.2 0.4 
M20† 0.2 0.2 0.8 0.8 0 0 0.4 0.4 
M25 0.7 1.1 0.5 0.8 2 3.2 0.4 0.5 
M26 0.1 0.2 0.1 0.4 0.2 0.5 0.1 0.1 
M28 0.2 0.6 0 0.2 0.3 1.1 0.1 0.4 
M29† 0 0.1 0 0 0 0 0.1 0.1 
M30 0.1 0.5 0.2 0.7 0 0.3 0.1 0.5 
M31 0.4 0.7 0.4 0.8 0.9 1.8 0.3 0.5 
M32† 0.1 0.1 0.1 0.2 0 0 0.1 0.1 
M33 0.5 1.1 0.9 2.9 0.5 1.3 0.5 1.2 
M41 0.9 4.1 2.7 14.6 0.3 0.8 1.2 5.6 
M44† 0 0 0.2 0.2 0 0 0.1 0.1 
M46 0 0.2 0.1 0.4 0 0.2 0 0.2 
M47 0.4 0.9 0.4 1.2 0.6 1.3 0.3 0.7 
M48† 0.4 0.5 0.3 0.4 0.2 0.3 0.3 0.5 
M49 0.7 1.3 0.7 1.2 0.9 1.7 0.7 1.2 
M50† 0.1 0.2 0.2 0.4 0 0 0.1 0.3 
† Sequences obtained from one time point only, ‡ outlier data excluded from mean calculations. Values in red highlight 
outlier pairwise distance values (excluded from mean calculations). 
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The average highest pairwise distances were 1.81% for the leader (median 0.7%; 
range from 0% to 14.6%), 1.5% for the V3-V5 region (median 0.5%; range from 0% 
to 19%) and 0.84% for the NV region (median 0.4%, range from 0.1% to 5.6%). 
It was apparent that sequences from cat M5, as already highlighted by the ML 
tree (section 4.3.1), showed the highest degree of diversity, with values 
regarded as outliers and therefore excluded from further analysis. Similarly, 
data obtained from only one time point (highlighted with “†” in Table 4-5) were 
limited and were excluded from adjusted intra-host diversity calculations. After 
excluding the outlier data, the overall mean distance for the entire env was 
0.33% (median 0.25%; range 0% - 0.9%) and the average highest pairwise distance 
was 0.83% (median 0.65%; range 0.2% - 4.1%). For the leader, V3-V5 and NV 
fragments, the average mean distances were calculated as 0.48% (median 0.35%; 
ranging from 0% to 2.7%), 0.49% (median 0.3%; ranging from 0% to 2%) and 0.3% 
(median 0.25%; ranging from 0% to 1.2%). The average highest pairwise distances 
were estimated as 1.73% for the leader (median 0.75%; ranging from 0.2% to 
14.6%), 1% for the V3-V5 region (median 0.95%; ranging from 0% to 3.2%) and 
0.8% for the NV region (median 0.45%; ranging from 0.1% to 5.6%).  
The mean and highest pairwise distances calculated for sequences isolated from 
the Chicago cohort are shown in Table 4-6. As highlighted previously (section 
4.3.1) cats P8 and P21 showed highest pairwise distances greater than 10% and 
so these cats were excluded from mean calculations. The average overall mean 
distance for the entire env sequences from the Chicago cats was calculated as 
0.42% (median 0.2%; range from 0% to 1.7%) and the average highest pairwise 
distance was 0.87% (median 0.4%; range from 0.1% to 2.9%). The average mean 
pairwise distances for the leader, V3-V5 and NV fragments were 0.48% (median 
0.35%; range from 0% to 1.4%), 0.43% (median 0.15%; range from 0% to 1.8%), 
and 0.42% (median 0.2%; range from 0% to 1.6%). The highest pairwise distances 
for the leader, V3-V5 and NV fragments were 1.07% (median 0.8%; range from 
0.2% to 2.4%), 1.13% (median 0.4%; range from 0.2% to 3.9%) and 0.88% (median 
0.55%; range from 0.1 to 2.7%). 
For the whole study group, the overall mean distances for the entire env ranged 
from 0% to 1.7% (mean 0.37%; median 0.2%) and highest pairwise distances 
ranged from 0.1% to 4.1% (mean 0.85%; median 0.5%). The overall mean 
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distances for the fragments of env ranged from 0% to 2.7% for the leader (mean 
0.48%; median 0.35 %), from 0 to 2% for the V3-V5 region (mean 0.47%, median 
0.25%,) and from 0% to 1.6% for the NV region (mean 0.35%, median 0.2%,). 
Highest pairwise distances ranged from 0.2% to 14.6% (mean 1.45%, median 
0.8%), from 0% to 3.9% (mean 1.05, median 0.65%) and from  0.1% to 5.6% (mean 
0.84%, median 0.5%) for the leader, V3-V5 region and NV region respectively. 
Table 4-6 Average and highest K2P distances (percentages) for the leader, V3V5, NV regions 
and the entire env sequences from each Chicago cat obtained over 12 months.  
Cat 
OVERALL MEAN AND HIGHEST PAIRWISE DISTANCE (%) 
entire env leader V3V5 NV 
mean highest mean highest mean highest mean highest 
P2 0.5 1.5 0.4 0.8 0.5 1.1 0.5 1.7 
P4 0.9 1.8 0.8 2.1 1 3.9 0.8 1.5 
P5 0.2 0.5 0.3 1.2 0.1 0.3 0.2 0.6 
P6 0.2 0.4 0.3 0.8 0 0.2 0.2 0.6 
P7 1.7 2.9 1.4 2.4 1.8 3.3 1.6 2.7 
P8 ζ 11 20.8 4.2 8.4 8.9 19 12.1 23 
P9 0.2 0.4 0.4 0.8 0.1 0.2 0.2 0.5 
P10 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 
P11 0 0.1 0.1 0.4 0.1 0.2 0 0.1 
P13 0.1 0.4 0.2 0.4 0.5 2 0.1 0.2 
P14 0.1 0.2 0 0.2 0.1 0.3 0.1 0.2 
P15 0.9 1.6 1.2 2.4 0.7 1.3 1 1.9 
P17 0.2 0.4 0.5 1.2 0.2 0.5 0.2 0.4 
P18*† n/a n/a n/a n/a n/a n/a n/a n/a 
P21ζ 7.1 11.9 3.2 5.8 21.8 36.5 10.5 17.7 
P22† 0.3 0.4 1.5 2.1 0.3 0.5 0.3 0.4 
Ϯ sequences available from one time point only and excluded from mean calculations 
* only one sequence available 
ζ outlier data (in red) excluded from mean calculations  
 
An overall comparison of intra-host diversity amongst the entire env sequences 
as well as fragments from both cohorts, represented as highest pairwise 
distances, is shown in Figure 4-7. It is evident that at the level of the study 
group that the highest mean intra-host diversity occurs in the leader/signal 
region of env (0.15% greater than for the V3-V5 fragment). A similar pattern of 
high intra-host diversity within the leader/signal region was evident in the 
Chicago cohort but not in the Memphis cohort. 
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Figure 4-7 K2P highest pairwise distances between fragments and the entire env sequences 
isolated over 12 months from 12 Chicago, 16 Memphis cats and the entire study group. 
Sequences obtained from cats from only one time point and outlier data from cats M5, P8 
and P21 were excluded from the analysis. Median values (horizontal bars) for the leader, V3-
V5, NV and env: Memphis (0.75%, 0.95%, 0.45% and 0.65%), Chicago (0.8%, 0.4%, 0.55% and 
0.4%), study group (0.8%, 0.65%, 0.5% and 0.5%) respectively. Values for the leader of env 
M41 (14.6) are not included for clarity. 
 
4.3.4 Selection (dN/dS ratio) 
The mean ω value (dN/dS ratio) for env sequences obtained from the study 
group was 0.34. Examining the entire data set, at p=0.05 significance level, SLAC 
indicate 14 (1.6%) positively and 201 (23%) negatively selected sites (Table 4-7). 
For the Memphis and Chicago cohorts, ω values were 0.29 and 0.36 respectively, 
with 7 and 2 positively selected sites respectively. However, a marked 
difference in the number of negatively selected sites was observed between the 
two cohorts; 169 and 37 negatively selected sites were identified for the 
Memphis and Chicago env sequences respectively. A similar trend in the number 
of negatively selected sites was evident when comparing selection forces acting 
upon recombinant and non-recombinant sequences (Table 4-7). 
A comparison of selection forces acting upon sequences from cats of different 
health status revealed that 5 and 3 sites were positively selected while 125 and 
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97 sites were under negative selection in alive and deceased cats respectively 
(p=1, Fisher’s exact test). 
Table 4-7 SLAC determined dN/dS ratios and tally of positively and negatively selected sites 
within each cohort examined. Positions of positively selected sites are highlighted in the 
final column. 
Cohort dN/dS Number of selected sites Positively selected sites 
positively negatively 
Study group (305†) 0.34 14 201 8, 62, 96, 156, 157, 364, 394, 400,  
456, 487, 565, 750, 853, 865 
Memphis(191†) 0.29 7 169 62, 364, 392, 400, 565, 567, 750 
PAWS (114†) 0.36 2 37 8, 364 
Non recombinants (172†) 0.28 5 121 62, 176, 364, 567, 750 
Recombinants (133†) 0.41 6 51 8, 96, 156, 392, 400, 726 
Alive (141†) 0.32 5 125 8, 168, 364, 455, 760 
Deceased (164†) 0.28 3 97 62, 103, 394 
† tally of sequences (identical, duplicate sequences were excluded prior to analysis) 
The sites identified as being under positive selection (at p=0.05) are listed in 
Table 4-7 and are restricted to specific regions of the viral Env: sites 8, 62, 96, 
103, 156, 168, 175,176 lie within the leader region, sites 364, 394, 400 in the V3 
region and sites 455, 456, and 487 in the V4 region while sites 565, 567 lie within 
the V5 region. The remaining positively selected sites, 726, 750, 760, 853 and 
865, were located within the TM region of Env (Figure 4-14). The selection hot 
spots at positions 394, 400, 487, 750 and 853 were located within B cell epitopes 
identified in previous studies (Pancino et al., 1993a), (Lombardi et al., 1993), as 
shown in Figure 4-8, suggesting that non-synonymous mutations at those 
positions may have arisen as a result of immune selection pressure. 
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Figure 4-8 Sites under positive (p<0.01) selection identified by SLAC in the complete data 
set, with corresponding ω values. Red lines along the X axis indicate the locations of B cell 
epitopes (Pancino et al., 1993a), (Lombardi et al., 1993). It was notable that positively 
selected sites at positions 394, 400, 487, 750 and 853 lay within previously identified B cell 
epitopes. 
 
4.3.5 Rates of molecular evolution 
Estimated evolutionary rates for the leader, V3-V5, NV regions as well as the 
entire env gene isolated from Memphis (M), Chicago (C) and whole study group 
(SG) were calculated under strict and relaxed lognormal clock models with 
unconstrained root prior and are shown in Table 4-8, together with HPD (higher 
posterior density) and effective sample size (ESS) values.  
As demonstrated in the Table 4-8, the entire env gene from the Memphis 
population evolved at the mean rate of 4.58 x 10-4 substitutions per site per 
year, corresponding to 0.46% per decade, under a strict clock model. Relaxing 
the clock model to the lognormal adjusted the evolutionary rate estimate to 
9.94 x 10-4 substitutions per site per year (0.99% per decade). To determine 
whether specific regions of the env gene in the Memphis population evolved at 
different rates, MCMC chain was used to estimate clock rates for the leader 
(approx. 509 bp), V3-V5 region (approx. 630 bp) and remaining concatenated 
fragments of the entire env gene after exclusion of the V3-V5 region, denoted 
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NV (1900 bp). As shown in Table 4-8, the leader region evolved at a rate of 1.2% 
per decade under strict clock model and 3.1% per decade under relaxed clock 
model. The V3-V5 region evolved at a significantly slower rate of 0.7% per 
decade (strict) and 0.8% per decade (relaxed). The remaining 1900 bp NV 
fragment was estimated to evolve, under strict and relaxed clock models 
respectively, at the mean rate of 0.52% and 0.95% per decade (Table 4-8). 
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Table 4-8 Evolutionary rates for the entire env gene, the leader, V3-V5 region and concatenated entire env excluding the V3-V5 region  (NV), estimated 
under strict and relaxed clock models for genes amplified from the Memphis and Chicago cohorts and the entire study group (Memphis and Chicago). 
Additional comparisons of evolutionary rates include: 1) entire env of recombinant and non-recombinant viruses and 2) the entire and fragments of env 
sequences from alive and deceased cats. Evolutionary rates are presented as the number of substitutions per site per year. Effective sample size (ESS) 
values and lower (95% HPD lower) and upper (95% HPD upper) posterior densities are denoted for each cohort and clock model.  
Cohort (†,*) Clock 
model 
Evolutionary rate (*10
-4
) 
substitutions/site/year) 
95% HPD lower (*10
-4
) 95% HPD upper (*10
-4
) ESS 
leaderζ V3-V5‡ NV Ŧ env₮ leaderζ V3-V5‡ NV Ŧ env₮ leaderζ V3-V5‡ NV Ŧ env₮ leaderζ V3-V5‡ NV Ŧ env₮ 
Memphis 
(17†,197*) 
Strict 11.8 7.05 5.29 4.58 4.49 2.56 2.19 1.7 19.5 11.6 8.76 7.7 449 262 323 225 
Relaxed 
lognormal 
31.4 7.82 9.52 9.94 9.36 2.58 4.02 1.6 59.4 14.1 16.3 16.2 328 337 157 303 
Chicago 
(12†,108*) 
Strict 21.2 11.5 6.39 7.85 9.56 3.48 1.46 2 32.7 19.9 11.6 13.3 1118 1208 307 640 
Relaxed 
lognormal 
33.4 21.1 17.7 17.3 15.27 5.25 5.76 5.7 56.4 39.9 31.9 30.3 1125 1452 530 584 
Study group 
(29†, 305*) 
Strict 15.25 7.92 5.49 5.11 8.59 3.83 2.78 2.25 22.3 12.2 8.2 7.9 246 370 216 137 
Relaxed 
lognormal 
34.3 10.8 12 11.6 15.52 4.99 5.94 6.99 56 17.4 18.7 16.7 383 350 123 243 
Non 
recombinants 
(18†,184*) 
Strict - - - 2.44 - - - 1 - - - 4.5 - - - 208 
Relaxed 
lognormal 
- - - 6.6 - - - 1.9 - - - 11.8 - - - 224 
Recombinants 
(11†,123*) 
Strict - - - 8.85 - - - 4.25 - - - 13.6 - - - 584 
Relaxed 
lognormal 
- - - 21.4 - - - 9 - - - 34.5 - - - 373 
ψ
ALIVE 
(6†,46*) 
Strict 17.69 23.8 8.24 6.72 1 6.57 2.51 1.3 34.9 42.5 14.68 12 2800 4129 5157 3105 
Relaxed 
lognormal 
20.5 27.38 8.61 8.7 1.3 6.28 2.39 1.0 40.8 50.9 15.26 17.3 979 3620 4204 1479 
ψ
DECEASED 
(11†,151*) 
Strict 13.1 5.91 5.11 4.58 4.4 1.29 1.39 1.7 23.15 10.3 8.67 7.8 601 695 363 260 
Relaxed 
lognormal 
33.7 6.49 10.53 10.5 9.7 2 3.39 4.2 66.6 11.7 18.51 17.6 232 398 376 315 
†tally of partitions; * tally of taxa; ζ leader – rates estimated for 509 bp fragment including leader/signal region; ‡ V3-V5 – rates estimated for highly variable region of viral env (630bp); Ŧ NV – rates 
estimated for “non-variable” regions of env comprising concatenated sequence after exclusion of V3-V5 region (~1900bp),  ₮ env – rates estimated for entire gene (~2500 bp); ψ – Memphis. Rates for 
recombinant/no recombinant sequences are calculated for the entire gene only due to various mosaic compositions of recombinant sequences. 
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Evolutionary rate estimates for the Chicago sequences were markedly higher 
than for the Memphis sequences (Figure 4-9). The mean evolutionary rates under 
the strict clock model for the entire, leader, V3-V5 and NV fragments of the env 
were estimated as 0.78%, 2.1%, 1.2% and 0.6% per decade respectively. Relaxing 
the clock model returned estimates of 1.7%, 3.3%, 2.1% and 1.8% per decade 
respectively (Table 4-8). 
Evolutionary rates under strict clock model for the whole study group (SG) were 
1.5%, 0.8%, 0.55% and 0.5% per decade for the leader, V3-V5, NV and the entire 
env respectively. Relaxing clock model returned estimates equivalent to 3.4%, 
1.1 %, 1.2 % and 1.16 % per decade per respective fragments (Table 4-8). 
Further, as demonstrated in Figure 4-9 A and B, we compared the rates of 
evolution under both clock models between and within the cohorts. The median 
rates of evolution of the entire gene and all three fragments under both clock 
models were markedly higher for the Chicago sequences compared to the 
Memphis sequences. Next we asked which region of the env gene evolved at the 
highest pace and which was most conserved. The rates calculated for the 
respective fragments across three data sets (Chicago and Memphis cohorts and 
the entire study group), under the strict clock model, consistently showed that 
the leader region evolved at a markedly higher rate compared to the V3-V5 or 
NV regions (Figure 4-9 A). This pattern across the three data sets was confirmed 
under the relaxed clock model for the leader region, which was consistently 
seen to evolve at a higher rate than the V3-V5 or NV regions (Figure 4-9 B). In 
contrast, the rate differences between the V3-V5 and NV regions under the 
relaxed clock model did not show the same pattern as the respective estimates 
under the strict model. Although the same pattern was visible within the 
Chicago cohort, the inverse was observed compared to the strict clock model 
estimates for the Memphis V3-V5 region which was found to evolve at slightly 
lower rates than the NV fragment. 
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Figure 4-9 Distribution (median, 5, 25, 75 and 95 percentiles shown) of the evolutionary rates 
calculated under A) strict and B) relaxed lognormal clock model for the: 1) leader (grey), 2) 
V3V5 fragment (green), 3) NV fragment (red) and 4) entire env gene (blue). Evolutionary 
rates are compared between sequences isolated from Memphis (M), Chicago (C) and entire 
study group (SG). Rates are represented as x10
-4 
substitutions per site per year. 
 
To test the hypothesis that the recombinant sequences (n=123) were 
evolutionary younger than the pure non-recombinant sequences (n=184), the 
distribution of their evolutionary rates were compared (Table 4-8). As 
demonstrated in Figure 4-10, a clear difference in the rates between the two 
groups was observed. Non recombinant envs were estimated to evolve at the 
rates of 2.44 and 6.6 x 10-4 substitutions per site per year (0.24% and 0.66% per 
B 
A 
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decade) under strict and relaxed clock models respectively, whereas the 
recombinant sequences evolved faster, at the rates of 8.85 and 24.4 x 10-4 
substitutions per site per year (0.89% and 2.4% per decade) under strict and 
relaxed clock models respectively. 
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Figure 4-10 Distribution of evolutionary rates of recombinant (n=123) and non-recombinant 
env sequences (n=184) calculated under strict (green) and relaxed (red) clock models. 
Compared groups are highlighted with horizontal bars. 
 
Finally we hypothesised that rates of evolution in healthy cats would be higher 
than in terminally ill (deceased) cats. Figure 4-11 A and B illustrate a comparison 
of the evolutionary rates under the two clock models for env sequences, and 
fragments, from 11 deceased and 6 animals which remained healthy and free 
from clinical signs during the study period. Under the strict clock model the 
entire env, the leader, V3-V5 and NV fragments from healthy cats evolved at 
markedly higher rates than those from deceased animals (6.72 and 4.58, 17.69 
and 13.1, 23.18 and 5.91, 8.24 and 5.11 x 10-4 substitutions per site per year 
respectively) (Figure 4-11 A). This relationship, however, was reversed under the 
relaxed clock model for all of the fragments (env, leader and NV) except for the 
V3-V5 region (Figure 4-11 B) which consistently, under both clock models, was 
shown to evolve at a higher rate in healthy cats.  
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Figure 4-11 Comparison of evolutionary rates under: A) strict and B) relaxed clock models 
of the leader, V3-V5, NV fragments and the entire env genes isolated from 6 alive (healthy, 
A) and 11 deceased (sick, D) cats during the 18 month observation period. 
 
4.3.6 Potential N-linked glycosylation sites 
Analysis of 329 FIV Env sequences revealed variation in length between 848 
(M30C C88) and 861 (M49C C76) amino acids. As shown in Figure 4-12, the tally 
of estimated N-linked glycosylation sites varied from 20 to 26 across the Env 
A 
B 
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glycoprotein. The majority of analysed sequences (32.5%) contained 25 N-linked 
glycosylation sites. 92 Envs (27.9%) contained 23 such sequons, while 79 (24%) 
Envs were predicted to be glycosylated at 24 positions. The lowest number, 20 
glycosylation sites, was observed in 6 Envs (1.8%), namely M2C C1, M2C C5, M47A 
C135, Shizuoka, Petaluma and Dixon. At the other extreme, 7 novel Envs (2.1%) 
contained 26 potential sequons: P5A C7, P5B C118, M27A C104, M27A C194, M27A 
C200, M27C C63 and M27C C65.  
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Figure 4-12 Frequency  of potential N-linked glycosylation sites (sequons) on the surface of 
the SU and TM region of Env (n=315) with inclusion of reference sequences (n=14) 
representing clades A, B, C and D: FIV Aomori 1; D37814.1, FIV Aomori 2; D37811.1, FIV C; 
AF474246.1, FIV Dixon; L00608.1, FIV Dutch; X60725, FIV Fukuoka; D37817.1, FIV Sendai 1; 
D37816, FIV Shizuoka; AY139094.1, FIV UK2; X57001, FIV UK8; X69494, FIV USIL2489; 
U11820.1, FIV Yokohama; D37815.1, FIV Petaluma M25381.1, FIV PPR X69496.1.  
 
An investigation of the global distribution of predicted N-linked glycosylation 
sites revealed that, regardless of the high genetic variability of the analysed 
sequences (which differed from each other by over 26%, calculated as K2P 
highest distance in peptide alignment), conserved sequon sites do indeed exist 
across all the analysed sequences. As shown in Figure 4-13, six sequons at 
positions 303, 335, 347, 536, 553 and 738 were fixed amongst all the Envs 
examined (n=329, 100%). Sequons at positions 263, 279, 423, 427, 504 and 734 
were fixed in 328 (99.6%) Envs, while positions 341, 523 and 746 were 
glycosylated in 327 (99.3%) sequences. Three other positions (namely 754, 274 
and 474) were frequently glycosylated and were present in 99%, 98.7% and 97.2% 
of sequences, respectively. Additional analyses revealed the existence of  
a second pattern of N-linked glycosylation sites for which the frequency at the 
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population level was inconsistent. These shifting sequons, shown in Figure 4-13, 
were mainly located between sites 120-225, 473-494 and 556-569 and at 
positions 377, 831 and 853 of the Env. To investigate whether those sites were 
common amongst diverse isolates of FIV we examined their variability at the 
intra-host level. For the purpose of this analysis we included sequences from 
21/44 (47.7%) cats in which intra-host variation of N-linked glycosylation sites 
was evident. Sequences from the remaining 23 (52.3%) cats were excluded 
because in those individuals there was no evidence of variation (data not 
shown). 
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Figure 4-13 Frequency of predicted N-linked glycosylation sites on the FIV Env. Analysis 
was performed on Env sequences isolated in this study and reference sequences 
representing clades A, B, C and D (n=319). Positions 303, 335, 347, 536, 553 and 738 (red) 
represent fixed sequons among all clades (n=329) from different geographic origins. 
Sequons at positions 263, 279, 423, 427, 504, 734 (green) and 341, 523, 746 (blue) were also 
fixed and were present in 328 and 327 sequences respectively. The remaining glycosylation 
sites were fixed in less than 97% of Env sequences (black). The positions of sequons in the 
peptide alignment are based on the reference isolate M49CC76. 
 
In Table 4-9 the positions in the alignment and intra-host range of N-linked 
glycosylation sites are highlighted. An analysis of shifting sequons revealed the 
existence of N-linked glycosylation sites, which, as a result of substitutions, 
appear and disappear and differ between Env variants from the same individual. 
Four shifting sites, at positions 486, 556, 561 and 831, were shared between  
3 (14%), 4 (19%), 4 (19%) and 5 (24%) cats respectively, suggesting that variations 
at those sites may play a role in immune evasion. The locations of the putative 
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sequons identified in this study are shown on the model of FIV SU and TM (Figure 
4-14) and coincide with previously identified B-cell epitopes (Lombardi et al., 
1993), (Pancino et al., 1993a).  
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Table 4-9 Frequency patterns and locations of predicted shifting N-linked glycosylation sites on Env. The comparison is based on the pattern of N-linked 
glycosylation sites from viral variants isolated from each cat over 3 time points. Note the shifting number of sequons within homologous viral variants 
isolated from each individual (column 3).  There were 4 “hot spots” for shifting sequons identified (positions 486, 556, 561 and 831, highlighted in red) 
which consistently appeared and disappeared within Env variants isolated from 3, 4, 4 and 5 cats respectively. For clarity, this comparison includes Env 
sequences isolated from 21/44 (47.7%) cats in which variation of N-linked glycosylation sites was identified. Position of sequons in peptide alignment is 
based on the reference sequence of isolate M49CC76. The sequon locations are shown relative to the V1-V9 regions of Env. 
Cat 
Tally of isolated 
functional envs 
Range of sequons 
on gp160 
Position in the alignment 
leader V1-V2  V3   V4   V5 V7-V9 
136 138 225 263 279 341 377 423 453 474 486 494 523 553 556 560 561 566 567 568 569 734 831 861 
P1 3 24-25                 •        
P2 15 24-25      •           •        
P4 10 23-25    •    •      • • • • • •     • 
P5 8 25-26                       •  
P7 2 22-23         • •  •             
P9 6 23-24                       •  
P10 4 24-25           •              
P17 8 23-24                       •  
P21 5 22-24       •                •  
M3 2 24-25 •                        
M5* 10 21-23     •            •      •  
M8 2 21-23      •     •              
M11 24 22-23             •            
M14 9 24-25                      •   
M25 6 24-25   •                      
M26 6 23-24               •          
M31 14 22-24  •        •               
M33 21 23-24               •          
M44 2 24-25 •                        
M47 8 20-22           •    •          
M49 6 23-25                    • •    
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Figure 4-14 Model of SU and TM proteins of FIV (adapted from (Pancino et al., 1993b) with modifications by (Willett et al., 2008)) illustrating location of 
predicted N-linked glycosylation sites identified in this study as fixed and shifting. Fixed sequons are highlighted in red, green and blue (see Figure 4-13). 
Sequons identified as shifting are highlighted in orange. Di-sulphate bonds are shown as red lines between Cysteines. Predicted α-helices are denoted with 
grey lines. Positions in peptide alignment are based on the reference isolate of M49CC76. 
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4.4 Discussion 
Analyses of the FIV env gene sequences isolated in this study offered a unique 
opportunity to examine the molecular epidemiology and dynamics of FIV in 
naturally infected cats. 
The phylogenetic relationship of the sequences isolated from both cohorts, as 
estimated using the ML method, was in agreement with previously published 
data demonstrating clade A and clade B viruses in the USA (Sodora et al., 1994). 
It should be emphasized, however, that the ML method initially employed, did 
not account for potential recombination and, indeed, erroneously classified 
isolated sequences. However subsequent, more rigorous, recombination testing 
demonstrated that Envs with shared recombination points and with inconsistent 
clade assignment were widely circulating in Memphis and Chicago; such results 
confound the current phylogenetic classification of FIV isolates. 
Recombination is an important event in retroviral evolution, which, in cases of 
super-infection, may lead to the emergence of novel viral variants. Newly 
created recombinants may exhibit novel pathogenicity compared to the parental 
strains, for example manifesting more severe clinical outcomes or spreading 
more easily within and amongst hosts (Onafuwa-Nuga and Telesnitsky, 2009). 
Cats living in free roaming populations, where the abundance of FIV is high, are 
likely to share viruses during multiple transmission events. This phenomenon has 
been documented in experimental FIV infection (Okada et al., 1994), with one 
study describing recombination following super-infection (Kyaw-Tanner et al., 
1994). Recombinant sequences in the present study were consistently identified 
in subsequent follow up samples, suggesting that such genotypes did not arise as 
a result of either PCR errors or contaminants. The high prevalence of clade A/B 
recombinants with common break points in our study group may suggest that 
these represent enzootic recombinant viruses with a significant fitness 
advantage that may be widely distributed in the field. A similar pattern of 
recombination, with a shared break point within gag, was reported in a Canadian 
study, suggesting the existence of enzootic circulating recombinant forms in 
Ontario (Reggeti and Bienzle, 2004). In HIV infection, recombinant viruses 
sharing identical mosaic structures play an important role in the HIV pandemic 
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and are referred to as circulating recombinant forms (CRF) (Robertson et al., 
2000). However, the term CRF can only be applied to viruses from distinct 
epidemiological areas. Therefore, taking into account the history of the Chicago 
and Memphis cohorts, we propose that the mosaic viruses identified in this study 
represent putative CRF of FIV.  
The results of this study highlight the advantage of examining entire gene 
sequences. The detection of recombination increases with the nucleotide length 
screened and therefore the majority of previous studies (which examined only 
short 500-700bp fragments of the env gene) underestimated the role of 
recombination using a simplified phylogenetic classification. It is apparent that 
applying the common approach of examining the most variable V3-V5 loop of the 
env gene may result in possible misidentification of intra- and inter-subtype 
recombinants and erroneous subtype assignment. For example, viruses from this 
study such as M2, M33 and M48 would be wrongly classified as clade A if only 700 
bp fragments of the env were examined. Indeed, there was no recognition of 
recombination in the study of Texas isolates of FIV that focused on the V3-V4 
sequence of env (Weaver et al., 2004). Similarly, a study by (Duarte and 
Tavares, 2006) focusing upon the V3-V5 region of env failed to consider 
recombination and, as proven by (Hayward and Rodrigo, 2008), erroneously 
classified isolated sequences as a result. 
The lack of information about CRF of FIV in the field has wider implications than 
FIV classification (Nishimura et al., 1998); most importantly it poses a significant 
question surrounding the efficacy of the current FIV vaccine. It is not known 
what degree of protection against clade A/B recombinant viruses is achieved 
following Fel-O-Vax FIV vaccination. Furthermore, the existence of recombinant 
sequences can also confound the molecular diagnosis of FIV infection as 
recombinant viruses may not be detected by the PCR-based diagnostic tests that 
are used to distinguish FIV vaccinated and FIV infected cats in countries where 
the vaccine is widely available (Little et al., 2011). 
Our analyses revealed the existence of at least two common recombination 
break points, located at the stems of the V1/V2 and V5 loops of the SU of FIV 
Env. Common recombination breakpoints, also referred to as hotspots (Onafuwa-
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Nuga and Telesnitsky, 2009) have been reported in both FIV (Reggeti and 
Bienzle, 2004) and HIV (Anderson et al., 1998), (Wooley et al., 1998), (Jetzt et 
al., 2000), (Zhuang et al., 2002), (Levy et al., 2004a), (Dykes et al., 2004) 
infections. Although recombination occurs frequently in vitro (An and 
Telesnitsky, 2002), (Rhodes et al., 2003), (Chen et al., 2006), it has been 
suggested that recombination hot spots depend on selection rather than 
reflecting RT template switching hotspots (Onafuwa-Nuga and Telesnitsky, 
2009). The vast majority of recombinant viruses display low fitness, do not 
survive within the host (Archer et al., 2008) and therefore the recombinant Envs 
identified in our study may possess a significant fitness advantage in comparison 
with parental sequences.  
Of particular interest is the first recombination breakpoint separating the leader 
region from the remainder of the env gene. Indeed several recombinant env 
sequences were identified in which the leader/signal region clustered with clade 
A while the other segments clustered with clade B. Given the location of this 
first recombination breakpoint, together with the relatively high number of 
positively selected sites and the highest evolutionary rate of this segment, it 
may be speculated that the leader region has a significant function in the virus 
life cycle. The N-terminal signal peptide of FIV plays an important role in post-
translational targeting of the Env precursor and its translocation through the 
endoplasmic reticulum (ER) (Verschoor et al., 1993). Recent studies of viral 
leader sequences highlighted their enormous complexity, suggesting a role not 
only in post-translational but also in post cleavage events (Lemberg and 
Martoglio, 2002), (Hegde and Bernstein, 2006). Leader encoded peptides can 
play a role in self-antigen presentation (Borrego et al., 1998), a property 
exploited by human cytomegalovirus that has a signal peptide with nine residues 
identical to the MHC I signal peptides (Tomasec, 2000) and facilitates evasion of 
NK cells detection by presenting a virus-encoded MHC I molecule (Ulbrecht et 
al., 2000). Furthermore, sequence variation amongst the signalling peptides of 
acute and chronic isolates of HIV has been demonstrated (Gnanakaran et al., 
2011). The present study highlights for the first time that the highest intra-host 
diversity and highest evolutionary rate occurs within the FIV leader/signal 
sequence when all env regions were examined. These findings suggest that the 
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leader/signal region is under positive selection and may play an important role 
in regulating Env expression on the viral surface (Hegde and Bernstein, 2006) and 
therefore viral infectivity. This hypothesis however requires validation in 
functional studies and warrants further investigation.  
Sequences isolated from the majority of animals (93%) formed highly 
monophyletic groups, suggesting that viruses were not transmitted between cats 
in spite of them being either continuously or at least at some point in contact 
with each other. In the Memphis cohort, where all cats live in the same 
household, sequences from a single cat (M5), isolated from the last sample 
collected prior to its death, did not cluster together with sequences from two 
previous time points; rather there was a high similarity to sequences from cats 
M1, M10 and M11. Given the clinical history of M5, a female cat that was not 
involved in territorial fights and lived a solitary lifestyle, the classical virus 
transmission via biting appears unlikely in this case. However, cat M5 did 
experience a severe cat flea (Ctenocephalides felis) infestation during the last 
months of her life, prior to the last blood sampling. Although FIV transmission by 
cat flea has not been documented, this blood sucking ectoparasite is a potential 
vector for transmission of FeLV (Vobis et al., 2003). If cat M5 had become 
superinfected between time points B and C via any route, we would have 
expected to isolate at least two groups of viral sequences (M5AB and M10 like), 
as well as possibly mosaic sequences arising following recombination between 
superinfecting and already existing viruses. But three sequences isolated from 
time point C did not have those features; rather there was high similarity to 
sequences from animals M1, M10 and M11. Given the small number of sequences 
isolated from this time point and sampling bias, it remains possible that M5A and 
M5B sequences remained but were less abundant than freshly acquired M10 like 
viruses. It is also possible that the degenerate primers used for amplification 
bound more effectively to the latter group of viruses. Sequencing more viral 
variants from the last sampling from cat M5 could possibly resolve this issue.  
In the Chicago group, sequences from two different time points from each of 
two cats (P8A, P8C and P21B, P21C) similarly did not form monophyletic groups 
and were even assigned, using the ML method, to two different clades. Given 
the sequencing and recombination testing data from other cats in the Chicago 
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cohort, it was apparent that cat P8 shared viral sequences from time point  
A with cat P14. Taking into account the shared accommodation and fight wounds 
reported on clinical examination of those two cats, one-way transmission might 
have occurred. However, time point A virus was not isolated from cat P8 at time 
point C, a finding that could be explained by primer sampling bias, as discussed 
above. Sequence data from cat P21 showed a similar pattern; in this case 
however, sequences from time point B were highly similar to that of cat P9 and 
classified as clade B, while sequences from time point C clustered within clade 
A. Although there was no reported history of fighting between those cats, super-
infection may still have occurred. 
Finally, it cannot be completely excluded that sequences from those three 
animals represented contaminants rather than viruses circulating in those cats. 
Special measures were undertaken to avoid contamination, both in the clinical 
and laboratory settings. Cats were double identified prior to blood sampling, 
PCR reactions were prepared in a designated UV treated room and fresh, 
unopened reagents were used at each separate time points throughout the 18 
months of study to avoid any possibility of cross-contamination. 
Analyses of sequences from three closely related animals (M1, M10 and M11) and 
their clinical history, age and date of first FIV diagnosis led to speculation that 
the oldest male cat M10 may have infected female M11 during mating, followed 
by vertical or horizontal transmission to its offspring M1. The overall mean 
distance between all sequences obtained from these three cats following at 
least two postulated transmission events is remarkably low. However, a study 
examining V3-V5 env sequence diversity of the Aomori-2 strain of FIV following 
vertical transmission demonstrated 100% homology between viruses isolated 
from the mother and kitten 48 weeks post transmission, suggesting that a high 
degree of homology is maintained for at least 2 years after infection (Motokawa 
et al., 2005). A similar study examining V3-V5 env sequence diversity in 3 cats 
over a period of 9 years found a single amino acid change compared to the initial 
inoculum, indicating the high genetic stability of FIV (Ikeda et al., 2004). Hence, 
in agreement with two previous studies (Ikeda et al., 2004), (Motokawa et al., 
2005) the results presented here suggest that the env sequences of clade B, M10 
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like viruses are stably maintained during vertical transmission and display little 
diversity following transmission to the new host. 
Although the leader signal sequence displayed the highest intra-host variation, 
overall the intra-host diversity of env in the majority of cases examined was 
surprisingly low in light of the high mutation rate of viruses carrying the error 
prone RT enzyme. However, differences in intra-host diversity and evolutionary 
rates were observed between different cats and can be attributed to replication 
tempo differences between wild type strains, as described for HIV-1 and the less 
pathogenic HIV-2. Although both viruses achieve similar proviral loads in infected 
individuals, HIV-2 replicates to lower titres in the plasma (Popper et al., 2000), 
(MacNeil et al., 2007b), displays a lower rate of sequence evolution (MacNeil et 
al., 2007a), lower pathogenicity reflected by a slower decline in CD4+ T cell 
numbers and slower disease progression (Marlink et al., 1988), (Marlink et al., 
1994), (Whittle et al., 1994), (Popper et al., 1999). Similarly, the low pathogenic 
bovine immunodeficiency virus (BIV) which is closer to FIV than primate 
lentiviruses in evolutionary terms, also exhibits very little sequence variation 
(Carpenter et al., 2000). The results presented here demonstrate a similar 
pattern to HIV-2 infection and are in agreement with previous studies indicating 
a relatively high genetic stability of FIV (Ikeda et al., 2004), (Motokawa et al., 
2005), (Huisman et al., 2008b). Similarly, low intra-host diversity was reported 
in a study of clade A GL-8 experimental infection employing end point dilution 
sequencing of the provirus (Kraase et al., 2010). The results obtained here from 
naturally infected cats and employing amplification direct from blood samples 
are in agreement with previous reports, despite the different methodologies. 
The range of the entire env intra-host diversity observed here is likely 
attributable to differences in the replication rates of wild type FIV isolates, as 
suggested for SIV infection (Eastman et al., 2008). Similarly it has been 
postulated that differences in intra-host sequence variation between HIV-1 and 
HIV-2 could be attributed to different rates of replication of those two closely 
related viruses (MacNeil et al., 2007a), (MacNeil et al., 2007b). 
The high genetic stability of some lentiviruses may be associated with the 
fidelity of their reverse transcriptase (Lewis et al., 1999) as well as with the 
replication rate. Mutations in the catalytic YMDD motif of HIV-1 RT have been 
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implicated in increasing fidelity (Olmsted et al., 1989), (Operario et al., 2005). 
However mutations in this particular motif were not evident in FIV RT 
sequences; instead, the V148S mutation associated with an increased fidelity of 
the SIV RT was apparent (Huisman et al., 2008b). This may lead to speculation 
that FIV RT has better proofreading capacity compared to the RT of HIV-1. The 
presence of identical or almost identical sequences, in the present study may 
indicate that a high proportion of FIV is present in a latent form within the 
cellular compartment. It is possible that virus evolution is constrained due to the 
high fitness cost associated with divergence from the parental virus. 
The slow rate of evolution documented in terminal HIV-1 infection has been 
suggested to be linked to a weakening immune system (Shankarappa et al., 
1999), (Delwart et al., 1997). In the present study, a comparison of the 
evolutionary rates between healthy and terminally sick cats of the leader, NV 
and the entire env gene did not show a consistent pattern under two clock 
models. However, the V3-V5 fragment which contains neutralisation epitopes 
and is under immune system surveillance (Pancino et al., 1993a), (Lombardi et 
al., 1993) was consistently shown, under both clock models, to evolve at  
a markedly higher rate in healthy cats. In addition, the rates of evolution across 
all data sets from the Chicago cats (which were generally in good health) were 
consistently higher that those estimated for sequences from the Memphis cats 
(which tended to have more clinical signs). Similarly we observed significantly 
higher evolutionary rates of recombinant compared to non-recombinant 
sequences. Those results support the hypothesis that as a result of strong 
selection pressure, the virus evolves at a higher rate in healthy immune-
competent animals and that the rate of viral evolution is increased following the 
recombination event. 
By comparing amino acid sequences and global patterns of potential N-linked 
glycosylation sites (PNGS), 19 sites were identified that were conserved among 
over 97% of the examined sequences, with six PNGS displaying 100% fixed cross-
clade pattern. This striking consistency at the population level suggests that 
glycosylation at these sites is likely to play an essential role in the folding and 
integrity of the viral glycoprotein. Patterns of fixed N-linked glycosylation sites 
have also been noted in infections with SIV (Chackerian et al., 1997) and HIV-1 
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group M subtypes A through G (Gao et al., 1996). A comparison of all FIV env 
sequences revealed that the number of N-linked glycosylation sites varies from 
20 to 26 between various isolates and a similar trend has been documented in 
HIV gp120, with numbers of PNGS ranging from 18 to 33 (Korber et al., 2001). In 
comparison to the range of N-linked glycosylation sites in HIV (Zhang et al., 
2004), the range reported here is lower.  
At the intra-host level, the existence of a second shifting in glycosylation 
pattern was evident. Shifting PNGS appeared and disappeared on the 
glycoprotein and differed between variants isolated from the same individual 
over a period of time. Although they are distributed throughout Env, we 
identified 4 shifting sites that were consistently present in 14 % of the analysed 
sequences, two of which were located in the V5 loop of SU. The role of these 
variable sequons, which as the result of mutation appear and disappear, might 
be associated with immune evasion, for example by masking epitopes for 
neutralising antibodies (Samman et al., 2010) or CTLs, as has been demonstrated 
for HIV (Chen et al., 2009). Indeed, glycosylation sites identified in this study 
overlapped with previously identified B cell epitopes (Pancino et al., 1993a), 
(Lombardi et al., 1993). Moreover, the alteration of a single N-linked 
glycosylation site in the FIV Env has been shown to modulate the virus-receptor 
interaction (Willett et al., 2008), highlighting the potential importance of 
shifting N-linked glycosylation sites in immune evasion and viral adaptation. 
Whether alterations in the glycan shield on the individual level play a role in the 
virus-host interaction and are responsible for escape from immune surveillance 
will be addressed in Chapter 5 of this thesis. 
Finally, the short (12 month) sampling period provided limited information about 
the intra-host diversity and rate of evolution compared to a longer study (Seo et 
al., 2002); additional longitudinal samples were not examined due to time 
restraints. The methodology used in this study also has potential limitations, 
attributed mainly to PCR sampling and cloning bias (Simmonds et al., 1990), (Liu 
et al., 1996b). However, in contrast to previous studies, the high fidelity Phusion 
enzyme was used rather than the error prone Taq polymerase. Furthermore, in 
order to minimize template switching during the PCR, three independent 
amplifications were set up from each blood sample. All procedures were 
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performed separately at various time points over a period of 18 months to 
exclude the possibility of cross-contamination. Indeed, the finding that this 
methodology yielded identical sequences, particularly those with shared 
recombination points over a period of 12 months, as well as the precautionary 
cross-contamination measures, provides evidence that the amplicons that were 
identified did reflect real circulating sequences and were neither the result of 
PCR induced errors nor associated with polymerase template switching. 
Moreover the results of the present study are in agreement with previous FIV 
studies employing “bulk” PCR (Ikeda et al., 2004), (Motokawa et al., 2005), end-
point dilution proviral DNA PCR (Kraase et al., 2010) as well as a study examining 
sequences from plasma viral RNA (Huisman et al., 2008b). These studies using 
different methodologies consistently suggested that FIV sequence variation is 
relatively low, highlighting its relatively high genetic stability.  
In conclusion, a high abundance of recombinant env sequences was found in 
naturally infected cats, with relatively low intra host diversity and a low rate of 
evolution of the entire FIV env. It was demonstrated that various fragments of 
the env gene evolve at significantly different rates, with the leader sequence 
displaying the largest number of substitutions over time. The results of this 
study suggest that the potential of the FIV reverse transcriptase to generate 
variation is likely offset by functional limitations and the fitness of the resulting 
virions. The relatively low rate of viral evolution and greater genetic stability of 
FIV compared to HIV-1 can perhaps be attributed to different replication 
kinetics, as has been suggested for HIV-1 and HIV-2. Based on the data presented 
here as well as clinical observations, it appears that FIV in naturally infected 
cats behaves more like HIV-2, being less pathogenic and exhibiting less dramatic 
clinical signs than have been reported in some experimental infections  
(de Rozières et al., 2004). 
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Chapter 5. Neutralising antibody response to FIV 
infection 
Little is known about the role of neutralising antibodies (NAbs) in controlling FIV 
infection and subsequent disease progression. Here we present studies 
examining the neutralisation of homologous and heterologous FIV env (HIV-luc) 
pseudoviruses by sequential plasma samples collected from naturally infected 
cats. We evaluated the breadth of the NAb response against non-recombinant 
homologous and heterologous clade A and clade B viral variants and 
recombinants and assessed the results, looking for evidence of an association 
with duration of infection, CD4 T lymphocyte numbers, the health status and 
survival times of the infected cats. 
Our results demonstrated that neutralisation profiles varied significantly 
between FIV infected cats and that strong autologous neutralisation, assessed 
using in vitro assays, was not related to the clinical outcome. No association was 
observed between strong NAb responses and either improved health status or 
survival time of infected animals, implying that other protective mechanisms are 
likely to be involved. Similarly, there was no correlation between the 
development of autologous NAbs and the duration of infection. Furthermore, we 
identified cross-neutralising antibodies in only a small proportion of animals. 
This may suggest, given the relatively long duration of infection prior to 
enrolment and the genetic stability of FIV env (as demonstrated in the previous 
chapter), that there was a low level of antigenic stimulation following natural 
FIV infection. Alternatively, the lack of cross-reactive antibodies may be related 
to the non-specific hypergamma-globulinemia that is induced following infection 
with FIV. 
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5.1 Introduction 
Neutralising antibodies (NAbs) are immunoglobulins (Ig) produced by plasma cells 
that comprise a crucial component of humoral immunity against various 
pathogens including viruses (Amanna et al., 2008), (Plotkin, 2008). NAbs are 
believed to comprise an essential component of the protective immune response 
induced by vaccines against FIV and HIV infections (Hosie et al., 2011), (Kwong 
et al., 2012). However, relatively little is known about the role of humoral 
immunity in controlling retroviral infections and subsequent disease progression, 
particularly for FIV infection (Hogan and Hammer, 2001a), (Hogan and Hammer, 
2001b), (Xiao et al., 2002), (Piantadosi et al., 2009), (Gray et al., 2011b), (Hosie 
et al., 2011). 
HIV infection results in the rapid production of binding and neutralising 
antibodies (Baum, 2010). Binding antibodies recognise viral particles but are not 
always capable of neutralisation; nevertheless such antibodies may still offer a 
modest degree of protection, as has been demonstrated in SIV (Demberg et al., 
2007) and HIV (Rerks-Ngarm et al., 2009b) vaccine trials. Neutralising antibodies 
specifically target epitopes on SU and TM, including receptor and co-receptor 
binding sites (Binley et al., 2008). However, their efficacy is subject to 
significant challenges. Env is covered with host glycans that shield neutralisation 
epitopes, often rendering them inaccessible to NAbs (Myers and Lenroot, 1992). 
Furthermore, HIV and FIV Envs may display significant length polymorphisms 
(Kraase et al., 2010), (Euler and Schuitemaker, 2012) that may result in 
conformational changes and concealment of neutralisation epitopes (Hoxie, 
2010). 
Mechanisms of blocking retroviral infection other than direct neutralisation of 
free viral particles include antibody dependent cell mediated cytotoxicity 
(ADCC) and antibody dependent cell mediated viral inhibition (ADCVI) (Baum, 
2010). Cells infected with HIV express viral epitopes on their surface which may 
be targeted by specific antibodies (Isitman et al., 2012). Following the initial 
binding to infected cells, the Fc region of such antibodies binds FcγIII receptors 
on the surface of effector cells, such as natural killer cells (NK) or monocytes, 
which subsequently kill virus-infected cells (Forthal and Moog, 2009).  
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Antibodies recognising HIV-1 Env appear approximately two weeks after 
infection but lack neutralising activity (Tomaras and Haynes, 2009). Autologous, 
highly strain-specific, polyclonal NAbs appear within 3 months after infection, 
exert selection pressure and lead to the emergence of escape mutants (Richman 
et al., 2003) (Li et al., 2006), (Li et al., 2007), (Moore et al., 2008), (Li et al., 
2009). It has been documented in HIV-1 infection that autologous NAbs have 
little or no protective effect on disease progression (Richman et al., 2003), 
(Bunnik et al., 2008), (Mahalanabis et al., 2009), (van Gils et al., 2010), (Gray et 
al., 2011b). The lack of correlation between autologous NAbs and disease 
progression is mainly attributed to the rapid emergence of escape mutants at 
low fitness cost (van Gils et al., 2010), (Bunnik et al., 2010).  
It has been suggested that NAbs appear too late following infection with HIV-1 in 
order to be effective in controlling disease progression, leading to the 
emergence of autologous neutralisation escape mutants (Richman et al., 2003), 
(Rong et al., 2009), (Moore et al., 2009). However, NAbs have been shown to 
have a potential role in controlling SHIV infection in macaques depleted of 
cytotoxic T lymphocytes (CTLs) (Rasmussen et al., 2002). Furthermore, pre-
exposure passive transfer of broadly neutralising monoclonal antibodies has been 
shown to confer protection against SIV and SHIV-1 in the rhesus macaque model 
(Mascola et al., 1999), (Mascola et al., 2000), (Baba et al., 2000), (Veazey et al., 
2003), (Ferrantelli et al., 2004), (Hessell et al., 2009a), (Hessell et al., 2009b), 
providing evidence that NAbs do indeed play a protective role and may be an 
essential component of a protective vaccine response (Hoxie, 2010).  
The emergence of neutralisation escape mutants with altered glycosylation 
patterns has been demonstrated both in HIV (Burton et al., 2005), (van Gils et 
al., 2010), and FIV (Samman et al., 2010) infections. Neutralisation escape, 
accompanied by the subsequent evolution of the antibody response following a 
delay, adapts during the course of infection in response to the evolving viral 
shield, until the eventual exhaustion of the immune system (Euler and 
Schuitemaker, 2012). This explains why NAbs from a specific time point can 
neutralise viruses isolated from earlier time points but fail to neutralise 
contemporaneous viral variants (Geffin et al., 2003), (Richman et al., 2003), 
(Mascola and Montefiori, 2010), (Overbaugh and Morris, 2012).  
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HIV infection, in the majority of patients, leads to a robust production of 
antibodies that often possess the ability to neutralise autologous (Zolla-Pazner 
et al., 2004) but not heterologous viral variants. Broadly cross-reactive 
neutralising antibodies (Cr-NAbs) are relatively rare; elicited in some individuals, 
Cr-NAbs neutralise not only autologous viral variants but also neutralise other 
viral subtypes (Walker et al., 2011). Several broadly neutralising monoclonal 
antibodies (mAbs) such as b12, 2G12, 2F5, 4E10 have been isolated, their binding 
epitopes characterized (Muster et al., 1993), (Gorny et al., 1994), (Trkola et al., 
1996b), (Burton et al., 1994), (Zwick et al., 2001) and protective roles in animal 
models demonstrated (Mascola et al., 1999), (Mascola et al., 2000), (Binley et 
al., 2004). Recent evidence suggests that Cr-NAbs are more common than 
previously estimated (Walker et al., 2011), (Bonsignori et al., 2011), (Medina-
Ramirez et al., 2011), (Mikell et al., 2011), (Euler and Schuitemaker, 2012), 
emerging in approximately one third of HIV-1 infected individuals (Stamatatos et 
al., 2009). However, neutralisation breadth does not develop until 
approximately 3 years post infection (Mikell et al., 2011), (Gray et al., 2011b). It 
remains unknown why, and by which mechanism, such antibodies develop in 
some individuals or why the broadly neutralising response is significantly delayed 
in response to infection (Gray et al., 2011b). Furthermore, it is unclear whether 
neutralisation cross-reactivity can be attributed to a single, highly potent 
antibody, or perhaps a combination of different antibodies that act in synergy 
(Scheid et al., 2009). 
It was observed that the strength and breadth of the NAb response was greater 
in progressors compared to aviraemic or long-term non-progressors (LTNP) 
(Doria-Rose et al., 2009). Studies of elite controllers (EC) revealed that 
individuals who controlled viral replication such that their viraemia was below 
detectable levels, had the lowest levels of NAbs (Pereyra et al., 2009), 
(Lambotte et al., 2009). Consistent with this observation, the breadth of Cr-NAbs 
was positively correlated with higher plasma viral loads, lower CD4 lymphocyte 
counts and disease progression (van Gils et al., 2009), (Piantadosi et al., 2009), 
(Sather et al., 2009), (Euler et al., 2010). These studies suggest that the 
development of Cr-NAbs is influenced by strong antigenic stimulation (Gray et 
al., 2011b). On the other hand, individuals who did not develop Cr-NAbs, fail to 
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do so as a result of insufficient antigenic stimulation and possibly non-specific 
hypergamma-globulinemia (Euler and Schuitemaker, 2012).  Despite the breadth 
and potency of Cr-NAbs in vitro, such antibodies do not appear to influence HIV-
1 disease progression; rather their incremental development is associated with 
increased viral loads and declining numbers of CD4+ T lymphocytes (Piantadosi 
et al., 2009), (van Gils et al., 2009), (Euler et al., 2010), (Gray et al., 2011a). 
Very little is known about the role of NAbs in controlling natural FIV infection 
and subsequent disease progression (Hosie et al., 2011). What is the relationship 
between the duration of infection, health status, survival time and NAb response 
in FIV infected cats? Can a strong NAb response delay disease progression? Is 
there evidence for broadly Cr-NAbs in plasma samples from naturally infected 
cats? In this chapter we address these questions by measuring the NAb responses 
in cats naturally infected with FIV, testing samples collected at 6 monthly 
intervals over an 18 month period. 
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5.2 Materials and methods 
5.2.1 FIV pseudotypes 
Full length wild type env genes amplified from 44 participating cats from various 
time points as well as reference envs from clade A (GL-8) and reference clade B 
(B2542) were cloned into the eukaryotic expression vector VR1012 (Hartikka et 
al., 1996) and transformed into Escherichia Coli MAX Efficiency® DH5α™ 
Competent Cells (Invitrogen), using methods described in Chapter 2. Next, the 
VR1012 plasmids expressing FIV env were transiently co-transfected with HIV 
pNL4-3-Luc-E-R-luc plasmid (an env-deleted HIV provirus containing the 
luciferase reporter gene) (Connor et al., 1995) into HEK 293T cells (Graham et 
al., 1977) using Superfect Transfection Reagent (Invitrogen) as per the 
manufacturer’s instructions. Following a 72 hour incubation in 6 well culture 
clusters (Corning), culture fluids containing pseudoviruses were harvested, 
centrifuged at 1000 rpm (~200 x g)for 5 minutes, passed through 0.45 µm filters 
and stored at -80°C until required. 
The resulting pseudotypes, bearing FIV Envs on an HIV backbone and denoted 
HIV(FIV Env)luc are single round, replication competent pseudoviruses that can 
be used to assess the neutralisation properties of test plasma samples.  
Pseudotypes bearing naturally occurring FIV Envs (1 to 23 per cat, subject to 
availability) and 2 reference HIV(GL-8) and HIV(B2542) pseudotypes were 
assessed in neutralisation assays. Pseudotypes were prepared that bore Envs 
from 38 cats (38/44, 86.4%); we were unable to produce viable pseudoviruses 
bearing Envs from 5 cats (5/44, 11.4%), (predominantly because of premature 
stop codons in the env sequences) and one cat dropped out of the study. 
The nomenclature for the pseudotypes bearing the naturally occurring FIV Env 
proteins that were isolated from three sequential sampling times (A, B and C) is 
detailed in Chapter 3. 
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5.2.2 Plasma samples  
Plasma samples were collected from 38 FIV infected cats from Memphis and 
Chicago at 6 monthly intervals over a period of 18 months, unless cats had died 
during the interim period (Chapter 3). Plasma samples denoted A, B, C and D 
relate to each time point respectively (Chapter 3). 
5.2.3 Neutralisation assay 
Plasma samples were tested for NAb using HIV(FIV)luc pseudotypes. Plasma 
samples were diluted 1 in 10, 100, 1000 and 10000 in complete RPMI 1640 medium 
(Invitrogen). 25μl of each plasma dilution were incubated in triplicate for one hour 
at 37°C with 25μl of HIV(FIV)luc pseudotype and then 5 × 104  of CLL-CD134 cells 
(Willett et al., 2006b) were added in 50µl. The cells were cultured in 
CulturPlate™-96 assay plates (Perkin Elmer) for 72 hours. Luciferase activity was 
quantified following the addition of 100μl of Steadylite HTS™ (Perkin Elmer) 
substrate and single photon counting was conducted using a MicroBeta 
luminometer (Perkin Elmer). 
The neutralisation activity of the tested plasma samples is presented here as “fold 
neutralisation”. Fold neutralisation was calculated by dividing the mean luciferase 
counts of control wells containing no plasma (NP luc) with the mean luciferase 
counts for wells containing 1 in 10 plasma dilutions (P luc) according to the 
following equation: 
                    
      
     
 
Fold neutralisation is comparable to percentage neutralisation (Table 5-1) 
calculated according to the following equation: 
                 
(              )
       
      
Plasma samples were classified as not neutralising, weakly, moderately or 
strongly neutralising according to empirical cut-off values as indicated in Table 
5-1. 
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Table 5-1 Classification of neutralisation potency of plasma samples. 
 Neutralisation potency 
absent weak moderate strong 
fold 
neutralisation 
1.0 1.6 1.7 2.4 2.5 5.0 5.6 10 100000 
% 
neutralisation 
0 % 39 % 40 % 59 % 60 % 80 % 81 % 90 % 100% 
 
5.2.4 Graphs and statistical analyses 
Graphs and statistical analyses were performed in GraphPad Prism v 5.00 
(GraphPad Software, San Diego, California, USA). For clarity, values for fold 
neutralisation at 1 in 10 plasma dilutions are shown in the summary table 
presented in this chapter.  
Data for individual cats are presented in Appendix 4. Pseudotypes bearing Envs 
isolated at time points A, B and C are highlighted in red, green and blue 
respectively in all graphs. The values for the reference pseudotypes HIV(GL-8) 
and HIV(B2542) are shown in orange and purple respectively. Plasma samples 
from time points A, B, C and D are shown on the x axis in red, green, blue and 
black respectively. 
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5.3 Results 
5.3.1 Autologous and heterologous neutralisation patterns in FIV 
infected cats 
In order to determine the potency and pattern of neutralisation, one to four 
sequential plasma samples (subject to availability) from each cat (n=38) were 
tested for neutralisation against a panel of pseudotypes bearing Envs of 
heterologous reference isolates of FIV (clade A, GL-8 and clade B, B2542) as well 
as Envs from autologous isolates (numbers varied from 1-23 autologous Envs from 
each cat tested). Plasma samples displayed variable autologous and heterologous 
neutralisation patterns, ranging from strong, through moderate to no 
neutralisation. 
As shown in Table 5-2, sixteen cats from the study group (16/38, 42.1%) 
displayed potent neutralisation against at least one of the pseudotypes bearing 
an autologous Env. This pattern was observed in eight (8/16, 50%) of the cats 
which remained alive for the duration of the study and eight (8/16, 50%) of the 
cats that died during the study. Six cats (6/38, 15.8%) displayed moderate 
neutralisation of pseudotypes bearing autologous Env variants; all but one of 
these cats remained alive during the observation period. Plasma samples from 
sixteen cats (16/38, 42.1%) failed to neutralise pseudotypes bearing autologous 
Env variants; nine of these cats (9/16, 56%) remained relatively healthy whereas 
seven (7/16, 44%) of the cats with no detectable NAbs died during the study 
period. Only five cats (5/38, 13%) demonstrated strong heterologous 
neutralisation of at least one pseudotype (Table 5-2). Graphs representing the 
neutralisation patterns of the plasma samples from each cat are presented in 
Appendix 4. 
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Table 5-2 Summary of autologous and heterologous NAb responses of plasma samples, 
expressed as fold neutralisation. Sequential plasma samples from 38 cats were assessed 
against pseudotypes bearing autologous Envs and two reference pseudotypes, bearing 
Envs of GL-8 and B2542 (shown below each set of autologous pseudotypes for each 
respective cat). Plasma samples collected at 6 monthly intervals (A, B, C and D) expressing 
weak, moderate and strong neutralisation are highlighted in yellow, orange and red 
respectively. Plasma samples that failed to neutralise are shown in background colours. 
The number of PNGS is shown next to the specific FIV Env variant assessed for its 
susceptibility to neutralisation. (NA-not available, PNGS-potential N-linked glycosylation 
site). 
FIV Env PNGS 
Plasma collected at sequential time 
points 
 FIV Env PNGS 
Plasma collected at sequential time 
points 
  
A B C D 
   
A B C D 
M15A C13 25 1 1 1 1 
 
P14A C25 24 303 381 357 356 
M15A C42 25 2483 2594 1744 2693 
 
P14A C26 24 3475 3498 3497 2953 
M15A C45 25 183 748 963 689 
 
P14A C27 24 80 99 54 109 
M15A C48 25 3017 4197 4134 774 
 
P14B C48 24 66 63 616 404 
M15B C53 25 2917 479 2927 4058 
 
P14B C28 24 552 927 1065 225 
M15B C57 25 704 2581 409 818 
 
P14B C52 24 552 927 1065 225 
M15C C13 25 2230 5908 5512 4114 
 
P14C C1 24 159 259 407 887 
M15C C14 25 3453 471 782 430 
 
P14C C2 24 158 261 755 493 
M15C C15 25 582 2306 2437 1859 
 
P14C C5 24 415 5500 532 1114 
GL-8 
 
1 1 1 1 
 
GL-8 
 
3 3 2 1 
B2542 
 
1 1 1 1 
 
B2542 
 
1 1 1 1 
 
PNGS A B C D 
  
PNGS A B C D 
M46A C73 23 2 3 4 3 
 
P13A C71 25 3 10 19 28 
M46A C74 23 7 6 7 10 
 
P13B C82 25 4 202 182 82 
M46A C75 23 9 7 8 9 
 
P13C C25 25 4 202 182 82 
M46B C82 23 6 10 5 11 
 
P13C C26 25 4 202 182 82 
M46B C83 23 8 10 9 9 
 
P13A C72 25 4 202 182 82 
M46C C48 23 9 5 10 7 
 
P13A C74 25 6 15 22 30 
M46C C49 23 6 5 9 7 
 
P13B C81 25 1 8 11 15 
M46C C50 23 9 8 7 8 
 
P13B C84 25 1 7 12 14 
GL-8 
 
1 1 1 1 
 
P13C C27 25 1 1 1 1 
B2542 
 
1 1 1 1 
 
GL-8 
 
1 3 4 4 
 
PNGS A B C D 
 
B2542 
 
1 1 2 2 
M25A C100 25 2 92 787 782 
  
PNGS A B C D 
M25A C98 25 579 890 3892 3321 
 
M14A C254 25 1 1 15 1258 
M25A C99 25 682 2390 3205 1610 
 
M14A C262 25 1 0 12 1813 
M25C C37 25 127 164 674 934 
 
M14A C267 25 1 1 16 887 
M25C C38 25 6 4 4 5 
 
M14B C20 25 0 1 25 3405 
M25C C39 24 6971 5261 4074 4602 
 
M14C C181 25 1 1 12 2320 
GL-8 
 
1 1 1 1 
 
M14C C183 25 1 1 14 891 
B2542 
 
2 1 1 1 
 
M14C C184 25 1 1 35 592 
 
PNGS A B C D 
 
M14C C64 25 1 1 16 1186 
M31A C253 22 64 72 332 NA 
 
M14C C65 25 1 1 10 1801 
M31C C1 22 1 1 1 NA 
 
M14C C7 25 1 1 19 990 
M31C C10 21 1 1 1 NA 
 
GL-8 
 
1 1 1 1 
M31C C11 22 1 1 1 NA 
 
B2542 
 
1 1 1 1 
M31C C12 22 43 50 137 NA 
  
PNGS A B C D 
M31C C13 22 1 1 1 NA 
 
M30A C39 25 1 1 2002 118 
M31C C14 22 60 48 213 NA 
 
M30B C29 25 1 1 622 109 
M31C C15 22 51 47 176 NA 
 
M30B C13 25 1 1 622 109 
M31C C16 22 12 14 37 NA 
 
M30B C8 25 1 1 622 109 
M31C C167 22 1 1 1 NA 
 
M30B C1 25 1 1 622 109 
M31C C17 22 1 1 1 NA 
 
M30A C40  25 1 1 622 109 
M31C C2 22 1 1 1 NA 
 
M30A C41 25 1 1 502 183 
M31C C4 23 17 17 60 NA 
 
M30A C42 25 1 1 1893 75 
M31C C5 22 1 1 1 NA 
 
M30A C45 25 1 1 3921 148 
M31C C7 22 1 1 2 NA 
 
M30T C12 25 1 1 2168 85 
M31C C8 22 18 18 28 NA 
 
M30T C27 25 1 2 174 146 
M31C C9 22 1 1 1 NA 
 
M30T C30 25 1 1 927 260 
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GL-8 
 
1 1 2 NA 
 
M30T C31 25 1 1 2513 85 
B2542 
 
1 1 1 NA 
 
M30T C4 25 1 1 2223 63 
 
PNGS A B C D 
 
M30T C7 25 1 2 759 147 
P2B C17 24 1 2 NA NA 
 
M30C C15 25 1 1 374 88 
P2B C18 24 32756 23812 NA NA 
 
M30C C16 25 1 1 1911 95 
P2B C21 24 2 3 NA NA 
 
M30C C88 25 1 1 1348 112 
P2B C24 24 530 3192 NA NA 
 
M30C C91 25 1 1 3769 103 
P2B C4 24 1 3 NA NA 
 
M30C C92 25 1 1 2555 75 
P2B C43 24 1 4 NA NA 
 
GL-8 
 
1 1 1 1 
P2B C44 24 2 3 NA NA 
 
B2542 
 
1 2 2 3 
P2B C52 24 2432 985 NA NA 
  
PNGS A B C D 
P2B C55 24 4 2 NA NA 
 
M26A C109 23 12 17 6 NA 
P2B C59 24 6752 6031 NA NA 
 
M26A C110 23 21 65 12 NA 
P2B C6 24 1573 4508 NA NA 
 
M26A C112 23 46 101 30 NA 
P2B C64 24 2 3 NA NA 
 
M26C C49 24 1 1 1 NA 
P2B C65 24 1015 4877 NA NA 
 
M26C C50 23 24 17 12 NA 
P2B C3 24 2 3 NA NA 
 
M26C C58 24 1 2 1 NA 
P2B C10 24 2 3 NA NA 
 
GL-8 
 
1 1 1 NA 
P2B C72 24 2 3 NA NA 
 
B2542 
 
1 1 1 NA 
GL-8 
 
1 1 NA NA 
  
PNGS A B C D 
B2542 
 
1 2 NA NA 
 
P9A C19 24 4 7 8 5 
 
PNGS A B C D 
 
P9A C20 23 6 9 11 5 
P4A C31 25 102 16 24 17 
 
P9A C22 24 8 12 12 7 
P4A C32 25 111 19 31 22 
 
P9C C49 24 8 11 12 6 
P4B C109 23 1 1 3 7 
 
P9C C52 24 5 7 8 6 
P4B C2 25 1 1 2 3 
 
GL-8 
 
1 1 2 1 
P4B C3 24 1 1 3 6 
 
B2542 
 
1 1 2 2 
P4C C20 24 2 1 1 1 
 
 
PNGS A B C D 
GL-8 
 
1 1 2 2 
 
M47A C135 19 1 2 1 11 
B2542 
 
1 1 1 1 
 
M47A C139 22 1 1 5 987 
 
PNGS A B C D 
 
M47A C144 22 1 1 6 926 
P5A C2 25 1 4 5 6 
 
M47B C90 22 1 1 10 1153 
P5B C118 26 0 2 4 3 
 
M47B C91 22 1 2 163 813 
P5B C3 25 1 4 5 5 
 
M47B C94 21 1 1 27 1634 
P5C C25 25 1 4 7 6 
 
M47C C65  22 1 1 8 994 
P5C C26 25 1 3 4 4 
 
M47C C68  22 1 1 7 957 
P5B C4 25 1 3 4 4 
 
GL-8 
 
1 1 1 1 
P5A C5 25 1 3 4 4 
 
B2542 
 
1 1 1 1 
P5C C27 25 1 3 4 4 
  
PNGS A B C D 
GL-8 
 
1 1 1 1 
 
M49A C85 25 1 1 0 0 
B2542 
 
1 1 1 1 
 
M49A C86 25 1 1 1 1 
 
PNGS A B C D 
 
M49A C87 23 88 167 152 70 
P7B C50 23 2 3 3 5 M49C C74  25 1 1 1 1 
P7C C61 22 2 2 2 8  M49C C76 24 1 1 1 1 
GL-8 
 
2 2 2 2 
 
M49C C77 25 1 1 1 1 
B2542 
 
2 2 2 2 
 
GL-8 
 
0.7 0.9 0.8 0.7 
 
PNGS A B C D 
 
B2542 
 
0.8 1.1 1 1.1 
P8A C10 24 3 4 3 NA 
  
PNGS A B C D 
GL-8 
 
3 5 4 NA 
 
P11B C35  25 2 3 3 2 
B2542 
 
8 15 14 NA 
 
P11B C40 25 2 3 3 2 
 
PNGS A B C D 
 
P11B C46 25 2 3 3 2 
      
 
P11C C87 25 2 3 3 2 
P22C C73 23 6217 14833 5678 NA 
 
P11C C89 25 2 3 3 2 
P22C C80 24 54080 31011 9650 NA 
 
P11C C90 25 2 3 3 2 
GL-8 
 
5 7 5 NA 
 
P11C C88 25 5 6 7 6 
B2542 
 
3 4 4 NA 
 
GL-8 
 
5 9 9 5 
 
PNGS A B C D 
 
B2542 
 
4 7 8 5 
M2C C1 20 4 4 277 69 
  
PNGS A B C D 
M2C C5 20 2 1 6 4 
 
P18B C13 25 3028 3084 2562 NA 
GL-8 
 
1 1 1 1 
 
GL-8 
 
7 10 6 NA 
B2542 
 
1 1 1 1 
 
B2542 
 
2 2 2 NA 
 
PNGS A B C D 
 
 
PNGS A B C D 
M3A C168 24 3 NA NA NA 
 
P21B C75 24 1 2 2 NA 
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GL-8  1.6 NA NA NA  P21B C76 24 1 2 2 NA 
B2542  4 NA NA NA  P21B C77 24 1 2 2 NA 
 PNGS A B C D  P21B C79 24 1 2 2 NA 
M33A C146 23 1 1 NA NA  P21C C51 22 1 2 2 NA 
M33A C147 24 2 1 NA NA 
 
P21C C52 22 2 2 3 NA 
M33A C150 23 2 1 NA NA 
 
GL-8 
 
2 3 2 NA 
M33A C152 23 2 1 NA NA 
 
B2542 
 
2 2 2 NA 
M33A C153 23 2 1 NA NA 
  
PNGS A B C D 
M33A C155 23 2 1 NA NA 
 
M28A C70 25 1 2 1 2 
M33B C36 23 2 2 NA NA 
 
M28A C74 24 1 1 1 1 
M33B C37 23 2 2 NA NA 
 
M28A C79 25 1 2 1 2 
M33B C39 23 1 2 NA NA 
 
M28B C62 25 1 1 1 1 
M33B C41 23 2 2 NA NA 
 
M28B C63 25 1 1 1 2 
M33B C42 23 1 2 NA NA 
 
M28B C65 25 1 1 1 1 
M33B C43 23 2 1 NA NA 
 
M28B C66 25 1 2 1 2 
M33B C44 23 2 1 NA NA 
 
M28B C67 25 1 1 1 1 
M33B C45 23 1 1 NA NA 
 
M28C C75 25 1 1 1 1 
M33B C46 23 2 1 NA NA 
 
M28C C76 25 1 1 1 1 
M33B C52 24 1 2 NA NA 
 
M28C C77 25 1 1 1 1 
M33B C54 23 2 1 NA NA 
 
GL-8 
 
1 1 1 1 
M33B C62 23 2 1 NA NA 
 
B2542 
 
1 1 1 1 
M33B C64 23 1 1 NA NA 
  
PNGS A B C D 
GL-8 
 
1 1 NA NA 
 
M8C C144 21 1 1 1 1 
B2542 
 
1 1 NA NA 
 
GL-8 
 
1 2 2 2 
 
PNGS A B C D 
 
B2542 
 
1 1 1 1 
M11A C250 23 1 1 1 NA 
  
PNGS A B C D 
M11A C242 22 1 1 1 NA 
 
M29C C1 25 1 1 1 1 
M11A C238 23 0 1 1 NA 
 
M29C C2 25 1 1 1 1 
M11B C53 23 1 1 1 NA 
 
M29C C52 25 1 1 1 1 
M11B C94 23 1 1 1 NA 
 
GL-8 
 
1 1 1 1 
M11B C96 23 0 0 0 NA 
 
B2542 
 
1 1 1 1 
M11C C150 23 1 1 1 NA 
  
PNGS A B C D 
M11C C82 23 1 1 1 NA 
 
M32A C159 25 1 1 1 1 
M11C C7 23 1 1 1 NA 
 
M32A C160 25 1 1 1 1 
M11C C168 23 1 1 1 NA 
 
M32A C161 25 1 1 1 1 
M11C C151 23 1 1 1 NA 
 
GL-8  1 1 1 1 
M11C C152 23 1 1 1 NA 
 
B2542  1 1 1 1 
M11C C78 23 1 1 1 NA 
 
 PNGS A B C D 
M11C C164 23 1 1 1 NA 
 
P17B C94 24 1 1 1 NA 
M11C C1 23 1 1 1 NA 
 
P17A C100 24 1 1 1 NA 
GL-8 
 
1 1 1 NA 
 
P17A C99 23 1 1 1 NA 
B2542 
 
1 1 1 NA 
 
P17B C1 24 1 1 1 NA 
 
PNGS A B C D 
 
P17B C3 24 1 1 1 NA 
M16AC130 24 1 1 1 NA 
 
 P17B C93 24 1 1 1 NA 
M16AC220 24 1 1 1 NA 
 
P17B C95 24 1 1 1 NA 
M16AC215 24 1 1 1 NA 
 
P17C C43 24 1 1 1 NA 
M16AC209 24 1 1 1 NA 
 
P17C C48 24 1 1 1 NA 
M16C C30 24 1 1 1 NA 
 
GL-8  1 1 1 NA 
M16C C32 24 1 1 1 NA 
 
B2542  1 1 1 NA 
M16C C80 24 1 1 1 NA 
 
 PNGS A B C D 
GL-8 
 
1 1 1 NA 
 
M5A C14 22 1 1 1 NA 
B2542 
 
1 1 1 NA 
 
M5A C15 22 1 1 1 NA 
 
PNGS A B C D 
 
M5A C17 22 1 1 1 NA 
M20A C284 23 1 1 NA 1 
 
M5B C62 23 1 1 1 NA 
GL-8 
 
1 1 NA 1 
 
M5B C68 22 1 1 1 NA 
B2542 
 
1 1 NA 1 
 
M5C C21 23 1 1 1 NA 
 
PNGS A B C D 
 
M5C C22 23 1 1 1 NA 
P6B C3 24 1 1 1 1 
 
M5C C28 23 1 1 1 NA 
P6A C68 24 1 1 1 1 
 
 PNGS A B C D 
PA C69 24 1 1 1 1 
 
M41A C120 22 1 1 1 NA 
P6A C70 24 1 1 1 1 
 
M41A C122 22 1 1 1 NA 
P6B C1 24 1 1 1 1 
 
M41C C32 22 1 1 1 NA 
P6B C2 24 1 1 1 1 
 
M41C C34 22 1 1 1 NA 
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P6C C22 24 1 1 1 1 
 
M41C C39 22 1 1 1 NA 
P6C C63 24 1 1 1 1 
 
M41C C66 22 1 1 1 NA 
GL-8  1 1 1 1 
 
M41C C67 22 1 1 1 NA 
B2542  1 1 1 1 
 
M41C C72 22 1 1 1 NA 
 
PNGS A B C D 
 
M41C C73 22 1 1 1 NA 
M1A C3 23 1 1 1 1 
 
M41C C82 22 1 1 1 NA 
M1C C100 23 1 1 1 1 
 
M41C C87 22 1 1 1 NA 
M1C C97 23 1 1 1 1 
 
GL-8  1 1 2 NA 
GL-8 
 
1 1 1 1 
 
B2542  1 1 1 NA 
B2542  1 1 1 1       
 
5.3.2 Association between development of autologous NAbs and 
duration of infection 
We tested the hypothesis that the development of autologous neutralisation is 
positively correlated with the age of the cats and the duration of infection.  
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Figure 5-1 Association between the duration of infection and the development of autologous 
NAbs. Cats with strong (n=16), moderate (n=6) and absent (n=16) autologous neutralisation 
responses are highlighted in red, orange and green respectively. 
 
Figure 5-1 depicts the relationship between the potency of autologous 
neutralising antibody response and the duration of infection for cats from the 
entire study group. The median duration of infection for cats with strong, 
moderate and absent autologous NAb responses was: 3.1 (range: 1.1 to 6.3) 
years, 2.8 (range: 1.5 to 5.4) years and 3.6 (range: 0.8 to 8.8) years 
respectively. No statistically significant differences between each of the groups 
(unpaired two tailed t test) were observed. 
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5.3.3 NAb responses in cats infected with recombinant and non-
recombinant viruses. 
We hypothesised that cats infected with recombinant viruses would have more 
potent autologous and heterologous NAb responses than cats infected with non-
recombinant viruses. However, as demonstrated in Figure 5-2, there were no 
statistically significant differences between the strength of autologous 
neutralisation in cats infected with recombinant and non-recombinant viruses 
(Fisher’s exact test, p=0.45). 
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Figure 5-2 Autologous neutralisation responses in cats infected with non-recombinant 
(n=24; green) and recombinant (n=14; red) viruses.  
 
Next, we asked whether cross reactive NAb responses were more common in cats 
infected with recombinant clade A/B viruses compared to cats infected with 
non-recombinant viruses. There was no statistically significant difference 
between the two groups; of 5 cats that demonstrated heterologous 
neutralisation (against at least one pseudotype), 3 were infected with non-
recombinant viruses while 2 were infected with recombinant viruses (Fisher’s 
exact t test, p=1) (Figure 5-3).  
 164 
 
 
 
YES NO
0
5
10
15
20
25
2
21
3
12
Non-recombinant
Recombinant
Heterologous neutralisation
N
u
m
b
e
r 
o
f 
c
a
ts
 
Figure 5-3 Heterologous neutralisation in cats infected with recombinant and non-
recombinant viruses. Of the 38 cats tested, only 5 displayed heterologous neutralisation:  
2 were infected with recombinant and 3 with non-recombinant viruses.  
 
5.3.4 Association between NAb response and health status of 
infected animals 
In addition, we tested for an association between the presence of an autologous 
NAb response and the health status of infected cats. 
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Figure 5-4 Relationship between the health status and neutralising antibody response. 
Within the group of cats expressing autologous NAb responses (n=21) there were 12 
healthy and 9 sick cats. Within the group with no autologous neutralisation (n=17), there 
were 8 healthy and 9 sick cats. The differences between the groups were not statistically 
significant (Fisher’s exact test, p=0.53). 
 
Because health status assessments are subjective, we also examined the data to 
determine whether autologous NAbs might provide protection against a 
progressive decline in CD4 lymphocytes. As demonstrated in Table 5-3, all but 
two of the cats within the Memphis cohort (n=24) demonstrated a progressive 
decline in CD4+ T lymphocytes. The median ΔCD4 over the 18 month observation 
period was - 340 cells/ µl (ranging from -1120 to + 30 cells/µl). 
Table 5-3 CD4 lymphocyte counts (K/µl) for cats in Memphis cohort for each time point (A, 
B, C and D) unless cat was deceased (D) or sample was not available (NA). ΔCD4 in the final 
column represents the difference between the first (A) and the last available sampling. All 
but two cats (highlighted in red) displayed a progressive decline in CD4 lymphocyte 
numbers over the 18 month observation period.  
Cat CD4 count (K/µl) ΔCD4 (K/µl) 
 
Time point 
 
A B C D 
M2 1.74 0.36 0.76 0.62 -1.12 
M29 1.48 0.62 0.93 0.62 -0.86 
M1 0.87 0.36 0.34 0.26 -0.61 
M15 0.87 1.03 1.09 0.47 -0.4 
M8 0.55 0.21 0.2 0.15 -0.4 
M49 0.41 0.31 0.27 0.04 -0.38 
M28 1.23 0.89 1.77 0.9 -0.34 
M14 0.45 0.29 0.15 0.14 -0.3 
M25 0.36 0.39 0.68 0.09 -0.27 
M20 1.5 0.81 NA 1.25 -0.25 
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M47 0.29 0.14 0.14 0.1 -0.19 
M32 0.38 0.32 0.35 0.21 -0.17 
M30 0.13 0.15 0.26 0.1 -0.04 
M46 0.15 0.19 0.18 0.18 +0.03 
M11 0.98 0.14 0.48 D -0.5 
M16 0.35 0.37 0.36 D +0.01 
M26 0.54 0.14 0.13 D -0.41 
M31 0.8 0.88 0.26 D -0.55 
M41 0.34 0.35 0.12 D -0.22 
M5 0.56 0.15 0.16 D -0.4 
M50 1.38 1.32 D D -0.07 
M33 0.2 D D D N/A 
M3 0.33 D D D N/A 
M44 1.24 D D D N/A 
D – Deceased, NA – not available. 
Within the Chicago group (n=14), 7 cats displayed progressive declines in CD4 T 
lymphocyte numbers, 5 displayed increased numbers, while 2 cats maintained 
their CD4 T lymphocyte numbers over a period of 12 months (Table 5-4). The 
median ΔCD4 was calculated as -15 cells/ µl (ranging from - 760 to + 240 
cells/µl). 
Table 5-4 CD4 lymphocyte counts (K/µl) for Chicago cats for each time point (A, B and C) 
unless the cat died during the study (D). ΔCD4 in the final column represents the difference 
between first (A) and the last available sampling. 5 cats (highlighted in red) displayed 
increasing CD4 lymphocyte numbers over the 12 month observation period). 
Cat CD4 count (K/µl) ΔCD4 (K/µl) 
 
Time point 
 
A B C 
P4 0.09 0.34 0.33 +0.24 
P14 0.97 1.16 1.09 +0.12 
P8 0.50 0.86 0.60 +0.10 
P6 0.48 0.35 0.57 +0.09 
P7 0.40 0.26 0.40 0.00 
P11 0.45 0.35 0.45 0.00 
P13 0.46 0.28 0.27 -0.18 
P17 0.49 0.55 0.28 -0.21 
P9 0.63 0.35 0.18 -0.45 
P5 0.79 0.72 0.30 -0.49 
P2 0.40 0.36 D -0.03 
P21 NA 0.93 0.57 -0.36 
P22 NA 1.55 0.79 -0.76 
P18 NA 0.73 0.75 +0.02 
NA – not available 
We then asked whether a strong autologous NAb response can protect cats 
against a progressive decline in CD4 T lymphocytes. We compared three groups 
of cats: 1) with absent (n=15) 2) moderate (n=5) and 3) strong (n=15) NAb 
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responses for which ΔCD4 values were available (n=35).  As demonstrated in 
Figure 5-5, there was no evidence that cats with strong NAb responses were less 
likely to display progressively declining CD4 T lymphocyte numbers (median 
ΔCD4= -0.27 K/µl) as a similar range of ΔCD4 values was observed within the 
group of cats which failed to mount autologous NAb responses (median ΔCD4= 
-0.25 K/µl). There were no statistically significant differences between the two 
groups (unpaired 2-tailed t test, p=0.97). Three animals with moderate levels of 
NAb maintained their CD4 counts, while two animals showed declining CD4 
lymphocyte numbers. 
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Figure 5-5 Changes in CD4 lymphocyte count (K/µl) over the course of infection in three 
groups of cats: 1) strong (n=15) (median -0.27, range -1.12 to +0.24)) 2) moderate (n=5) 
(median 0.0, range -0.49 to +0.03) and 3) with absent (n=15) (median -0.25, range -0.86 to 
+0.1) NAb responses. 
 
5.3.5 Association between NAb response and survival time of 
infected animals 
We examined the relationship between the autologous neutralisation responses 
and survival times of infected cats since the (estimated) time of infection. 
Kaplan-Meyer survival curves were constructed for 3 groups of cats expressing: 
1) strong (n=16), 2) moderate (n=6) or 3) no (n=16) autologous neutralisation 
(Figure 5-6). 
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The estimated median survival time for cats with strong autologous NAb 
responses was 2840 (range 1061 – 2840) days and for the group with no NAb was 
2476 (range 1384 – 3387) days. There was insufficient data within the moderate 
neutralisation group to estimate median survival. A comparison of the Kaplan-
Meyer curves (Log-rank (Mantel-Cox) test) revealed that survival times were not 
significantly different amongst the three groups (p=0.48). Further testing (Log-
rank test for trend) revealed no significant trend between the three survival 
curves (p=0.36).  
0 1000 2000 3000 4000
0
20
40
60
80
100
Strong neutralisation
Moderate neutralisation
Absent neutralisation
Duration of infection
P
e
rc
e
n
t 
s
u
rv
iv
a
l
 
Figure 5-6 Kaplan-Meyer survival curves for cats with strong (n=16) (red), moderate (n=6) 
(orange) or absent (n=16) (green) autologous neutralisation.  
 
5.3.6 NAbs in the terminal stages of disease 
Finally, we asked whether the NAb response was preserved in the terminal 
stages of disease when the immune system was weakened. There were 13 cats in 
the study group with CD4 lymphocyte counts below 200 cells/µl recorded at the 
final sampling (Table 5-3 and Table 5-4), indicative of terminal infection. Plasma 
samples from 6 (46%) of these cats in the terminal stage of disease did not 
neutralise pseudotypes bearing homologous Envs, while plasmas from 7 (54%) of 
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the cats showed NAb responses against pseudotypes bearing autologous Envs, in 
spite of being in the terminal stages of disease. 
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5.4 Discussion 
Here, we demonstrated that cats naturally infected with FIV have variable NAb 
responses against pseudotypes bearing autologous and heterologous Envs. When 
neutralisation assays were conducted against pseudotypes bearing Envs from 
autologous and heterologous viruses, we observed no correlation between either 
the health status or survival time following infection and the NAb response. 
Similar neutralisation profiles were observed for plasmas from healthy and un-
healthy cats as well as cats that survived or died during the study period. Such 
findings argue against a role for NAb in controlling disease progression. 
Furthermore, our results demonstrate that FIV infected cats, regardless of 
strength of NAb response, showed progressive declines in CD4+ T lymphocyte 
numbers; NAb responses, even when potent, did not appear to protect against 
the loss of CD4 lymphocytes. A similar trend has been observed in HIV-1 
infection, where the presence of autologous (Cecilia et al., 1999), (Geffin et al., 
2003), (Schmitz et al., 2003) and cross-reactive NAbs was not associated with  
a prolonged AIDS free, asymptomatic period (Piantadosi et al., 2009)Piantadosi 
et al., 2009), (van Gils et al., 2010), (Euler et al., 2010). Several studies 
suggested that neutralisation breadth and potency depends on the duration of 
infection (Moog et al., 1997), (Deeks et al., 2006), (Sather et al., 2009). 
However, the results presented here do not support this proposal; rather, no 
association was observed between the duration of infection and the potency of 
autologous neutralisation. 
Almost half of the cats examined showed strong autologous NAb responses, and 
in 24% of those animals a steady increase in neutralisation potency was observed 
during the course of infection. A similar increase in the strength of autologous 
NAb response has been reported for HIV-1 infection (Arendrup et al., 1992), 
(Richman et al., 2003), (Geffin et al., 2003). Although NAbs failed to protect 
against contemporaneous viruses, it was suggested that such antibodies might 
exert selection pressure on the emergence of viral variants of lower fitness, for 
example with decreased replicative capacity, and thus might indirectly delay 
HIV-1 associated disease progression (Friedrich et al., 2004), (Leslie et al., 
2004). However, in this study no correlation was observed between the strength 
of NAb response and survival time in cats naturally infected with FIV. 
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The remaining half of the cats that were examined did not develop NAbs. A high 
level of antigenic stimulation is crucial for the development of broad and potent 
NAb responses (Deeks et al., 2006), (Rodriguez et al., 2007), (Doria-Rose et al., 
2009), (Sather et al., 2009). It is possible that the immune systems of those cats 
that did not neutralise pseudotypes bearing autologous Envs had not had 
sufficient antigenic stimulation following infection to induce NAbs. This is most 
likely the case with cat M1, which acquired the virus vertically and failed to 
mount a NAb response. Given that a high viral load and high viral diversity 
following infection influences the development of potent and broad NAbs (Sather 
et al., 2009), (Piantadosi et al., 2009), (Euler et al., 2010), (Gray et al., 2011a), 
(Gray et al., 2011b), it is tempting to speculate that the cats in our study group 
which failed to develop NAb response may have had relatively low viral load set 
points compared to the cats which developed NAbs. An analysis of the viral and 
proviral loads in these cats would allow this speculation to be tested.  
In addition, the marked, highly non-specific CD4+ T lymphocyte-dependent 
polyclonal hyper-gammaglobulinaemia (Recher et al., 2004), (Lang et al., 2007) 
that arises as an initial response to FIV infection might also contribute to the 
lack of effective neutralisation observed in this group. It is possible that high 
CD4+ T lymphocyte counts at the time of virus acquisition might be responsible 
for a non-specific, overwhelming hyper-gammaglobulinaemia and subsequent 
failure of NAb responses to develop (Euler et al., 2010), (Gray et al., 2011a). 
This scenario could also explain why only a small fraction of cats in our study 
demonstrated cross neutralisation of the heterologous GL-8 and B2542 
pseudotypes, regardless of whether they were infected with recombinant or non-
recombinant viruses.  
A study examining a similar number of HIV-1 infected individuals (n=40) for the 
breadth of neutralisation found that 17.5% of patients developed broadly NAbs 
(Gray et al., 2011a). Other studies reported higher numbers of individuals with 
broadly NAb, up to 30% of samples examined (Doria-Rose et al., 2009), (Gray et 
al., 2009), (Piantadosi et al., 2009), (Sather et al., 2009), (Euler et al., 2010). In 
contrast, only 13% of plasma samples collected from our study group displayed 
cross reactivity. This may suggest that Cr-NAb are rarer in FIV infected cats than 
in HIV-1 infected individuals. However, in this study plasma samples were tested 
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for neutralisation against only two reference pseudotypes bearing FIV Envs. It is 
possible that testing a greater number of pseudotypes bearing Envs from more 
strains of FIV could have revealed a higher prevalence of Cr-NAbs. Had we found 
broadly and strongly neutralising plasma, we could have included it in our assays 
as a control to tackle the possible differences in infectivity of pseudotypes 
bearing wild type envs. 
It has been suggested that neutralisation breadth develops slowly over a period 
of two to four years post seroconversion (Mikell et al., 2011), (Gray et al., 
2011a). Given the duration of infection in our study group, it would be 
predicted, by analogy, that more cats would have developed Cr-NAbs, but this 
scenario was not supported by the data presented here. 
Finally, differences in neutralisation profiles might also be related to different 
kinetics of viral replication between various strains of FIV infecting cats in the 
study group. It is possible that more virulent, and more replication competent, 
strains are more likely to induce effective humoral responses compared to 
isolates with a lower replicative capacity. 
The results presented here demonstrate that humoral immunity was preserved in 
cats that subsequently developed AIDS (CD4 counts below 200 cells/µl), 
consistent with the observation that the rate of viral evolution slows during the 
terminal stage of disease (Chapter 4). Thus, autologous antibodies elicited 
during the earlier stages of infection remain capable of neutralisation, owing to 
the relatively high genetic stability of the virus terminally. However, these NAb, 
although capable of neutralisation in vitro and while preserved in terminal 
disease, fail to prevent disease progression.  
In this study we tested pseudotypes bearing 1 to 18 Env variants from each time 
point to assess sensitivity to neutralisation by autologous plasma. It is difficult to 
assess how representative the cloned Envs were, compared to the pool of Env 
variants within the cats. Nevertheless, the alternative approach of testing  
a single representative clonal Env variant would have led to an underestimation 
of viral diversity within the host. The sensitivities to neutralisation amongst 
pseudotypes bearing Env variants isolated from each cat tended to be similar; 
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this suggests that, where changes were observed, these were likely a true 
indication of the range of neutralisation sensitivity and resistance amongst the 
pool of variants in individual cats. 
Taken together, the results presented here demonstrated that humoral immunity 
did not significantly alter the clinical course of natural FIV infection. One 
explanation for the lack of correlation is that any factor promoting a strong NAb 
response may negatively influence other immune responses, leading to 
exhaustion of polyfunctional CD4 and CD8 lymphocytes (Harari et al., 2004), 
(Betts et al., 2006), (Streeck et al., 2008). In light of recent evidence from 
studies with HIV-1, it is plausible that cell mediated immunity, as well as host 
genetic factors, are more likely to influence the clinical course of infection than 
NAbs (Nomura and Matano, 2012), (Huang et al., 2012a).  
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Chapter 6. Cell tropism of FIV 
Data from both in vitro culture experiments and in vivo experimental FIV 
infections suggest that the FIV-receptor interaction changes as disease 
progresses, similar to the switch of co-receptor usage from CCR5 to CXCR4 
observed during the course of HIV-1 infection. 
In order to validate experimental observations and assess whether similar 
findings extend to naturally acquired infection, we analysed the cell tropism of 
sequential FIV Env variants isolated from 38 cats. In this study we employed the 
previously proposed model (Willett and Hosie, 2008) wherein “early” viral 
variants which demonstrate a strong affinity interaction with CD134 evolve 
during the course of infection towards CD134 independence. 
It was demonstrated that sick cats were more likely to harbour “late” viruses 
than healthy animals, suggesting that variants with the “late” phenotype are 
likely to contribute to the decline in CD4 lymphocyte counts and disease 
progression. Depending on the grouping criteria used, we found that putative 
“late” viruses were present in 61.5-75% of cats presenting with clinical signs. In 
contrast, variants with a similar “late” phenotype were present in only 22.7-36% 
of healthy cats. There was no correlation between the strength of the 
autologous neutralisation response and the existence of viruses with “early” or 
“late” phenotypes, suggesting that other mechanisms may drive the emergence 
of the “late” phenotype during the course of infection. 
These results are consistent with a proposed model in which FIV isolates 
requiring complex determinants on the host cell receptor for infection evolve 
towards requiring a less stringent interaction during the course of infection. 
Such a shift may contribute to more widespread viral dissemination, extending 
to other cellular compartments and subsequently leading to disease progression. 
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6.1 Introduction 
The interaction between the virus and its receptor on the susceptible cell is the 
first event of lentiviral infection. The specificity of this interaction influences 
viral cell tropism and pathogenicity (Willett et al., 2008). 
Primate immunodeficiency retroviruses predominantly target helper T cells using 
the CD4 molecule as an entry receptor (Sattentau and Weiss, 1988) and 
subsequently induce a progressive decline in CD4 expressing cells during the 
course of infection (Weiss, 1993), (Douek et al., 2009). For productive infection 
to occur, the initial binding with CD4 is followed by a viral Env interaction with 
chemokine co-receptors, including CXCR4 (Bleul et al., 1997), (Feng et al., 
1996), CCR5 (Alkhatib et al., 1996), (Trkola et al., 1996a). The utilisation of the 
two major co-receptors partially explains the differential cell tropism of primate 
lentiviruses. Generally, CXCR4-dependent strains are T-cell tropic (Correa and 
Munoz-Fernandez, 2001), while CCR5-dependent strains preferentially target 
memory CD45RA+ T cells and macrophages (Collman et al., 1989). Nevertheless, 
macrophage tropic X4 strains (Simmons et al., 1998) and dual tropic R5X4 
strains, which utilize both co-receptors (Yi et al., 1999), (Whitcomb et al., 2007) 
have been identified. Furthermore, co-receptors other than CXCR and CCR5 such 
as CCR8 (Rucker et al., 1997), CCR3 (Doranz et al., 1996), GPR1 (Shimizu et al., 
2000), GPR15 (Farzan et al., 1997), CXCR6 (Alkhatib et al., 1997) and RDC1 
(Willey et al., 2003) and six other chemokine receptors (Meehan et al., 2010) 
also can be used by HIV and SIV to establish productive infection in vitro, 
highlighting the complex role of the viral Env in cell tropism. 
It has been demonstrated for HIV-1 that an assessment of cell tropism can be 
useful to monitor disease progression (Waters et al., 2008), (Shepherd et al., 
2008). For example, R5 strains predominate during the early stages of infection 
and there is a subsequent evolution towards CXCR4 usage as disease progresses 
(Shankarappa et al., 2001). The emergence of X4 variants is usually accompanied 
by a rapid decline in CD4 lymphocyte numbers and the onset of 
immunodeficiency (Jekle et al., 2003). It has been reported that this cell 
tropism pattern is observed in only ~50% of infected individuals (Regoes and 
Bonhoeffer, 2005); however, recent studies employing more sensitive detection 
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techniques reported this proportion as higher (Wilkin et al., 2011). It is not well 
understood why this co-receptor switch occurs in only a fraction of infected 
individuals (Regoes and Bonhoeffer, 2005). The switch from CCR5 to CXCR4 
usage has been associated with the loss of potential N-linked glycosylation sites 
(PNGS) within the V3 region of the SU domain of Env (Pollakis et al., 2001) as 
well as with mutations that increase the positive charge of the V3 region 
(Cardozo et al., 2007). Furthermore, mutations within other domains of SU and 
TM, such as V1/V2 and C4 respectively, have also been linked with altered co-
receptor usage by various strains of HIV-1 (Hoffman et al., 2002), (Otto et al., 
2003), (Nabatov et al., 2004). 
FIV, like its human and simian counterparts, induces a progressive decline of 
CD4+ T lymphocytes, subsequently leading to immunodeficiency and death 
(Yamamoto et al., 1989), (Novotney et al., 1990). FIV shares a similar cell 
tropism to HIV and productively infects T lymphocytes (Novotney et al., 1990),  
B cells (English et al., 1994), macrophages (Brunner and Pedersen, 1989), 
monocytes (Dow et al., 1999), megakaryocytes (Beebe et al., 1992), dendritic 
cells (Reggeti et al., 2008), microglia and astrocytes (Nakagaki et al., 2001), 
(Johnston et al., 2002), (Hein et al., 2003). 
Despite sharing a similar cell tropism and pathogenicity, and in contrast to its 
human counterpart, FIV utilizes feline CD134 as the primary entry receptor 
(Shimojima et al., 2004), (de Parseval et al., 2004a) and CXCR4 as a co-receptor 
(Willett et al., 1997b), (Richardson et al., 1999). No other co-receptors for FIV 
have been identified to date (Willett et al., 2010), (Hu et al., 2010).  
A determinant of FIV tropism is located within the V3 region of Env (Hohdatsu et 
al., 1996), (Lerner and Elder, 2000), (Hu et al., 2010). 
CD134, the primary entry receptor for FIV, is a 43 kDa glycoprotein (Hong et al., 
2010) which belongs to the tumour necrosis factor/nerve growth factor receptor 
superfamily (TNFR/NGFR) (Locksley et al., 2001) and is expressed on feline CD4+ 
T cells in vitro (Shimojima et al., 2004) and in vivo (Joshi et al., 2005), 
consistent with the cell tropism of FIV and the progressive depletion of the CD4+ 
lymphocyte subset that occurs during the course of FIV infection. FIV binds 
specifically to cells expressing CD134 but, when pre-treated with soluble CD134, 
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can productively infect CD134(-) CXCR4(+) cells (de Parseval et al., 2005). The 
structure of CD134 resembles that of classical TNFR molecules, with an 
extracellular binding domain comprising three cysteine rich domains (CRD1, 
CRD2, CRD3) and an additional C-terminal domain (Bodmer et al., 2002).  
Various strains of FIV differ in the affinity of their interaction with the primary 
binding receptor (Willett et al., 2006a). The PPR and B2542 strains (thought to 
be late, chronic isolates) of FIV achieve productive infection following an 
interaction with residues within the cysteine rich domain 1 (CRD1) of CD134 (de 
Parseval et al., 2005), (Willett et al., 2006b) while primary strains such as GL-8 
and CPG41 (defined as early, acute isolates) require a more stringent interaction 
involving not only CRD1 but also determinants within the cysteine rich domain 2 
(CRD2) of CD134 (Willett et al., 2006a), (Willett et al., 2006b), (Willett et al., 
2010). It has been proposed that viruses which require only CRD1 of CD134 (or 
are able to infect via CXCR4 alone) emerge during the terminal stage of disease 
(Willett and Hosie, 2008). Therefore, it is likely that FIV may evolve in vivo 
towards a less CD134-dependent or  CD134-independent mechanism of infection, 
facilitating viral spread to different cellular compartments (Willett et al., 
2006b) consistent with the expanded cell tropism observed during the course of 
infection (English et al., 1993), (Dean et al., 1996).  
Experimental data support this hypothesis; infection with the PPR strain of FIV 
can occur in CD134 (-) cells simply by overexpression of CXCR4 (de Parseval et 
al., 2004b), which is not the case with the primary isolate GL-8 (Willett et al., 
2002). It has been speculated that FIV variants that emerge in sick cats differ 
from those isolated during the acute phase of infection (Willett and Hosie, 
2008), similar to the switch from CCR5 to CXCR4 co-receptor usage observed 
during the course of HIV-1 infection. Furthermore, late, chronic FIV isolates 
require a lower affinity interaction with CD134; such isolates have a more 
exposed CXCR4 binding site, rendering them more susceptible to neutralising 
antibodies (Willett et al., 2010). It has been proposed that the emergence of 
more readily neutralised variants with broader cell tropism is a result of  
a weakened immune system, which in sick animals mounts an insufficient 
autologous humoral response (Willett et al., 2006b). 
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The switch of coreceptor usage in HIV-1 infection is a predictive indicator of 
disease progression (Weiser et al., 2008), (Shepherd et al., 2008), (Lin and 
Kuritzkes, 2009), (Wilkin et al., 2011). The emergence of X4 viruses coincides 
with the accelerated decline in CD4+ lymphocyte numbers and the subsequent 
onset of AIDS (Connor et al., 1997), (Wilkin et al., 2011). Taken together with 
the results of studies on experimental FIV infection and proposed hypotheses 
(Willett et al., 2006a), (Willett and Hosie, 2008), (Willett et al., 2009), (Willett 
et al., 2010), we asked whether a similar pattern of FIV evolution (from a 
complex to a more simple interaction with CD134) is indicative of disease 
progression in cats naturally infected with FIV. Do the experimental data extend 
to natural infection? Can the onset of immunodeficiency in FIV infected cats be 
predicted by defining the receptor usage of their autologous viral variants? 
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6.2 Materials and methods 
6.2.1 FIV pseudotypes 
HIV(FIV) pseudotypes bearing wild type and reference FIV Envs (GL-8 as the 
representative early, acute isolate and B2542 as the representative late, chronic 
isolate) were prepared according to the protocol described in Chapter 2. 
Pseudotypes bearing wild type FIV Envs which were tested for neutralisation 
(Chapter 5) were subsequently examined in receptor usage assays. Accordingly 
the cell tropism was assessed for 1 to 23 pseudotypes bearing wild type Envs 
isolated from each of 38 cats.  
6.2.2 Receptor usage assay 
MCC FFF, MCC F(FH)H, MCC HHH and CLL-CD134 cells (Willett et al., 2006b) 
(Figure 6-1) were seeded (1 × 104 cells per well) in triplicate in a CulturPlate™-96 
assay plate (Perkin Elmer). The cells were infected with 50 μl of each HIV-luc (FIV 
wild type Env) pseudotype, alongside reference controls of HIV-luc (GL-8) and HIV-
luc (B2542).  
 
 
Figure 6-1 Schematic representation of the panel of cell lines bearing chimaeric CD134 
molecules, used to assess receptor usage by isolates of FIV. CD134 consists of 3 CRDs; 
MCC-HHH comprises the entire human CD134, while CLL-CD134 comprises the entire feline 
CD134. These constructs served as negative and positive controls respectively. MCC-FFF 
stably expresses feline CD134 while MCC-F(FH)H bears a chimeric feline/human CD134 and 
is permissive for the entry of prototypic “late” isolates of FIV such as B2542 (Willett et al., 
2006a). Adapted from (Willett et al., 2006a). 
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After 72 hours incubation at 37°C in an atmosphere of 5% CO2, the luciferase 
activity was quantified following the addition of 100 μl of Steadylite HTS™ 
(Perkin Elmer) luciferase substrate and single photon counting using a MicroBeta 
luminometer (Perkin Elmer). 
The MCC cells used in the receptor usage assays had been stably transduced with 
different chimeric constructs of feline/human CD134 (Willett et al., 2006b). As 
shown in Figure 6-1, each of three MCC cell lines expressed three CD134 
molecules: 1) MCC-FFF, 2) MCC-F(FH)H and 3) MCC-HHH, where F and H denotes 
feline and human cysteine reach domains (CRDs) of CD134 respectively. CLL-
CD134 cells expressed the complete feline CD134 molecule and served as  
a positive control in the assay. This panel of cell lines allowed a comparison of 
CD134 utilization by diverse strains of FIV (Willett et al., 2006a), (Willett et al., 
2006b). The control pseudotype bearing the GL-8 Env (an early, acute isolate) 
required a strong affinity interaction with CD134 and was only able to infect 
CLL-CD134 and MCC-FFF cells. The control B2542 pseudotype (a late, chronic 
isolate) required a less stringent interaction with CD134, displayed broader cell 
tropism and could infect cells bearing feline CRD1 only in the context of 
feline/human CRD2 and human CRD3 (cell line MCC- F(FH)H). 
The affinities of the receptor interactions with wild type FIV Envs isolated in this 
study were compared to the interactions with the GL-8 and B2542 Envs, in order 
to assess receptor usage by Env variants isolated at different stages of natural 
FIV infection. 
6.2.3 Site directed mutagenesis 
A PCR based mutagenesis strategy, employing The Quick Change II site-directed 
mutagenesis kit (Agilent Technologies, UK), was used to introduce the desired 
mutations into the env gene. PCR reactions and thermo cycling conditions were 
set up as per the manufacturer’s instructions. Primers and their description are 
detailed in Table 6-1. 
Following PCR amplification, the methylated parental DNA template was 
digested with DpnI endonuclease as per the manufacturer’s instructions. Treated 
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DNA was subsequently transformed into XL1-Blue Supercompetent® Cells (Agilent 
Technologies, UK) and the introduced mutations were confirmed by sequencing 
on an ABI 3700 genetic analyser (Applied Biosystems). 
Table 6-1 Oligonucleotides used for the site directed mutagenesis of clones isolated from 
cat M11 with description of sequence targets within the env. 
Primer sequence (5’ to 3’) Used for: 
ACCTTATTGTACATTTCAATATGACAAGAGCTGTGGAAATGT Fwd primer to reinstate Ala520 to Thr in C242 
ACATTTCCACAGCTCTTGTCATATTGAAATGTACAATAAGGT Rev primer to reinstate Ala520 to Thr in C242 
TGAAGAAGAATACTTATCAATGGAATTGAGGAGAAATGGCAGGC Fwd primer to reinstate Lys838 to Glu in C242 
GCCTGCCATTTCTCCTCAATTCCAATTTCATTGATAAGTATTCTTCTTCA Rev primer to reinstate Lys838 to Glu in C242 
ACCTTATTGTACATTTCAATATGGCAAGAGCTGTGGAAATGT Fwd primer to reinstate Thr520 to Ala in C164 
ACATTTCCACAGCTCTTGCCATATTGAAATGTACAATAAGGT Rev primer to reinstate Thr520 to Ala in C164 
  
Site directed mutagenesis studies on viral variants isolated from cat M11C were 
designed by myself but were performed by Nicola Logan and Kuan Liang Liu as 
part of the latter’s MRes degree project placement in our laboratory. 
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6.3 Results 
Pseudotypes bearing FIV Envs isolated from 38 infected cats displayed a broad 
spectrum of cell tropism, as determined by the receptor usage assay based on 
cells expressing human/feline chimaeric CD134 molecules, with the results as 
summarized in Table 6-2. Of the 284 pseudotypes tested bearing wild type envs, 
219 (77.1%) utilised CD134 in the same manner as the representative “early” GL-
8 pseudotype. Forty four (15.5%) pseudotypes displayed CD134 utilisation more 
similar to that of the representative “late” B2542 pseudotype. Sixteen (5.6%) 
displayed an intermediate pattern of receptor usage, with results between those 
of the reference GL-8 and B2542 pseudotypes. Interestingly, five pseudotypes 
(1.8%) achieved higher titres on MCC F(FH)H cells than the B2542 pseudotype, 
suggesting that these pseudotypes may have the capacity to infect CD134 (-) 
target cells, binding CXCR4 directly. As a representative example, the receptor 
usage of pseudotypes bearing selected Env variants from cat M31 are shown in 
Figure 6-2. 
Table 6-2 Mode of CD134 utilisation displayed by 284 pseudotypes bearing Envs from 38 
cats. Cats were classified according to their health status (H=healthy, S=sick), CD4 count (< 
and > 200 cells/µl) and survival during the study period (A=alive, D=deceased). Mode of 
CD134 interaction: 1) GL-8 like-stringent, high affinity utilization of CRD-1 and requiring 
determinants on CRD-2 of CD134; 2) B2542 like-requiring only CRD1 of CD134; 3) >B2542-
very low interaction with CD134, isolates potentially can utilise CXCR4 alone; 4) 
undetermined-intermediate requirement for determinants within the CRD2 of CD134 (neither 
GL-8 nor B2542-like). Numbers and percentages (in brackets) of pseudotypes classified in 
each group are shown. 
Cat 
Alive/ 
Dead 
Health 
status 
CD4  
count 
Mode of CD134 interaction No. of 
pseudotypes 
tested GL-8 like B2542 like >B2542 undetermined 
M28 A H < 200 11 (100%) 0 0 0 11 
M47 A H < 200 8 (100%) 0 0 0 8 
M8 A S < 200 2 (100%) 0 0 0 2 
P9 A S < 200 6 (100%) 0 0 0 6 
M1 A H > 200 4 (100%) 0 0 0 4 
M2 A H > 200 2 (100%) 0 0 0 2 
M29 A H > 200 3 (100%) 0 0 0 3 
P1 A H > 200 3 (100%) 0 0 0 3 
P11 A H > 200 7 (100%) 0 0 0 7 
P14 A H > 200 9 (100%) 0 0 0 9 
P18 A H > 200 1 (100%) 0 0 0 1 
P21 A H > 200 6 (100%) 0 0 0 6 
P22 A H > 200 2 (100%) 0 0 0 2 
P4 A H > 200 4 (44.4%) 2 (22.2%) 0 3 (33.3%) 9 
P5 A H > 200 7(87.5%) 1 (12.5%) 0 0 8 
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P6 A H > 200 8 (100%) 0 0 0 8 
M15 A S > 200 6 (66.6%) 3 (33.3%) 0 0 9 
M20 A S > 200 1 (100%) 0 0 0 1 
M32 A S > 200 3 (75%) 1 (25%) 0 0 4 
P13 A S > 200 8 (88.9%) 1 (11.1%) 0 0 9 
P17 A S > 200 9 (100%) 0 0 0 9 
P7 A S > 200 1 (50%) 0 0 1 (50%) 2 
P8 A S > 200 5 (100%) 0 0 0 5 
M25 D H < 200 3 (50%) 2 (33.3%) 0 1 (16.7%) 6 
M46 D H < 200 7 (87.5%) 1 (12.5%) 0 0 8 
M49 D H < 200 6 (100%) 0 0 0 6 
M14 D S < 200 9 (90%) 1 (10%) 0 0 10 
M26 D S < 200 4 (66.7%) 2 (33.3%) 0 0 6 
M30 D S < 200 15 (94%) 1 (6%) 0 0 16 
M33 D S < 200 2 (11%) 16 (84%) 1 (5%) 0 19 
M41 D S < 200 9 (75%) 1 (8.3%) 1 (8.3%) 1 (8.3%) 12 
M5 D S < 200 5 (55.6%) 3 (33.3%) 0 1 (11.1%) 9 
M11 D H > 200 17 (81%) 2 (10%) 1 (5%) 1 (5%) 21 
M50 D H > 200 2 (100%) 0 0 0 2 
P2 D H > 200 16 (100%) 0 0 0 16 
M16 D S > 200 0 1 (14.3%) 0 6 (85.7%) 7 
M3 D S > 200 0 1 (50%) 0 1 (50%) 2 
M31 D S > 200 9 (53%) 5 (29%) 2 (12%) 1 (6%) 17 
M44 D S > 200 2 (100%) 0 0 0 2 
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Figure 6-2 Representative example of results from receptor utilisation test of 6 selected 
autologous viral variants isolated from cat M31 and 2 reference pseudotypes, GL-8 
(prototypic “early”) and B2542 (prototypic “late”). Note the differences in titres on MCC 
F(FH)H cells (blue) and subsequent pseudotype classification as “early” and “late”. The 
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mean luciferase counts (cpm) for each cell line with standard errors (n=3) are presented for 
MCC HHH, MCC F(FH)H, MCC FFF and CLL-CD134 cells, shown in purple, blue, red and 
green respectively. 
 
6.3.1 “Late” Env phenotype prevalent amongst terminally infected 
cats 
During the study period 16/38 cats (42.1%) died, while 22/38 cats remained alive 
(57.9%). Amongst the deceased cats, 12/16 (75%) gave rise to at least one FIV 
Env variant that utilised CD134 in a similar manner to the representative “late” 
B2542 Env. In the “alive” group, 5/22 cats (22.7%) gave rise to at least one Env 
variant demonstrating similar receptor usage to B2542 Env. The remaining 17/22 
cats, (77.3%) in the “alive“ group had only GL-8-like Envs, with the exception of 
cat P7 which harboured both GL-8-like Env variants as well as a variant of 
intermediate, undetermined receptor utilisation. The median number of 
pseudotypes bearing Env variants from each individual and assessed for receptor 
usage in this analysis was 6 and 8.5, for alive and deceased animals respectively. 
By comparing receptor utilisation between the “alive” and “deceased” cats 
(Figure 6-3), we observed that “late” B2542-like Env variants were more 
common in cats that died during the study; in comparison, healthy cats were 
more likely to harbour “early” GL-8-like Envs (Fisher’s exact test, p=0.0026). 
6.3.2 Receptor usage of viruses isolated from healthy and sick 
cats 
Employing different grouping criteria to analyse the data, we compared the 
receptor usage of Env variants between healthy and sick cats (Figure 6-3). Of the 
38 cats examined, 19 (50%) were classified as healthy and the remaining 19 cats 
(50%) displayed clinical signs and were therefore classified as sick. The median 
number of pseudotypes assessed for receptor usage from each healthy and sick 
cat was 7, minimising any bias in the analysis. Amongst the group of nineteen 
sick cats, twelve cats (63.2%) had at least one Env variant that utilized CD134 in 
a similar manner to the representative “late” B2542 Env. However, this pattern 
was not observed amongst the healthy group; in contrast, 5/19 healthy cats 
(26.3%) gave rise to at least one B2542-like Env variant. A statistically significant 
difference was observed between the two groups; sick cats were more likely to 
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harbour B2542 like “late” Env variants than healthy cats (p=0.0489, Fisher’s 
exact test). 
Since an assessment of health status may be subjective, we further compared 
receptor utilisation by pseudotypes with CD4 lymphocyte values collected at the 
last sampling time point from each cat. Thirteen of 38 cats (34.2%) were 
considered to be in the AIDS stage of disease (CD4 lymphocyte counts below 200 
cells/µl). Eight of these 13 cats (61.5%) gave rise to at least one B2542-like Env 
variant. Amongst the remaining 25 cats (65.8%) with CD4 lymphocyte numbers 
greater than 200 cells/µl, nine cats (36%) gave rise to at least one Env variant 
with similar receptor usage to B2542 Env. Although those nine animals were 
arbitrarily classified in the non-AIDS group according to their CD4 values, it was 
apparent that they had relatively low CD4 lymphocyte counts (median value of 
330 cells/µl) compared to the remaining 16 cats (median CD4 lymphocyte count 
was 610 cells/µl), suggesting that the existence of B2542-like Envs is associated 
with lower CD4 lymphocyte values. By comparing these two groups (CD4> 200 
cells/µl and CD4< 200 cells/µl, median number of pseudotypes assessed for each 
group being 7 and 8 respectively), we observed a similar trend as previously; Env 
variants with the “late” phenotype were more common in terminally sick cats. 
Nevertheless there was no statistically significant correlation between the 
existence of “late” Env variants and CD4 counts below 200 cells/µl compared to 
cats with CD4 counts above 200 cells/µl (Fisher’s exact test, p=0.1776). 
6.3.3 Prognostic value of receptor utilisation for predicting 
disease progression 
As demonstrated above, by employing three different grouping criteria, we 
identified a trend for the presence of “late” B2542-like Env variants in sick cats 
compared to healthy ones. Healthy cats with CD4 counts >200 cells/µl were 
more likely to harbour “early” GL-8-like Env variants. 
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Figure 6-3 Numbers of cats harbouring prototypic “early” and “late” Envs. Cats were 
classified into 3 groups: 1) alive/deceased 2) healthy/sick 3) CD4 lymphocyte counts above 
and below 200 cells/µl. The cats which died during the study, displayed clinical signs (sick) 
or had CD4 counts below 200 cells/µl were more likely to harbour at least one prototypic 
“late” Env variant (green). Conversely, the majority of alive, healthy cats with CD4 counts 
>200 cell/µl were more likely to harbour only “early” GL-8-like Env variants (red). P-values 
(Fisher’s exact test) are denoted below x axis. 
 
Taking these results together, depending on grouping criterion (alive/deceased, 
healthy/sick or absolute CD4 lymphocyte counts above and below 200 cells/µl), 
at least one “late” Env variant was present in 61.5 to 75% of animals considered 
as being in the terminal, symptomatic stage of disease. In contrast, such “late” 
Env variants were only present in 22.7% to 36% of cats considered to be in the 
“asymptomatic” stage of FIV infection. 
6.3.4 Correlation between FIV receptor utilisation and neutralising 
antibody response 
To determine whether the existence of putative “late” Env variants is associated 
with the presence or absence of neutralising antibodies, neutralisation profiles 
from cats harbouring at least one “late” Env variant were compared against 
those that harboured only “early” GL-8-like Envs. Amongst the 17 cats 
harbouring at least one “late” Env variant, 10 cats neutralised pseudotypes 
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bearing homologous Envs while the remaining 7 cats did not (Fisher’s exact test, 
p=0.75). 
6.3.5 Loss of a single PNGS within the V5 region of Env alters 
receptor utilisation 
When examining the receptor utilisation of Env variants from 38 cats, we 
observed a complete spectrum of receptor utilisation by Env variants isolated 
from cat M11. We examined pseudotypes bearing twenty-one Env variants 
isolated from three time points up until the cats’ death. As demonstrated in 
Figure 6-4, 17/21 (81%) of M11 Env pseudotypes demonstrated an “early” 
phenotype; these Env variants utilised CD134 in the same way as the 
representative “early” GL-8 Env. Two Env variants (10%) utilised CD134 in the 
same manner as the prototypic “late” B2542, indicating a late phenotype. One 
Env variant (5%) displayed an intermediate requirement for CRD2 on CD134. 
Strikingly, the remaining pseudotype M11A C242 (5%), infected MCC F(FH)H cells 
more effectively, achieving higher titres than the representative “late” B2542 
Env pseudotype. Analysis of peptide sequence alignments identified two unique 
residues: 1) T520A and 2) E838K that were present in M11A C242 Env but not in 
any other Env variant from this cat. Furthermore, by analysing potential 
glycosylation patterns, we observed that substitution of T520 with A520 resulted 
in the loss of a PNGS, suggesting that T520A rather than E838K was associated 
with altered utilisation of CD134. 
To confirm this observation, PCR-based site directed mutagenesis was employed 
to reinstate 1) alanine at position 520 to threonine and 2) lysine at position 838 
to glutamic acid in order to create M11A C242 A520 and M11A C242 K838 mutants 
respectively. By comparing the receptor utilisation of these mutant Envs with 
the wild type M11A C242 Env, we found that the M11A C242 A520 mutant 
achieved a 10 fold lower titre on MCC F(FH)H cells compared to either the 
parental wild type M11A C242 or the M11A C242 K838 mutant Env, confirming 
that the T520, with the subsequent loss of a PNGS, played an important role in 
receptor utilisation (Figure 6-5). 
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Figure 6-4 Receptor usage of 21 autologous viral variants isolated from cat M11 at 3 time points (A, B and C) and 2 reference pseudotypes bearing the Envs 
of GL-8 (prototypic “early”) and B2542 (prototypic “late”) assessed on MCC HHH (purple), MCC F(FH)H (blue), MCC FFF (red) and CLL-CD134 (green). 
Seventeen (17/21, 81%) pseudotypes expressed the same mode of interaction with CD134 as GL-8, two (2/21, 10%) interacted with CD134 in the same 
manner as prototypic B2542 and one (1/21, 5%) showed an intermediate requirement for the CRD2 of CD134. M11C C242 (1/21, 5%), infected MCC F(FH)H 
cells more effectively than B2542. Each bar represents mean luciferase activity (cpm) ± standard error (n=3). 
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Figure 6-5 Results of site directed mutagenesis; a PNGS within the V5 region was 
associated with receptor utilisation. Receptor utilisation by M11A C242 WT was compared 
with the respective K838 and A520 mutants. To confirm the role of the PNGS at position 520, 
receptor usage of M11A C164 was compared with the respective A520 mutant. GL-8 and 
B2542 pseudotypes were tested in parallel as representative “early” and “late” pseudotypes 
respectively. Each bar represents mean luciferase activity (cpm) ± standard error (n=3). 
 
To confirm the role of A520 and the subsequent loss of a PNGS determining 
receptor utilisation, mutants of the Env clone M11C C164, (which expressed the 
“early” phenotype of CD134 usage, similar to the representative “early” GL-8 
Env) were constructed. Substitution of T520 with A520 resulted in the generation 
of mutant M11C C164 A520 which productively infected MCC F(FH)H cells. These 
results confirmed our hypothesis that the PNGS at position 520 within the V5 
region of the SU of Env was responsible for modulating the virus-receptor 
interaction. 
We next asked whether Env variants with different phenotypes for CD134 
utilisation display different susceptibilities to neutralisation. However, analysis 
of the neutralisation profile of three plasma samples collected from cat M11 
(results presented in Appendix 4) revealed that none of the plasma samples 
tested neutralised pseudotypes bearing homologous Env variants, regardless of 
the Env phenotype for CD134 utilisation. 
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6.4 Discussion 
The aim of this study was to examine whether there was a shift in receptor 
utilisation and cell tropism as infection progressed and to assess the prognostic 
value of alterations in receptor utilisation observed during natural FIV infection. 
In vitro culture and in vivo experimental infection data suggested that FIV Env 
variants isolated during the early, acute stage of infection required a more 
stringent interaction with the CRD1 and CRD2 of CD134 (Willett et al., 2006a), 
known as the “early” phenotype. During disease progression, “late” Env variants 
(which interact only with CRD1 of CD134) emerge. These Envs may further 
evolve towards CD134 independence, facilitating virus dissemination to CD134-
negative cellular compartments, contributing to disease progression (Willett et 
al., 2006b), (Willett et al., 2007), (Willett et al., 2008), (Willett et al., 2009), 
(Willett et al., 2010). 
The data presented here suggest that sick cats are more likely to harbour 
putative “late” viral variants than healthy cats, in agreement with the model 
proposed previously (Willett and Hosie, 2008); “early” viruses shift from  
a “complex” to a “simple” interaction with CD134 as disease progresses. 
Employing three different grouping criteria to analyse the data, similar trends 
were observed; Env variants with the “simple”, less stringent interaction with 
CD134 arose during the advancement of FIV infection, concomitant with 
declining health status, lower CD4 lymphocyte counts and leading to shorter 
survival times. It was apparent however, that the shift from “complex” to 
“simple” interaction with CD134 was not a necessary prerequisite for disease 
progression, as 25% of the cats that died during the study did not harbour Env 
variants displaying the “late” phenotype. Similar observations have been 
recorded in HIV-1 infected individuals (Berger et al., 1999); CXCR4 dependent 
“late” viruses emerge only in 50% of individuals who progress to AIDS (Regoes 
and Bonhoeffer, 2005), (Waters et al., 2008), (Shepherd et al., 2008). 
Nevertheless, taking together these various hypotheses and empirical evidence, 
it remains difficult to explain why R5 viruses predominate during early HIV 
infection and why the proportion of R5:X4 viruses is reversed in the terminal 
disease stages in some individuals (Regoes and Bonhoeffer, 2005). 
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It is important to emphasize that the trend in receptor usage shift observed here 
may have been biased by differences in the detection and cloning of envs with 
the “late” phenotype compared to “early” envs and to produce viable 
pseudotypes bearing those Envs. The median number of pseudotypes assessed 
was matched in the comparison of healthy and sick cats. Nevertheless, the 
results of this comparison would have been more convincing if we had assessed 
the tropism of a larger number of Env variants. The detection and cloning of 
Envs occurring in low abundance (which may have different tropisms compared 
to the majority of quasispecies circulating in the blood) poses a significant 
challenge (Lin and Kuritzkes, 2009). This may explain why recent studies, 
employing more sensitive detection methods, report higher numbers of HIV 
progressors infected with X4 viruses (Wilkin et al., 2011) than previous reports 
(Berger et al., 1999). 
It is difficult to assess how representative were the Envs analysed in this study of 
the entire pool of Env variants circulating within infected animals, especially 
those within immune privileged compartments rather than peripheral blood. It 
appears that FIV tends to infect cells in vivo which do not express CXCR4 (Troth 
et al., 2008). A similar trend of evolution from classic usage of CXCR4 and CCR5 
towards usage of CCR8 (Rucker et al., 1997), CCR3 (Doranz et al., 1996) or GPR1 
(Shimizu et al., 2000) has been observed in HIV and SIV infections. Hence it is 
possible that FIV infects cells via a non-CXCR4, as yet unknown, co-receptor, 
especially in the bone marrow which appears to be a major reservoir of FIV 
infected cells and where the majority of cells do not express either B- or T-cell 
markers (Troth et al., 2008). 
In spite of the potential limitations described above in detecting less abundant 
Envs, it was observed that FIV Env variants with “late” phenotypes occurred 
more frequently in sick animals in our study group. How do such variants 
contribute to the onset of immunodeficiency and what is the molecular basis of 
disease pathogenesis induced by “late” variants of FIV? It has been proposed 
that, as disease progresses, the viral Env may evolve towards a less stringent 
interaction with CD134, subsequently leading to CD134-independent infection of 
cells via CXCR4 alone and consequently a broadening of cell tropism (Willett and 
Hosie, 2008). The “simple” mode of interaction with CD134 was observed for 
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both pseudotypes bearing the Envs of i.) B2542 (Diehl et al., 1995a) and ii.) PPR 
(Sparger et al., 1994); both B2452 and PPR are pathogenic in vivo, indicating 
that alterations in receptor usage resulting in the “late” phenotype are not 
directly related to the ability of such variants to cause disease. The molecular 
basis of the hypothetical pathogenic properties of “late” isolates of FIV has yet 
to be validated. Indeed, the emergence of such “late” variants may be  
a consequence rather than a cause of disease 
It has been suggested that the Env of “late” viruses has a more exposed CXCR4 
binding site and therefore may be more susceptible to NAbs (Willett et al., 
2010). A similar scenario was suggested for CCR5- and CXCR4-dependent viruses 
in HIV-1 infection (Bou-Habib et al., 1994) but other studies provided evidence 
that there were no differences in susceptibility to neutralisation between the 
two phenotypes (Zhang et al., 1999). Data from this study suggested that there 
were no differences between “early” and “late” Env variants in susceptibility to 
autologous neutralisation. Whereas pseudotypes bearing Envs with both “early” 
and “late” phenotypes were equally well neutralised in some cats, no 
neutralisation was observed in other cats.  
So if NAbs are not responsible for driving viral evolution towards CD134 
independence, do cytotoxic T lymphocytes (CTL) play a role? Perhaps cells 
infected with “early” viruses are more efficient at antigen presentation and are 
more susceptible to CTL-mediated killing? If CTLs were involved in promoting the 
shift in receptor usage, it would be important to examine selection pressures on 
proteins other than Env to validate this hypothesis. In this scenario, the 
diversifying selection would be predicted to be uniform across the entire viral 
genome. 
It is intriguing to ask, why does FIV evolves towards CD134 independence? 
According to the transmission-mutation hypothesis proposed for HIV-1 (Regoes 
and Bonhoeffer, 2005), the change in co-receptor usage during the course of 
infection is a consequence of viral evolution, which by chance may result in the 
emergence of X4 viruses. Accordingly, co-receptor switching may simply be  
a chance event and hence occurs in only a fraction of individuals infected with 
HIV-1 (Berger et al., 1999). Based on the results of site directed mutagenesis 
presented here, together with previous results (Willett et al., 2008) and since  
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a single amino acid substitution can modulate the virus-receptor interaction, it 
is plausible to conclude that the observed switch is a chance event. 
Furthermore, it appears that a single point mutation across the whole Env 
glycoprotein, within the V1/V2 (Willett et al., 2008) or the V5 region (as 
demonstrated here), alters CD134 utilisation. It appears that no intermediate 
mutants are required for this shift to occur, as demonstrated by cat M11. 
Nevertheless, in other cats variants were identified that displayed an 
intermediate dependency on CD134; such variants could potentially revert, 
following subsequent mutation events, to either full dependency or 
independency on CD134. 
Another intriguing question is why do viruses requiring a stringent interaction 
with CD134 predominate in early FIV infection? In HIV-1 infection R5 viruses 
predominate shortly after transmission (van't Wout et al., 1994). The importance 
of CCR5 for the establishment of infection was demonstrated by studies of 
individuals with a homozygous defect in CCR5 (Liu et al., 1996a) who were highly 
resistant to HIV infection (Wilkinson et al., 1998). A likely explanation of the 
hypothetical abundance of “early” viruses following viral transmission could be 
that such variants are selected in the infecting or infected animal. Given the 
major route of transmission of FIV, which occurs via biting and possibly blood 
sharing, it is tempting to speculate that selection forces during natural 
transmission of FIV are not as strong as during mucosal transmission of HIV-1 
(Schuitemaker, 1994). Indeed, epithelial and dendritic cells (which are 
responsible for HIV-1 transmission and transfer) predominantly express CCR5 but 
not CXCR4, which could in part explain why CCR5 viruses predominate following 
infection (Reece et al., 1998), (Granelli-Piperno et al., 1998), (Meng et al., 
2002). However, given the route of transmission it is difficult to assess how  
a similar mechanism might be involved in the transmission of FIV. More plausible 
is the explanation that “early” FIV variants are more pathogenic and therefore 
expand more rapidly following transmission, dominating the viral population. 
Similarly it has been observed in HIV-1 infection that R5 isolates are more fit 
than X4 variants early in infection (Meng et al., 2002). Further research to assess 
putative differences in replication rates between “early” and “late” variants 
isolated from animals in this study would be required to validate this hypothesis. 
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It has been suggested that FIV infection can occur via a CXCR4-independent 
route; FIV DNA has been detected in CXCR4 negative cells, particularly within 
the bone marrow (Troth et al., 2008). It is therefore possible that FIV can infect 
cells using an alternative co-receptor. FIV DNA has been demonstrated also in 
non-lymphoid cells, such as primary erythroid progenitors which do not express 
CXCR4 (Troth et al., 2008). This observation, together with the evidence that 
the bicyclam analogue AMD3100 showed equivocal antiviral effects in vivo 
(Hartmann et al., 2012) and the fact that FIV targets cells such as CD8+ T cells 
and B cells which do not express (or express very low levels) of CD134 (de 
Parseval et al., 2004a), it is likely that existing in vitro models of FIV tropism do 
not fully reflect the complexity of the virus-host interaction in vivo.  
In summary, the results presented in this chapter support a model whereby 
viruses which require less stringent interactions with CD134 emerge during 
disease progression, facilitating viral dissemination to CD134-negative cellular 
compartments and accelerating disease progression. However further research is 
needed to confirm this model, including an assessment of the sensitivity of Env 
variants to soluble CD134 (sFc-CD134), CD134 ligand (fCD134L) and anti-CD134 
antibody (7D6) (Willett et al., 2009). A comparison of the replication rates in 
vivo of isolates identified as “early” and “late” is crucial to elucidate 
differences in disease-inducing potential. Finally, a bioinformatics approach 
correlating the phenotype and genotype pairs identified in this study is required 
in order to establish a prospective genotypic method to predict receptor usage 
in FIV infection. Such information might provide a useful prognostic indicator for 
veterinarians following the diagnosis of FIV in cats in their care. 
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Chapter 7. Efficacy of commercial FIV vaccine in 
Australia 
Since its discovery in 1987, much FIV research activity has focused on the design 
of a fully efficacious vaccine since, as well as preventing the spread of FIV 
infection, such a vaccine would inform the design of vaccines FIV’s human 
counterpart, HIV. The idea of using the feline model to understand correlates of 
immune protection has been embraced by several conventional and molecular 
vaccine trials over the last two decades. The efforts of FIV researchers have 
resulted in many significant discoveries, which eventually led to the release in 
the US of the first dual subtype commercial FIV vaccine in 2002 (Fel-O-Vax FIV, 
Fort Dodge Animal Health). 
Nevertheless, this vaccine attracted criticism for confounding diagnosis of FIV 
infection and concerns have been raised about its efficacy against heterologous 
challenge. Moreover, a single independent study assessing its efficacy reported 
an early enhancement of the viral load in vaccinated cats following experimental 
challenge with the GL-8 isolate of FIV (Dunham et al., 2006). Most importantly 
however, despite the vaccine having been marketed for over a decade, no 
studies have been conducted to evaluate its performance under natural 
conditions, against field strains. 
In the present study we assessed the neutralizing antibody response induced by 
the Fel-O-Vax vaccine against a representative panel of FIV isolates, using 
samples collected from a group of privately owned Australian vaccinates. 
Furthermore, we examined the molecular and phenotypic properties of the virus 
isolated from one cat which had been vaccinated and which most likely became 
infected following natural exposure to FIV. We showed that Fel-O-Vax does not 
induce cross-reactive neutralizing antibodies, suggesting that other mechanisms 
may be involved in vaccine-induced protection. Although we found no evidence 
of antibody dependent enhancement of infection in vaccinates, the data 
presented in this chapter suggest that the commercial vaccine may not protect 
against virulent clade A field strains of FIV in Australia. However, further 
independent research is required to evaluate the performance of the Fel-O-Vax 
FIV vaccine under field conditions. Such studies will broaden our understanding 
of the mechanisms of protection elicited by the vaccine, as well as informing the 
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design of more efficacious vaccine immunogens, with the potential to impact 
upon HIV vaccine research. 
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7.1 Introduction 
The development of a safe and fully efficacious anti-lentiviral vaccine is urgently 
needed to halt the HIV pandemic. The challenges lying ahead of the 
development of such a vaccine are, however, immense and very complex. 
Despite over 25 years of research in the field, vaccine induced protection against 
the virus remains elusive (Rerks-Ngarm et al., 2009b), (Girard et al., 2011). 
A major obstacle is the fact that spontaneous cure from the disease has neither 
been documented in HIV nor FIV infection (Hosie et al., 2009), (Haase, 2010). 
Both viruses target CD4+ T cells and subsequently establish persistent, latent 
infection of memory cells (Pedersen et al., 1989), (Haase, 2010). Infection is 
followed by chronic immune activation, manifest by increased T-cell turnover 
and B-cell hyperactivation. During the course of disease, MHC-I antigen 
presentation on the surface of infected cells is down-regulated, facilitating viral 
escape from CTL surveillance (Collins et al., 1998). The high genetic diversity of 
the viral env (particularly that of HIV-1, being the result of intra-and inter-clade 
recombination) leads to the emergence of neutralization and CTL escape 
mutants, subsequently leading to the exhaustion of the immune system. How 
then can we design an efficacious and safe vaccine that will protect under such 
unfavourable conditions? 
Numerous vaccine candidates have been developed, with variable outcomes 
ranging from full protection to enhancement of infection (Girard et al., 2011). 
From the various regimens tested in non-human primate models, only four 
vaccine compositions were advanced to phase IIb or III efficacy trials in human 
volunteers (Robinson, 2007), (Wijesundara et al., 2011). These included two 
VaxGen gp120 (B/B' and B/E) trials in the USA (Flynn et al., 2005), (Gilbert et 
al., 2005) and Thailand (Pitisuttithum et al., 2006), Merck’s Ad5-HIV-1 STEP trial  
(Buchbinder et al., 2008), (McElrath et al., 2008) and lastly the ALVAC+gp120 
(RV144) study (Rerks-Ngarm et al., 2009a). Only a modest degree of protection 
was observed in the RV144 study (Kresge, 2009), while the Merck vaccine trial 
was halted prematurely when it became evident that vaccination increased the 
risk of HIV acquisition (Duerr et al., 2012). The failure of these trials raised  
a very valid question: is our current understanding of the viral biology and 
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immune correlates of protection sufficient to design a safe and fully efficacious 
lentiviral vaccine? 
The discovery of FIV shortly after its human counterpart offered a unique 
opportunity to study a virus that resembled HIV in morphology, and most 
importantly in its ability to induce immunodeficiency in its natural host 
(Bendinelli et al., 1995). Several FIV vaccine candidates were designed and 
evaluated using the feline model, yielding valuable insights into the virus biology 
and correlates of protection induced by these formulations (reviewed in Chapter 
1). From all compositions, whole inactivated virus and fixed infected-cell 
vaccines proved to be the most successful (Bendinelli et al., 1995), (Elyar et al., 
1997), (Hesselink et al., 1999). 
The knowledge gained from these studies led to the production of the whole 
inactivated virus, dual-subtype FIV vaccine which induced protection in vivo 
against subsequent challenge with homologous and heterologous subtype virus 
isolates (Pu et al., 2001). The prototypic vaccine underwent safety and efficacy 
evaluation by USDA (US Department of Agriculture), resulting in it being released 
on the market in the US in 2002 (Uhl et al., 2002). Within the first four years 
after its release, over 1.8 million doses of the vaccine had been sold in the US 
(Zwijnenberg and Yamamoto, 2007). Subsequently, the vaccine has been 
licensed for veterinary use in Canada, Australia, New Zealand and Japan. 
The Fel-O-Vax FIV vaccine consists of inactivated infected cells and whole 
inactivated viruses of two distinct strains of FIV: Clade A, FIV Petaluma and 
Clade D, FIV Shizuoka (Pu et al., 2005). These two strains differ from each other 
by 21% in a comparison of env sequences. The vaccine contains a commercial 
adjuvant and is reported to protect against homologous and heterologous FIV 
challenge, with adverse reactions being as low as 1.07% following the field 
evaluation (Huang et al., 2004). According to the current manufacturer’s 
description, the vaccine is engineered to aid, together with other preventive 
measures, the preclusion of FIV infection (Boehringer Ingelheim Vetmedica).  
Several safety and efficacy studies of the vaccine have been conducted (Pu et 
al., 2001), (Omori et al., 2004), (Huang et al., 2004), (Pu et al., 2005), 
(Kusuhara et al., 2005b), (Uhl et al., 2008), (Huang et al., 2010), but most of 
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these were undertaken by researchers collaborating either directly or indirectly 
with the vaccine manufacturer. 
In the first study which assessed the safety and efficacy of the dual subtype 
prototypic vaccine, vaccinated SPF cats were challenged intravenously with the 
(in vivo obtained) heterologous Bangston strain of FIV, as well as the homologous 
FIV Shizuoka and Petaluma strains (Pu et al., 2001). Several experimental 
protocols were used in this study, particularly concerning the selection and dose 
of the challenge inoculum. Protection against low-dose (10 CID50) of FIV Bangston 
was observed in 4 of 5 animals. However, increasing the infectious dose of the 
same inoculum to 100 CID50 resulted in protection of only 2 of 5 animals. Further 
challenge of the 4 vaccinates from the first group that had resisted infection 
following the first challenge, using 50 CID50 of FIV Petaluma, led to full 
protection, suggesting that the dual subtype vaccine is efficacious. Further 
evaluation included challenging 6 vaccinates with homologous in vivo and in 
vitro derived FIV Petaluma; all cats were protected against homologous 
challenge (Pu et al., 2001). 
A further efficacy study (Huang et al., 2004), reported that 16% (4/25) of 
vaccinated cats become infected, while 90% (17/19) of animals in the control 
group became infected following challenge with a heterologous strain of FIV. 
This again led to the conclusion that the vaccine was safe and efficacious (Huang 
et al., 2004). However, the challenge virus used in this study had undergone 
passage in cell culture before the challenge of 11 median infectious doses was 
inoculated intramuscularly. Unfortunately, the authors did not provide detailed 
information concerning the challenge strain used, except that it belonged to 
clade A and differed in the outer env sequence by 11% from FIV Petaluma (Huang 
et al., 2004). 
To address concerns about how representative were the challenge strains used in 
the previous studies, the Fel-O-Vax vaccine was tested against a heterologous 
Clade B virus challenge, using the FC1 strain of FIV that was isolated from  
a naturally infected cat in Florida (Pu et al., 2005). The virulence of FIV FC1 was 
compared against FIV GL-8 and Petaluma; based on the measurement of proviral 
load following experimental infection of SPF cats with these three strains, it was 
concluded that FIV FC1 was much more virulent that Petaluma and of 
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comparable virulence to GL-8. Nevertheless, such a conclusion based only on the 
assessment of the proviral load is questionable and requires further confirmation 
of infectivity and replication. Nevertheless, without providing any data, 
researchers collaborating with the vaccine manufacturer argued that FIV FC1 can 
induce severe immunodeficiency and induce more consistent loss of CD4+ T cells 
than a similar dose of GL-8 (Zwijnenberg and Yamamoto, 2007). 
Concerns that previous studies may not reflect the route of natural exposure 
were further addressed in a study in which six vaccinated and eight 
unvaccinated cats were housed together in one room with five entire (not 
castrated) male cats that have previously been infected with the subtype B, 
Aomori-2 strain of FIV for a period of nineteen months (Kusuhara et al., 2005a). 
The challenge virus infecting the five infected cats differed from FIV Petaluma 
and FIV Shizuoka by 18.5% and 19.6% respectively at the level of the env 
sequence (Kakinuma et al., 1995). The authors observed territorial fights and 
mating behaviour throughout the study period and, four of eight unvaccinated 
control cats became FIV gag PCR positive during the study, while all six 
vaccinated animals remained protected. This led to the conclusion that the Fel-
O-Vax FIV vaccine protected cats against heterologous subtype B challenge in 
conditions resembling natural exposure (Kusuhara et al., 2005a). 
A more recent study (Huang et al., 2010) assessed vaccine efficacy once again, 
using the same challenge strain of FIV FC1 and reporting protection in 10 of 14 
(71%) vaccinated cats. Interestingly, the plasma viral loads (PVL) in four 
unprotected vaccinates ranged from 2620 to 177310 copies/ml in comparison to 
the range of 4160 to 66170 copies/ml reported for control cats. Although the 
difference in PVL between the two groups was not statistically significant, it is 
apparent that some vaccinated, unprotected cats had almost three fold higher 
levels of viral RNA in the peripheral blood than infected, unvaccinated cats. This 
may suggest that the Fel-O-Vax vaccine, when it does not protect, may indeed 
enhance viral infection following exposure and subsequently lead to more rapid 
disease progression. Indeed, although the observed differences in PVL were 
reported as not significant, post mortem examination of lymphoid organs 
collected from 19 cats examined in this study revealed that vaccinated, 
unprotected cats had higher PVL in thymus, popliteal and mesenteric lymph 
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nodes compared to viremic controls inoculated with the same dose and strain of 
FIV (Huang et al., 2010), suggesting that vaccination induced enhancement of 
infection in the cats that were not protected following challenge. 
Similarly, enhancement of the viral load in Fel-O-Vax vaccinated, unprotected 
cats was demonstrated in an independent study (Dunham et al., 2006). All six 
SPF vaccinated cats become infected following challenge with the GL-8 strain of 
FIV. Strikingly, these cats showed enhanced viral loads two weeks post challenge 
compared to control cats (Dunham et al., 2006), which subsequently declined to 
levels more similar to those of the controls. This experimental study 
demonstrated that Fel-O-Vax does not protect against the clade A, GL-8 isolate 
which is regarded as a representative strain of FIV in the UK (Hosie and Beatty, 
2007), (Samman et al., 2011). The results of this study raise a valid question 
about the efficacy and safety of the vaccine under field conditions, particularly 
since vaccine induced enhancement of viral infection was described previously 
for FIV (Huisman et al., 2009). 
The lack of protection against a primary isolate of FIV was demonstrated 
(Dunham et al., 2006) but subsequently no independent research has been 
undertaken to evaluate the commercial vaccine’s efficacy under the field 
conditions (Doornenbal et al., 2012). As demonstrated in this thesis, FIV 
recombination is abundant; it is apparent that putative circulating recombinant 
forms of the virus are very common at least in the US. How efficacious is the 
Fel-O-Vax FIV against these recombinant and non-recombinant strains circulating 
in the field? Can we identify cats that have been vaccinated and subsequently 
become infected with the virus? Is there any evidence for enhancement of 
infection following vaccination and, ultimately, does the current vaccine bring 
more benefit or harm, complicating the diagnosis of infection? This and many 
more unresolved questions concerning not only efficacy but most importantly 
the mechanisms and correlates of protection induced by the dual subtype 
vaccine remain to be answered. 
To address some of these questions, a group of privately owned Australian cats 
with known history of FIV vaccination was studied; we evaluated breadth of NAbs 
induced by the Fel-O-Vax FIV. Furthermore, in order to determine the strains 
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that overcame vaccine-induced protection, we aimed to identify cats that had 
been vaccinated and which subsequently became infected with FIV. 
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7.2 Materials and methods 
7.2.1 Cats  
Cats were recruited into the study based on a retrospective search of the 
administrative search system (AIS) of electronic medical records (EMR) of all 
feline patients that visited the Valentine Charlton Cat Centre (VCCC) at the 
University of Sydney between January 2005 and September 2010. The search 
included cats referred by their veterinarians or presented to either the general 
practice or emergency service of the hospital. Key words used for the search 
were: “FIV”, “feline immunodeficiency virus”, “FIV PCR”, “Fel-O-Vax FIV” and 
“FIV vaccine”. 
Thus cats with a known history of FIV vaccination were identified. There were 8 
vaccinates of known ELISA and FIV PCR status (Gribbles Veterinary Laboratories, 
Bella Vista, NSW, Australia) and another 2 of unknown ELISA and PCR status, 
from which blood samples were stored in the hospital. As demonstrated in Table 
7-1, one cat (S1V) yielded a positive result for FIV proviral DNA. 
7.2.2 Plasma and blood samples 
Having obtained the consent of the cat owners, blood samples had been 
collected into heparinized and EDTA collection tubes during diagnostic 
procedures performed at the VCCC between January 2005 and September 2010. 
Samples had been centrifuged at 2000 rpm (~370 x g) for 10 minutes and plasma 
and cell fractions had been separated and frozen at -80oC. For the present 
study, stored samples were thawed, 200µl aliquots obtained, re-frozen and 
shipped on dry ice to our laboratory in Glasgow. 
7.2.3 Molecular biology techniques and phylogenetic analysis  
The entire FIV env was amplified directly from blood from S1V (vaccinated, FIV 
provirus positive cat) using the primers and nested PCR protocol described in 
Chapter 2 and appendices 1 and 2. The FIV env thus obtained was cloned into  
an eukaryotic expression vector and 24 Env variants were obtained, sequenced 
using the chain terminator method and transfected in 293T cells, using the 
methods described previously (Chapter 2). 
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Table 7-1 Clinical history of Fel-O-Vax FIV vaccinated cats. Age is accurate for the blood samples collection dates. All except two entirely indoor cats were 
tested both on FIV ELISA and FIV PCR. One vaccinated cat, S1V tested positive for FIV proviral DNA, while all others were negative. Housing: I-indoor, O-
outdoor. 
Cat 
 
Breed Sex Age 
(y.) 
Housing ELISA  PCR  Date of FIV 
vaccination 
Blood 
collection 
Chief complaint Diagnosis Other 
S1V DSH MN 11 I/O + + Oct 2006, Nov 
2007, Oct 2008, Sep 
2009 
09.12.09 no nasal and facial sensation, 
dribbling 
trigeminal nerve paralysis, 
cavernous sinus syndrome 
renomegaly, fights, 
unknown FIV status at the 
first vaccination 
S2V DMH FS 10 I/O + - Oct 2008. 19.11.08 inappetent and lethargic  anaemia, hepatitis, 
splenomegaly, inflammatory 
bone marrow disease 
 
S3V Ragdoll FS 3 I + - regularly since 
kitten 
06.05.10 lethargy, inappetence and weight 
loss 
idiopathic hypercalcemia renal insufficiency 
S4V Burmese MN 6 I/O + - unknown 25.06.09 lethargy, depression, weight loss, 
multiple joint effusion 
polyarthritis immune mediated 
(?) 
fight wounds 
S5V Abyssinian MN 10 I/O + - regularly, last one 
Jan 2009 
23.07.09 sneezing, ocular and nasal 
discharge 
active chronic rhinitis n/a 
S6V DSH FS 9 I + - unknown 14.10.09 sudden onset ataxia meningioma, right occipital lobe n/a 
S7V DLH MN 12 I/O + - unknown 02.03.10 presented for radio-iodine 
treatment 
hyperthyroidism n/a 
S8V DSH MN 6 I/O + - unknown 26.10.10 swollen left hind leg non-regenerative anaemia  fight wounds 
S9V DSH FS 8 I n/a n/a regularly since 
kitten 
30.04.09 acute vomiting pancreatitis n/a 
S10V British 
short hair 
F 1 I n/a n/a once as a kitten 20.07.09 pyrexia, lethargy, inappetence effusive feline infectious 
peritonitis 
euthanized following 
diagnosis 
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Twenty-four complete env sequences obtained from cat S1V and 17 reference 
isolates (as listed in Chapter 4 plus sequences of FIV Bangston; AY620002.1 and 
FIV FC1; AY621093) were included in phylogenetic analyses. These analyses were 
performed according to methods described previously (Chapter 4) and included: 
phylogenetic inference of isolated sequences, recombination testing and intra-
host diversity calculation.  
Neutralisation assays were set up using the protocol described in Chapter 5. 
Plasma samples collected from 10 vaccinates were tested for NAbs using a panel 
of reference pseudotypes bearing Envs of 7 heterologous isolates of FIV: 1) clade 
A, GL-8 (Hosie et al., 1995), 2) clade, B B2542 (Sodora et al., 1995), 3) clade C, 
CPG41 (Diehl et al., 1995b), 4) clade A, PPR (Phillips et al., 1990), 5) clade A, 
M2PET (Giannecchini et al., 2007), 6) clade A, NCSU (Yang et al., 1996), and 7) 
clade A, KKS (Pistello et al., 2010) .  
Twelve pseudotypes bearing Envs obtained from the vaccinated, FIV provirus 
positive cat S1V were prepared and tested for their cell tropism and sensitivity 
to autologous neutralization, as described previously (Chapters 4 and 5).  
7.2.4 Graphs and statistical analyses 
Graphs were drawn using GraphPad Prism v 5.00 (GraphPad Software, San Diego, 
California, USA). 
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7.3 Results 
7.3.1 Breadth of VNAb response in vaccinated cats 
In order to assess the breadth and strength of NAbs in cats vaccinated with Fel-
O-Vax, we tested plasma samples collected from vaccinated cats for the ability 
to neutralise pseudotypes bearing the Envs of 7 reference isolates of FIV. 
Surprisingly, as demonstrated in Figure 7-1, none of the plasma samples 
displayed cross neutralising activity. A degree of neutralisation breadth was 
observed for plasma S3V, which strongly neutralised KKS (17.3 fold) and 
moderately B2542 (3.5 fold), PPR (3.4 fold) and CPG41 (3.9 fold). In addition,  
a degree of moderate cross reactivity was displayed by plasma S5V, which 
neutralised KKS (4.3 fold) and PPR (3.4 fold). 
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Figure 7-1 Neutralisation profiles of plasmas from 10 vaccinees, shown as fold 
neutralisation. Plasma samples were tested against a panel of pseudotypes bearing 7 
reference Envs (GL-8, B2542, PPR, CPG41, M2PET, NCSU and KKS). Greater than 5.6 fold 
neutralisation (above dashed horizontal line) indicates strong neutralisation.  
 
Amongst all pseudotypes tested, only the KKS pseudotype (KKS closely resembles 
FIV Petaluma which is a component of the Fel-O-Vax FIV vaccine), was strongly 
neutralised by 50% of plasmas (from cats S3V, S4V, S6V, S8V and S9V with 17.3, 
20.8, 16.9, 33 and 16.5 fold neutralisation respectively). From the remaining 5 
 207 
 
samples, only two moderately neutralised KKS (S5V and S10V with 4.3 and 3 fold 
neutralisation respectively) while the remaining 3 did not neutralise any of the 
pseudotypes tested. 
7.3.2 Vaccinated, provirus positive cat S1V 
7.3.2.1 Phylogenetic inference  
The maximum likelihood analysis revealed that the vaccinated, provirus positive 
cat S1V harboured viruses containing clade A env genes. For clarity, only one env 
sequence, representative of the 24 env variants isolated from cat S1V (red node) 
is shown in Figure 7-2 compared against reference sequences. 
 
Figure 7-2 Maximum likelihood tree based on the HKY model rooted on the reference env of 
clade C. The tree is drawn to scale, with branch lengths denoting the number of 
substitutions per site. The analysis included 44 sequences from the Memphis and Chicago 
cohorts (as described previously in this thesis), 19 reference sequences (detailed in 4.2.1.3) 
and one sequence representative of 24 env genes isolated from cat S1V (red node). Note 
that sequence S1V clusters closely with GL-8 (red star). Vaccine strains: Petaluma and 
Shizuoka (FIV Clade D) are highlighted in green. Challenge strains (FC1 and Bangston) used 
in vaccine manufacturer’s efficacy trials are highlighted in turquoise.  
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The overall mean intra-host diversity (K2P) of the 24 env variants isolated from 
S1V was as low as 0.1% and the highest pairwise distance was 0.2%. By employing 
rigorous recombination testing (as described in Chapter 4 (4.2.4)), it was noted 
that all envs from cat S1V were non-recombinant clade A sequences. 
7.3.2.2 Autologous neutralising antibody response 
Plasma S1V did not contain heterologous NAbs since no neutralisation of 
pseudotypes bearing heterologous Envs was observed. This plasma was also 
tested against 12 pseudotypes bearing autologous Envs isolated from the same 
cat. 
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Figure 7-3 Neutralisation of plasma S1V against 12 pseudotypes bearing autologous S1V 
Envs variants. Graph represents differences between mean (n=3) luciferase activity (cpm) 
for wells with plasma at 1:10 dilution (red) and wells without plasma (NP, green). Note that 
all autologous pseudotypes were strongly neutralised by plasma S1V, producing 
significantly decreasing luciferase counts compared to the no plasma control. 
 
As demonstrated in Figure 7-3, plasma S1V strongly neutralised all pseudotypes 
bearing homologous Envs (ranging from 65 to 3042 fold neutralisation), in 
contrast to the lack of neutralisation observed against the reference 
pseudotypes. 
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7.3.2.3 Receptor usage 
Next, to assess the cell tropism of Envs isolated from S1V, pseudotypes bearing 
12 Envs that were representative of the 24 Envs obtained from this cat were 
tested for their receptor utilisation phenotype. As demonstrated in Figure 7-4, 
all Envs from cat S1V required a stringent, high affinity interaction with CD134 
for productive infection, displaying a phenotype similar to that of the prototypic 
“early”, acute GL-8 isolate. 
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Figure 7-4 Receptor usage of 12 pseudotypes bearing Envs isolated from cat S1V. All 
pseudotypes displayed a similar phenotype to the prototypic “early”, acute GL-8 strain of 
FIV (for description refer to Chapter 5). 
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7.4 Discussion 
A review of the literature describing studies that have been performed over the 
last decade concerning safety and efficacy of the Fel-O-Vax FIV vaccine, 
revealed significant gaps in the current understanding of correlates of protection 
and it is not clear how the vaccine performs against natural challenge under 
field conditions. 
Given that Fel-O-Vax FIV vaccine did not protect experimental cats against the 
heterologous challenge with GL-8 (Dunham et al., 2006), the aim of this study 
was to identify cats which had been vaccinated against FIV and which had 
subsequently become infected following natural exposure. A search of the 
electronic medical records of VCCC enabled us to identify one cat (S1V) which 
had been vaccinated and which tested provirus positive using a diagnostic PCR 
test; blood samples had been stored and were available for molecular analyses. 
Although only an incomplete history was available, cat S1V had been vaccinated 
with Fel-O-Vax FIV annually for at least three years, with the last vaccination 
having been administered in September 2009, three months prior to its FIV 
diagnosis and death due to cavernous sinus syndrome. 
Phylogenetic analysis revealed that cat S1V was infected with an entirely non-
recombinant clade A isolate of FIV, relatively closely related to FIV GL-8. Taking 
together the receptor utilisation phenotype of S1V Envs, which resembled that 
of GL-8 and the hypothesis that “early” acute isolates display a distinct receptor 
utilisation phenotype compared to “late” isolates (Willett et al., 2006a), it is 
tempting to speculate that the Env variants isolated from S1V represent the 
putative “early” acute isolates of the virus which are thought to be transmitted 
in the field (Willett et al., 2006a). This brings to the fore the valid question: is 
the protection induced by the vaccine sufficiently potent to protect cat S1V 
against infection with an “acute” virus, entirely belonging to clade A? The 
incomplete medical history of this cat prevents a definite conclusion in this 
case. The vaccination and FIV status of cat S1V prior to 2006 was not 
documented. What is known, however, is the fact that the cat was not tested for 
FIV prior to vaccination. Therefore it is not possible to rule out the possibility 
that S1V may have been infected prior to being vaccinated. Nevertheless, given 
the cat’s documented medical history, it is known that it was presented to its 
 211 
 
veterinarian on multiple occasions after relocation from Sydney to Canberra in 
late 2006. Given the territorial behaviour of male cats and a documented history 
of fight wounds following the relocation at this time, it is likely that cat S1V 
acquired FIV between 2006 and 2009, when it was thought to be protected 
against FIV infection as a result of vaccination. Although we cannot be certain, 
given the information from the cat’s owner and its veterinarian, it is likely that 
the FIV Envs isolated here are indeed representative of Envs from virus isolates 
that overcame vaccine-induced protection. Furthermore, as demonstrated by 
the low intra-host diversity of the 24 Env variants isolated from this cat, it is 
tempting to speculate that vaccination may have contributed to  
a homogenization of the viral population following infection.  
The correlates of protection induced by the Fel-O-Vax FIV vaccine remain 
unclear (Uhl et al., 2008). Here, the breadth and potency of NAbs elicited 
against the Env following immunization were measured. To our surprise, none of 
the ten plasma samples from vaccinated cats that were tested displayed broad 
cross-reactivity against the panel of seven pseudotypes bearing reference Envs 
from three different clades of FIV. Strong NAbs were induced only in 5 cats (50%) 
against the pseudotype bearing KKS Env, which very closely resembles the 
Petaluma isolate (Pistello et al., 2010) that is contained within the Fel-O-Vax 
vaccine (Uhl et al., 2002). A strong NAb response has been proposed as an 
essential correlate of vaccine induced protection (Hosie et al., 2011), (Kwong et 
al., 2012) and a crucial component of humoral immunity against virus infections 
(Amanna et al., 2008), (Plotkin, 2008). Initial studies evaluating Fel-O-Vax 
induced protection reported that NAbs recognising the homologous Petaluma and 
Shizuoka strains were detected in most of the vaccinated cats (Pu et al., 2001). 
In the same study, eight of twelve cats displayed NAbs against the heterologous 
FIV Bangston, leading to the conclusion that the two distinct isolates of FIV 
contained within the vaccine act synergistically to enhance the development of 
NAbs against heterologous strains of FIV (Pu et al., 2001). The results of this 
study, however, demonstrate that strong NAb were elicited only in 50% of the 
vaccinated cats and were potent only against the Env most closely related to one 
of the Envs contained within the FIV vaccine (Pu et al., 2001). There was no 
evidence for strong, cross-reactive NAbs in any of the samples from vaccinated 
cats that were tested here. It is tempting to speculate that a lack of broadly 
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cross-reactive NAbs may have resulted in infection of cat S1V following challenge 
with a field strain of FIV. 
Vaccine induced enhancement of lentiviral infection has been described 
previously (Huisman et al., 2009). Also, antibody-dependent enhancement (ADE) 
of infection plays an important role in the pathogenesis of Dengue virus (DENV) 
(Burke and Kliks, 2006), feline coronavirus (FCoV) (Corapi et al., 1992) and 
several other viral diseases (Takada and Kawaoka, 2003). In the present study 
there was no evidence of ADE against either heterologous or homologous Envs, 
concordant with a previous study of the Fel-O-Vax vaccine (Pu et al., 2001). 
However enhancement by a mechanism other than ADE, such as following 
activation of cell mediated immunity (Wahl and Orenstein, 1997), (Huisman et 
al., 2009) may have been involved, but were not examined here. 
It was observed that plasma S1V strongly neutralised pseudotypes bearing all of 
the homologous Envs tested. Together with the results of neutralisation studies 
of FIV and HIV-1 (Chapter 5), it is likely that the robust NAb response observed in 
cat S1V was a consequence of antigenic stimulation following infection with an 
acute, highly replicating strain of FIV. It was demonstrated that experimentally 
vaccinated cats, following challenge with the virulent GL-8 isolate, displayed 
significantly enhanced viral loads compared to non-vaccinated controls (Dunham 
et al., 2006). It is therefore tempting to speculate, given the severe onset of 
clinical symptoms in cat S1V, that vaccination led to an enhancement of 
infection and subsequent antigenic hyper-stimulation leading to a robust 
autologous NAb response by the previously primed immune system. Measuring 
plasma viral and proviral loads in cat S1V could validate this hypothesis.  
It is unclear whether sterilising immunity following FIV vaccination can be 
achieved without eliciting broadly cross reactive NAbs. It is apparent that virus 
specific cell mediated immunity plays an important role in restraining retroviral 
infections (Huisman et al., 2008a); however HIV vaccine candidates which 
elicited cellular immune response have been shown to be ineffective (Casimiro 
et al., 2003), (Nature, 2007), (Dubey et al., 2007). Nevertheless it has been 
demonstrated that immunization with Fel-O-Vax FIV elicits strong cellular 
immunity (Uhl et al., 2002), namely adaptive T cell immunity, protecting cats 
against homologous challenge in the absence of NAbs (Omori et al., 2004). Given 
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the case of cat S1V, however, it can be speculated that any CTL response 
elicited by the vaccine was not sufficiently potent on its own to protect against 
a natural challenge with a virulent field isolate of FIV. 
In conclusion, the safety and efficacy concerns associated with the release of 
the Fel-O-Vax FIV vaccine over a decade ago are as valid as ever before (Little et 
al., 2011). It is apparent that the majority of studies with the dual subtype 
vaccine have been undertaken by researchers collaborating, either directly or 
indirectly, with the vaccine manufacturer. As demonstrated in this chapter, 
vaccination with Fel-O-Vax FIV may not always protect cats against natural field 
exposure to FIV in Australia, where the vaccine has been licensed since 2004. It 
was observed that vaccination does not elicit, or at least lead to maintained 
levels of, broadly NAbs. Given that the correlates of protection induced by the 
vaccine are not fully understood and the abundance of recombinant strains of 
FIV (Chapter 4), more research is required to fully assess vaccine efficacy under 
field conditions. Although it appears that a safe, protective and affordable HIV 
vaccine remains elusive (Douek et al., 2009), (Mascola and Montefiori, 2010), 
(Hoxie, 2010), further studies of the current FIV vaccine will likely inform the 
design of improved formulations against human and feline immunodeficiency 
viruses and therefore such studies are urgently needed. 
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Chapter 8. Final discussion 
Studying feline viral infections under field conditions can be very challenging 
and hence relatively little is known about the longitudinal course of FIV infection 
in the domestic cat (Felis catus). The aim of the present study was to investigate 
FIV infection in cats that had been naturally infected and to assess the efficacy 
of the commercial FIV vaccine. The observations and insights into natural FIV 
infection gained during this study were compared with results and hypotheses 
that arose from studying experimental FIV infections (Willett et al., 2006b), 
(Willett et al., 2007), (Willett et al., 2008), (Kraase et al., 2010), (Samman et 
al., 2010), (Willett et al., 2010). 
The novel study described in this thesis examined host and viral factors likely to 
be associated with disease progression over the course of infection in  
a relatively large study group comprising cats living under two different housing 
conditions, in two distinct geographical locations. Moreover, in contrast to 
previous studies, the molecular analyses described here examined the entire env 
gene, not solely the short V3-V5 fragment. This approach provided answers to 
many intriguing questions surrounding the clinical presentation of FIV infection, 
dynamics of intra-host evolution, humoral response, cell tropism and lastly the 
efficacy of the commercial FIV vaccine. However, before drawing final 
conclusions, it is important to recognize and acknowledge the potential 
limitations of the study. 
Firstly, clinical parameters such as age and time of infection were often 
estimated on the basis of physical examinations rather than comprehensive 
clinical histories. Although performed by experienced feline medicine specialist, 
it is inevitable that these estimates carry some degree of uncertainty.  
It can be argued that blood direct PCR amplicons, subsequently cloned into 
eukaryotic expression vector may not fully represent the complexity of viral 
variants circulating within the host (Salazar-Gonzalez et al., 2008). It should be 
emphasized, however, that viral loads in “asymptomatic” FIV infection often fall 
below the limit of detection (Dieter Klein, personal communication). Use of the 
single genome amplification (SGA) method to decipher intra-host diversity in 
acute, peak high HIV-1 infection (Keele et al., 2008), would have biased the 
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results of the present study by including only those cats with detectable plasma 
viral loads. Indeed, evolutionary studies of HIV-2, which during asymptomatic 
phase often achieves undetectable plasma viral loads (Popper et al., 2000), have 
not employed the SGA method in order to minimise bias (MacNeil et al., 2007a), 
(MacNeil et al., 2007b).  
It has been argued that studies examining amplicons obtained by Taq polymerase 
may i.) give rise to some products as a result of template switching (Meyerhans 
et al., 1990), (Shriner et al., 2004), ii.) introduce errors during PCR amplification 
(Palmer et al., 2005) or iii.) introduce cloning bias (Liu et al., 1996b). Unlike 
previous studies, the Phusion enzyme with 25 fold higher fidelity than Taq 
polymerase (Frey, 1995) was used for the studies conducted as part of this 
thesis. To minimize the possibility of template switching during the PCR, we 
carried out three independent amplifications from each blood sample. All 
procedures were performed separately at various time points over a period of 18 
months to exclude the possibility of cross-contamination. Since this methodology 
yielded identical sequences, particularly those with shared recombination 
points, provides strong evidence that the amplicons that were obtained 
reflected genuine, in vivo circulating sequences and were neither the result of 
PCR induced errors nor associated with polymerase template switching. 
Moreover, the results of the present study are in agreement with previous FIV 
studies employing “bulk” PCR (Ikeda et al., 2004), (Motokawa et al., 2005), end-
point dilution proviral DNA PCR (Kraase et al., 2010) as well as a study examining 
viral RNA sequences in plasma (Huisman et al., 2008b); hence, despite the 
different methodologies used, it can be concluded that there is relatively low 
FIV sequence variation, highlighting its relatively high genetic stability. 
Finally, the relatively short length of the present study provides only limited 
information about the longitudinal course of FIV infection and it would be useful 
to follow up the recruited cats over a longer period of time. Nevertheless, 
bearing in mind possible limitations, the present study answered several 
intriguing questions, as discussed below, and broadened our understanding of 
natural FIV infection. 
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8.1 Living conditions are likely to influence the outcome 
of FIV infection 
Contrasting clinical outcomes of FIV infection were observed in the two distinct 
cat populations. Unlike HIV infection, there are no well-established prognostic 
indicators for FIV and, despite significant differences being observed between 
CD4 and CD8 lymphocyte subsets between FIV positive and negative cats, it was 
difficult to distinguish cats with and without clinical signs using these 
parameters. An examination of CD4 and CD8 lymphocytes in conjunction with 
PVL could prove valuable and is on-going as part of a collaborative research 
project. 
It has become clear that housing conditions, nutrition and health care access 
dramatically influence the survival times of FIV infected cats. Supported by 
studies published previously (Addie et al., 2000), (Ravi et al., 2010) as well as 
the general impression of veterinarians, the outcome of natural FIV infection is 
not always as dramatic as has been described following experimental infections. 
Indeed, the observations of the Chicago cohort were consistent with these 
reports. However, the outcome for the Memphis cats was dramatically different; 
the most common cause of morbidity identified in this population was 
lymphoma. Although virus induced immunodysregulation can be linked with 
neoplastic transformation of B-cells, a direct carcinogenic role for FIV was 
unlikely. It is possible that another, unknown infectious agent could have been 
reactivated in immunocompromised cats, leading to the high incidence of 
neoplasia. This hypothesis is currently under investigation, using next generation 
sequencing of tissue samples collected from the cats that developed lymphoma. 
8.2 FIV env is relatively stable genetically 
The overall env intra-host diversity in the majority of cases examined here was 
surprisingly low, given the general expectation of high mutation rates in viruses 
carrying the error-prone RT. Yet differences in intra-host diversity and 
evolutionary rates are evident between HIV-1 and the less pathogenic HIV-2. 
Although both viruses achieve similar proviral load, HIV-2 replicates to lower 
titres in the plasma (Popper et al., 2000), (MacNeil et al., 2007b), displays lower 
rates of sequence evolution (MacNeil et al., 2007a) and lower pathogenicity 
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reflected by a slower decrease in CD4+ T cell counts and subsequently requires a 
longer time interval for disease progression (Marlink et al., 1988), (Marlink et 
al., 1994), (Whittle et al., 1994), (Popper et al., 1999). Similarly, the low 
pathogenic bovine immunodeficiency virus (BIV), which is evolutionarily more 
closely related to FIV than the primate lentiviruses, also exhibits little sequence 
variation (Carpenter et al., 2000). The results presented in this thesis 
demonstrate  
a similar pattern to that of HIV-2 infection and are in agreement with previous 
studies indicating a relatively high genetic stability of FIV (Ikeda et al., 2004), 
(Motokawa et al., 2005), (Huisman et al., 2008b), (Kraase et al., 2010). 
At the population level, a surprisingly high abundance of recombinant viruses 
circulated amongst cats in the field. The results presented here, therefore, 
confound the current phylogenetic classification of the virus (Nishimura et al., 
1998) and call for its revision. 
In this thesis the existence of at least two common recombination break points 
was demonstrated, located at the stems of the V1/V2 and V5 loops of the SU of 
the viral Env. Taking the location of the first recombination breakpoint together 
with the relatively high number of positively selected sites and the highest 
evolutionary rate of this segment, it is likely that the leader region has  
a significant function in the virus life cycle. Studies of viral leader sequences 
highlighted their enormous complexity, suggesting a role, not only in post-
translational, but also in post cleavage events (Lemberg and Martoglio, 2002), 
(Hegde and Bernstein, 2006). Leader encoded peptides can be involved in self-
antigen presenting (Borrego et al., 1998) and in regulating Env expression levels 
on the viral surface (Hegde and Bernstein, 2006), subsequently affecting viral 
infectivity. This hypothesis, however, requires to be tested in functional studies. 
8.3 Humoral immunity does not alter the clinical course 
of FIV infection 
It was demonstrated that cats infected with FIV develop variable NAb responses 
against pseudotypes bearing autologous and heterologous FIV Envs. No 
correlation was observed between either health status or survival time following 
infection; similar neutralisation profiles were observed for plasmas from healthy 
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and non-healthy cats as well as cats that survived or died during the study. Such 
findings argue against a role for NAb in influencing disease progression. 
Furthermore, the results demonstrated that FIV infected cats, regardless of 
strength of NAb response, experience progressive declines in CD4+ T cell 
numbers; NAb responses, even when potent, did not protect against the loss of 
CD4 cells. A similar trend was observed in HIV-1 infection, where the presence of 
autologous (Cecilia et al., 1999), (Geffin et al., 2003), (Schmitz et al., 2003) and 
cross-reactive NAbs was not associated with a prolonged AIDS free, 
asymptomatic period (Piantadosi et al., 2009), (van Gils et al., 2010), (Euler et 
al., 2010). 
The data demonstrated that the humoral immune responses monitored in this 
study did not impact upon the clinical course of natural FIV infection. One 
plausible explanation for the apparent lack of correlation is that any factor 
which promotes a strong NAb response may negatively influence other immune 
responses, leading to exhaustion of polyfunctional CD4 and CD8 cells (Harari et 
al., 2004), (Betts et al., 2006), (Streeck et al., 2008). It is likely that cell 
mediated immunity, as well as host genetic factors, may influence the clinical 
course of infection rather than NAb (Nomura and Matano, 2012), (Huang et al., 
2012a). Further research is needed to decipher these mechanisms. 
8.4 FIV variants with altered cell tropism emerge in 
terminal disease 
The data revealed that sick cats were more likely to harbour putative “late” 
viral variants than healthy cats and were in agreement with the model proposed 
previously (Willett and Hosie, 2008); there is a switch from “early” viruses that 
require a “complex” interaction with CD134 to “late”: viruses requiring  
a “simple” interaction, as disease progresses. It was apparent, however, that 
the shift from a “complex” to a “simple” interaction with CD134 was not  
a necessary prerequisite for disease progression. Analogous observations were 
recorded in HIV-1 infected individuals (Berger et al., 1999); CXCR4 dependent, 
“late” viruses emerged only in 50% of individuals who progressed to AIDS (Regoes 
and Bonhoeffer, 2005), (Waters et al., 2008), (Shepherd et al., 2008).  
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A comparison of the replication rates of FIV isolates identified as displaying 
“early” and “late” phenotypes will be crucial to determine whether there may 
be differences in their hypothetical disease-inducing potential. From the 
prognostic point of view, a bioinformatics approach to test for correlations 
between the phenotype and genotype pairs identified in this study will be 
required in order to establish a prospective genotypic method for predicting 
receptor usage in FIV infection which might allow an estimation of the likelihood 
of disease progression. 
8.5 Fel-O-Vax FIV does not induce broadly neutralising 
antibodies 
Broad and strong NAb responses have been proposed as essential correlates of 
vaccine induced protection (Kwong et al., 2012). Initial studies evaluating Fel-O-
Vax FIV-induced protection reported that NAbs recognising the vaccine strains 
Petaluma and Shizuoka were detected in most vaccinated cats, leading to the 
conclusion that the two isolates of FIV contained within the vaccine act 
synergistically to enhance the development of NAbs against heterologous strains 
of FIV (Pu et al., 2001). Surprisingly, none of the ten plasma samples that were 
collected from Australian vaccinated cats and tested as part of this thesis 
displayed broad cross-reactivity; strong NAb were observed only in 50% of the 
vaccinated cats and were potent against only the pseudotype that bore an Env 
most closely related to the Petaluma Env contained within the FIV vaccine (Pu et 
al., 2001). Furthermore, a strain of FIV that had most likely overcome vaccine-
induced protection was identified, demonstrating that the Fel-O-Vax FIV vaccine 
may not always protect against natural exposure to FIV in the field. This 
apparent lack of protection may have been related to the lack of induction of  
a strong cross-reactive NAb response in the vaccinated cat that subsequently 
became infected. 
Since the correlates of protection induced by FIV vaccination are not fully 
characterised and the high abundance of recombinant strains of FIV described in 
this thesis, further research will be required to properly assess vaccine efficacy 
under field conditions.  
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8.6 Concluding remarks 
FIV, as well as being an important pathogen of domestic cats, has significant 
comparative value. Despite almost thirty years of research it is still largely 
unclear how HIV causes death and what are the correlates of protection. Many 
competing hypotheses have been proposed, often promoting primate animal 
models over the non-primate lentiviral models. Perhaps an inevitable 
anthropocentrism precluded HIV researchers from taking on board the lessons 
learned from the cat? This question is particularly valid in light of the failure of 
phase III, HIV vaccine clinical trials in human volunteers (Gilbert et al., 2005), 
(Flynn et al., 2005), (Pitisuttithum et al., 2006), (McElrath et al., 2008), 
(Buchbinder et al., 2008) (Rerks-Ngarm et al., 2009a) as well as the fact that in 
some cases vaccination increased the risk of HIV acquisition (Duerr et al., 2012). 
Are expensive, high-risk trials on human volunteers justified if we do not even 
fully understand the correlates of protection induced by the commercial FIV 
vaccine in the feline model? It is apparent that differences between FIV and HIV-
1 are more profound than those between HIV-1 and its simian counterpart. 
Paradoxically, these differences, and the fact that FIV has coexisted with its 
host for longer than HIV-1, may prove crucial to better understand the interplay 
between the lentivirus and its host and to achieve the highly desired fully 
efficacious vaccine. 
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Appendix 1: Primers  
Name Sequence (5’ to 3’) 
1F4 TGTAATCAACGYTTTGTKTCTCCTTACAG 
1R4 CCAATAMTCWTCCCAGTCCACCCTT 
2F2 TATTATTGGCARTTGCAATCTACMTTATC 
XR2 CCTCAAAGGGAAGAAATCAGCTCA 
G8_Sal1_fwd GGGTCGACACCATGGCAGAAGGGTTTGCAGCA 
M9M12_Sal1_fwd ACTGGTCGACACCATGGCAGCAGGGAGGATTTACTCAA 
M14M25_Sal1_fwd ACTGGTCGACACCATGGCAGAGGGAGGATTTACTCAA 
M8M33M43_Sal1_fwd ACTGGTCGACACCATGGCAGAAGGATTTGCAGCC 
M30M31M49_Sal1_fwd ACTGGTCGACACCATGGCAGAGGGAGGATTTACTCAA 
M47M50_Sal1_fwd ACTGGTCGACACCATGGCAGAAGGATTTGCAGTC 
M6_Sal1_fwd ACTGGTCGACACCATGGCAGAGGGAGGATTTGCTCAA 
M2_Sal1_fwd 
 
ACTGGTCGACACCATGGCAGAAAGATTTGCAGCC 
 M11_Sal1_fwd 
ACTGGTCGACACCATGGCAGAGGGAGGATTTAATCAA 
M46_Sal1_fwd ACTGGTCGACACCATGGCAGAGGGAGGATTTACTCAG 
M48_Sal1_fwd ACTGGTCGACACCATGGCAGAAGGATTCACTCAA 
M6_Not1_rev ACAGCGGCCGCCATCATTTCTCCTCTTTTTCAGAC 
M31_Not1_rev ACAGCGGCCGCGATCATTCCTCCTCTTTTTCAGAC 
M9M25M33M43M46_Not1 ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAGAC 
M14M30M48_Not1_rev ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAGAT 
M47_Not1_rev ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAGGT 
P4P5P13P15_Sal1_fwd  ACTGGTCGACACCATGGCAGAAGGATTTGCAGCC 
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Name Sequence (5’ to 3’) 
P2P6P11P14P17_Sal1 ACTGGTCGACACCATGGCAGAGGGAGGATTTACTCAA 
P10_Sal1_fwd ACTGGTCGACACCATGGCAGAGGGAAGGTTTACTCAA 
P2P5P13_Not1_rev ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAGAT 
P14_Not1_rev ACAGCGGCCGCCATCATTCCTCCTCTTTTTCAGAC 
P6P7_Not1_rev GGGCGGCCGCCATCGCCTCCTCTTTTTCAGA 
G8_Not1_rev GGGCGGCCGCCATCATTCCTCCTCTTTTTCAGAC 
VR1012_fwd CTTTTCTGCAGTCACCGTCG 
VR1012_rev CTGGATCCAGGCGCCTGGTCTA 
Memphis780_fwd TGGAATGAGACTATAACAGG 
Memphis2090_rev GATTACATCCTAATTCTTGCATAG 
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Appendix 2: PCR cycling conditions 
Table A2-1. Thermocycling conditions for Phusion Blood II Direct DNA Polymerase Kit.  
 Cycles Time (minutes) Temperature 
Initial denaturation 1 3 minutes 98°C 
Denaturation 
35 
10 seconds 98°C 
Annealing 30 seconds 64.5°C 
Elongation 90 seconds 72°C 
Final elongation 1 10 minutes 72°C 
 
Table A2-2. Thermocycling conditions for Roche Master DNA Polymerase. 
 Cycles Time Temperature 
Initial denaturation 1 5 minutes 94°C 
Denaturation 
30 
30 seconds 94°C 
Annealing 60 seconds 50°C 
Elongation 180 seconds 72°C 
Final elongation 1 10 minutes 72°C 
 
Table A2-3. Thermocycling conditions for Big Dye Terminator V1.1 sequencing PCR. 
 Cycles Time Temperature 
Initial denaturation 1 1 minute 96°C 
Denaturation 
25 
10 seconds 96°C 
Annealing 5 seconds 50°C 
Elongation 4 minutes 60°C 
Hold 1 ∞ 4°C 
 
Table A2-4. Thermocycling conditions for GoTaq colony screening PCR. 
 Cycles Time (minutes) Temperature 
Initial denaturation 1 5 minutes 95°C 
Denaturation 
30 
30 seconds 95°C 
Annealing 30 seconds 60.5°C 
Elongation 150 seconds 72°C 
Final elongation 1 5 minutes 72°C 
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Appendix 3: Buffers and solutions 
Name Contents 
HEPES buffered 
saline 
50 mM HEPES, 250 mM NaCl, 1.5 mM NaHPO4 
;  
pH 7.2 
Loading dye (10X) 60% glycerol, 0.25% bromophenol blue 
LB agar 1 % bactotryptone, 0.5% yeast extract, 1% NaCl, 7% agar 
LB broth 1% bactotryptone, 0.5% yeast extract, 0.5% NaCl; pH 7.0 
PBS-BSA 1% bovine serum albumin (BSA) in PBS 
PBS-Tween 0.1% Tween® 20 in PBS 
PBS 137mM NaCl, 27 mM KCl, 1.5 mM KH2PO4,10.2 mM Na2HPO4; pH 
7.4 
SOC medium LB broth, 0.04% glucose, 10 mM MgSO4, 10 mM MgCl 
TBE 1.25 M Tris, 27 mM EDTA, 0.4 M boric acid 
TE Buffer 10 mM Tris.HCl pH 8.0, 1 mM EDTA 
RBC lysis buffer 0.88% NH4Cl, 10 mM; pH 7.4 
 
All other buffers were provided with kits detailed in Chapter 2 and their 
contents are specified by manufacturers in product documentation. 
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Appendix 4: Autologous and heterologous 
neutralisation patterns in FIV infected cats 
Strong neutralisation 
Strong neutralisation displayed by plasma samples collected from cats that 
remained alive during the study period. 
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Figure A4-1 Autologous and cross reactive NAb response of plasma from cat P14. Plasma 
samples from each time point A, B, C and D (letters highlighted on the X axis in red, green, 
blue and black respectively) were tested against pseudotypes bearing: 1) 3 Env variants 
isolated from time point A (highlighted in red) 2) 3 Env variants from time point B 
(highlighted in green) and 3) 3 Env variants from time point C (highlighted in blue). Cross 
neutralisation activity was assessed against two reference pseudotypes bearing the Envs of 
GL-8 (orange) and B2542 (purple). Pseudotypes, named according to their Envs (from left to 
right), are shown in the same order as in the graph legend (top to bottom). 
 
Cat P14.  As demonstrated in Figure A4-1, all plasma samples from cat P14 
strongly neutralised pseudotypes bearing contemporaneous, earlier and later 
autologous Env variants (fold neutralisation ranged from 53 to 5499 at a 1 in 10 
plasma dilution). The genetic diversity of the Env variants (calculated for the 
entire env) was relatively low (0.2%) (highest K2P pairwise distance) and no 
changes were observed in the number (24) or the pattern of PNGS (see results in 
Chapter 4). Cat P14 had been infected for approximately 2 years and maintained 
CD4 lymphocyte counts around 1000 cells/µl (ΔCD4 over the observation period  
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= +0.12 K/µl) (Table 5-3). No cross neutralisation of the GL-8 or B2542 
pseudotypes was detected. 
Cat P13. An increased potency of autologous neutralisation was observed in cat 
P13 (Figure A4-2). Plasma collected from time point A either did not, or only 
moderately, neutralised pseudotypes bearing autologous Envs (1.2 to 5.7 fold), 
but  neutralisation potency increased at time point B and remained high against 
all but one autologous pseudotype during the observation period (10.2 to 201 
fold). 
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Figure A4-2 Autologous and cross reactive NAb response of plasma P13. Plasma samples 
from each time point A, B, C and D (highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 3 Env variants isolated from time 
point A (highlighted in red) 2) 3 Env variants from time point B (highlighted in green) and 3) 
3 Env variants from time point C (highlighted in blue). The cross neutralisation activity of 
each plasma sample was assessed against two reference pseudotypes bearing the Envs of 
GL-8 (orange) and B2542 (purple). Pseudotypes tested are shown (from left to right) in the 
same order as in the legend (top to bottom). Note that pseudotype P13C C27 was resistant 
to neutralisation by all plasma samples tested (hatched blue). 
 
A single pseudotype bearing an Env variant from time point C (P13C C27) 
remained resistant to neutralisation. The genetic diversity amongst the Env 
variants (calculated for the entire env as highest K2P pairwise distance) was 
0.4%. We did not observe changes in the number (25) or location of N-linked 
glycosylation sites (Chapter 4). However, we identified 2 mutations, K450E and 
G556D unique to isolate P13C C27 that may have rendered it resistant to 
neutralisation (sequence alignments are provided on the CD that accompanies 
 227 
 
this thesis). Cat P13 had been infected for approximately 1 year and  
a progressive decline in CD4 lymphocyte counts (from 460 to 270 cells/µl) was 
observed during the follow-up period (ΔCD4 = -180 cells/µl) (Table 5-3). No cross 
neutralisation of GL-8 or B2542 pseudotypes was detected, although during the 
course of infection we observed a slight increase in potency against the GL-8 
pseudotype (from 1 to 4.1 fold). 
Cat M47. Similar to cat P13, an increase in potency of autologous neutralisation 
was observed for cat M47 (Figure A4-3). Plasma samples from time points A and 
B did not neutralise autologous pseudotypes (1 to 2.4 fold), but neutralisation 
potency gradually increased over the course of infection, becoming strong at 
time point D (10.5 fold for M47A C135 to 1634 fold for M47B C94). 
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Figure A4-3 Autologous and cross reactive NAb response of plasma samples from cat M47. 
Plasma samples from each time point (A, B, C and D highlighted on the X axis in red, green, 
blue and black respectively) were tested against pseudotypes bearing: 1) 3 Env variants 
isolated from time point A (highlighted in red) 2) 3 Env variants from time point  
B (highlighted in green) and 3) 2 Env variants from time point C (highlighted in blue). Cross 
neutralisation activity was assessed against two reference pseudotypes bearing GL-8 
(orange) and B2542 (purple) Envs. Pseudotypes are shown (from left to right) in the same 
order as in the legend (top to bottom). Note the progressive development of neutralisation 
potency: plasma D neutralised all M47 pseudotypes tested. M47A C135 was least 
susceptible to neutralisation. 
 
Genetic diversity amongst the M47 env clones was 0.9%. The number of N-linked 
glycosylation sites varied between viral variants from 19 to 22. The least 
neutralised viral variant M47A C135 (fold neutralisation 10.5) surprisingly, had 
 228 
 
the lowest number (19) of N-linked glycosylation sites (discussed in Chapter 4). 
Cat M47 had been infected for approximately 3 years and, despite the 
development of a vigorous NAb response, experienced a progressive decline in 
CD4 T lymphocytes from 290 to only 100 cells/µl at the final sampling time 
(ΔCD4 = -190 cells/µl) (Table 5-3). No cross neutralisation of the GL-8 or B2542 
pseudotypes was detected (Figure A4-3). 
Cat M15. Plasma from each time point from cat M15 neutralised all the 
pseudotypes bearing autologous Env variants that were tested (fold 
neutralisation ranged from 183 to 5908), with the exception of one pseudotype 
bearing an Env variant from time point A (M15A C13) which was neutralisation 
resistant (Figure A4-4). Intra-host genetic diversity calculated for the entire env 
as highest K2P pairwise distance of 0.2% was surprisingly low. There were no 
changes in the number or positions of N-linked glycosylation sites (25). Cat M15 
had been infected for approximately 2 years at the start of the study and 
demonstrated a progressive decline in CD4 T lymphocytes from 870 to 470 
cells/µl during the 18 months of observation (ΔCD4 = -400 cells/µl) (Table 5-3). 
No cross neutralisation of the GL-8 or B2542 pseudotypes was detected (Figure 
A4-4). 
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Figure A4-4 Autologous and cross reactive NAb response of plasma M15. Plasma samples 
from each time point A, B, C and D (highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 4 Env variants isolated from time 
point A (highlighted in red) 2) 2 Env variants from time point B (highlighted in green) and 3) 
3 Env variants from time point C (highlighted in blue). Cross neutralisation activity of each 
plasma sample was assessed against two reference pseudotypes bearing GL-8 (orange) and 
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B2542 (purple) Envs. Pseudotypes are shown (from left to right) in the same order as in the 
legend (top to bottom). M15A C13 remained resistant to neutralisation throughout the 
observation period (hatched red). No Cr-NAb responses were observed. 
 
Cat P4. All P4 plasma samples neutralised autologous pseudotypes from time 
point A but there was decreased neutralisation potency against pseudotypes 
bearing time point A Envs during the course of infection (approx. 110 fold for 
plasma A compared to approx.17 fold neutralisation for plasma D) (Figure A4-5). 
There was a delayed NAb response against pseudotypes bearing Env variants 
from time point B, which were moderately to strongly neutralised only by plasma 
D (2.7 to 6.6 fold). 
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Figure A4-5 Autologous and Cr-NAb responses of plasma P4. Plasma samples from each 
time point A, B, C and D (highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 2 Env variants isolated from time 
point A (highlighted in red) 2) 3 Env variants from time point B (highlighted in green) and 3) 
1 Env variant from time point C (highlighted in blue). Cross neutralisation activity of each 
plasma sample was assessed against two reference pseudotypes bearing GL-8 (orange) and 
B2542 (purple) Envs. Pseudotypes are shown (from left to right) in the same order as in the 
legend (top to bottom). Note delayed neutralisation response against pseudotypes bearing 
Envs from time point B (P4B, green). 
 
The pseudotype bearing the Env variant P4C C20 resisted neutralisation by the 
contemporaneous plasma C and the later plasma D. We did not observe Cr-NAb 
against the GL-8 or B2542 pseudotypes (Figure A4-5). The genetic diversity of 
the P4 envs (highest K2P pairwise distance of 1.8%) was high compared to other 
cats and there were changes in the number and positions of N-linked 
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glycosylation sites, ranging from 22 to 25. Cat P4 had been infected for 
approximately 3.5 years at the start of the study and showed a marked increase 
in CD4 T lymphocytes, from 90 to 330 cells/µl over the 18 months of observation 
(ΔCD4 = +240 cells/µl) (Table 5-3). 
Cat M2. Only 2 pseudotypes bearing Env variants from cat M2 were available 
(Figure A4-6). All plasma samples showed different neutralisation potencies 
against pseudotypes bearing these two variants; the M2C C1 pseudotype was 
consistently more susceptible to neutralisation than the M2C C5 pseudotype. The 
strongest neutralisation against M2C C1 (276 fold) and M2C C5 (5.8 fold) was 
observed with the contemporaneous plasma sample from time point C but 
decreasing neutralisation was observed at time point D (69.2 and 3.7 fold for C1 
and C5 respectively). 
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Figure A4-6 Autologous and Cr-NAb response of plasma from cat M2. Plasma samples from 
each time point (A, B, C and D highlighted on the X axis in red, green, blue and black 
respectively) were tested against 2 pseudotypes bearing Env variants from time point C 
(highlighted in blue). The cross neutralising activity of each plasma sample was assessed 
against two reference pseudotypes, GL-8 (orange) and B2542 (purple). Values indicative of 
strong neutralisation (>5.6 fold) are above the dashed horizontal line. Pseudotypes are 
shown (left to right) in the same order as in the legend (top to bottom). Plasma C and D 
displayed strong neutralisation against M2C C1 and only moderate to strong neutralisation 
against M2C C5. No cross neutralisation was observed. 
 
The highest K2P pairwise distance between the two envs was 0.9 %. Both Env 
variants had the same number of PNGs but the differences in susceptibility to 
neutralisation may have been attributed to differences in the N-linked 
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glycosylation patterns between the two Envs (M2C C1 at position 550, M2C C5 at 
position 553). Cat M2 had been infected for approximately 6.3 years at the start 
of the study and displayed a marked decline in the number of circulating CD4 T 
lymphocytes (from 1740 to 620 cells/µl over 18 months of observation (ΔCD4 = 
-1120 cells/µl) (Table 5-2). No neutralisation of the GL-8 or B2542 pseudotypes 
was observed (Figure A4-6). 
Cat P22. Plasma samples from cat P22 were available at time points B, C and D 
and only two Env variants were obtained from this cat (Figure A4-7). All plasma 
samples strongly neutralised the P22C C73 and P22C C80 pseudotypes (5678 to 
54080 fold), the envs of which differed from each other by 0.4% (calculated for 
the entire env as the highest K2P pairwise distance). 
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Figure A4-7 Autologous and Cr-NAb response of plasma P22. Plasma samples from time 
points B, C and D (highlighted on the X axis in green, blue and black respectively) were 
tested against pseudotypes bearing 2 Env variants from time point C (highlighted in blue). 
The cross neutralisation activity of each plasma sample was assessed against reference 
pseudotypes GL-8 (clade A) (orange) and B2542 (clade B) (purple). Values indicative of 
strong neutralisation (>5.6 fold) are above dashed horizontal line. Pseudotypes are shown 
(from left to right) in the same order as in the legend (top to bottom). Moderate cross 
neutralisation against the B2542 and GL-8 pseudotypes was observed. 
 
Although both pseudotypes were strongly neutralised, the P22C C73 and P22C 
C80 env genes contained 23 and 24 N-linked glycosylation sites respectively. Cat 
P22 had been infected for approximately 2 years at the start of the study and 
showed a decline in the number of circulating CD4 T lymphocytes, from 1550 to 
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790 cells/µl over the 6 month observation period (ΔCD4 = -760 cells/µl) (Table 5-
3). Moderate to strong neutralisation was observed against the GL-8 pseudotype 
(4.9 to 6.5 fold), compared to moderate neutralisation of the B2542 pseudotype 
(3.2 to 4.3 fold) (Figure A4-7). 
Cat P18. Plasma samples from cat P18 were available only from time points B,  
C and D and only one Env variant was isolated from this cat (Figure A4-8). All 
plasma samples strongly neutralised pseudotypes bearing P18B C13 (2561 to 3083 
fold) which contained 25 PNGs. Cat P18 had been infected for approximately  
3 years at the start of the study and showed increasing numbers of circulating 
CD4 T lymphocytes, from 730 to 750 cells/µl over 6 months of observation (ΔCD4 
= +20 cells/µl) (Table 5-3). Moderate to strong cross-reactivity against the GL-8 
pseudotype was observed (5.5 to 9.6 fold) (Figure A4-8). 
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Figure A4-8 Autologous and Cr-NAb response of plasma from cat P18. Plasma samples 
from time points B, C and D (highlighted on the X axis in green, blue and black respectively) 
were tested against a pseudotype bearing an Env variant from time point B (highlighted in 
green). The cross neutralising activity of each plasma sample was assessed against two 
reference pseudotypes bearing GL-8 (orange) and B2542 (purple) Envs. Values indicative of 
strong neutralisation (>5.6 fold) are above dashed horizontal line. Pseudotypes are shown 
(left to right) in the same order as in the legend (top to bottom). The P18B C13 pseudotype 
was neutralised by all plasma samples. Moderate to strong cross-neutralisation of the GL-8 
pseudotype was observed. 
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Strong neutralisation pattern displayed by plasma from cats which died 
during the study. 
Cat M30. Plasma samples from cat M30 from time points A and B failed to 
neutralise pseudotypes bearing contemporaneous Env variants (Figure A4-9). 
Strong neutralisation of all 20 pseudotypes tested was observed by plasma 
collected at time point C (neutralisation from 173 to 3768 fold) but a decrease in 
neutralisation potency was observed at time point D (from 63 to 259 fold), 
shortly before the cat’s death (19.09.11). The genetic diversity, calculated for 
the entire env as the highest K2P pairwise distance, was 0.5%. No changes in the 
number (25) or location of N-linked glycosylation sites were observed (Chapter 
4). 
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Figure A4-9 Autologous and Cr-NAb response of plasma from cat M30. Plasma samples 
from each time point (A, B, C and D highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 5 Env variants isolated from time 
point A (highlighted in red) 2) 10 Env variants from time point B (highlighted in green) and 3) 
5 Env variants from time point C (highlighted in blue). The cross neutralising activity of each 
plasma sample was assessed against two reference pseudotypes, GL-8 (orange) and B2542 
(purple). Pseudotypes are shown (from left to right) in the same order as in the graph legend 
(top to bottom). Autologous NAbs were measured at time point C but neutralisation was 
lower at time point D, before the cat’s death. 
 
Cat M30 had been infected for approximately 1.5 years at the time of enrolment 
and, despite vigorous NAb responses, demonstrated a decline in CD4 counts from 
130 to 100 cells/µl over 18 months (ΔCD4 = -30 cells/µl). Interestingly, the high 
neutralisation observed at time point C coincided with the highest CD4 
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lymphocyte count (260 cells/µl). Subsequently the CD4 lymphocyte count 
decreased to 100 cells/µl (Table 5-2). No cross neutralisation against the GL-8 or 
B2542 pseudotypes was observed (Figure A4-9). 
Cat M14. Plasma samples from cat M14 collected at time points A and B failed to 
neutralise pseudotypes bearing contemporaneous Env variants (Figure A4-10) 
Strong, increasing in potency neutralisation was observed from time point C 
onwards until the cat’s death (20.08.11). 
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Figure A4-10 Autologous and Cr-NAb response of plasma from cat M14. Plasma samples 
from each time point (A, B, C and D highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 3 Env variants isolated from time 
point A (highlighted in red) 2) an Env variant from time point B (highlighted in green) and 3) 
6 Env variants from time point C (highlighted in blue). The cross neutralising activity of each 
plasma sample was assessed against two reference pseudotypes bearing GL-8 (orange) and 
B2542 (purple) Envs. Pseudotypes are shown (from left to right) in the same order as in the 
graph legend (top to bottom). Strong autologous NAb responses were present at time point 
C, with increasing potency observed at time point D, 6 months later. 
 
Plasma D, obtained shortly before the cat’s death, strongly neutralised all 10 
pseudotypes tested (neutralisation values ranged from 591 to 3404 fold). The 
genetic diversity amongst the envs, calculated for the entire env as the highest 
K2P pairwise distance, was 0.2%. Despite the strong NAb response, there were 
no changes in the number (25) or location of N-linked glycosylation sites. Cat 
M14 had been infected for approximately 4.5 years at the time of enrolment 
and, despite a vigorous NAb response, demonstrated a progressive decline in CD4 
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lymphocyte counts from 450 to 140 cells/µl over 18 months (ΔCD4 = -310 
cells/µl) (Table 5-2). No cross neutralisation of the GL-8 or B2542 pseudotypes 
was observed (Figure A4-10). 
Cat M25. Plasma samples from cat M25 were tested against pseudotypes bearing 
3 Env variants from time point A and 3 from time point C (Figure A4-11). Plasma 
A neutralised the contemporaneous M25A C98 and M25A C99 pseudotypes, but 
failed to neutralise the M25A C100 pseudotype which became susceptible to 
neutralisation by later plasma samples. Resistance to neutralisation of the M25A 
C100 pseudotype by contemporaneous plasma can most likely be attributed to 
one or more of the several mutations (K452R, H453Y, N495K, D552G, K554D, 
G555I, N556S, N558T and deletion at position 559) observed in the M25A Env 
compared to M25A C98 and M25A C99 Env sequences (sequence alignments are 
provided on the CD that accompanies this thesis). 
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Figure A4-11 Autologous and Cr-NAb response of plasma from cat M25. Plasma samples 
from each time point (A, B, C and D highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 3 Env variants isolated from time 
point A (highlighted in red) and 2) 3 Env variants from time point C (highlighted in blue). 
Cross neutralisation activity of each plasma sample was assessed against two reference 
pseudotypes bearing the GL-8 (orange) and clade B, B2542 (purple) Envs. Pseudotypes are 
shown (left to right) in the same order as in the graph legend (top to bottom). Autologous 
NAb responses were potent against all pseudotypes except M25A C100 (red with dotted 
pattern), which was susceptible to neutralisation by sera collected from time point B 
onwards. Pseudotype M25C C38 (blue chequered pattern) was only moderately to strongly 
neutralised. 
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Within the Env variants isolated from blood collected at time point C, we 
observed that one pseudotype, bearing the M25C C38 Env, was moderately to 
strongly neutralised by all plasma samples (from 3.6 to 6.1 fold), while the 
remaining two pseudotypes were strongly neutralised (from 126 to 6971 fold). 
These differences in resistance to neutralisation can most likely be attributed to 
several differences in the sequences of the Env variants (N218D, R395K and 
several mutations at positions from 552 to 559). The genetic diversity calculated 
for the entire env, was 1.1%. All but one Env variant contained 25 PNGS; M25C 
C39 contained 24 PNGS. Cat M14 had been infected for approximately 1.5 years 
at the time of enrolment and displayed a progressive decline in CD4 lymphocyte 
numbers, from 360 to 90 cells/µl recorded shortly before it died (04.09.11) 
(ΔCD4 = -270 cells/µl) (Table 5-2). There was no cross neutralisation of the GL-8 
or B2542 pseudotypes (Figure A4-11). 
Cat M49. Plasma samples from cat M49 were tested against 3 pseudotypes 
bearing Envs from time point A and 3 bearing Envs from time point C (Figure 
A4-12). 
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Figure A4-12 Autologous and Cr-NAb response of plasma M49. Plasma samples from time 
point A, B, C and D highlighted on the X axis in red, green, blue and black respectively were 
tested against pseudotypes bearing: 1) 3 Env variants isolated from time point A 
(highlighted in red) and 2) 3 Env variants from time point C (highlighted in blue). The cross 
reactivity of each plasma sample was assessed against two reference pseudotypes bearing 
clade A GL-8 (orange) and clade B B2542 (purple) Envs. Pseudotypes are shown (from left 
to right) in the same order as in the legend (top to bottom). Only M49A C87 was susceptible 
to neutralisation. 
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Plasma A neutralised one pseudotype bearing a contemporaneous Env (M49A 
C87) while the remaining two pseudotypes (M49A C85 and M49A C86) were 
neutralisation resistant. 
These two pseudotypes were also resistant to neutralisation by subsequent 
plasma samples (B, C and D). Similarly 3 pseudotypes bearing Envs from time 
point C were also neutralisation resistant. All neutralisation resistant 
pseudotypes bore Envs containing 25 PNGS while the neutralisation susceptible 
pseudotype bore an Env variant containing only 23 PNGS; this Env was 
genetically the most distant (highest pairwise distance 1.3%) Cat M49 had been 
infected for approximately 3.5 years at the time of enrolment and showed  
a dramatic decline in CD4 lymphocyte counts, from 410 to 40 cells/µl recorded 
shortly before it died of lymphoma (18.07.11) (ΔCD4 = -370 cells/µl) (Table 5-2). 
No cross neutralisation was observed against the GL-8 or B2542 pseudotypes 
(Figure A4-12). 
Cat M26.Plasma samples from cat M26 were available from 3 time points and 
were tested against 3 pseudotypes bearing Envs from time point A and 3 from 
time point C (Figure A4-13). 
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Figure A4-13 Autologous and Cr-NAb response of plasma from cat M26. Plasma samples 
from time points A, B and C highlighted on the X axis in red, green and blue respectively, 
were tested against pseudotypes bearing: 1) 3 Env variants isolated from time point A  
(highlighted in red) and 2) 3 Env variants from time point C (highlighted in blue). The cross 
neutralisation activity of each plasma sample was assessed against two reference 
pseudotypes, GL-8 (orange) and B2542 (purple). Pseudotypes are shown (from left to right) 
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in the same order as in the graph legend (top to bottom). Pseudotypes M26C C49 and C58 
were resistant to neutralisation. Cat M26 died before time point D. 
 
All pseudotypes bearing Envs from time point A (M26 A C109, C110 and C112) and 
one time point C pseudotype (M26C C50) were strongly neutralised by all plasma 
samples. Two pseudotypes bearing Env variants from time point C (M26C C49 and 
C58) remained resistant to neutralisation until the cat’s death (15.04.11). 
Although the genetic distances amongst the Envs was very low (0.2%), resistant 
Env variants contained additional PNGS at position 551 compared to 
neutralisation sensitive Envs. Cat M26 had been infected for approximately 3.5 
years and showed a dramatic decline in CD4 lymphocyte counts, from 540 to 130 
cells/µl recorded shortly before it died (ΔCD4 = -410 cells/µl) (Table 5-2). No 
cross neutralisation was observed against the GL-8 or B2542 pseudotypes (Figure 
A4-13). 
Cat M31. Plasma samples from cat M31 were available from 3 time points and 
were tested against a pseudotype bearing an Env from time point A and 16 
pseudotypes bearing Envs from time point C (Figure A4-14). Pseudotype M31A 
C253 was strongly neutralised by all plasma samples. Similarly, 6 pseudotypes 
bearing time point C Envs (M31C C4, C8, C12, C14, C15 and C16) were 
susceptible to neutralisation. 
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Figure A4-14 Autologous and Cr-NAb responses of plasma from cat M31. Plasma samples 
from each time point (A, B and C highlighted on the X axis in red, green and blue 
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respectively) were tested against pseudotypes bearing: 1) 1 Env variant isolated from time 
point A  (highlighted in red) and 2) 16 Env variants from time point B (highlighted in blue). 
Cross neutralisation activity of each plasma sample was assessed against two reference 
pseudotypes, GL-8 (orange) and B2542 (purple). Values indicative of strong neutralisation 
(>5.6 fold) lie above the dashed horizontal line. Pseudotypes are shown (from left to right) in 
the same order as in the graph legend (top to bottom). A significant proportion of 
pseudotypes bearing time point C Env variants (10) resisted neutralisation shortly before 
the cat’s death. 
 
In contrast, the remaining 10 pseudotypes bearing time point C Envs remained 
neutralisation resistant until the cat’s death (10.03.11). Although the Env 
variants had various N-linked glycosylation patterns (ranging from 21 to 23), 
neutralisation sensitivity appeared to be influenced by various amino acid 
substitutions within Env rather than by the presence or absence of PNGS. Cat 
M31 had been infected for approximately 6 years at the time of enrolment and 
CD4 lymphocyte counts decreased from 800 to 260 cells/µl recorder shortly 
before it died (ΔCD4 = -540 cells/µl) (Table 5-2). No cross neutralisation was 
observed against GL-8 or B2542 pseudotypes (Figure A4-14). 
Cat P2. Plasma samples from cat P2 were available from two time points (A and 
B) and were tested against sixteen pseudotypes bearing Envs from time point B 
(Figure A4-15). Six pseudotypes (P2B C6, C18, C24, C52, C59 and C65) were 
susceptible to neutralisation, but the remaining 10 were resisted neutralisation 
by plasma collected until the cat’s death (13.12.10). Resistance to neutralisation 
was most likely associated with the absence of a PNGS at position 554 compared 
to Env variants which were neutralisation sensitive. 
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Figure A4-15 Autologous and Cr-NAb response of plasma from cat P2. Plasma samples 
from time points A and B (highlighted on the X axis in red and green respectively) were 
tested against 16 pseudotypes bearing Envs from time point B (highlighted in green). The 
cross reactivity of each plasma sample was assessed against two reference pseudotypes, 
GL-8 (orange) and B2542 (purple). Values indicative of strong neutralisation (>5.6 fold) lie 
above the dashed horizontal line. Pseudotypes are shown (left to right) in the same order as 
in the graph legend (top to bottom). No Cr-NAb response was observed. 
 
For the env genes isolated from cat P2, the genetic diversity, calculated for the 
entire env as the highest K2P pairwise distance, was 1.5%. Cat P2 had been 
infected for approximately 4 years at the time of enrolment and showed a slight 
decline in CD4 lymphocyte counts from 400 to 360 cells/µl over the 6 months 
observation period (ΔCD4 = -40 cells/µl) (Table 5-3). No cross neutralisation was 
observed against the GL-8 or B2542 pseudotypes (Figure A4-15). 
Cat M44. A single plasma sample was available from cat M44 and this was tested 
against two pseudotypes bearing contemporaneous time point A Envs (Figure 
A4-16). M44A C91 and C92 were strongly neutralised (12.9 and 17.6 fold 
respectively). The M44A C91 Env contained 24 PNGS, while the M44A C92 Env 
contained 25. Cat M44 had been infected for approximately 3.5 years and, 
shortly prior to death (14.04.10), displayed high CD4 lymphocyte counts (1240 
cells/µl) (Table 5-2). Again, no cross neutralisation was observed against either 
the GL-8 or B2542 pseudotypes (Figure A4-16). 
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Figure A4-16 Autologous and Cr-NAb response of plasma M44. Plasma from time point A 
(highlighted on the X axis in red) was tested against pseudotypes bearing 2 Env variants 
isolated from time point A (highlighted in red). Cross neutralisation was assessed against 
two reference pseudotypes, GL-8 (orange) and B2542 (purple). Pseudotypes are shown (left 
to right) in the same order as in the legend (top to bottom). This cat died shortly after 
sampling A. 
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Moderate neutralisation 
Cat M46. All plasma samples collected from cat M46 moderately to strongly 
neutralised all but one of the pseudotypes bearing autologous Envs (from 4.8 to 
10.6 fold). The remaining pseudotype, bearing an Env from time point A (M46A 
C73), was weakly to moderately neutralised (from 2 to 4.2 fold) (Figure A4-17). 
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Figure A4-17. Autologous and Cr-NAb response of plasma from cat M46. Plasma samples 
from each time point (A, B, C and D highlighted on the X axis in red, green, blue and black 
respectively) were tested against: 1) 3 pseudotypes bearing Envs isolated from time point A 
(highlighted in red), 2) 2 time point B pseudotypes (highlighted in green) and 3) 3 time point 
C pseudotypes (highlighted in blue). Cross neutralisation was assessed against GL-8 
(orange) and B2542 (purple) pseudotypes. Values indicative of strong neutralisation (>5.6 
fold) lie above the dashed horizontal line. All autologous pseudotypes were moderately to 
strongly neutralised except M46A C73 (in red with dotted pattern). 
 
The genetic diversity amongst the autologous env sequences was 0.2% and all 
Envs contained 23 PNGS. The decreased sensitivity to neutralisation of the 
pseudotype bearing the M46A C73 Env was associated with mutation W440L, 
unique to this Env and absent from all other Env variants tested. Cat M46 had 
been infected for approximately 3 years at the start of the study and 
demonstrated a slight increase in CD4 T lymphocyte numbers, from 150 to 180 
cells/µl recorded shortly before death (23.07.11) (ΔCD4 = +30 cells/µl) (Table 
5-2). No cross neutralisation against the GL-8 or B2542 pseudotypes was 
detected (Figure A4-17). 
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Cat P5. An increase in neutralisation potency of sequential plasma samples from 
cat P5 was observed. Whereas plasma A did not neutralise any pseudotypes 
tested, the neutralisation potency of subsequent plasma samples increased and 
ranged from moderate to strong neutralisation (up to 6.9 fold neutralisation) for 
pseudotypes bearing autologous Envs isolated from later time points (Figure 
A4-18). 
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Figure A4-18 Autologous and Cr-NAb response of plasma samples from cat P5. Plasma 
samples from each time point (A, B, C and D highlighted on the X axis in red, green, blue 
and black respectively) were tested against: 1) 2 pseudotypes bearing Envs isolated from 
time point A  (highlighted in red), 2)  3 pseudotypes from time point B (highlighted in green) 
and 3) 3 pseudotypes from time point C (highlighted in blue). Cross neutralisation was 
assessed against two reference pseudotypes, GL-8 (orange) and B2542 (purple). Values 
indicative of strong neutralisation (>5.6 fold) lie above the dashed horizontal line. 
 
The genetic diversity amongst the env genes was 0.5% and the Env contained 
either 25 or 26 PNGS. (The Env variant P5 C118 of the least neutralised 
pseudotype; 0.4 to 3.5 fold neutralisation) contained 26 PNGS. Cat P5 had been 
infected for approximately 1.5 years at the start of the study and displayed a 
progressive decline in CD4 T lymphocyte numbers, from 790 to 300 cells/µl 
(ΔCD4 = -490 cells/µl) (Table 5-3). No cross neutralisation of the GL-8 or B2542 
pseudotypes was detected (Figure A4-18). 
Cat P9. Pseudotypes bearing autologous Envs from cat P9 were moderately to 
strongly neutralised by all plasmas (4 to 12.4 fold); however the neutralisation 
potency of plasma D against all pseudotypes was slightly less (Figure A4-19). The 
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genetic diversity amongst the autologous envs, expressed as highest K2P pairwise 
distance, was 0.4% and Envs had either 23 or 24 PNGS (Chapter 4). Cat P5 had 
been infected for approximately 3 years at the start of the study and developed 
a decline in CD4 T lymphocyte numbers, from 630 to 180 cells/µl over the 12 
months of observation (ΔCD4 = -450 cells/µl) (Table 5-3). No cross neutralisation 
against the GL-8 or B2542 pseudotypes was detected (Figure A4-18). 
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Figure A4-19 Autologous and Cr-NAb responses of plasma samples from cat P9. Plasma 
samples from each time point  (A,B,C and D highlighted on the X axis in red, green, blue and 
black respectively) were tested against: 1) 3 pseudotypes isolated from time point A 
(highlighted in red), 2)  2 pseudotypes from time point C (highlighted in blue). Pseudotypes 
from time point B were not available. Cross neutralisation assessed against two 
pseudotypes, GL-8 (orange) and B2542 (purple). Values indicative of strong neutralisation 
(>5.6 fold) lie above the dashed horizontal line. 
 
Cat P11. Pseudotypes bearing autologous Envs from cat P11 were weakly 
neutralised, with the exception of the P11C C88 pseudotype which was 
moderately to strongly neutralised by all plasmas tested (5.4 to 6.5 fold) (Figure 
A4-20). The genetic diversity amongst envs, expressed as highest K2P pairwise 
distance, was 0.1% and all isolates had 25 PNGS (Chapter 4). Pseudotype P11C 
C88 was most susceptible to neutralisation; this Env contained an E511G 
mutation which was not present in other autologous Envs. Cat P11 had been 
infected for approximately 1.5 years at the start of the study and maintained  
a stable CD4 T lymphocytes count at 450 cells/µl over the 12 month study period 
(Table 5-3). Interestingly, plasma from this cat moderately to strongly 
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neutralised the heterologous GL-8 pseudotype (from 4.9 to 9.2 fold) as well as 
B2542 pseudotype (4.2 to 8.3 fold; Figure A4-20). 
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Figure A4-20 Autologous and Cr-NAb responses of plasma samples from cat P11. Plasma 
samples from each time point (A, B, C and D highlighted on the X axis in red, green, blue 
and black respectively) were tested against: 1) 3 pseudotypes bearing Envs isolated from 
time point B (highlighted in green) and 2) 4 pseudotypes bearing Envs from time point C 
(highlighted in blue). Pseudotypes bearing Envs from time point A were not available. Cross 
neutralisation was assessed against two reference pseudotypes, GL-8 (orange) and B2542 
(purple). Values indicative of strong neutralisation (>5.6 fold) lie above the dashed 
horizontal line. Note moderate to strong cross-reactive neutralising activity was observed 
against the GL-8 and B2542 pseudotypes. 
 
Cat P7. Two pseudotypes bearing Envs from cat P7 were available: one each 
from time point B and C. Both pseudotypes were moderately (4.9 fold for P7B 
C50) or strongly neutralised (7.5 fold for P7C C61) by plasma D but not plasma A, 
B or C (Figure A4-21). The envs on the sequence level differed from each other 
by 0.5%. Cat P7 had been infected for approximately 5.5 years at the start of the 
study and stably maintained its CD4 T lymphocytes count at 400 cells/µl over the 
12 month observation period (Table 5-3). No cross neutralisation was observed 
against pseudotypes bearing the heterologous GL-8 or B2542 Envs (Figure A4-21). 
Cat P8. A single pseudotype bearing an autologous Env from cat P8 was tested 
and found to be weakly to moderately neutralised (3.1 to 4.4 fold; Figure 
A4-22). Notably, plasma from cat P8 cross neutralised pseudotypes bearing 
heterologous Envs; the GL-8 pseudotype was moderately neutralised (3.1 to 4.5 
fold), while the B2542 pseudotype was strongly neutralised (8.1 to 14.6 fold). 
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Cat P8 had been infected for approximately 3.5 years at the start of the study 
(suspected super-infection) and over the 12 month follow up, an increase in CD4 
T lymphocytes count, from 500 to 600 cells/µl (Table 5-3), was observed. 
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Figure A4-21 Autologous and Cr-NAb response of plasma from cat P7. Plasma samples 
from each time point (A, B, C and D highlighted on the X axis in red, green, blue and black 
respectively) were tested against: 1) 1 pseudotype bearing Env isolated from time point B 
(highlighted in green), 2)  1 pseudotype bearing Env from time point C (highlighted in blue). 
Pseudotypes bearing Envs from time point A were not available. Cross neutralisation was 
assessed against GL-8 (orange) and B2542 (purple) pseudotypes. Values indicative of 
strong neutralisation (>5.6 fold) lie above the dashed horizontal line.  
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Figure A4-22 Autologous and Cr-NAb responses of plasma from cat P8. Plasma samples 
from time points A, B and C (highlighted on the X axis in red, green and blue respectively) 
were tested against 1 pseudotype bearing an Env variant from time point A (highlighted in 
red). Cross neutralisation activity was assessed against two reference pseudotypes bearing 
the Envs of GL-8 (orange) and B2542 (purple). Values indicative of strong neutralisation 
(>5.6 fold) lie above the dashed horizontal line. Pseudotypes are shown (from left to right) in 
the same order as in the legend (top to bottom). Moderate to strong Cr-NAb responses were 
observed against the GL-8 and B2542 pseudotypes respectively. 
 
Absent neutralisation 
No NAbs in cats that remained alive during the study. 
Cat M28. None of the pseudotypes bearing Env variants isolated from cat M28 
were neutralised by autologous plasma (Figure A4-23). The diversity amongst the 
envs was 0.6% and each Env had either 24 or 25 PNGS. Cat M28 had been 
infected for approx. 4 years and, despite the lack of NAb response, remained 
healthy during the 18 month observation period. This cat did, however, display  
a progressive decline in CD lymphocyte numbers, from 1230 to 900 cells/µl, over 
the 18 month observation period (ΔCD4 = -330 cells/µl) (Table 5-2). No cross 
neutralisation of the GL-8 or B2542 pseudotypes was detected (Figure A4-23). 
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Figure A4-23 Autologous and Cr-NAb response of plasma collected from cat M28. Plasma 
samples from time points A, B, C and D (highlighted on the X axis in red, green, blue and 
black respectively) were tested against pseudotypes bearing: 1) 3 Envs from time point A (in 
red), 2) 5 Envs from time point B (in green), and 3) 3 Envs from time point C (in blue). Cross 
neutralisation was assessed against two reference pseudotypes, bearing the clade A GL-8 
(orange) and clade B B2542 (purple) Envs. Values indicative of strong neutralisation (>5.6 
fold) lie above the dashed horizontal line. Pseudotypes are shown (left to right) in the same 
order as in the legend (top to bottom). No Cr-NAb responses were observed. 
 
Cat P17. None of the pseudotypes bearing Env variants from cat P17 were 
neutralised by autologous plasma samples (Figure A4-24). The env diversity was 
0.5% and Env variants had 23 or 24 PNGS. Cat P17 had been infected for approx. 
5 years and demonstrated a progressive decline in CD4 lymphocyte numbers, 
from 490 to 280 cells/µl, over the 18 month observation period (ΔCD4 = -210 
cells/µl) (Table 5-3). No cross neutralisation of the GL-8 or B2542 pseudotypes 
was detected (Figure A4-24). 
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Figure A4-24 Autologous and Cr-NAb response of plasma collected from cat P17. Plasma 
samples from time points A, B, C and D (highlighted on the X axis in red, green, blue and 
black respectively) were tested against pseudotypes bearing: 1) 2 Env variants from time 
point A (highlighted in red), 2) 5 Env variants from time point B (highlighted in green), and 3) 
2 Env variants from time point C (in blue). Cross neutralisation was assessed against two 
reference pseudotypes bearing GL-8 (orange) or B2542 (purple) Envs. Values indicative of 
strong neutralisation (>5.6 fold) lie above the dashed horizontal line. Pseudotypes are 
shown (left to right) in the same order as in the legend (top to bottom). No Cr-NAb 
responses were observed. 
 
Cat P6. Similarly, no autologous or cross-reactive NAb responses were observed 
in plasma collected from cat P6 (Figure A4-25). Intra-host env diversity was 0.4% 
and all Env variants contained 24 PNGS. Cat P6 had been infected for 3.5 years 
and, despite the lack of NAbs, displayed increased numbers of CD4 lymphocytes 
from 480 to 570 cells/µl over 12 months of study (ΔCD4 = +90 cells/µl) (Table 
5-3). No cross neutralisation of the GL-8 or B2542 pseudotypes was detected 
(Figure A4-25). 
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Figure A4-25 Autologous and Cr-NAb response of plasma from cat P6. Plasma samples 
from time points A, B, C and D (highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 3 Env variants from time point A 
(in red), 2) 3 Envs from time point B (in green), and 3) 2 Env variants from time point C. 
Cross neutralisation was assessed against GL-8 (orange) and B2542 (purple) pseudotypes. 
Pseudotypes are shown (from left to right) in the same order as in the legend (top to 
bottom). 
 
Cat M1. Pseudotypes bearing one and three Envs from time points A and C 
respectively were tested for neutralisation but none was neutralised by 
homologous plasma from cat M1 (Figure A4-26). The genetic diversity amongst 
the envs was 0.4%. Cat M1 had most likely acquired its infection following 
vertical transmission from its mother and at the start of the study was 1.5 years 
old. M1 displayed a progressive decline in the number of CD4 lymphocytes, from 
870 to 260 cells/µl (ΔCD4 = -610 cells/µl) (Table 5-2), but remained healthy 
during the 18 month study period. No cross neutralisation of the GL-8 or B2542 
pseudotypes was detected (Figure A4-26). 
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Figure A4-26 Autologous and Cr-NAb response of plasma from cat M1. Plasma samples 
from each time point (A, B, C and D highlighted on the X axis in red, green, blue and black 
respectively) were tested against pseudotypes bearing: 1) 1 Env variant isolated from time 
point A (red) and 2) 3 Env variants from time point C (blue). Cross neutralisation was 
assessed against the GL-8 (orange) and B2542 reference pseudotypes (purple). 
 
Cat P21. Plasma from cat P21 did not neutralise any of the 6 pseudotypes 
bearing either autologous Envs or 2 heterologous Envs (Figure A4-33). The 
autologous env diversity was 11.9% and this cat was thought to have been super-
infected. Despite the possibly high antigenic stimulation by the clade B (P21B) 
and recombinant A/B (P21C) strains that were isolated from this animal, no NAb 
responses were detected. Cat P21 had been infected for 1 year at recruitment 
and, during 6 months of observation, showed a decline of the CD4 lymphocyte 
count from 930 to 570 cells/µl (ΔCD4 = -360 cells/µl) (Table 5-3). 
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Figure A4-27 Autologous and Cr-NAb response of plasma P21. Plasma samples from time 
points B, C and D (highlighted on the X axis in green, blue and black respectively) were 
tested against pseudotypes bearing: 1) 4 Env variants from time point B (highlighted in 
green), and 2) 2 Env variants from time point C. Cross neutralisation was assessed against 
the GL-8 (orange) and B2542 (purple) reference pseudotypes. Values indicative of strong 
neutralisation (>5.6 fold) lie above the dashed horizontal line. Pseudotypes are shown (from 
left to right) in the same order as in the legend (top to bottom). There was no Cr-NAb 
response observed. 
 
Cat M32. No neutralising activity by plasma collected from cat M32 was observed 
(Figure A4-28). The env diversity was 0.1% and all Envs contained 25 PNGS. Cat 
M32 had been infected for 8 years and, despite this long duration of infection, 
no NAbs were detected. During the 18 month follow up period, the CD4 
lymphocyte count declined from 380 to 210 cells/µl (ΔCD4 = -170 cells/µl) (Table 
5-2). 
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Figure A4-28 Autologous and Cr-NAb response of plasma from cat M32. Plasma samples 
from time points A, B, C and D (highlighted on the X axis in red, green, blue and black 
respectively) were tested against 3 pseudotypes bearing Env variants from time point A 
(red). Cross neutralisation was assessed against two reference pseudotypes, GL-8 (orange) 
and B2542 (purple). Pseudotypes are shown (left to right) in the same order as in the legend 
(top to bottom).  
 
Cat M29. No NAbs were observed in plasma collected from this animal (Figure 
A4-29). The env diversity was 0.1% and all Envs contained 25 PNGS. The cat had 
been infected for 3.5 years and its CD4 lymphocyte count decreased from 1480 
to 620 cell/µl over the 18 month observation period (ΔCD4 = -560 cells/µl) 
(Table 5-2). 
Cat M8. One pseudotype (M8C C144) bearing an autologous Env from this animal 
was tested and plasma M8 did not neutralise either this autologous pseudotype 
or the two heterologous reference pseudotypes (Figure A4-30). Cat M8 had been 
infected for 5.5 years at the time of recruitment and demonstrated a progressive 
decline in CD4 lymphocyte counts, from 550 to 150 cells/µl over the 18 month 
follow up period (ΔCD4 = -400 cells/µl) (Table 5-2). 
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Figure A4-29 Autologous and Cr-NAb response of plasma M29. Plasma samples from time 
points A, B, C and D (highlighted on the X axis in red, green, blue and black respectively) 
were tested against 3 pseudotypes bearing Env variants isolated from time point C (in blue). 
Cross neutralisation was assessed against two reference pseudotypes, bearing clade A GL-
8 (orange) or clade B B2542 (purple) Envs. Values indicative of strong neutralisation (>5.6 
fold) lie above the dashed horizontal line. Pseudotypes are shown (left to right) in the same 
order as in the legend (top to bottom). No Cr-NAb response was observed. 
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Figure A4-30 Autologous and Cr-NAb response of plasma M8. Plasma samples from time 
points A, B, C and D (highlighted on the X axis in red, green, blue and black respectively) 
were tested against a pseudotype bearing an Env variant from time point C (in blue). Cross 
neutralisation was assessed against two reference pseudotypes, GL-8 (orange) and B2542 
(purple). Values indicative of strong neutralisation (>5.6 fold) lie above the dashed 
horizontal line. Pseudotypes are shown (left to right) in the same order as in the legend (top 
to bottom). No Cr-NAb response was observed. 
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Cat M20. Similarly no neutralisation was observed with plasma collected from 
cat M20 (Figure A4-31), although plasma collected from time point C was not 
available. Cat M20 had been infected for 2.5 years and during the 18 month 
observation period its CD4 lymphocyte count decreased from 1500 to 1250 
cells/µl (ΔCD4 = -250 cells/µl) (Table 5-2). 
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Figure A4-31 Autologous and Cr-NAb response of plasma from cat M20. Plasma samples 
from time points A, B and D (highlighted on the X axis in red, green and black respectively) 
were tested against a pseudotype bearing an Env variant from time point A (highlighted in 
green). Plasma C was not available. Cross reactivity was assessed against two reference 
pseudotypes, GL-8 (orange) and B2542 (purple). Values indicative of strong neutralisation 
(>5.6 fold) lie above the dashed horizontal line. Pseudotypes are shown (from left to right) in 
the same order as in the legend (top to bottom). No Cr-NAb response was observed. 
 
No neutralisation in cats that died during the study. 
Cat M11. None of pseudotypes bearing autologous Envs (n=15) or heterologous 
Envs (n=2) was neutralised by plasma from cat M11 (Figure A4-32). The intra-
host env diversity was 0.7% and Env variants contained either 22 or 23 PNGS. Cat 
M11 had been infected for 2 years at the time of recruitment and, during the 12 
months of observation, displayed a progressive decline in CD4 lymphocyte counts 
from 980 to 480 cell/µl recorded shortly before death (04.02.11) (ΔCD4 = -500 
cells/µl) (Table 5-2). 
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Figure A4-32 Autologous and Cr-NAb response of plasma M11. Plasma samples from each 
time point (A, B and C highlighted on the X axis in red, green and blue respectively) were 
tested against pseudotypes bearing: 1) 3 Env variants isolated from time point A (red), 2) 3 
Env variants from time point B (green) and 3) 9 Env variants from time point C (highlighted 
in blue). 
 
Cat M5. No neutralisation of pseudotypes bearing autologous Envs was observed 
in cat M5 (Figure A4-33). Cat M5 had been infected for approx. 2.5 years prior to 
enrolment in the study and likely became superinfected between samplings B 
and C. The env diversity was as high as 4.2% and the number of PNGS ranged 
from 21 to 23 amongst Env variants. CD4 lymphocyte counts decreased from 560 
to 160 cell/µl recorded at sampling C, 4 months before death (18.05.11) (ΔCD4 = 
-400 cells/µl) (Table 5-2). 
Cat M41. None of the 11 pseudotypes bearing autologous Env variants that were 
tested was neutralised by plasma collected from cat M41 (Figure A4-34). The env 
diversity was 4.1% but all Env variants contained 22 PNGS. This cat had been 
infected for approx. 4.5 years at the time of enrolment and, during the 12 
months of observation, displayed a decline in CD4 lymphocytes, from 340 to 120 
cells/µl recorded shortly before death (03.02.11) (ΔCD4 = -220 cells/µl) (Table 
5-2). 
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Figure A4-33 Autologous and Cr-NAb response of plasma from cat M5. Plasma samples 
from each time point (A, B and C highlighted on the X axis in red, green and blue 
respectively) were tested against pseudotypes bearing: 1) 3 Env variants isolated from time 
point A (highlighted in red), 2) 2 Env variants from time point B (highlighted in green) and 3) 
3 Env variants from time point C (highlighted in blue). Cross neutralisation was assessed 
against GL-8 (orange) and B2542 (purple) reference pseudotypes. 
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Figure A4-34 Autologous and Cr-NAb response of plasma from cat M41. Plasma samples 
from time points A, B and C (highlighted on the X axis in red, green and blue) were tested 
against pseudotypes bearing: 1) 2 Env variants isolated from time point A (highlighted in 
red), 2) 9 Env variants from time point C (highlighted in blue). Env variants isolated from 
time point B were not available. Cross neutralisation was assessed against the GL-8 
(orange) and B2542 (purple) reference pseudotypes.  
 
 258 
 
Cat M16. Plasma from cat M16 did not neutralise any of the pseudotypes bearing 
autologous or heterologous Env variants (Figure A4-35). The env diversity was 
0.4% and all Env variants contained 24 PNGS. Cat M16 had been infected for 5.5 
years prior to enrolment in the study and, during the 12 months of observation, 
maintained a stable CD4 lymphocyte count at around 350 cells/µl until the time 
of death (19.06.10) (Table 5-2).  
Cat M33. Plasma from cat M33 did not neutralise any of the 19 pseudotypes 
bearing autologous Envs (Figure A4-36). The env diversity was 1.1 % and Env 
variants contained either 23 or 24 PNGS. The cat had been infected for 5.5 years 
prior to enrolment in the study. The last CD4 lymphocyte count, recorded 4 
months before death, was 200 cells/µl (Table 5-2).  
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Figure A4-35 Autologous and Cr-NAb response of plasma from cat M16. Plasma samples 
from each time point (A, B and C highlighted on the X axis in red, green and blue 
respectively) were tested against pseudotypes bearing: 1) 4 Envs isolated from time point A 
(highlighted in red) and 2) 3 Envs from time point C (highlighted in blue). Cross 
neutralisation was assessed against two reference pseudotypes, GL-8 (orange) and B2542 
(purple). Values indicative of strong neutralisation (>5.6 fold) lie above the dashed 
horizontal line. 
 
Cat M50. Cat M50 had been infected for approx. 2 years and its plasma did not 
neutralise pseudotypes bearing 2 autologous Envs. M50 died on 27.10.10 (10 
months into the study) and its CD4 lymphocyte count 3 months earlier had been 
1320 cells/µl (Table 5-2). 
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Figure A4-36 Autologous and Cr-NAb response of plasma from cat M33. Plasma samples 
from time points A and B (highlighted on the X axis in red and green respectively) were 
tested against pseudotypes bearing: 1) 6 Envs isolated from time point A (highlighted in 
red) and 2) 13 Envs from time point B (highlighted in green). Cross neutralisation was 
assessed against two reference pseudotypes bearing the clade A GL-8 (orange) and the 
clade B B2542 (purple) Envs. Values indicative of strong neutralisation (>5.6 fold) lie above 
the dashed horizontal line. Samples from further time points were not available as the cat 
died after sample B was collected. 
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Figure A4-37 Autologous and Cr-NAb response of plasma from cat M50. Plasma from time 
point A (highlighted on the X axis in red) was tested against pseudotypes bearing 2 Envs 
from time point A (highlighted in red). Cross neutralisation activity was assessed against 
two reference pseudotypes bearing the clade A GL-8 (orange) and the clade B B2542 
(purple) Envs. Values indicative of strong neutralisation (>5.6 fold) lie above the dashed 
horizontal line. Pseudotypes are shown (left to right) in the same order as in the graph 
legend (top to bottom).  
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Cat M3. Plasma from cat M3 failed to neutralise a pseudotype bearing a 
homologous Env but moderately neutralised a pseudotype bearing the 
heterologous GL-8 Env (3.8 fold), despite M3 having been infected with a non-
recombinant clade B virus. Cat M3 had been infected for almost 9 years prior to 
enrolment in the study and its CD4 lymphocyte count, recorded 2 months before 
death, was 330 cells/µl (Table 5-2). 
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Figure A4-38 Autologous and Cr-NAb response of plasma from cat M3. Plasma collected at 
time point A (highlighted on the X axis in red) was tested against 1 pseudotype bearing 
homologous Env from time point A (highlighted in red). Cross reactivity was assessed 
against two reference pseudotypes bearing GL-8 (orange) or B2542 (purple) Envs. There 
were no values indicative of strong neutralisation (>5.6 fold) above the dashed horizontal 
line. Pseudotypes are shown (left to right) in the same order as in the legend (top to 
bottom). 
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